[CLS]
(
5
.
3
)
*
High
blood
pressure
:
Do
not
pre
##s
##cribe
Nat
##azi
##a
for
women
with
un
##con
##tro
##lled
h
##yper
##tens
##ion
or
h
##yper
##tens
##ion
with
vascular
disease
.
[SEP]
[CLS]
f
##F
##ata
##l
bleed
:
Ad
##ju
##dicated
major
bleed
as
defined
above
with
investigator
reported
fatal
outcome
and
ad
##ju
##dicated
death
with
primary
cause
from
bleeding
.
[SEP]
[CLS]
XI
##AF
##LE
##X
was
not
associated
with
short
##ening
of
pen
##ile
length
in
clinical
trials
in
the
treatment
of
P
##ey
##ron
##ie
'
s
disease
.
[SEP]
[CLS]
My
##oc
##ard
##ial
is
##che
##mia
or
my
##oc
##ard
##ial
in
##far
##ction
led
to
death
in
3
patients
in
the
place
##bo
arms
and
2
deaths
in
the
Z
##Y
##TI
##GA
arms
.
[SEP]
[CLS]
Inc
##reased
levels
of
thy
##roid
s
##ti
##mulating
hormone
(
T
##S
##H
)
were
observed
in
57
%
of
patients
receiving
CO
##ME
##TR
##I
##Q
after
the
first
dose
compared
to
19
%
of
patients
receiving
place
##bo
[SEP]
[CLS]
(
regardless
of
base
##line
value
)
.
[SEP]
[CLS]
The
decrease
in
serum
potassium
is
usually
trans
##ient
,
not
requiring
supplement
##ation
.
[SEP]
[CLS]
The
adverse
reactions
reported
in
more
than
one
subject
within
the
studies
are
shown
in
Table
2
.
[SEP]
[CLS]
The
place
##bo
-
adjusted
change
at
the
di
##stal
forearm
for
patients
random
##ized
to
IN
##VO
##KA
##NA
100
mg
was
0
%
.
[SEP]
[CLS]
(
5
.
4
)
*
Skin
Re
##actions
:
Disco
##ntin
##ue
for
severe
skin
reactions
.
[SEP]
[CLS]
All
##op
##uri
##no
##l
has
also
been
used
during
the
beginning
of
T
##RE
##AN
##DA
therapy
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Most
patients
(
87
%
)
were
less
than
65
years
of
age
;
58
.
4
%
were
women
.
[SEP]
[CLS]
The
incidence
of
G
##I
events
was
higher
early
in
the
course
of
treatment
(
primarily
in
month
1
)
and
usually
decreased
over
time
in
patients
treated
with
T
##EC
##FI
##DE
##RA
compared
[SEP]
[CLS]
with
place
##bo
.
[SEP]
[CLS]
Ser
##ious
adverse
events
were
reported
in
58
patients
(
34
%
)
treated
with
X
##AL
##KO
##RI
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
[SEP]
[CLS]
f
##etus
.
[SEP]
[CLS]
The
increased
risk
of
as
##th
##ma
-
related
death
is
considered
a
class
effect
of
the
long
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
##s
,
including
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
Trans
##ient
increases
in
pain
were
commonly
observed
on
the
day
of
treatment
in
patients
treated
with
Q
##ute
##nza
.
[SEP]
[CLS]
Do
##se
should
be
reduced
for
patients
with
mild
(
total
bi
##li
##ru
##bin
>
1
to
<
=
1
.
5
*
U
##L
##N
or
AS
##T
>
1
.
5
*
U
##L
##N
)
and
moderate
(
total
[SEP]
[CLS]
bi
##li
##ru
##bin
>
1
.
5
to
<
=
3
.
0
*
U
##L
##N
and
any
AS
##T
)
he
##pa
##tic
imp
##air
##ment
,
based
on
to
##ler
##ability
data
in
these
patients
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
[SEP]
[CLS]
)
and
Use
in
S
##pecific
Population
##s
(
8
.
7
)
]
.
[SEP]
[CLS]
However
,
some
patients
may
require
treatment
with
SA
##P
##H
##RI
##S
despite
the
presence
of
the
syndrome
.
[SEP]
[CLS]
The
incidence
of
op
##port
##uni
##stic
infections
was
similar
to
that
reported
with
place
##bo
.
[SEP]
[CLS]
(
2
.
4
,
5
.
2
)
*
He
##pa
##tic
To
##xi
##city
:
Monitor
liver
enzymes
at
least
monthly
for
the
first
three
months
and
as
needed
.
[SEP]
[CLS]
Therefore
,
the
combination
of
T
##NF
-
block
##ers
including
S
##IM
##PO
##NI
ARIA
and
a
##bat
##ace
##pt
is
not
recommended
[
see
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
Mon
##otherapy
in
Adult
Pat
##ients
with
B
##ip
##olar
Man
##ia
:
The
following
findings
are
based
on
the
short
-
term
place
##bo
-
controlled
trials
for
bi
##pol
##ar
man
##ia
(
a
pool
of
two
3
-
week
flexible
-
dose
trials
)
[SEP]
[CLS]
in
which
sub
##ling
##ual
SA
##P
##H
##RI
##S
was
administered
in
doses
of
5
mg
or
10
mg
twice
daily
.
[SEP]
[CLS]
Among
those
17
subjects
,
10
subjects
developed
neutral
##izing
antibodies
.
[SEP]
[CLS]
Ad
##ju
##st
total
fluid
intake
as
clinical
##ly
appropriate
in
patients
with
base
##line
cardiac
failure
or
who
are
at
risk
for
cardiac
failure
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
There
have
been
post
-
marketing
reports
of
serious
breathing
difficulties
,
including
respiratory
failure
.
[SEP]
[CLS]
Before
using
O
##TE
##Z
##LA
in
patients
with
a
history
of
depression
and
/
or
su
##icidal
thoughts
or
behavior
pre
##s
##cribe
##rs
should
carefully
weigh
the
risks
and
benefits
of
treatment
with
O
##TE
##Z
##LA
in
such
patients
[SEP]
[CLS]
.
[SEP]
[CLS]
The
clinical
relevance
of
the
presence
of
anti
-
be
##lim
##uma
##b
antibodies
is
not
known
.
[SEP]
[CLS]
Ren
##al
imp
##air
##ment
(
including
the
terms
re
##nal
imp
##air
##ment
,
re
##nal
failure
,
and
re
##nal
failure
acute
)
led
to
disco
##ntin
##uation
of
treatment
in
5
/
101
##5
(
0
.
5
%
)
subjects
receiving
[SEP]
[CLS]
Z
##ER
##BA
##X
##A
and
none
in
the
com
##par
##ator
arms
.
[SEP]
[CLS]
I
##mme
##dia
##te
gentle
pressure
at
the
injection
site
can
limit
that
risk
.
[SEP]
[CLS]
In
some
cases
the
elevations
in
trans
##ami
##nas
##es
were
consistent
with
immune
re
##con
##st
##itution
syndrome
or
he
##pa
##titis
B
react
##ivation
particularly
in
the
setting
where
anti
-
he
##pa
##titis
therapy
was
withdrawn
.
[SEP]
[CLS]
Fifty
percent
(
50
%
)
of
the
population
was
male
and
72
%
were
Caucasian
,
12
%
were
Asian
,
and
5
%
were
Black
or
African
American
[SEP]
[CLS]
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
P
##OS
##T
-
T
##RA
##NS
##PL
##AN
##T
L
##Y
##MP
##H
##OP
##RO
##L
##IF
##ER
##AT
##IVE
D
##IS
##OR
##DE
##R
,
O
##TH
##ER
MA
##L
##IG
##NA
##NC
##IE
##S
,
AND
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
S
##ym
##pt
##oms
associated
with
these
reactions
have
included
chest
discomfort
,
flush
##ing
,
p
##har
##yn
##ge
##al
ed
##ema
,
p
##ru
##rit
##us
,
r
##hino
##rr
##hea
,
s
##nee
##zing
,
nasal
congestion
,
throat
irritation
,
u
##rt
##ica
##ria
,
[SEP]
[CLS]
w
##hee
##zing
,
and
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
A
##pp
##rise
women
of
potential
harm
to
the
f
##etus
.
[SEP]
[CLS]
Primary
prop
##hyl
##ax
##is
with
G
-
CS
##F
should
be
considered
in
patients
with
high
-
risk
clinical
features
.
[SEP]
[CLS]
Some
of
these
abnormal
##ities
were
considered
potentially
clinical
##ly
significant
.
[SEP]
[CLS]
At
the
end
of
treatment
,
0
.
6
%
,
2
.
7
%
,
and
3
.
5
%
of
patients
with
hem
##ato
##c
##rits
initially
within
the
reference
range
had
values
above
the
upper
limit
[SEP]
[CLS]
of
the
reference
range
with
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
,
respectively
.
[SEP]
[CLS]
(
5
.
1
)
*
In
##fect
##ions
:
Inc
##reased
risk
of
infections
,
some
fatal
.
[SEP]
[CLS]
There
is
insufficient
information
to
character
##ize
the
risks
of
re
##sumption
of
X
##AL
##KO
##RI
in
patients
with
a
severe
visual
loss
;
a
decision
to
resume
X
##AL
##KO
##RI
should
consider
the
potential
benefits
[SEP]
[CLS]
to
the
patient
.
[SEP]
[CLS]
If
pulmonary
toxicity
is
confirmed
,
M
##U
##LT
##A
##Q
should
be
discontinued
.
[SEP]
[CLS]
Monitor
patients
closely
during
and
after
administration
of
G
##ada
##vist
(
5
.
2
)
5
.
1
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
ne
##ph
##rogen
##ic
systemic
fi
##bro
##sis
(
[SEP]
[CLS]
N
##SF
)
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
There
were
no
reported
th
##rom
##boe
##mbo
##lic
events
in
the
patients
treated
with
E
##Y
##LE
##A
in
the
first
six
months
of
the
R
##VO
studies
.
[SEP]
[CLS]
Follow
the
dose
adjustment
guidelines
to
achieve
and
maintain
target
plate
##let
counts
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
,
2
.
2
,
2
.
3
)
]
.
[SEP]
[CLS]
Neither
clinical
studies
nor
e
##pid
##em
##iol
##og
##ic
studies
conducted
to
date
have
shown
an
association
between
chronic
administration
of
this
class
of
drugs
and
tumor
##ige
##nes
##is
in
humans
,
but
the
available
evidence
[SEP]
[CLS]
is
too
limited
to
be
con
##clusive
.
[SEP]
[CLS]
In
Trial
2
,
13
%
of
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
experienced
adverse
reactions
resulting
in
permanent
disco
##ntin
##uation
of
trial
medication
(
s
)
.
[SEP]
[CLS]
In
this
trial
,
use
of
E
##SA
##s
was
associated
with
an
increased
risk
of
th
##rom
##boe
##mbo
##lic
events
including
pulmonary
em
##bol
##ism
,
acute
my
##oc
##ard
##ial
in
##far
##ction
,
c
##ere
##bro
##vas
##cular
accident
,
and
deep
vein
[SEP]
[CLS]
th
##rom
##bos
##is
compared
to
rib
##avi
##rin
dose
reduction
alone
.
[SEP]
[CLS]
Dec
##rease
##s
in
ne
##ut
##rop
##hil
counts
may
require
dose
reduction
or
disco
##ntin
##uation
of
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
Eight
of
12
patients
treated
with
D
##AL
##VA
##NC
##E
and
one
com
##par
##ator
patient
had
underlying
conditions
which
could
affect
liver
enzymes
,
including
chronic
viral
he
##pa
##titis
and
a
history
of
alcohol
abuse
[SEP]
[CLS]
.
[SEP]
[CLS]
For
current
full
pre
##s
##cribing
information
,
please
visit
www
.
p
##fi
##zer
.
com
.
[SEP]
[CLS]
At
these
doses
,
SA
##P
##H
##RI
##S
was
associated
with
increases
in
Q
##T
##c
interval
ranging
from
2
to
5
m
##se
##c
compared
to
place
##bo
.
[SEP]
[CLS]
Consider
the
risks
and
benefits
of
treatment
with
S
##IM
##PO
##NI
ARIA
prior
to
in
##iti
##ating
therapy
in
patients
with
chronic
or
re
##current
infection
.
[SEP]
[CLS]
If
E
##L
##I
##Q
##UI
##S
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
,
consider
coverage
with
another
anti
##coa
##gu
##lant
[
see
Do
##sa
##ge
and
Administration
(
[SEP]
[CLS]
2
.
4
)
and
##C
##lini
##cal
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
*
Monitor
all
patients
for
active
T
##B
during
treatment
,
even
if
initial
late
##nt
T
##B
test
is
negative
(
5
.
1
)
.
[SEP]
[CLS]
*
Ana
##phy
##lax
##is
and
in
##fusion
reactions
:
If
an
in
##fusion
reaction
occurs
,
interrupt
the
in
##fusion
.
[SEP]
[CLS]
A
total
of
275
##7
subjects
with
h
##yper
##uri
##ce
##mia
and
go
##ut
were
treated
with
U
##L
##OR
##IC
40
mg
or
80
mg
daily
in
clinical
studies
.
[SEP]
[CLS]
Other
Risk
Factor
##s
Other
known
risk
factors
for
PT
##LD
include
c
##yt
##ome
##gal
##ov
##ir
##us
(
C
##M
##V
)
infection
and
T
-
cell
-
de
##ple
##ting
therapy
.
[SEP]
[CLS]
(
5
.
12
,
8
.
1
)
5
.
1
Non
-
infectious
P
##ne
##um
##oni
##tis
Non
-
infectious
p
##ne
##um
##oni
##tis
is
a
class
effect
of
rap
##am
##y
##cin
derivatives
,
including
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
The
risk
of
h
##y
##po
##gly
##ce
##mia
is
increased
when
J
##AR
##DI
##AN
##CE
is
used
in
combination
with
insulin
secret
##ago
##gues
(
e
.
g
.
,
su
##lf
##ony
##lu
##rea
)
or
insulin
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
is
con
##tra
##ind
##ica
##ted
in
patients
with
ne
##ut
##rop
##hil
##s
<
=
1
,
500
/
mm
3
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
The
overall
safety
profile
of
N
##eur
##ace
##q
is
based
on
data
from
978
administration
##s
of
N
##eur
##ace
##q
to
87
##2
subjects
and
12
subjects
who
received
vehicle
only
.
[SEP]
[CLS]
Table
8
compares
the
incidence
of
adverse
reactions
reported
with
an
incidence
of
>
=
10
%
for
patients
receiving
A
##FI
##NI
##TO
##R
and
occurring
more
frequently
with
A
##FI
##NI
##TO
##R
than
with
place
##bo
[SEP]
[CLS]
.
[SEP]
[CLS]
No
Grade
4
laboratory
abnormal
##ities
were
reported
.
[SEP]
[CLS]
At
base
##line
the
population
had
diabetes
for
an
average
of
7
.
3
years
,
had
a
mean
H
##b
##A
##1
##C
of
8
.
0
%
and
20
%
had
established
micro
##vas
##cular
complications
of
diabetes
.
[SEP]
[CLS]
FA
##NA
##P
##T
is
not
approved
for
use
in
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
.
[SEP]
[CLS]
c
Includes
p
##ne
##um
##oni
##tis
,
inter
##st
##iti
##al
lung
disease
,
lung
in
##fi
##ltration
,
pulmonary
al
##ve
##olar
hem
##or
##r
##hage
,
pulmonary
toxicity
,
and
al
##ve
##oli
##tis
.
[SEP]
[CLS]
Table
3
:
Monitor
##ed
Ad
##verse
Re
##actions
-
P
##ru
##rit
##us
,
E
##ry
##them
##a
,
P
##yo
##der
##ma
and
O
##cular
I
##rri
##tation
with
On
##set
After
Treatment
Sign
##s
/
S
##ym
##pt
##oms
U
##LE
##SF
##IA
(
r
)
Lot
##ion
Vehicle
P
##ru
##rit
##us
12
%
(
[SEP]
[CLS]
14
/
116
)
4
%
(
3
/
67
)
E
##ry
##them
##a
10
%
(
32
/
30
##9
)
9
%
(
19
/
217
)
P
##yo
##der
##ma
7
%
(
22
/
308
)
4
%
(
10
/
230
)
[SEP]
[CLS]
O
##cular
irritation
6
%
(
26
/
42
##8
)
1
%
(
3
/
313
)
Other
less
common
reactions
(
less
than
1
%
but
more
than
0
.
1
%
)
were
,
in
[SEP]
[CLS]
decreasing
order
of
incidence
:
application
site
dry
##ness
,
application
site
ex
##cor
##iation
,
para
##est
##hesia
,
application
site
der
##mat
##itis
,
ex
##cor
##iation
,
thermal
burn
,
da
##nd
##ruff
,
er
##yt
##hem
##a
,
r
##ash
,
[SEP]
[CLS]
and
skin
ex
##folia
##tion
.
[SEP]
[CLS]
El
##eva
##ting
the
head
of
the
bed
less
##ens
the
risk
of
su
##pine
h
##yper
##tens
##ion
,
and
blood
pressure
should
be
measured
in
this
position
.
[SEP]
[CLS]
In
clinical
trials
,
subjects
who
received
a
higher
dose
of
D
##Y
##SP
##OR
##T
(
r
)
had
an
increased
incidence
of
eye
##lid
p
##tosis
.
[SEP]
[CLS]
Therefore
,
pre
##s
##cribe
##rs
should
exercise
caution
when
considering
re
##sumption
of
T
##NF
-
block
##ers
in
this
situation
and
monitor
patients
closely
.
[SEP]
[CLS]
age
>
60
years
,
h
##yper
##tens
##ion
,
diabetes
)
,
estimate
the
g
##lo
##mer
##ular
fi
##ltration
rate
(
G
##F
##R
)
through
laboratory
testing
(
5
.
1
)
.
[SEP]
[CLS]
An
additional
51
subjects
from
a
separate
repeat
dose
study
were
tested
for
the
presence
of
neutral
##izing
antibodies
only
.
[SEP]
[CLS]
This
risk
was
greater
in
patients
with
a
base
##line
reduced
estimated
c
##rea
##tin
##ine
clearance
(
calculated
using
Co
##ck
##croft
and
G
##ault
equation
)
.
[SEP]
[CLS]
The
Study
2
population
included
patients
with
a
median
age
of
7
years
(
1
to
17
years
)
;
63
%
were
male
,
27
%
were
Hispanic
or
[SEP]
[CLS]
Latino
,
83
%
were
White
,
3
%
were
Black
/
African
American
,
7
%
were
Asian
,
and
7
%
were
other
(
American
Indian
,
Alaska
Native
or
[SEP]
[CLS]
Indian
)
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
7
15
13
13
P
##sy
##chia
##tric
disorders
In
##so
##m
##nia
13
16
15
15
V
##as
##cular
disorders
H
##yper
##tens
##ion
2
2
3
2
Do
##se
-
Re
##lated
Ad
##verse
Re
##actions
:
In
the
short
term
s
##chi
##zophrenia
trials
the
incidence
[SEP]
[CLS]
of
aka
##thi
##sia
appeared
to
be
dose
-
related
(
see
##T
##able
8
)
.
[SEP]
[CLS]
The
na
##dir
in
serum
calcium
level
occurs
at
approximately
day
10
after
Pro
##lia
dos
##ing
in
subjects
with
normal
re
##nal
function
.
[SEP]
[CLS]
Females
of
child
##be
##aring
potential
should
be
advised
to
avoid
becoming
pregnant
during
treatment
with
J
##E
##V
##TA
##NA
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Four
percent
(
4
%
)
of
patients
treated
with
T
##EC
##FI
##DE
##RA
and
less
than
1
%
of
place
##bo
patients
discontinued
due
to
gas
##tro
##int
##est
##inal
events
.
[SEP]
[CLS]
Ad
##verse
reactions
leading
to
dose
reduction
occurred
in
14
%
of
patients
.
[SEP]
[CLS]
Local
skin
reactions
were
assessed
within
the
selected
treatment
area
and
graded
by
the
investigator
on
a
scale
of
0
to
4
.
[SEP]
[CLS]
IN
##VO
##KA
##NA
can
increase
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
combined
with
insulin
or
an
insulin
secret
##ago
##gue
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
trials
,
the
proportion
of
patients
with
total
ch
##ole
##ster
##ol
elevations
>
=
240
mg
/
d
##L
(
at
End
##point
)
was
8
.
7
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
[SEP]
[CLS]
8
.
6
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
If
into
##ler
##able
symptoms
occur
following
a
decrease
in
the
dose
or
upon
disco
##ntin
##uation
of
treatment
,
then
re
##suming
the
previously
prescribed
dose
may
be
considered
.
[SEP]
[CLS]
Sign
##s
or
symptoms
that
may
reflect
serious
injury
to
the
injected
finger
/
hand
should
be
promptly
evaluated
because
surgical
intervention
may
be
required
.
[SEP]
[CLS]
5
.
3
Skin
Disco
##lora
##tion
P
##OT
##IG
##A
can
cause
skin
disco
##lora
##tion
.
[SEP]
[CLS]
Table
6
:
Change
in
Body
Weight
FA
##NA
##P
##T
FA
##NA
##P
##T
Place
##bo
10
-
16
mg
/
day
20
-
24
mg
/
day
n
=
57
##6
n
=
48
##1
n
=
39
##1
Weight
(
kg
)
Change
from
Basel
##ine
-
0
.
1
2
.
0
2
.
7
Weight
G
##ain
>
[SEP]
[CLS]
=
7
%
increase
from
Basel
##ine
4
%
12
%
18
%
5
.
6
Se
##iz
##ures
In
short
-
term
place
##bo
-
controlled
trials
(
4
-
to
6
-
weeks
)
,
seizure
##s
occurred
in
0
.
1
%
(
1
/
134
##4
[SEP]
[CLS]
)
of
patients
treated
with
FA
##NA
##P
##T
compared
to
0
.
3
%
(
2
/
58
##7
)
on
place
##bo
.
[SEP]
[CLS]
Control
##led
Study
The
data
in
Table
##s
1
and
2
below
reflect
exposure
of
229
E
##G
##F
##R
-
T
##K
##I
naive
G
##IL
##OT
##RI
##F
-
treated
patients
with
E
##G
##F
##R
mutation
-
positive
,
meta
##static
,
non
-
sq
##ua
##mous
,
N
##SC
##LC
enrolled
in
a
[SEP]
[CLS]
random
##ized
,
multi
##cent
##er
,
open
-
label
trial
(
Study
1
)
.
[SEP]
[CLS]
5
.
10
Inter
##st
##iti
##al
Lu
##ng
Disease
and
E
##os
##ino
##phi
##lic
P
##ne
##um
##onia
Inter
##st
##iti
##al
lung
disease
and
e
##os
##ino
##phi
##lic
pneumonia
associated
with
ve
##n
##la
##fa
##xin
##e
(
the
parent
drug
of
PR
##IS
##TI
##Q
)
therapy
have
been
rarely
reported
.
[SEP]
[CLS]
Given
these
considerations
,
FA
##NA
##P
##T
should
be
prescribed
in
a
manner
that
is
most
likely
to
minimize
the
occurrence
of
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
.
[SEP]
[CLS]
Per
##cent
##age
(
%
)
of
Pat
##ients
##a
Y
##ER
##VO
##Y
##3
mg
/
kg
##n
=
131
Y
##ER
##VO
##Y
##3
mg
/
kg
+
g
##p
##100
##n
=
380
g
##p
##100
##n
=
132
System
Organ
Class
/
Pre
##ferred
Te
##rm
Any
##G
##rade
Grade
##3
-
5
Any
##G
##rade
Grade
##3
-
5
Any
##G
##rade
Grade
##3
-
5
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
Di
##ar
##r
##hea
32
5
37
4
20
1
[SEP]
[CLS]
Col
##itis
8
5
5
3
2
0
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
P
##ru
##rit
##us
31
0
21
<
1
11
0
Ra
##sh
29
2
25
2
8
0
General
Di
##sor
##ders
and
[SEP]
[CLS]
Administration
Site
Con
##ditions
Fat
##ig
##ue
41
7
34
5
31
3
Table
2
presents
the
per
-
patient
incidence
of
severe
,
life
-
threatening
,
or
fatal
immune
-
mediated
adverse
reactions
from
Study
1
.
[SEP]
[CLS]
a
mass
in
the
neck
,
d
##ys
##pha
##gia
,
d
##ys
##p
##nea
,
persistent
hoarse
##ness
)
.
[SEP]
[CLS]
Table
4
:
Laboratory
A
##b
##nor
##mal
##ities
in
>
15
%
of
Pat
##ients
in
the
Z
##Y
##TI
##GA
Arm
of
Study
2
A
##bir
##ater
##one
(
N
=
54
##2
)
Place
##bo
(
N
=
540
)
Laboratory
A
##b
##nor
##mal
##ity
Grade
1
-
4
[SEP]
[CLS]
%
Grade
3
-
4
%
Grade
1
-
4
%
Grade
3
-
4
%
He
##mat
##ology
L
##ymph
##ope
##nia
38
.
2
8
.
7
31
.
7
7
.
4
Chemistry
H
##yper
##gly
##ce
##mia
56
.
6
6
.
5
50
.
9
5
.
2
High
AL
##T
41
.
9
6
.
1
29
.
1
0
.
7
[SEP]
[CLS]
High
AS
##T
37
.
3
3
.
1
28
.
7
1
.
1
H
##yper
##nat
##rem
##ia
32
.
8
0
.
4
25
.
0
0
.
2
H
##y
##po
##kal
##emia
17
.
2
2
.
8
10
.
2
1
.
7
Card
##iovascular
Ad
##verse
Re
##actions
:
In
the
combined
data
for
studies
1
and
2
,
[SEP]
[CLS]
cardiac
failure
occurred
more
commonly
in
patients
treated
with
Z
##Y
##TI
##GA
compared
to
patients
on
the
place
##bo
arm
(
2
.
1
%
versus
0
.
7
%
)
.
[SEP]
[CLS]
Use
of
CO
##Cs
also
increases
the
risk
of
art
##erial
th
##rom
##bos
##es
such
as
strokes
and
my
##oc
##ard
##ial
in
##far
##ctions
,
especially
in
women
with
other
risk
factors
for
these
events
.
[SEP]
[CLS]
The
possibility
of
more
extensive
systemic
involvement
has
not
been
excluded
.
[SEP]
[CLS]
N
##eu
##tro
##pen
##ia
may
pre
##cede
the
development
of
a
##gra
##nu
##loc
##yt
##osis
.
[SEP]
[CLS]
There
was
no
fatal
pneumonia
in
subjects
receiving
v
##ila
##nter
##ol
or
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
50
m
##c
##g
/
25
m
##c
##g
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
88
##8
-
82
##5
-
52
##4
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
After
the
fourth
injection
of
XI
##AF
##LE
##X
,
every
XI
##AF
##LE
##X
-
treated
patient
developed
high
t
##iter
##s
of
antibodies
to
both
AU
##X
-
I
and
AU
##X
-
II
.
[SEP]
[CLS]
General
disorders
and
administration
site
conditions
:
chill
##s
,
p
##yre
##xia
,
ed
##ema
peripheral
,
multi
-
organ
failure
.
[SEP]
[CLS]
The
median
duration
of
exposure
was
118
days
for
patients
receiving
H
##AL
##AV
##EN
and
63
days
for
patients
receiving
control
therapy
.
[SEP]
[CLS]
In
patients
who
do
require
chronic
treatment
,
the
smallest
dose
and
the
shortest
duration
of
treatment
producing
a
satisfactory
clinical
response
should
be
sought
.
[SEP]
[CLS]
In
the
place
##bo
-
controlled
studies
,
a
total
of
48
##5
patients
with
Parkinson
'
s
disease
,
multiple
system
at
##rop
##hy
,
pure
auto
##no
##mic
failure
,
do
##pa
##mine
beta
-
h
##ydro
##xy
##lase
deficiency
,
or
non
-
di
##abe
##tic
auto
##no
##mic
[SEP]
[CLS]
ne
##uro
##pathy
were
random
##ized
and
treated
,
245
with
NO
##RT
##H
##ER
##A
and
240
with
place
##bo
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Per
##sistence
of
sin
##us
ta
##chy
##card
##ia
(
reported
at
more
than
2
visits
)
was
reported
in
0
.
2
%
,
0
.
4
%
and
1
.
6
%
of
patients
treated
with
place
##bo
,
T
##R
##U
##L
##IC
##IT
##Y
[SEP]
[CLS]
0
.
75
mg
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
,
respectively
.
[SEP]
[CLS]
5
.
6
Se
##vere
Gas
##tro
##int
##est
##inal
Disease
Use
of
T
##R
##U
##L
##IC
##IT
##Y
may
be
associated
with
gas
##tro
##int
##est
##inal
adverse
reactions
,
sometimes
severe
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
All
patients
treated
with
V
##im
##iz
##im
2
mg
/
kg
once
per
week
in
the
place
##bo
-
controlled
trial
developed
anti
-
drug
antibodies
by
Week
4
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
Re
##actions
In
a
pool
##ed
analysis
,
the
overall
incidence
of
h
##yper
##sen
##si
##ti
##vity
reactions
was
0
.
6
%
with
NE
##SI
##NA
25
mg
compared
to
0
.
8
%
with
all
com
##par
##ators
.
[SEP]
[CLS]
In
the
MS
place
##bo
controlled
trials
,
mean
l
##ymph
##oc
##yte
counts
decreased
by
approximately
30
%
during
the
first
year
of
treatment
with
T
##EC
##FI
##DE
##RA
and
then
remained
stable
.
[SEP]
[CLS]
Close
##ly
observe
patients
during
and
after
V
##im
##iz
##im
administration
and
be
prepared
to
manage
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
In
individual
clinical
trials
[
see
Clinical
Studies
(
14
)
]
,
episodes
of
h
##y
##po
##gly
##ce
##mia
occurred
at
a
higher
rate
when
IN
##VO
##KA
##NA
was
co
-
administered
with
insulin
or
su
##lf
##ony
##lu
##rea
##s
(
[SEP]
[CLS]
Table
4
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
*
A
28
-
week
,
place
##bo
-
controlled
US
study
comparing
the
safety
of
another
long
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
(
sa
##lm
##eter
##ol
)
with
place
##bo
,
each
added
to
usual
as
##th
##ma
therapy
,
[SEP]
[CLS]
showed
an
increase
in
as
##th
##ma
-
related
deaths
in
patients
receiving
sa
##lm
##eter
##ol
(
13
/
13
,
176
in
patients
treated
with
sa
##lm
##eter
##ol
vs
.
3
/
13
,
179
in
patients
treated
with
place
##bo
;
R
##R
4
.
37
,
95
%
[SEP]
[CLS]
C
##I
1
.
25
,
15
.
34
)
.
[SEP]
[CLS]
Case
##s
of
Stevens
-
Johnson
syndrome
(
S
##J
##S
)
and
T
##EN
,
some
fatal
,
have
been
reported
when
T
##RE
##AN
##DA
was
administered
con
##com
##ita
##ntly
with
all
##op
##uri
##no
##l
and
other
medications
known
to
cause
these
[SEP]
[CLS]
syndrome
##s
.
[SEP]
[CLS]
Of
these
patients
,
35
##2
p
##ediatric
patients
were
treated
with
SA
##P
##H
##RI
##S
for
at
least
180
days
and
58
p
##ediatric
patients
treated
with
SA
##P
##H
##RI
##S
had
at
least
1
year
of
exposure
[SEP]
[CLS]
.
[SEP]
[CLS]
In
clinical
trials
(
Studies
1
,
2
,
and
3
)
,
a
total
of
121
##2
patients
with
re
##lap
##sing
forms
of
multiple
s
##cle
##rosis
received
G
##IL
##EN
##Y
##A
0
.
5
mg
.
[SEP]
[CLS]
Across
controlled
and
un
##con
##tro
##lled
trials
in
patients
receiving
ad
##junct
##ive
therapy
for
partial
-
onset
seizure
##s
,
119
##5
patients
received
AP
##TI
##OM
,
of
whom
58
##6
were
treated
for
longer
than
6
months
and
[SEP]
[CLS]
46
##2
for
longer
than
12
months
.
[SEP]
[CLS]
5
.
2
Q
##T
Pro
##long
##ation
In
an
open
-
label
Q
##T
##c
study
in
patients
with
s
##chi
##zophrenia
or
s
##chi
##zo
##af
##fect
##ive
disorder
(
n
=
160
)
,
FA
##NA
##P
##T
was
associated
with
Q
##T
##c
pro
##long
##ation
of
9
m
##se
##c
at
an
[SEP]
[CLS]
il
##oper
##ido
##ne
dose
of
12
mg
twice
daily
.
[SEP]
[CLS]
No
Grade
3
or
4
AD
##R
##s
were
reported
.
[SEP]
[CLS]
(
5
.
5
)
Met
##ab
##olic
Changes
:
At
##y
##pical
anti
##psy
##cho
##tic
drugs
have
been
associated
with
metabolic
changes
that
may
increase
c
##ere
##bro
##vas
##cular
risk
.
[SEP]
[CLS]
Pat
##ients
taking
H
##OR
##I
##Z
##AN
##T
should
not
drive
until
they
have
gained
sufficient
experience
to
assess
whether
H
##OR
##I
##Z
##AN
##T
imp
##air
##s
their
ability
to
drive
.
[SEP]
[CLS]
K
##y
##p
##rol
##is
can
cause
increased
serum
trans
##ami
##nas
##es
.
[SEP]
[CLS]
Table
6
:
Ad
##verse
Re
##actions
Report
##ed
in
at
Lea
##st
10
%
of
Pat
##ients
with
RC
##C
and
at
a
Higher
Rate
in
the
A
##FI
##NI
##TO
##R
Arm
than
in
the
Place
##bo
Arm
G
##rading
[SEP]
[CLS]
according
to
CT
##CA
##E
Version
3
.
0
a
St
##oma
##titis
(
including
a
##ph
##th
##ous
s
##tom
##ati
##tis
)
,
and
tongue
ul
##cer
##ation
.
[SEP]
[CLS]
Sub
##jects
received
1
in
##hala
##tion
once
daily
of
the
following
:
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
,
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
,
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
50
m
##c
##g
/
25
m
##c
##g
,
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
,
flu
##tica
##son
##e
[SEP]
[CLS]
fur
##oat
##e
200
m
##c
##g
,
v
##ila
##nter
##ol
25
m
##c
##g
,
or
place
##bo
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
related
to
as
##th
##ma
ex
##ace
##rb
##ation
were
reported
for
2
patients
in
the
in
##da
##cate
##rol
300
m
##c
##g
group
,
3
patients
in
the
in
##da
##cate
##rol
600
m
##c
##g
group
,
and
no
[SEP]
[CLS]
patients
in
the
sa
##lm
##eter
##ol
active
control
group
.
[SEP]
[CLS]
Some
I
##g
##G
-
positive
patients
in
clinical
trials
who
were
retrospective
##ly
evaluated
for
the
presence
of
inhibitor
##y
antibodies
tested
positive
for
in
##hibition
of
enzyme
activity
and
/
or
up
##take
in
in
v
##it
##ro
ass
##ays
.
[SEP]
[CLS]
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
For
the
subgroup
of
187
patients
treated
with
sub
##cut
##aneous
K
##AL
##BI
##TO
##R
,
5
patients
(
3
%
)
experienced
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
K
##AL
##BI
##TO
##R
should
not
be
administered
to
any
patients
with
known
clinical
h
##yper
##sen
##si
##ti
##vity
to
K
##AL
##BI
##TO
##R
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
(
5
.
1
)
*
Eye
irritation
:
A
##vo
##id
eye
exposure
.
[SEP]
[CLS]
Li
##pid
##s
El
##eva
##tions
in
fast
##ing
serum
total
ch
##ole
##ster
##ol
occurred
in
the
controlled
studies
.
[SEP]
[CLS]
Monitor
re
##nal
function
periodically
.
[SEP]
[CLS]
5
.
2
In
##fusion
-
Re
##lated
Re
##actions
D
##AL
##VA
##NC
##E
is
administered
via
in
##tra
##ven
##ous
in
##fusion
,
using
a
total
in
##fusion
time
of
30
minutes
to
minimize
the
risk
of
in
##fusion
-
related
reactions
.
[SEP]
[CLS]
During
the
initial
phase
of
combination
anti
##ret
##rov
##ira
##l
treatment
,
patients
whose
immune
system
responds
may
develop
an
inflammatory
response
to
in
##do
##lent
or
residual
op
##port
##uni
##stic
infections
[
such
as
[SEP]
[CLS]
My
##co
##ba
##cter
##ium
a
##vi
##um
infection
,
c
##yt
##ome
##gal
##ov
##ir
##us
,
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
##i
pneumonia
(
PC
##P
)
,
or
tuberculosis
]
,
which
may
ne
##cess
##itate
further
evaluation
and
treatment
.
[SEP]
[CLS]
In
##vasive
Fun
##gal
In
##fect
##ions
For
patients
who
reside
or
travel
in
regions
where
my
##cos
##es
are
endemic
,
invasive
fun
##gal
infection
should
be
suspected
if
they
develop
a
serious
systemic
illness
.
[SEP]
[CLS]
*
Disco
##ntin
##ue
S
##IM
##PO
##NI
ARIA
if
a
patient
develops
a
serious
infection
or
se
##psis
(
5
.
1
)
.
[SEP]
[CLS]
5
.
7
H
##y
##po
##kal
##emia
and
H
##y
##po
##ma
##gne
##se
##mia
with
Po
##tas
##sium
-
De
##ple
##ting
Di
##ure
##tics
H
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
may
occur
with
con
##com
##ita
##nt
administration
of
potassium
-
de
##ple
##ting
di
##ure
##tics
.
[SEP]
[CLS]
Anti
##gen
and
anti
##body
testing
for
his
##top
##las
##mos
##is
may
be
negative
in
some
patients
with
active
infection
.
[SEP]
[CLS]
Do
not
give
D
##U
##AV
##EE
to
other
people
,
even
if
they
have
the
same
symptoms
you
have
.
[SEP]
[CLS]
Other
important
serious
adverse
reactions
reported
include
PM
##L
,
Stevens
-
Johnson
syndrome
,
and
tumor
l
##ys
##is
syndrome
.
[SEP]
[CLS]
In
a
3
-
week
,
bi
##pol
##ar
man
##ia
p
##ediatric
trial
,
s
##ync
##ope
was
reported
in
1
%
(
1
/
104
)
of
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
,
1
%
[SEP]
[CLS]
(
1
/
99
)
of
patients
treated
with
SA
##P
##H
##RI
##S
5
mg
twice
daily
,
and
0
%
(
0
/
99
)
for
patients
treated
with
SA
##P
##H
##RI
##S
10
mg
twice
daily
compared
to
[SEP]
[CLS]
0
%
(
0
/
101
)
for
patients
treated
with
place
##bo
.
[SEP]
[CLS]
MA
##L
##IG
##NA
##NC
##Y
L
##ymph
##oma
and
other
ma
##li
##gna
##ncies
,
some
fatal
,
have
been
reported
in
children
and
adolescent
patients
treated
with
T
##NF
block
##ers
,
of
which
C
##IM
##Z
##IA
is
a
member
[
see
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
What
can
I
do
to
lower
my
chances
of
a
serious
side
effect
with
D
##U
##AV
##EE
?
[SEP]
[CLS]
Pre
##s
##cribe
##rs
and
patients
should
be
alert
for
signs
and
symptoms
of
pro
##static
h
##yper
##p
##lasia
or
bladder
-
neck
o
##bs
##truction
(
e
.
g
.
,
difficulty
passing
urine
,
painful
u
##rina
##tion
)
.
[SEP]
[CLS]
T
##rea
##t
patients
with
re
##hy
##dra
##tion
,
anti
-
di
##ar
##r
##hea
##l
or
anti
-
em
##etic
medications
as
needed
.
[SEP]
[CLS]
The
trans
##fusion
rate
was
4
%
in
subjects
random
##ized
to
receive
rib
##avi
##rin
dose
reduction
and
2
%
in
subjects
random
##ized
to
receive
E
##SA
.
[SEP]
[CLS]
If
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
are
permanently
discontinued
,
then
VI
##CT
##RE
##L
##IS
must
also
be
discontinued
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Em
##pi
##ric
anti
-
fun
##gal
therapy
should
be
considered
in
patients
at
risk
for
invasive
fun
##gal
infections
who
develop
severe
systemic
illness
.
[SEP]
[CLS]
Stop
S
##IM
##PO
##NI
ARIA
if
new
or
worse
##ning
symptoms
occur
(
5
.
3
)
.
[SEP]
[CLS]
The
following
serious
adverse
reactions
are
described
below
and
elsewhere
in
the
label
##ing
:
*
Ana
##phy
##lax
##is
and
h
##yper
##sen
##si
##ti
##vity
reactions
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
has
occurred
in
patients
with
impaired
elimination
of
GB
##CA
##s
.
[SEP]
[CLS]
Consider
the
potential
for
drug
interactions
prior
to
and
during
ST
##RI
##BI
##LD
therapy
;
review
con
##com
##ita
##nt
medications
during
ST
##RI
##BI
##LD
therapy
;
and
monitor
for
the
adverse
reactions
associated
with
the
con
##com
##ita
##nt
[SEP]
[CLS]
drugs
.
[SEP]
[CLS]
5
.
8
I
##mm
##une
Re
##con
##st
##itution
S
##yn
##drome
I
##mm
##une
re
##con
##st
##itution
syndrome
has
been
reported
in
patients
treated
with
combination
anti
##ret
##rov
##ira
##l
therapy
,
including
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
In
one
case
,
insufficient
information
was
obtained
to
establish
or
re
##fu
##te
a
drug
-
related
ca
##usal
##ity
.
[SEP]
[CLS]
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
E
##L
##I
##Q
##UI
##S
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
:
Pre
##mat
##ure
disco
##ntin
##uation
of
any
oral
anti
##coa
##gu
##lant
,
including
E
##L
##I
##Q
##UI
##S
,
increases
the
risk
of
[SEP]
[CLS]
th
##rom
##bot
##ic
events
.
[SEP]
[CLS]
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
require
immediate
disco
##ntin
##uation
of
the
J
##E
##V
##TA
##NA
in
##fusion
and
administration
of
appropriate
therapy
.
[SEP]
[CLS]
5
.
1
Per
##ip
##her
##al
N
##eur
##op
##athy
AD
##CE
##TR
##IS
treatment
causes
a
peripheral
ne
##uro
##pathy
.
[SEP]
[CLS]
The
most
commonly
reported
adverse
reactions
associated
with
IL
##AR
##IS
treatment
in
the
CA
##PS
patients
were
na
##so
##pha
##ryn
##git
##is
,
di
##ar
##r
##hea
,
in
##fluenza
,
headache
,
and
nausea
.
[SEP]
[CLS]
Cy
##tom
##eg
##alo
##virus
and
p
##ne
##um
##oc
##ys
##tis
prop
##hyl
##ax
##is
are
recommended
after
transplant
##ation
.
[SEP]
[CLS]
No
additional
post
##market
##ing
adverse
reactions
specific
for
em
##tric
##ita
##bine
have
been
identified
.
[SEP]
[CLS]
Table
5
lists
adverse
reactions
occurring
in
1
%
or
greater
of
patients
receiving
Z
##ER
##BA
##X
##A
in
Phase
3
clinical
trials
.
[SEP]
[CLS]
The
observed
incidence
of
anti
##body
p
##os
##iti
##vity
in
an
ass
##ay
is
highly
dependent
on
several
factors
,
including
ass
##ay
sensitivity
and
specific
##ity
,
ass
##ay
methodology
,
sample
handling
,
timing
of
[SEP]
[CLS]
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
Pat
##ients
or
care
##gi
##vers
should
be
advised
to
seek
immediate
medical
care
if
swallowing
,
speech
,
or
respiratory
disorders
occur
.
[SEP]
[CLS]
Clinical
manifest
##ations
include
h
##yper
##py
##re
##xia
,
muscle
rigid
##ity
,
altered
mental
status
(
including
cat
##aton
##ic
signs
)
and
evidence
of
auto
##no
##mic
instability
(
irregular
pulse
,
ta
##chy
##card
##ia
,
di
##aph
##ores
##is
,
and
[SEP]
[CLS]
cardiac
d
##ys
##r
##hy
##th
##mia
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
associated
with
disco
##ntin
##uation
in
patients
treated
with
SA
##P
##H
##RI
##S
(
rates
at
least
1
%
and
at
least
twice
the
place
##bo
rate
)
were
anxiety
(
[SEP]
[CLS]
1
.
1
%
)
and
oral
h
##y
##po
##est
##hesia
(
1
.
1
%
)
compared
to
place
##bo
(
0
%
)
.
[SEP]
[CLS]
Pat
##ients
in
the
X
##AL
##KO
##RI
arm
(
n
=
172
)
received
X
##AL
##KO
##RI
250
mg
oral
##ly
twice
daily
until
documented
disease
progression
,
into
##ler
##ance
to
therapy
,
or
the
investigator
determined
that
the
[SEP]
[CLS]
patient
was
no
longer
experiencing
clinical
benefit
.
[SEP]
[CLS]
Mean
changes
(
percent
changes
)
from
base
##line
in
L
##D
##L
-
C
relative
to
place
##bo
were
4
.
4
mg
/
d
##L
(
4
.
5
%
)
and
8
.
2
mg
/
d
##L
(
8
.
0
%
)
with
IN
##VO
##KA
##NA
100
[SEP]
[CLS]
mg
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
The
relationship
to
T
##RE
##AN
##DA
can
not
be
determined
.
[SEP]
[CLS]
Across
the
340
patients
who
were
treated
in
Study
1
,
the
median
age
was
53
years
;
16
%
of
patients
were
older
than
65
years
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
have
occurred
in
patients
treated
with
K
##AL
##BI
##TO
##R
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
Anti
-
drug
anti
##body
t
##iter
##s
were
sustained
or
increased
for
the
duration
of
V
##im
##iz
##im
treatment
.
[SEP]
[CLS]
*
Cy
##top
##enia
##s
:
Check
complete
blood
counts
monthly
(
5
.
3
)
.
[SEP]
[CLS]
A
grade
of
0
represented
no
reaction
present
in
the
treated
area
,
and
a
grade
of
4
indicated
a
marked
and
severe
skin
reaction
that
extended
beyond
the
treated
[SEP]
[CLS]
area
.
[SEP]
[CLS]
Se
##vere
pen
##ile
hem
##ato
##ma
was
also
reported
as
an
adverse
reaction
in
39
of
104
##4
(
3
.
7
%
)
XI
##AF
##LE
##X
-
treated
patients
(
5
.
2
)
.
[SEP]
[CLS]
While
these
events
are
generally
self
-
limiting
,
there
have
been
reports
of
serious
disco
##ntin
##uation
symptoms
.
[SEP]
[CLS]
Case
##s
of
skin
lace
##ration
requiring
skin
g
##raft
after
finger
extension
procedures
have
been
reported
post
-
marketing
.
[SEP]
[CLS]
Table
1
:
Selected
Ad
##verse
Re
##actions
in
Study
1
a
Inc
##iden
##ces
presented
in
this
table
are
based
on
reports
of
adverse
events
regardless
of
ca
##usal
##ity
.
[SEP]
[CLS]
However
,
the
development
of
neutral
##izing
antibodies
may
be
under
##re
##port
##ed
due
to
lack
of
ass
##ay
sensitivity
.
[SEP]
[CLS]
The
population
in
these
studies
was
48
%
white
,
13
%
African
/
African
American
,
7
%
Asian
,
and
29
%
Hispanic
/
Latino
.
[SEP]
[CLS]
b
Includes
the
terms
injection
site
ha
##em
##or
##r
##hage
,
injection
site
irritation
,
and
injection
site
pain
.
[SEP]
[CLS]
As
appropriate
,
administer
prop
##hyl
##actic
anti
##biotics
and
employ
surveillance
testing
during
treatment
with
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
In
those
diseases
causing
thin
##ning
of
the
corn
##ea
or
s
##cle
##ra
,
per
##fo
##rations
have
been
known
to
occur
with
the
use
of
topic
##al
s
##tero
##ids
.
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
has
not
been
evaluated
in
patients
with
a
prior
history
of
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
Table
2
reports
the
most
common
adverse
reactions
occurring
in
at
least
10
%
of
patients
in
either
group
.
[SEP]
[CLS]
Most
adverse
reactions
were
local
events
of
the
penis
and
the
majority
of
these
events
were
of
mild
or
moderate
severity
,
and
most
(
79
%
)
resolved
within
[SEP]
[CLS]
14
days
of
the
injection
.
[SEP]
[CLS]
In
the
Du
##pu
##yt
##ren
'
s
contract
##ure
clinical
studies
(
Studies
1
and
2
)
,
at
30
days
post
the
first
injection
of
XI
##AF
##LE
##X
0
.
58
mg
,
92
%
of
patients
[SEP]
[CLS]
had
antibodies
against
AU
##X
-
I
detected
and
86
%
of
patients
had
antibodies
against
AU
##X
-
II
detected
.
[SEP]
[CLS]
Clinical
correlation
,
including
his
##top
##ath
##ological
evaluation
of
the
suspected
re
##cu
##rrence
site
,
is
essential
to
proper
use
of
the
P
##ET
imaging
information
.
[SEP]
[CLS]
Monitor
fast
##ing
glucose
prior
to
treatment
and
periodically
thereafter
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Inter
##rup
##t
and
then
reduce
or
disco
##ntin
##ue
Z
##yd
##eli
##g
.
[SEP]
[CLS]
Ser
##um
chemistry
abnormal
##ities
AL
##T
increased
73
(
50
)
20
(
14
)
7
(
5
)
AS
##T
increased
60
(
41
)
12
(
8
)
6
(
4
[SEP]
[CLS]
)
He
##mat
##ology
abnormal
##ities
ne
##ut
##rop
##hil
##s
decreased
78
(
53
)
20
(
14
)
16
(
11
)
hem
##og
##lo
##bin
decreased
41
(
28
)
3
(
2
)
0
[SEP]
[CLS]
plate
##lets
decreased
38
(
26
)
4
(
3
)
5
(
3
)
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
FA
##TA
##L
AND
SE
##RI
##O
##US
TO
##X
##IC
##IT
##IE
##S
,
SE
##VE
##RE
D
##IA
##R
##R
##H
##EA
,
CO
##L
##IT
##IS
,
[SEP]
[CLS]
P
##NE
##UM
##ON
##IT
##IS
,
and
IN
##TE
##ST
##IN
##AL
P
##ER
##F
##OR
##AT
##ION
WA
##R
##NI
##NG
:
FA
##TA
##L
AND
SE
##RI
##O
##US
TO
##X
##IC
##IT
##IE
##S
,
SE
##VE
##RE
D
##IA
##R
##R
##H
##EA
,
CO
##L
##IT
##IS
,
P
##NE
##UM
##ON
##IT
##IS
,
and
IN
##TE
##ST
##IN
##AL
P
##ER
##F
##OR
##AT
##ION
*
Fat
##al
and
/
or
serious
he
##pa
##to
##to
##xi
##city
occurred
in
14
[SEP]
[CLS]
%
of
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
An
analyses
of
ad
##ju
##dicated
events
revealed
5
cases
of
confirmed
pan
##cre
##ati
##tis
in
patients
exposed
to
T
##R
##U
##L
##IC
##IT
##Y
(
1
.
4
cases
per
1000
patient
years
)
versus
1
case
in
non
-
in
##cre
##tin
com
##par
##ators
[SEP]
[CLS]
(
0
.
88
cases
per
1000
patient
years
)
.
[SEP]
[CLS]
Del
##ay
##ed
Ad
##re
##V
##ie
##w
clearance
may
also
reduce
the
target
to
background
ratios
and
decrease
the
quality
of
s
##cin
##ti
##graphic
images
.
[SEP]
[CLS]
Brent
##ux
##ima
##b
ve
##do
##tin
caused
em
##b
##ryo
-
f
##etal
toxic
##ities
,
including
significantly
decreased
em
##b
##ryo
via
##bility
and
f
##etal
ma
##lf
##orm
##ations
,
in
animals
at
maternal
exposure
##s
that
were
similar
to
human
exposure
##s
at
the
recommended
doses
[SEP]
[CLS]
for
patients
with
classical
H
##L
and
s
##AL
##CL
.
[SEP]
[CLS]
Del
##ay
administration
of
H
##AL
##AV
##EN
and
reduce
subsequent
doses
in
patients
who
experience
f
##eb
##ril
##e
ne
##ut
##rop
##enia
or
Grade
4
ne
##ut
##rop
##enia
lasting
longer
than
7
days
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
How
the
dose
,
route
,
and
duration
of
co
##rt
##ico
##ster
##oid
administration
affect
the
risk
of
developing
a
di
##sse
##minated
infection
is
not
known
.
[SEP]
[CLS]
Consider
an
alternate
con
##tra
##ceptive
method
for
women
with
un
##con
##tro
##lled
d
##ys
##lip
##ide
##mia
.
[SEP]
[CLS]
Therefore
,
XI
##AF
##LE
##X
should
be
injected
only
into
the
co
##lla
##gen
cord
with
a
MP
or
P
##IP
joint
contract
##ure
,
and
care
should
be
taken
to
avoid
in
##ject
##ing
into
tend
##ons
,
[SEP]
[CLS]
nerves
,
blood
vessels
,
or
other
co
##lla
##gen
-
containing
structures
of
the
hand
.
[SEP]
[CLS]
Subsequently
,
the
physician
may
continue
decreasing
the
dose
,
but
at
a
more
gradual
rate
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
for
h
##yper
##tensive
crisis
.
[SEP]
[CLS]
On
electro
##card
##io
##gram
##s
,
a
PR
interval
increase
to
at
least
220
mill
##ise
##con
##ds
was
observed
in
0
.
7
%
,
2
.
5
%
and
3
.
2
%
of
patients
treated
with
place
##bo
,
T
##R
##U
##L
##IC
##IT
##Y
[SEP]
[CLS]
0
.
75
mg
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
,
respectively
.
[SEP]
[CLS]
This
ass
##ay
has
substantial
limitations
in
detect
##ing
anti
-
i
##pi
##lim
##uma
##b
antibodies
in
the
presence
of
i
##pi
##lim
##uma
##b
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
Control
##led
Trials
The
data
in
Table
1
are
derived
from
4
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
F
##U
##L
##Y
##Z
##A
##Q
is
not
indicated
for
the
treatment
of
infectious
di
##ar
##r
##hea
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
be
##lat
##ace
##pt
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Pat
##ients
in
the
study
received
a
median
of
4
doses
(
range
:
1
-
4
doses
)
.
[SEP]
[CLS]
Sign
##s
and
symptoms
have
included
difficulty
breathing
,
u
##rt
##ica
##ria
,
and
swelling
of
the
throat
.
[SEP]
[CLS]
Table
5
:
Change
in
Body
Weight
in
Adult
Pat
##ients
from
Basel
##ine
N
*
=
Number
of
subjects
who
had
assessments
at
both
Basel
##ine
and
End
##point
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
after
in
##iti
##ating
therapy
.
[SEP]
[CLS]
In
the
pool
##ed
analysis
of
8
controlled
trials
,
p
##him
##osis
was
reported
in
0
.
3
%
of
un
##ci
##rc
##um
##cise
##d
male
patients
treated
with
IN
##VO
##KA
##NA
and
0
.
2
%
required
c
##ir
##cum
##cision
to
treat
the
[SEP]
[CLS]
p
##him
##osis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
Female
patients
who
developed
g
##eni
##tal
my
##cot
##ic
infections
on
IN
##VO
##KA
##NA
were
more
likely
to
experience
re
##cu
##rrence
and
require
treatment
with
oral
or
topic
##al
anti
##fu
##nga
##l
agents
and
anti
-
micro
##bial
agents
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IR
##TU
##RO
if
significant
vent
##ric
##ular
a
##rr
##hy
##th
##mia
or
Q
##T
##c
##F
interval
>
500
m
##s
develops
.
[SEP]
[CLS]
There
is
a
risk
for
transmission
of
C
##re
##utz
##feld
##t
-
Jakob
disease
(
C
##J
##D
)
however
,
no
cases
of
transmission
of
viral
diseases
or
C
##J
##D
have
ever
been
identified
for
album
##in
(
[SEP]
[CLS]
5
.
6
)
5
.
1
Lac
##k
of
Inter
##chang
##ea
##bility
between
Bo
##tu
##lin
##um
To
##xin
Products
The
pot
##ency
Units
of
D
##Y
##SP
##OR
##T
(
r
)
are
specific
to
the
preparation
and
ass
##ay
method
utilized
.
[SEP]
[CLS]
and
un
##tre
##ated
or
inadequate
##ly
treated
extra
##py
##ram
##idal
signs
and
symptoms
(
EP
##S
)
.
[SEP]
[CLS]
The
other
patient
developed
probable
PM
##L
after
taking
G
##IL
##EN
##Y
##A
for
approximately
4
years
.
[SEP]
[CLS]
The
early
diagnosis
of
this
condition
is
important
for
the
appropriate
management
of
these
patients
.
[SEP]
[CLS]
If
an
an
##aph
##yla
##ctic
reaction
to
Z
##ER
##BA
##X
##A
occurs
,
disco
##ntin
##ue
the
drug
and
institute
appropriate
therapy
.
[SEP]
[CLS]
Del
##ay
##ed
-
onset
reactions
,
defined
as
adverse
reactions
occurring
2
-
48
hours
after
completion
of
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
,
that
were
observed
in
>
=
3
%
more
patients
in
[SEP]
[CLS]
the
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
group
compared
to
patients
in
the
place
##bo
-
treated
group
in
the
controlled
trial
,
included
h
##yper
##hi
##dr
##osis
.
[SEP]
[CLS]
The
events
were
reported
in
less
than
1
%
of
subjects
receiving
T
##I
##VI
##CA
##Y
in
Phase
3
clinical
trials
.
[SEP]
[CLS]
The
causes
of
death
varied
and
included
complications
of
infection
,
surgery
and
underlying
conditions
.
[SEP]
[CLS]
The
average
age
was
53
years
(
range
from
0
.
1
to
97
years
)
.
[SEP]
[CLS]
H
##y
##po
##kal
##emia
(
and
/
or
h
##y
##po
##ma
##gne
##se
##mia
)
may
increase
the
risk
of
Q
##T
pro
##long
##ation
and
a
##rr
##hy
##th
##mia
.
[SEP]
[CLS]
With
##hold
tram
##eti
##ni
##b
if
R
##P
##ED
is
diagnosed
.
[SEP]
[CLS]
Mortal
##ity
related
to
di
##ar
##r
##hea
has
been
reported
.
[SEP]
[CLS]
Physicians
pre
##s
##cribing
D
##IF
##IC
##ID
to
patients
with
a
known
mac
##rol
##ide
all
##er
##gy
should
be
aware
of
the
possibility
of
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
(
5
.
3
)
*
Use
in
children
:
U
##LE
##SF
##IA
(
r
)
Lot
##ion
should
only
be
used
on
children
under
the
direct
supervision
of
an
adult
.
[SEP]
[CLS]
*
He
##mat
##olo
##gic
toxic
##ities
:
Monitor
complete
blood
counts
prior
to
each
dose
of
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
5
.
6
Re
##bound
H
##yper
##tens
##ion
Pat
##ients
who
receive
prolonged
C
##lev
##ip
##re
##x
in
##fusion
##s
and
are
not
transitioned
to
other
anti
##hy
##pert
##ens
##ive
the
##rap
##ies
should
be
monitored
for
the
possibility
of
re
##bound
h
##yper
##tens
##ion
for
at
least
8
[SEP]
[CLS]
hours
after
the
in
##fusion
is
stopped
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
drug
reactions
were
infections
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rate
observed
in
clinical
practice
.
[SEP]
[CLS]
Development
of
card
##io
##my
##op
##athy
resolved
in
all
five
patients
following
dose
reduction
(
4
/
55
)
and
/
or
dose
interrupt
##ion
(
1
/
55
)
.
[SEP]
[CLS]
Disco
##ntin
##ue
SA
##P
##H
##RI
##S
in
patients
with
severe
ne
##ut
##rop
##enia
(
absolute
ne
##ut
##rop
##hil
count
<
1000
/
mm
3
)
and
follow
their
W
##BC
until
recovery
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
for
example
,
age
>
60
years
,
h
##yper
##tens
##ion
or
diabetes
)
,
estimate
the
g
##lo
##mer
##ular
fi
##ltration
rate
(
G
##F
##R
[SEP]
[CLS]
)
through
laboratory
testing
.
[SEP]
[CLS]
Re
##fer
to
the
pre
##s
##cribing
information
for
rib
##avi
##rin
and
p
##eg
##int
##er
##fer
##on
al
##fa
for
guidelines
for
disco
##ntin
##uation
of
therapy
based
on
laboratory
parameters
.
[SEP]
[CLS]
Abd
##omi
##nal
pain
and
tender
##ness
,
fever
,
persistent
con
##st
##ip
##ation
,
di
##ar
##r
##hea
,
with
or
without
ne
##ut
##rop
##enia
,
may
be
early
manifest
##ations
of
serious
gas
##tro
##int
##est
##inal
toxicity
and
should
be
evaluated
and
[SEP]
[CLS]
treated
promptly
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
Report
##ed
by
Greater
Than
or
Equal
to
2
%
of
Pat
##ients
T
##reate
##d
With
ST
##EN
##DR
##A
in
an
Open
-
Label
Extension
Trial
Ad
##verse
Re
##action
ST
##EN
##DR
##A
(
N
=
[SEP]
[CLS]
71
##1
)
Head
##ache
5
.
6
%
F
##lus
##hing
3
.
5
%
Na
##so
##pha
##ryn
##git
##is
3
.
4
%
Na
##sal
congestion
2
.
1
%
Ad
##verse
reactions
reported
by
greater
than
or
equal
to
1
%
,
but
less
than
[SEP]
[CLS]
2
%
of
patients
in
the
open
-
label
extension
study
included
:
upper
respiratory
infection
(
U
##RI
)
,
in
##fluenza
,
sin
##us
##itis
,
br
##on
##chi
##tis
,
di
##zzi
##ness
,
back
pain
,
[SEP]
[CLS]
art
##hra
##l
##gia
,
h
##yper
##tens
##ion
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
Disco
##ntin
##ue
PR
##OM
##AC
##TA
if
anti
##vir
##al
therapy
is
discontinued
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
In
Studies
1
and
2
,
serious
adverse
reactions
,
regardless
of
ca
##usal
##ity
,
were
reported
in
31
%
of
patients
receiving
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
Pat
##ients
should
be
instructed
to
report
any
symptoms
suggest
##ive
of
end
##op
##ht
##hal
##mit
##is
or
re
##tina
##l
detachment
without
delay
and
should
be
managed
appropriately
[
see
##D
##osa
##ge
and
Administration
(
2
.
7
)
and
##P
##ati
##ent
Counsel
##ing
[SEP]
[CLS]
Information
(
17
)
]
.
[SEP]
[CLS]
Disco
##ntin
##ue
X
##AL
##KO
##RI
in
patients
with
new
onset
of
severe
visual
loss
(
best
corrected
vision
less
than
20
/
200
in
one
or
both
eyes
)
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##ders
:
H
##yper
##sen
##si
##ti
##vity
manifest
##ing
as
bull
##ous
r
##ash
.
[SEP]
[CLS]
Assessment
of
B
##MD
should
be
considered
for
HIV
-
1
infected
patients
who
have
a
history
of
path
##olo
##gic
bone
fracture
or
other
risk
factors
for
o
##ste
##op
##oro
##sis
or
bone
loss
.
[SEP]
[CLS]
Care
##ful
medical
history
is
necessary
because
CD
##AD
has
been
reported
to
occur
more
than
2
months
after
the
administration
of
anti
##ba
##cter
##ial
agents
.
[SEP]
[CLS]
There
is
no
established
way
to
reverse
the
anti
##coa
##gu
##lant
effect
of
a
##pi
##xa
##ban
,
which
can
be
expected
to
per
##sist
for
at
least
24
hours
after
the
last
dose
,
i
.
e
.
[SEP]
[CLS]
,
for
about
two
drug
half
-
lives
.
[SEP]
[CLS]
AT
##Es
are
defined
as
non
##fa
##tal
stroke
,
non
##fa
##tal
my
##oc
##ard
##ial
in
##far
##ction
,
or
vascular
death
(
including
deaths
of
unknown
cause
)
.
[SEP]
[CLS]
El
##ec
##tro
##card
##io
##gram
(
EC
##G
)
measurements
were
taken
at
various
time
points
during
the
SA
##P
##H
##RI
##S
clinical
trial
program
(
5
mg
or
10
mg
twice
daily
doses
)
.
[SEP]
[CLS]
Pro
##per
as
##ept
##ic
injection
technique
must
always
be
used
when
administer
##ing
E
##Y
##LE
##A
.
[SEP]
[CLS]
Table
5
presents
adverse
reactions
from
Trial
2
,
a
multi
##cent
##er
,
open
-
label
,
random
##ized
trial
of
162
patients
with
BR
##AF
V
##60
##0
##E
or
V
##60
##0
##K
mutation
-
positive
me
##lan
##oma
receiving
T
##AF
##IN
##LA
##R
150
mg
[SEP]
[CLS]
twice
daily
in
combination
with
tram
##eti
##ni
##b
2
mg
oral
##ly
once
daily
(
n
=
55
)
,
T
##AF
##IN
##LA
##R
150
mg
oral
##ly
twice
daily
in
combination
with
tram
##eti
##ni
##b
1
mg
once
[SEP]
[CLS]
daily
(
n
=
54
)
,
and
T
##AF
##IN
##LA
##R
as
a
single
agent
150
mg
oral
##ly
twice
daily
(
n
=
53
)
[
see
Clinical
Studies
(
14
.
2
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
*
If
you
have
high
blood
pressure
,
high
ch
##ole
##ster
##ol
(
fat
in
the
blood
)
,
diabetes
,
are
over
##weight
,
or
if
you
use
tobacco
,
you
may
[SEP]
[CLS]
have
higher
chances
of
getting
heart
disease
.
[SEP]
[CLS]
5
.
2
He
##pa
##to
##to
##xi
##city
PR
##OM
##AC
##TA
can
cause
liver
enzyme
elevations
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
total
,
53
##6
(
approximately
75
%
)
patients
increased
their
dose
to
200
mg
and
5
(
less
than
1
%
)
patients
reduced
their
dose
to
50
[SEP]
[CLS]
mg
.
Table
2
presents
the
adverse
reactions
reported
when
ST
##EN
##DR
##A
was
taken
as
recommended
(
on
an
as
-
needed
basis
)
in
this
open
-
label
extension
trial
.
[SEP]
[CLS]
Monitor
patients
with
clinical
##ly
significant
ne
##ut
##rop
##enia
for
fever
or
other
symptoms
or
signs
of
infection
and
treat
promptly
if
such
symptoms
or
signs
occur
.
[SEP]
[CLS]
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
E
##O
##VI
##ST
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
from
the
body
[SEP]
[CLS]
prior
to
any
re
-
administration
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
Inc
##reased
su
##s
##ce
##pt
##ibility
to
infection
and
the
possible
development
of
ma
##li
##gna
##ncies
may
result
from
im
##mu
##nos
##up
##press
##ion
.
[SEP]
[CLS]
Across
clinical
trials
of
T
##AF
##IN
##LA
##R
administered
in
combination
with
tram
##eti
##ni
##b
(
N
=
202
)
,
8
%
of
patients
developed
evidence
of
card
##io
##my
##op
##athy
(
decrease
in
L
##VE
##F
below
institutional
[SEP]
[CLS]
lower
limits
of
normal
with
an
absolute
decrease
in
L
##VE
##F
>
=
10
%
below
base
##line
)
.
[SEP]
[CLS]
In
the
AM
##PL
##IF
##Y
study
,
E
##L
##I
##Q
##UI
##S
was
statistical
##ly
superior
to
en
##ox
##apa
##rin
/
war
##fari
##n
in
the
primary
safety
end
##point
of
major
bleeding
(
relative
risk
0
.
31
,
95
%
C
##I
[
0
.
17
,
[SEP]
[CLS]
0
.
55
]
,
P
-
value
<
0
.
000
##1
)
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Pi
##rama
##l
at
1
-
85
##5
-
54
##5
-
52
##45
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
One
(
n
=
122
)
or
2
(
n
=
18
)
doses
of
V
##OR
##A
##X
##A
##Z
##E
were
administered
in
##tra
##ven
##ously
;
the
number
of
doses
was
not
specified
for
1
patient
.
[SEP]
[CLS]
Close
##ly
monitor
patients
for
fever
.
[SEP]
[CLS]
Keep
out
of
reach
of
children
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
and
all
##ergic
contact
der
##mat
##itis
,
have
been
reported
post
-
marketing
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
FA
##NA
##P
##T
should
be
avoided
in
patients
with
histories
of
significant
card
##iovascular
illness
,
e
.
g
.
,
Q
##T
pro
##long
##ation
,
recent
acute
my
##oc
##ard
##ial
in
##far
##ction
,
un
##com
##pen
##sat
##ed
heart
failure
,
or
cardiac
a
##rr
##hy
##th
##mia
[SEP]
[CLS]
.
[SEP]
[CLS]
These
findings
were
consistent
with
data
from
an
earlier
144
-
week
trial
of
treatment
-
naive
subjects
receiving
ten
##of
##ov
##ir
D
##F
+
la
##mi
##vu
##dine
+
e
##fa
##vir
##en
##z
.
[SEP]
[CLS]
Ad
##verse
reactions
similar
in
nature
and
frequency
were
observed
to
those
seen
in
the
controlled
phase
of
the
trials
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Mortal
##ity
:
There
were
more
deaths
reported
with
B
##EN
##L
##Y
##ST
##A
than
with
place
##bo
during
the
controlled
period
of
clinical
trials
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
S
##UP
##IN
##E
H
##YP
##ER
##TE
##NS
##ION
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Additional
h
##yper
##sen
##si
##ti
##vity
reactions
observed
in
infant
##ile
-
onset
Po
##mp
##e
disease
patients
treated
in
other
clinical
trials
and
expanded
access
programs
with
al
##g
##lu
##cos
##idas
##e
al
##fa
included
lived
##o
re
##tic
##ular
##is
,
i
##rri
##ta
##bility
,
re
##tch
##ing
,
[SEP]
[CLS]
increased
la
##c
##rima
##tion
,
vent
##ric
##ular
extra
##sy
##sto
##les
,
nod
##al
rhythm
,
r
##ales
,
respiratory
tract
irritation
,
and
cold
sweat
.
[SEP]
[CLS]
5
.
3
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
Di
##ar
##r
##hea
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
for
nearly
all
systemic
anti
##ba
##cter
##ial
agents
,
including
Z
##ER
##BA
##X
##A
,
and
may
range
in
severity
[SEP]
[CLS]
from
mild
di
##ar
##r
##hea
to
fatal
co
##lit
##is
.
[SEP]
[CLS]
Additional
delayed
-
onset
reactions
occurring
in
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patients
included
fatigue
,
my
##al
##gia
,
and
nausea
.
[SEP]
[CLS]
Monitor
glucose
regularly
in
patients
at
risk
for
diabetes
.
[SEP]
[CLS]
In
both
indication
##s
,
about
25
%
of
the
subjects
were
65
years
of
age
or
older
.
[SEP]
[CLS]
Consider
u
##ric
acid
lowering
drugs
in
patients
at
risk
for
T
##LS
.
[SEP]
[CLS]
*
Do
not
take
additional
est
##rogen
products
while
you
are
taking
D
##U
##AV
##EE
.
[SEP]
[CLS]
*
Using
est
##rogen
##s
may
increase
your
chances
of
getting
strokes
or
blood
c
##lot
##s
.
[SEP]
[CLS]
E
##stro
##gens
should
be
prescribed
at
the
lowest
effective
doses
and
for
the
shortest
duration
consistent
with
treatment
goals
and
risks
for
the
individual
woman
.
[SEP]
[CLS]
Two
patients
died
of
her
##pet
##ic
infections
during
controlled
trials
.
[SEP]
[CLS]
The
patient
should
be
carefully
monitored
,
since
re
##cu
##rrence
##s
of
N
##MS
have
been
reported
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
D
##AL
##VA
##NC
##E
can
not
be
directly
compared
to
rates
in
[SEP]
[CLS]
the
clinical
trials
of
another
drug
and
may
not
reflect
rates
observed
in
practice
.
[SEP]
[CLS]
Table
1
sum
##mar
##izes
all
adverse
reactions
,
regardless
of
ca
##usal
##ity
,
occurring
in
>
=
1
%
of
patients
with
post
##her
##pet
##ic
neural
##gia
in
the
Q
##ute
##nza
group
for
which
the
incidence
[SEP]
[CLS]
was
greater
than
in
the
control
group
.
[SEP]
[CLS]
X
##AL
##KO
##RI
was
discontinued
for
adverse
reactions
in
15
%
of
patients
.
[SEP]
[CLS]
5
.
2
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
IN
##VO
##KA
##NA
increases
serum
c
##rea
##tin
##ine
and
decreases
e
##G
##F
##R
.
[SEP]
[CLS]
Since
patients
with
CO
##PD
often
have
multiple
risk
factors
for
reduced
B
##MD
,
assessment
of
B
##MD
is
recommended
prior
to
in
##iti
##ating
BR
##E
##O
E
##LL
##IP
##TA
and
periodically
thereafter
.
[SEP]
[CLS]
(
5
.
3
)
*
N
##eur
##ops
##ych
##ia
##tric
symptoms
:
Monitor
for
confusion
##al
state
,
ps
##ych
##otic
symptoms
,
and
hall
##uc
##ination
##s
.
[SEP]
[CLS]
5
.
8
Se
##iz
##ure
Case
##s
of
seizure
have
been
reported
in
pre
-
marketing
clinical
studies
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
Contact
As
##tra
##Z
##ene
##ca
at
1
-
800
-
236
-
99
##33
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
(
5
.
4
)
*
lip
##id
metabolic
effects
:
Monitor
pre
##dia
##bet
##ic
and
di
##abe
##tic
women
taking
Nat
##azi
##a
.
[SEP]
[CLS]
Monitor
complete
blood
counts
prior
to
each
dose
;
increase
the
frequency
of
monitoring
in
patients
who
develop
Grade
3
or
4
c
##yt
##ope
##nia
##s
.
[SEP]
[CLS]
The
racial
and
ethnic
distribution
was
Caucasian
(
83
%
)
,
Black
(
5
%
)
,
Asian
(
2
%
)
,
and
other
(
5
%
)
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
1
)
*
Fat
##al
and
/
or
serious
and
severe
di
##ar
##r
##hea
or
co
##lit
##is
occurred
in
14
%
of
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
6
.
2
Post
Marketing
Experience
The
following
additional
adverse
reactions
have
been
identified
during
post
approval
use
of
Z
##Y
##TI
##GA
.
[SEP]
[CLS]
e
##O
##n
-
treatment
analysis
based
on
the
safety
population
,
compared
to
IT
##T
analysis
presented
in
Section
14
Clinical
Studies
.
[SEP]
[CLS]
(
5
.
6
)
*
Head
##ache
:
Eva
##lu
##ate
significant
change
in
headache
##s
and
disco
##ntin
##ue
Nat
##azi
##a
if
indicated
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
in
patients
diagnosed
with
treatment
-
related
IL
##D
/
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
Major
N
##eur
##ops
##ych
##ia
##tric
S
##ym
##pt
##oms
in
Place
##bo
-
Control
##led
E
##pile
##psy
Trials
Ad
##verse
Re
##action
Number
(
%
)
with
Ad
##verse
Re
##action
Number
(
%
)
Disco
##ntin
##uing
P
##OT
##IG
##A
(
n
=
81
##3
)
Place
##bo
(
n
[SEP]
[CLS]
=
42
##7
)
P
##OT
##IG
##A
(
n
=
81
##3
)
Place
##bo
(
n
=
42
##7
)
Con
##fusion
##al
state
75
(
9
%
)
11
(
3
%
)
32
(
4
[SEP]
[CLS]
%
)
4
(
<
1
%
)
P
##sy
##cho
##sis
9
(
1
%
)
0
6
(
<
1
%
)
0
Hall
##uc
##ination
##sa
14
(
2
%
)
2
(
[SEP]
[CLS]
<
1
%
)
6
(
<
1
%
)
0
a
Hall
##uc
##ination
##s
includes
mixed
hall
##uc
##ination
##s
.
[SEP]
[CLS]
The
contribution
of
the
underlying
disease
and
/
or
prior
co
##rt
##ico
##ster
##oid
treatment
to
the
risk
is
also
not
known
.
[SEP]
[CLS]
Disco
##lora
##tion
of
the
p
##ala
##te
has
also
been
reported
.
[SEP]
[CLS]
However
,
based
on
its
mechanism
of
action
and
findings
in
animals
,
AD
##CE
##TR
##IS
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
In
##jection
-
site
Re
##actions
In
the
place
##bo
-
controlled
studies
,
injection
-
site
r
##ash
)
were
reported
in
0
.
5
%
of
T
##R
##U
##L
##IC
##IT
##Y
-
treated
patients
and
in
0
.
0
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
In
##jection
into
these
structures
may
result
in
possible
permanent
injury
such
as
co
##rp
##oral
r
##up
##ture
(
pen
##ile
fracture
)
.
[SEP]
[CLS]
U
##rina
##ry
retention
was
reported
as
an
adverse
event
in
29
of
1
,
365
(
approximately
2
%
)
patients
treated
with
P
##OT
##IG
##A
in
the
open
-
label
and
place
##bo
-
controlled
e
##pile
##psy
database
[
see
[SEP]
[CLS]
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Card
##iac
disorders
:
Ang
##ina
p
##ector
##is
,
a
##rr
##hy
##th
##mia
##s
,
at
##rial
fi
##bri
##lla
##tion
,
cardiac
failure
,
h
##yper
##tensive
heart
disease
,
my
##oc
##ard
##ial
in
##far
##ction
,
my
##oc
##ard
##ial
is
##che
##mia
,
per
##ica
##rdi
##al
e
##ff
##usion
,
per
##ica
##rdi
##tis
,
[SEP]
[CLS]
stroke
and
trans
##ient
is
##che
##mic
attack
.
[SEP]
[CLS]
Basel
##ine
re
##nal
function
was
normal
or
mildly
impaired
in
92
%
of
patients
and
moderately
impaired
in
8
%
of
patients
(
mean
e
##G
##F
##R
86
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
Pro
##tein
##uria
At
Month
1
after
transplant
##ation
in
Studies
1
and
2
,
the
frequency
of
2
+
protein
##uria
on
urine
dip
##stick
in
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
was
33
[SEP]
[CLS]
%
(
130
/
390
)
and
28
%
(
107
/
38
##4
)
in
patients
treated
with
the
c
##y
##c
##los
##por
##ine
control
regime
##n
.
[SEP]
[CLS]
5
.
3
In
##fect
##ions
In
patients
receiving
B
##L
##IN
##C
##Y
##TO
in
clinical
trials
,
serious
infections
such
as
se
##psis
,
pneumonia
,
b
##act
##ere
##mia
,
op
##port
##uni
##stic
infections
,
and
cat
##he
##ter
-
site
infections
were
observed
in
approximately
[SEP]
[CLS]
25
%
of
patients
,
some
of
which
were
life
-
threatening
or
fatal
.
[SEP]
[CLS]
There
were
no
elevations
in
trans
##ami
##nas
##es
>
=
3
times
the
U
##L
##N
with
con
##com
##ita
##nt
elevations
in
total
bi
##li
##ru
##bin
>
2
times
the
U
##L
##N
.
[SEP]
[CLS]
Poole
##d
analyses
of
199
place
##bo
-
controlled
clinical
trials
(
mon
##o
-
and
ad
##junct
##ive
therapy
)
of
11
different
A
##ED
##s
showed
that
patients
random
##ized
to
one
of
the
A
##ED
##s
had
approximately
twice
the
[SEP]
[CLS]
risk
(
adjusted
Re
##lative
Risk
1
.
8
,
95
%
confidence
interval
[
C
##I
]
:
1
.
2
,
2
.
7
)
of
su
##icidal
thinking
compared
to
patients
random
##ized
to
place
##bo
.
[SEP]
[CLS]
T
##AB
##LE
3
:
Changes
in
Li
##pid
##s
in
Adult
Pat
##ients
N
*
=
Number
of
subjects
who
had
assessments
at
both
Basel
##ine
and
End
##point
.
[SEP]
[CLS]
The
incidence
of
all
-
cause
mortality
was
0
.
0
%
in
the
D
##U
##AV
##EE
group
and
0
.
2
%
in
the
place
##bo
group
.
[SEP]
[CLS]
(
5
.
8
)
*
In
##fusion
Re
##actions
:
Pre
-
me
##dicate
with
de
##xa
##met
##has
##one
.
[SEP]
[CLS]
There
is
no
general
agreement
about
specific
p
##har
##ma
##cological
treatment
regime
##ns
for
N
##MS
.
[SEP]
[CLS]
Z
##ER
##BA
##X
##A
was
evaluated
in
Phase
3
com
##par
##ator
-
controlled
clinical
trials
of
c
##IA
##I
and
c
##UT
##I
,
which
included
a
total
of
101
##5
patients
treated
with
Z
##ER
##BA
##X
##A
and
103
##2
patients
treated
with
com
##par
##ator
[SEP]
[CLS]
(
le
##vo
##f
##lo
##xa
##cin
750
mg
daily
in
c
##UT
##I
or
me
##rop
##ene
##m
1
g
every
8
hours
in
c
##IA
##I
)
for
up
to
14
days
.
[SEP]
[CLS]
Additional
adverse
drug
reactions
observed
with
ST
##RI
##BI
##LD
included
su
##icidal
idea
##tion
and
suicide
attempt
(
0
.
3
%
)
,
all
in
subjects
with
a
pre
-
existing
history
of
depression
or
psychiatric
illness
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
1
)
*
Pat
##ients
with
underlying
he
##pa
##titis
B
or
C
may
be
at
increased
risk
for
worse
##ning
or
development
of
trans
##ami
##nas
##e
elevations
with
use
of
T
##I
##VI
##CA
##Y
.
[SEP]
[CLS]
Pat
##ients
were
treated
with
F
##IR
##A
##Z
##Y
##R
30
mg
and
could
receive
up
to
3
doses
of
F
##IR
##A
##Z
##Y
##R
30
mg
administered
at
least
6
hours
apart
for
each
attack
.
[SEP]
[CLS]
5
.
6
Risk
of
Ser
##ious
Ad
##verse
Re
##actions
in
Pat
##ients
with
Complete
Gas
##tro
##int
##est
##inal
O
##bs
##truction
No
studies
have
been
conducted
in
patients
with
complete
gas
##tro
##int
##est
##inal
o
##bs
##truction
or
in
patients
who
have
surgery
for
[SEP]
[CLS]
correction
of
complete
bow
##el
o
##bs
##truction
.
[SEP]
[CLS]
Death
##s
as
a
com
##plication
of
severe
d
##ys
##pha
##gia
have
been
reported
after
treatment
with
b
##ot
##ulin
##um
to
##xin
.
[SEP]
[CLS]
Pat
##ients
were
aged
1
to
18
years
with
a
median
duration
of
treatment
of
43
##7
days
(
range
13
to
46
##6
days
)
.
[SEP]
[CLS]
In
##stance
##s
of
su
##icidal
behavior
have
been
observed
in
0
.
1
%
(
1
/
130
##8
)
of
subjects
while
receiving
O
##TE
##Z
##LA
,
compared
to
0
.
2
%
(
1
/
50
##6
)
in
place
##bo
-
treated
subjects
.
[SEP]
[CLS]
Pre
##med
##ica
##te
with
co
##rt
##ico
##ster
##oids
and
H
##2
antagonist
##s
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
S
##UI
##CI
##DA
##L
T
##H
##O
##U
##G
##HT
##S
WA
##R
##NI
##NG
:
S
##UI
##CI
##DA
##L
T
##H
##O
##U
##G
##HT
##S
Anti
##de
##press
##ants
increased
the
risk
of
su
##icidal
thoughts
in
children
,
adolescent
##s
,
and
young
adults
in
short
-
term
studies
.
[SEP]
[CLS]
(
5
.
4
)
*
Ren
##al
failure
:
Case
##s
of
re
##nal
failure
(
including
acute
re
##nal
failure
)
,
some
with
a
fatal
outcome
,
have
been
observed
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Advanced
H
##R
+
BC
,
advanced
P
##NE
##T
,
advanced
RC
##C
:
Most
common
adverse
reactions
(
incidence
>
=
30
%
)
include
s
##tom
##ati
##tis
,
infections
,
r
##ash
,
[SEP]
[CLS]
fatigue
,
di
##ar
##r
##hea
,
ed
##ema
,
abdominal
pain
,
nausea
,
fever
,
as
##the
##nia
,
cough
,
headache
and
decreased
appetite
.
[SEP]
[CLS]
*
Car
##cin
##ogenic
##ity
of
al
##bi
##g
##lut
##ide
could
not
be
assessed
in
rode
##nts
,
but
other
g
##lu
##ca
##gon
-
like
p
##eptide
-
1
(
G
##LP
-
1
)
receptor
ago
##nist
##s
have
caused
thy
##roid
C
-
cell
tumors
in
rode
##nts
at
clinical
##ly
relevant
[SEP]
[CLS]
exposure
##s
.
[SEP]
[CLS]
With
##hold
tram
##eti
##ni
##b
for
up
to
3
weeks
for
Grade
3
hem
##or
##r
##ha
##gic
events
;
if
improved
,
resume
at
a
lower
dose
level
.
[SEP]
[CLS]
Table
5
:
B
##lee
##ding
Results
in
the
AM
##PL
##IF
##Y
Study
E
##L
##I
##Q
##UI
##SN
=
26
##7
##6
##n
(
%
)
En
##ox
##apa
##rin
/
War
##fari
##n
##N
=
26
##8
##9
##n
(
%
)
Re
##lative
Risk
(
95
%
C
##I
)
*
CR
##N
##M
=
[SEP]
[CLS]
clinical
##ly
relevant
non
##ma
##jo
##r
bleeding
.
Events
associated
with
each
end
##point
were
counted
once
per
subject
,
but
subjects
may
have
contributed
events
to
multiple
end
##points
.
[SEP]
[CLS]
No
definite
ca
##usal
##ity
assessment
or
benefit
risk
assessment
could
be
made
for
these
events
due
to
the
presence
of
con
##found
##ing
factors
and
lack
of
random
##ization
of
E
##SA
use
.
[SEP]
[CLS]
Card
##iovascular
Safety
Card
##iovascular
events
and
deaths
were
ad
##ju
##dicated
to
one
of
the
pre
-
defined
end
##points
from
the
Anti
-
Plate
##let
Trial
##ists
'
Col
##la
##bor
##ations
(
AP
##TC
)
(
card
##iovascular
death
,
non
-
fatal
[SEP]
[CLS]
my
##oc
##ard
##ial
in
##far
##ction
,
and
non
-
fatal
stroke
)
in
the
random
##ized
controlled
and
long
-
term
extension
studies
.
[SEP]
[CLS]
*
Monitor
all
patients
for
active
T
##B
during
treatment
,
even
if
initial
late
##nt
T
##B
test
is
negative
(
5
.
1
)
*
L
##ymph
##oma
and
other
ma
##li
##gna
##ncies
,
some
fatal
,
[SEP]
[CLS]
have
been
reported
in
children
and
adolescent
patients
treated
with
T
##NF
block
##ers
,
of
which
C
##IM
##Z
##IA
is
a
member
(
5
.
2
)
.
[SEP]
[CLS]
*
Ad
##ren
##oc
##ort
##ical
In
##su
##ff
##iciency
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Table
1
lists
selected
adverse
reactions
occurring
in
more
than
2
%
of
patients
treated
with
D
##AL
##VA
##NC
##E
in
clinical
trials
.
[SEP]
[CLS]
O
##bs
##erve
patients
closely
for
h
##yper
##sen
##si
##ti
##vity
reactions
,
especially
during
the
first
and
second
in
##fusion
##s
.
[SEP]
[CLS]
*
Keep
D
##U
##AV
##EE
in
the
b
##list
##er
until
you
are
ready
to
take
it
to
protect
the
tablet
from
moisture
.
[SEP]
[CLS]
Ad
##vise
patients
of
signs
and
symptoms
of
blood
loss
and
to
report
them
immediately
or
go
to
an
emergency
room
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
for
life
-
threatening
bra
##dy
##card
##ia
due
to
X
##AL
##KO
##RI
;
however
,
if
associated
with
con
##com
##ita
##nt
medications
known
to
cause
bra
##dy
##card
##ia
or
h
##y
##pot
##ens
##ion
,
hold
X
##AL
##KO
##RI
until
recovery
to
as
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
[SEP]
[CLS]
or
to
a
heart
rate
of
60
b
##pm
or
above
,
and
if
con
##com
##ita
##nt
medications
can
be
adjusted
or
discontinued
,
restart
X
##AL
##KO
##RI
at
250
mg
once
daily
with
frequent
[SEP]
[CLS]
monitoring
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
If
he
##pa
##tic
injury
is
suspected
,
promptly
disco
##ntin
##ue
M
##U
##LT
##A
##Q
and
test
serum
enzymes
,
as
##par
##tate
amino
##tra
##ns
##fer
##ase
(
AS
##T
)
,
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
(
AL
##T
)
and
al
##kal
##ine
p
##hos
##pha
##tase
,
as
[SEP]
[CLS]
well
as
serum
bi
##li
##ru
##bin
,
to
establish
whether
there
is
liver
injury
.
[SEP]
[CLS]
There
were
no
reports
of
Tor
##sad
##e
de
Point
##es
or
any
other
adverse
reactions
associated
with
delayed
vent
##ric
##ular
re
##pol
##ari
##zation
.
[SEP]
[CLS]
If
rib
##avi
##rin
is
permanently
discontinued
for
management
of
an
##emia
,
then
p
##eg
##int
##er
##fer
##on
al
##fa
and
VI
##CT
##RE
##L
##IS
must
also
be
discontinued
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
End
##op
##ht
##hal
##mit
##is
and
Re
##tina
##l
Detachment
##s
In
##tra
##vi
##tre
##al
injection
##s
,
including
those
with
E
##Y
##LE
##A
,
have
been
associated
with
end
##op
##ht
##hal
##mit
##is
and
re
##tina
##l
detachment
##s
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Sign
##ificant
##ly
elevated
serum
ca
##l
##ci
##ton
##in
may
indicate
M
##TC
and
patients
with
M
##TC
usually
have
ca
##l
##ci
##ton
##in
values
>
50
ng
/
L
.
[SEP]
[CLS]
Inc
##iden
##ce
of
Laboratory
A
##b
##nor
##mal
##ities
Inc
##reased
From
Basel
##ine
O
##cc
##ur
##ring
at
a
Higher
Inc
##iden
##ce
in
Pat
##ients
T
##reate
##d
With
T
##AF
##IN
##LA
##R
in
Trial
1
[
Between
-
Arm
Di
##fference
of
>
=
5
%
(
All
Grades
[SEP]
[CLS]
)
or
>
=
2
%
(
Grades
3
or
4
)
]
Test
T
##AF
##IN
##LA
##R
N
=
187
D
##TI
##C
N
=
59
All
Grades
(
%
)
Grades
3
and
4
[SEP]
[CLS]
(
%
)
All
Grades
(
%
)
Grades
3
and
4
(
%
)
H
##yper
##gly
##ce
##mia
50
6
43
0
H
##y
##pop
##hos
##phate
##mia
37
6
##a
14
2
Inc
##reased
al
##kal
##ine
p
##hos
##pha
##tase
19
0
[SEP]
[CLS]
14
2
H
##y
##po
##nat
##rem
##ia
8
2
3
0
a
Grade
4
laboratory
abnormal
##ity
limited
to
h
##y
##pop
##hos
##phate
##mia
(
n
=
1
)
.
[SEP]
[CLS]
5
.
5
Se
##vere
Visual
Loss
Across
all
clinical
trials
,
the
incidence
of
Grade
4
visual
field
defect
with
vision
loss
was
0
.
2
%
(
4
/
166
##9
)
.
[SEP]
[CLS]
Pat
##ients
with
his
##top
##las
##mos
##is
,
rather
than
localized
disease
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##der
:
h
##yper
##sen
##si
##ti
##vity
.
[SEP]
[CLS]
Table
##1
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
R
##IS
##K
F
##OR
H
##EP
##AT
##IC
DE
##CO
##MP
##EN
##SA
##TI
##ON
IN
PA
##TI
##EN
##TS
W
##IT
##H
CH
##RO
##NI
##C
H
##EP
##AT
##IT
##IS
C
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
6
.
2
Post
Marketing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
The
following
serious
and
otherwise
important
adverse
drug
reactions
(
AD
##R
##s
)
are
discussed
in
detail
in
another
section
of
the
label
##ing
:
*
An
##emia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
[SEP]
[CLS]
(
5
.
2
)
]
*
N
##eu
##tro
##pen
##ia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Pan
##cy
##top
##enia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
H
##yper
##sen
##si
##ti
##vity
[
see
[SEP]
[CLS]
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
The
most
commonly
reported
adverse
reactions
(
more
than
35
%
of
subjects
regardless
of
investigator
'
s
ca
##usal
##ity
[SEP]
[CLS]
assessment
)
in
adult
subjects
were
fatigue
,
an
##emia
,
nausea
,
headache
,
and
d
##ys
##ge
##us
##ia
when
VI
##CT
##RE
##L
##IS
was
used
in
combination
with
P
##eg
##I
##nt
##ron
and
R
##E
##BE
##TO
##L
.
[SEP]
[CLS]
In
this
extension
trial
,
all
eligible
patients
were
initially
assigned
to
ST
##EN
##DR
##A
100
mg
.
At
any
point
during
the
trial
,
patients
could
request
to
have
their
dose
of
[SEP]
[CLS]
ST
##EN
##DR
##A
increased
to
200
mg
or
decreased
to
50
mg
based
on
their
individual
response
to
treatment
.
[SEP]
[CLS]
(
5
.
3
)
*
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
:
increased
risk
;
consider
in
the
diagnosis
of
patients
reporting
new
or
worse
##ning
ne
##uro
##logical
,
cognitive
,
or
behavioral
[SEP]
[CLS]
signs
and
symptoms
.
[SEP]
[CLS]
Major
15
(
0
.
6
)
49
(
1
.
8
)
0
.
31
(
0
.
17
,
0
.
55
)
p
<
0
.
000
##1
CR
##N
##M
*
103
(
3
.
9
)
215
(
8
.
0
)
Major
+
[SEP]
[CLS]
CR
##N
##M
115
(
4
.
3
)
261
(
9
.
7
)
Minor
313
(
11
.
7
)
50
##5
(
18
.
8
)
All
40
##2
(
15
.
0
)
67
##6
(
25
.
1
)
Ad
##verse
reactions
occurring
[SEP]
[CLS]
in
>
=
1
%
of
patients
in
the
AM
##PL
##IF
##Y
study
are
listed
in
Table
6
.
[SEP]
[CLS]
(
4
,
5
.
1
)
*
Only
physicians
experienced
in
im
##mu
##nos
##up
##pressive
therapy
and
management
of
kidney
transplant
patients
should
pre
##s
##cribe
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
With
##hold
T
##AF
##IN
##LA
##R
for
Grade
3
hem
##or
##r
##ha
##gic
events
;
if
improved
resume
at
a
lower
dose
level
.
[SEP]
[CLS]
Red
##uction
of
Risk
of
St
##roke
and
System
##ic
Em
##bol
##ism
in
Non
-
v
##al
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
Red
##uce
the
dose
of
PR
##AD
##A
##X
##A
to
75
mg
twice
daily
when
drone
##dar
##one
or
systemic
k
##eto
##cona
##zo
##le
is
co
##ad
##mini
##stered
with
[SEP]
[CLS]
PR
##AD
##A
##X
##A
in
patients
with
moderate
re
##nal
imp
##air
##ment
(
C
##r
##C
##l
30
-
50
m
##L
/
min
)
.
[SEP]
[CLS]
Monitor
patients
for
symptoms
of
ne
##uro
##pathy
,
such
as
h
##y
##po
##est
##hesia
,
h
##yper
##est
##hesia
,
par
##est
##hesia
,
discomfort
,
a
burning
sensation
,
ne
##uro
##pathic
pain
,
or
weakness
.
[SEP]
[CLS]
If
accidental
exposure
occurs
,
the
area
should
be
flushed
with
water
and
the
patient
should
seek
medical
care
as
soon
as
possible
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Ad
##verse
reactions
occurring
in
at
least
1
%
of
U
##L
##OR
##IC
-
treated
patients
,
and
at
least
0
.
5
%
greater
than
place
##bo
,
are
[SEP]
[CLS]
liver
function
abnormal
##ities
,
nausea
,
art
##hra
##l
##gia
,
and
r
##ash
.
[SEP]
[CLS]
CA
##PS
Study
1
investigated
the
safety
of
IL
##AR
##IS
in
an
8
-
week
,
open
-
label
period
(
Part
1
)
,
followed
by
a
24
-
week
,
random
##ized
withdrawal
period
(
Part
2
[SEP]
[CLS]
)
,
followed
by
a
16
-
week
,
open
-
label
period
(
Part
3
)
.
[SEP]
[CLS]
The
criterion
for
allowing
patients
to
receive
a
second
g
##lu
##car
##pid
##ase
dose
was
not
specified
in
the
protocol
.
[SEP]
[CLS]
Safety
was
also
evaluated
in
99
patients
(
51
male
,
48
females
)
with
Po
##mp
##e
disease
in
an
ongoing
,
open
-
label
,
prospective
study
in
patients
12
months
of
[SEP]
[CLS]
age
and
older
who
were
previously
treated
with
the
160
L
scale
of
al
##g
##lu
##cos
##idas
##e
al
##fa
and
switched
to
the
4000
L
scale
of
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
5
.
6
He
##pa
##tic
I
##mp
##air
##ment
To
##via
##z
has
not
been
studied
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
and
therefore
is
not
recommended
for
use
in
this
patient
population
[
see
Use
in
S
##pecific
[SEP]
[CLS]
Population
##s
(
8
.
7
)
and
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
Monitor
su
##pine
blood
pressure
prior
to
and
during
treatment
and
more
frequently
when
increasing
doses
.
[SEP]
[CLS]
The
median
duration
of
blinded
study
treatment
was
48
weeks
(
range
2
to
115
weeks
)
for
patients
receiving
A
##FI
##NI
##TO
##R
and
45
weeks
(
range
9
to
115
weeks
[SEP]
[CLS]
)
for
those
receiving
place
##bo
.
[SEP]
[CLS]
Clinical
status
,
including
liver
amino
##tra
##ns
##fer
##ases
,
should
be
monitored
and
appropriate
therapy
initiated
.
[SEP]
[CLS]
6
.
6
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
Study
1
excluded
the
use
of
con
##com
##ita
##nt
medications
that
may
lower
the
seizure
threshold
,
whereas
Study
2
permitted
the
use
of
these
medications
.
[SEP]
[CLS]
A
##vo
##id
use
of
GB
##CA
##s
among
these
patients
unless
the
diagnostic
information
is
essential
and
not
available
with
non
-
contrast
MR
##I
or
other
m
##oda
##lities
.
[SEP]
[CLS]
6
.
3
I
##mm
##uno
##genic
##ity
As
with
all
therapeutic
proteins
,
there
is
a
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
5
.
3
Tu
##mor
L
##ys
##is
S
##yn
##drome
Case
##s
of
tumor
l
##ys
##is
syndrome
(
T
##LS
)
,
including
fatal
outcomes
,
have
been
reported
in
patients
who
received
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
Case
##s
of
chronic
le
##uke
##mia
have
been
reported
with
post
-
marketing
T
##NF
-
block
##er
use
in
r
##he
##uma
##to
##id
art
##hr
##itis
and
other
indication
##s
.
[SEP]
[CLS]
Most
adverse
reactions
were
mild
or
moderate
in
severity
and
trans
##ient
in
nature
.
[SEP]
[CLS]
PM
##L
is
an
op
##port
##uni
##stic
viral
infection
of
the
brain
caused
by
the
J
##C
virus
(
J
##C
##V
)
that
typically
only
occurs
in
patients
who
are
im
##mu
##no
##com
##p
##rom
##ised
,
and
that
usually
[SEP]
[CLS]
leads
to
death
or
severe
disability
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
>
=
2
%
of
post
##men
##op
##aus
##al
women
with
o
##ste
##op
##oro
##sis
and
more
frequently
in
the
Pro
##lia
-
treated
women
than
in
the
place
##bo
-
treated
women
are
shown
in
the
table
[SEP]
[CLS]
below
.
[SEP]
[CLS]
(
4
,
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Do
not
initiate
in
acute
##ly
de
##ter
##ior
##ating
CO
##PD
patients
(
5
.
2
)
*
Do
not
use
for
relief
of
[SEP]
[CLS]
acute
symptoms
.
[SEP]
[CLS]
(
5
.
5
)
*
Use
with
caution
in
patients
with
card
##iovascular
or
con
##vu
##lsive
disorders
,
thy
##rot
##ox
##ico
##sis
or
sensitivity
to
s
##ym
##path
##omi
##met
##ic
drugs
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
in
patients
treated
with
D
##AL
##VA
##NC
##E
were
nausea
(
5
.
5
%
)
,
headache
(
4
.
7
%
)
,
and
di
##ar
##r
##hea
(
4
.
4
%
[SEP]
[CLS]
)
.
[SEP]
[CLS]
5
.
3
Un
##int
##ended
Skin
Expo
##sure
If
skin
not
intended
to
be
treated
comes
in
contact
with
Q
##ute
##nza
,
apply
Clean
##sing
G
##el
for
one
minute
and
wipe
off
with
dry
g
##au
##ze
.
[SEP]
[CLS]
(
5
.
7
)
*
Em
##b
##ryo
-
f
##etal
toxicity
:
Fe
##tal
harm
can
occur
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
P
##ediatric
Pat
##ients
:
Data
from
the
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
trial
are
presented
in
Table
4
.
[SEP]
[CLS]
El
##eva
##tions
of
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
to
>
=
3
times
the
U
##L
##N
occurred
in
a
small
number
of
patients
treated
with
both
T
##EC
##FI
##DE
##RA
and
place
##bo
and
were
balanced
between
groups
.
[SEP]
[CLS]
N
##eu
##tral
##izing
anti
##body
t
##iter
##s
were
not
determined
in
the
patients
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
U
##rina
##ry
retention
:
Pat
##ients
should
be
carefully
monitored
for
u
##rol
##og
##ic
symptoms
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
reported
adverse
reaction
was
headache
,
occurring
in
2
%
of
patients
,
followed
by
m
##us
##cu
##los
##kel
##etal
pain
,
blood
pressure
increased
,
[SEP]
[CLS]
fatigue
,
nausea
,
and
injection
site
reaction
,
all
occurring
in
<
1
%
of
patients
(
6
)
.
[SEP]
[CLS]
Therefore
,
close
monitoring
is
warrant
##ed
in
patients
with
a
change
in
vision
or
with
a
history
of
increased
in
##tra
##oc
##ular
pressure
,
g
##lau
##com
##a
,
and
/
or
cat
##ara
##cts
.
[SEP]
[CLS]
This
patient
had
pre
##tre
##at
##ment
ca
##l
##ci
##ton
##in
levels
approximately
8
times
the
upper
limit
of
normal
(
U
##L
##N
)
.
[SEP]
[CLS]
Of
the
64
du
##lag
##lut
##ide
-
treated
patients
that
developed
du
##lag
##lut
##ide
AD
##As
,
34
patients
(
0
.
9
%
of
the
overall
population
)
had
du
##lag
##lut
##ide
-
neutral
##izing
antibodies
,
and
36
patients
(
0
.
9
%
[SEP]
[CLS]
of
the
overall
population
)
developed
antibodies
against
native
G
##LP
-
1
.
[SEP]
[CLS]
(
5
.
2
)
*
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
:
Healthcare
providers
should
be
prepared
to
address
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
following
XI
##AF
##LE
##X
injection
##s
.
[SEP]
[CLS]
Eleven
of
the
13
fracture
##s
were
reported
within
the
first
52
weeks
.
[SEP]
[CLS]
The
data
described
below
reflect
the
exposure
to
C
##IM
##Z
##IA
in
2
,
36
##7
RA
patients
,
including
2
,
03
##0
exposed
for
at
least
6
months
,
1
,
66
##3
exposed
for
at
least
one
year
[SEP]
[CLS]
and
28
##2
for
at
least
2
years
;
and
1
,
77
##4
in
adequate
and
well
-
controlled
studies
.
[SEP]
[CLS]
Approximately
10
%
of
patients
in
long
-
term
clinical
trials
developed
skin
disco
##lora
##tion
,
generally
after
2
or
more
years
of
treatment
and
at
higher
doses
(
900
mg
or
greater
[SEP]
[CLS]
)
of
P
##OT
##IG
##A
.
[SEP]
[CLS]
The
risk
of
V
##TE
is
highest
during
the
first
year
of
use
.
[SEP]
[CLS]
Because
of
the
risks
of
co
##rp
##oral
r
##up
##ture
or
other
serious
pen
##ile
injury
,
XI
##AF
##LE
##X
is
available
for
the
treatment
of
P
##ey
##ron
##ie
'
s
disease
only
through
a
restricted
program
under
a
[SEP]
[CLS]
Risk
Evaluation
and
Mi
##ti
##gation
Strategy
(
R
##EM
##S
)
called
the
XI
##AF
##LE
##X
R
##EM
##S
Program
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
5
.
5
Di
##zzi
##ness
and
So
##m
##no
##len
##ce
P
##OT
##IG
##A
causes
dose
-
related
increases
in
di
##zzi
##ness
and
so
##m
##no
##len
##ce
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
d
Includes
:
con
##tus
##ion
,
e
##cc
##hy
##mos
##es
,
pen
##ile
hem
##or
##r
##hage
,
and
injection
site
hem
##or
##r
##hage
.
[SEP]
[CLS]
The
median
duration
of
treatment
with
Z
##Y
##TI
##GA
was
13
.
8
months
.
[SEP]
[CLS]
The
incidence
of
r
##ash
was
higher
in
women
compared
to
men
in
the
IN
##TE
##LE
##NC
##E
(
r
)
arm
in
the
Phase
3
trials
(
r
##ash
>
=
Grade
2
was
[SEP]
[CLS]
reported
in
9
/
60
[
15
.
0
%
]
women
versus
51
/
53
##9
[
9
.
5
%
]
men
;
disco
##ntin
##uations
due
to
r
##ash
were
reported
in
3
/
60
[
5
.
0
%
]
women
versus
[SEP]
[CLS]
10
/
53
##9
[
1
.
9
%
]
men
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
can
have
more
than
one
site
of
bleeding
.
[SEP]
[CLS]
Skin
:
case
of
severe
skin
reactions
,
including
Stevens
-
Johnson
syndrome
,
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
,
er
##yt
##hem
##a
multi
##form
##e
,
and
new
or
worse
##ning
ps
##oria
##sis
)
have
been
identified
during
post
-
approval
[SEP]
[CLS]
use
of
T
##NF
block
##ers
.
[SEP]
[CLS]
After
re
##sumption
of
treatment
at
a
lower
dose
,
26
%
of
patients
had
re
##cu
##rrence
of
AL
##T
and
AS
##T
elevations
.
[SEP]
[CLS]
Based
on
patient
di
##aries
from
three
clinical
trials
evaluating
the
safety
and
efficacy
of
Nat
##azi
##a
for
con
##tra
##ception
,
10
-
23
%
of
women
experienced
in
##tra
##cy
##c
##lic
bleeding
per
cycle
.
[SEP]
[CLS]
With
##hold
Y
##ER
##VO
##Y
dos
##ing
for
moderate
enter
##oc
##oli
##tis
;
administer
anti
-
di
##ar
##r
##hea
##l
treatment
and
,
if
persistent
for
more
than
1
week
,
initiate
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
0
.
5
mg
/
kg
/
day
pre
##dn
##ison
##e
[SEP]
[CLS]
or
equivalent
.
[SEP]
[CLS]
Se
##vere
h
##y
##po
##gly
##ce
##mia
occurred
in
2
.
4
%
and
3
.
4
%
of
patients
when
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
1
.
5
mg
,
respectively
,
was
co
-
administered
with
p
##rand
##ial
insulin
.
[SEP]
[CLS]
In
##fect
##ions
The
incidence
of
infections
in
controlled
studies
in
C
##ro
##hn
'
s
disease
was
38
%
for
C
##IM
##Z
##IA
-
treated
patients
and
30
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Do
not
administer
CO
##ME
##TR
##I
##Q
to
patients
with
a
recent
history
of
hem
##or
##r
##hage
or
hem
##op
##ty
##sis
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
and
Active
-
Control
##led
Trials
The
occurrence
of
adverse
reactions
was
also
evaluated
in
a
larger
pool
of
patients
with
type
2
diabetes
participating
in
6
place
##bo
-
and
active
-
controlled
[SEP]
[CLS]
trials
evaluating
the
use
of
T
##R
##U
##L
##IC
##IT
##Y
as
mon
##otherapy
and
add
-
on
therapy
to
oral
medications
or
insulin
.
[SEP]
[CLS]
Risk
of
A
##cute
Re
##sp
##ira
##tory
Co
##mp
##lication
##s
:
Pat
##ients
with
acute
f
##eb
##ril
##e
or
respiratory
illness
may
be
at
higher
risk
of
life
-
threatening
complications
from
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Red
##uce
##d
f
##etal
weights
were
observed
at
lower
exposure
##s
.
[SEP]
[CLS]
The
incidence
of
anti
##body
formation
is
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
(
5
.
14
)
5
.
1
Inc
##reased
Mortal
##ity
in
Elder
##ly
Pat
##ients
with
De
##ment
##ia
-
Re
##lated
P
##sy
##cho
##sis
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
treated
with
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
.
[SEP]
[CLS]
Monitor
AL
##T
,
as
##par
##tate
amino
##tra
##ns
##fer
##ase
(
AS
##T
)
and
bi
##li
##ru
##bin
before
initiation
of
and
periodically
throughout
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
In
studies
of
AC
##E
inhibitor
##s
in
patients
with
un
##ila
##teral
or
bilateral
re
##nal
artery
s
##ten
##osis
,
increases
in
serum
c
##rea
##tin
##ine
have
been
reported
.
[SEP]
[CLS]
Amy
##vid
scan
results
are
in
##dicative
of
the
brain
ne
##uri
##tic
am
##yl
##oid
plaque
content
only
at
the
time
of
image
acquisition
and
a
negative
scan
result
does
not
pre
##c
##lude
the
development
of
[SEP]
[CLS]
brain
am
##yl
##oid
in
the
future
.
[SEP]
[CLS]
*
Fat
Red
##ist
##ri
##but
##ion
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
The
majority
of
patients
were
able
to
be
re
##chal
##len
##ged
with
al
##g
##lu
##cos
##idas
##e
al
##fa
using
lower
doses
and
/
or
pre
##tre
##at
##ment
with
anti
-
inflammatory
drugs
and
/
or
co
##rt
##ico
##ster
##oids
and
were
able
to
continue
treatment
under
close
[SEP]
[CLS]
clinical
supervision
.
[SEP]
[CLS]
Among
these
patients
,
63
%
had
a
history
of
h
##yper
##tens
##ion
,
51
%
had
a
history
of
d
##ys
##lip
##ide
##mia
,
25
%
had
a
history
of
my
##oc
##ard
##ial
in
##far
##ction
,
8
[SEP]
[CLS]
%
had
a
history
of
unstable
an
##gin
##a
and
7
%
had
a
history
of
con
##ges
##tive
heart
failure
.
[SEP]
[CLS]
There
were
no
reports
of
pro
##la
##ct
##in
elevations
>
=
4
times
U
##L
##N
(
at
End
##point
)
for
patients
treated
with
SA
##P
##H
##RI
##S
or
place
##bo
.
[SEP]
[CLS]
The
population
was
45
-
77
years
of
age
,
63
%
male
,
100
%
white
,
and
were
treatment
naive
.
[SEP]
[CLS]
Grade
3
or
4
s
##tom
##ati
##tis
was
reported
in
4
%
-
9
%
of
patients
[
see
Ad
##verse
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
,
6
.
4
,
6
.
5
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
S
On
-
treatment
analysis
based
on
the
safety
population
,
compared
to
IT
##T
analysis
presented
in
Section
14
.
[SEP]
[CLS]
The
mean
age
of
patients
treated
with
T
##AN
##Z
##E
##UM
was
55
years
,
1
.
5
%
of
the
population
in
these
studies
was
75
years
or
older
and
51
%
of
participants
[SEP]
[CLS]
were
male
.
[SEP]
[CLS]
The
incidence
of
u
##rina
##ry
tract
infections
in
male
patients
random
##ized
to
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
was
3
.
2
%
,
3
.
6
%
,
and
4
.
1
[SEP]
[CLS]
%
,
respectively
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
and
Use
in
S
##pecific
Population
##s
(
8
.
5
)
]
.
[SEP]
[CLS]
5
.
9
H
##yper
##gly
##ce
##mia
H
##yper
##gly
##ce
##mia
can
occur
when
T
##AF
##IN
##LA
##R
is
administered
as
a
single
agent
or
when
used
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Ren
##al
function
of
patients
should
be
monitored
particularly
where
patients
have
additional
risk
factors
that
may
further
imp
##air
re
##nal
function
.
[SEP]
[CLS]
d
Includes
the
following
terms
:
abdominal
pain
,
abdominal
pain
upper
,
abdominal
pain
lower
,
and
abdominal
discomfort
.
[SEP]
[CLS]
During
clinical
trials
with
SA
##P
##H
##RI
##S
,
including
long
-
term
trials
without
comparison
to
place
##bo
,
the
incidence
of
adverse
reactions
suggest
##ive
of
body
temperature
increases
(
p
##yre
##xia
and
feeling
hot
)
[SEP]
[CLS]
was
<
=
1
%
.
[SEP]
[CLS]
These
patients
may
have
an
increased
risk
for
a
h
##yper
##sen
##si
##ti
##vity
reaction
to
G
##ada
##vist
.
[SEP]
[CLS]
In
addition
,
ma
##mm
##ography
examinations
should
be
scheduled
based
on
patient
age
,
risk
factors
,
and
prior
ma
##mm
##ogram
results
.
[SEP]
[CLS]
When
v
##as
##od
##ila
##tors
are
taken
in
combination
,
blood
-
pressure
-
lowering
effects
of
each
individual
compound
may
be
increased
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
A
##vo
##id
use
in
patients
with
known
Q
##T
pro
##long
##ation
,
those
with
h
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
,
and
those
taking
other
drugs
that
pro
##long
the
[SEP]
[CLS]
Q
##T
interval
.
[SEP]
[CLS]
The
potential
risk
of
using
a
T
##NF
block
##er
in
combination
with
a
##za
##thi
##op
##rine
or
6
-
MP
should
be
carefully
considered
.
[SEP]
[CLS]
Ren
##al
and
U
##rina
##ry
Di
##sor
##ders
:
tub
##ulo
##int
##ers
##ti
##tial
ne
##ph
##rit
##is
.
[SEP]
[CLS]
The
con
##com
##ita
##nt
use
of
PR
##IS
##TI
##Q
with
MA
##O
##I
##s
intended
to
treat
psychiatric
disorders
is
con
##tra
##ind
##ica
##ted
.
[SEP]
[CLS]
No
Grade
4
in
##fusion
-
related
reactions
were
reported
.
[SEP]
[CLS]
Another
patient
developed
severe
inflammatory
art
##hr
##op
##athy
in
association
with
p
##yre
##xia
and
elevated
er
##yt
##hr
##oc
##yte
sediment
##ation
rate
.
[SEP]
[CLS]
V
##ent
##ric
##ular
a
##rr
##hy
##th
##mia
##s
and
bra
##dy
##card
##ia
,
resulting
in
cardiac
arrest
or
death
,
or
requiring
cardiac
re
##sus
##citation
or
def
##ib
##rilla
##tion
have
been
observed
in
infant
##ile
-
onset
Po
##mp
##e
disease
patients
with
cardiac
h
##yper
##tro
##phy
during
[SEP]
[CLS]
general
an
##est
##hesia
for
central
ve
##nous
cat
##he
##ter
placement
.
[SEP]
[CLS]
Blood
and
l
##ymph
##atic
system
disorders
:
A
##gra
##nu
##loc
##yt
##osis
.
[SEP]
[CLS]
All
women
should
receive
yearly
breast
examinations
by
a
healthcare
provider
and
perform
monthly
breast
self
-
examinations
.
[SEP]
[CLS]
Whether
any
of
the
symptoms
described
above
represent
such
a
conversion
is
unknown
.
[SEP]
[CLS]
5
.
4
New
On
##set
or
W
##orse
##ning
Heart
F
##ail
##ure
worse
##ning
of
heart
failure
has
been
reported
during
treatment
with
M
##U
##LT
##A
##Q
in
the
post
##market
##ing
setting
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reaction
occurring
in
approximately
25
%
of
patients
was
a
mild
taste
following
ins
##til
##lation
.
[SEP]
[CLS]
The
potential
role
of
T
##NF
block
##er
therapy
in
the
development
of
ma
##li
##gna
##ncies
in
adults
is
not
known
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
S
##IM
##PO
##NI
ARIA
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
In
the
controlled
phase
of
Trial
1
,
through
Week
24
,
AL
##T
elevations
>
=
5
*
U
##L
##N
occurred
in
0
.
8
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
and
0
%
[SEP]
[CLS]
of
control
-
treated
patients
and
AL
##T
elevations
>
=
3
*
U
##L
##N
occurred
in
2
.
3
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
and
2
.
5
%
of
control
-
treated
patients
.
[SEP]
[CLS]
5
.
2
Card
##iovascular
Death
and
Heart
F
##ail
##ure
in
Permanent
A
##F
M
##U
##LT
##A
##Q
doubles
the
risk
of
card
##iovascular
death
)
and
heart
failure
events
in
patients
with
permanent
A
##F
.
[SEP]
[CLS]
*
Ad
##mini
##ster
G
##ada
##vist
only
in
situations
where
trained
personnel
and
the
##rap
##ies
are
promptly
available
for
the
treatment
of
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
personnel
trained
in
re
##sus
##citation
.
[SEP]
[CLS]
*
El
##eva
##ted
Blood
Press
##ure
:
Control
h
##yper
##tens
##ion
before
in
##iti
##ating
treatment
.
[SEP]
[CLS]
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
Use
of
J
##AR
##DI
##AN
##CE
was
associated
with
increases
in
serum
c
##rea
##tin
##ine
and
decreases
in
e
##G
##F
##R
(
see
Table
2
)
.
[SEP]
[CLS]
A
ca
##usal
relationship
of
IL
##AR
##IS
to
these
events
can
not
be
excluded
.
[SEP]
[CLS]
Ava
##ila
##ble
data
from
controlled
clinical
trials
suggest
that
LA
##BA
increase
the
risk
of
as
##th
##ma
-
related
hospital
##ization
in
p
##ediatric
and
adolescent
patients
.
[SEP]
[CLS]
*
Monitor
for
worse
##ning
and
emergence
of
su
##icidal
thoughts
and
behaviors
(
5
.
1
)
.
[SEP]
[CLS]
5
.
8
Fe
##tal
Risk
Based
on
animal
studies
,
G
##IL
##EN
##Y
##A
may
cause
f
##etal
harm
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
from
clinical
trials
and
/
or
post
-
marketing
surveillance
.
[SEP]
[CLS]
The
long
-
term
effects
of
antibodies
to
K
##AL
##BI
##TO
##R
are
not
known
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
incidence
>
1
%
)
with
V
##OR
##A
##X
##A
##Z
##E
are
para
##est
##hesia
##s
,
flush
##ing
,
nausea
and
/
or
vomit
##ing
,
h
##y
##pot
##ens
##ion
,
and
headache
.
[SEP]
[CLS]
A
routine
oral
exam
should
be
performed
by
the
pre
##s
##cribe
##r
prior
to
initiation
of
Pro
##lia
treatment
.
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
has
not
been
tested
in
MS
patients
with
diabetes
me
##lli
##tus
.
[SEP]
[CLS]
In
this
pool
,
a
total
of
2
,
116
patients
with
type
2
diabetes
were
treated
with
T
##AN
##Z
##E
##UM
for
a
mean
duration
of
75
weeks
.
[SEP]
[CLS]
Se
##vere
H
##yper
##tens
##ion
The
adverse
events
for
patients
with
severe
h
##yper
##tens
##ion
are
based
on
an
un
##con
##tro
##lled
study
in
patients
with
severe
h
##yper
##tens
##ion
(
V
##EL
##OC
##IT
##Y
,
n
=
126
)
.
[SEP]
[CLS]
O
##besity
and
prolonged
n
##uc
##leo
##side
exposure
may
be
risk
factors
.
[SEP]
[CLS]
Once
as
##th
##ma
control
is
achieved
and
maintained
,
assess
the
patient
at
regular
intervals
and
step
down
therapy
(
e
.
g
.
,
disco
##ntin
##ue
BR
##E
##O
E
##LL
##IP
##TA
)
if
possible
without
loss
of
[SEP]
[CLS]
as
##th
##ma
control
and
maintain
the
patient
on
a
long
-
term
as
##th
##ma
control
medication
,
such
as
an
I
##CS
.
[SEP]
[CLS]
The
mean
duration
of
diabetes
was
seven
years
,
the
mean
body
mass
index
(
B
##MI
)
was
31
kg
/
m
2
(
51
%
of
patients
had
a
B
##MI
>
[SEP]
[CLS]
=
30
kg
/
m
2
)
,
and
the
mean
age
was
57
years
(
24
%
of
patients
>
=
65
years
of
age
)
.
[SEP]
[CLS]
In
patients
with
confirmed
PM
##L
,
consider
stopping
im
##mu
##nos
##up
##press
##ant
therapy
,
including
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
(
2
.
3
,
5
.
1
)
*
Bull
##ous
and
Ex
##folia
##tive
Skin
Di
##sor
##ders
:
Se
##vere
bull
##ous
,
b
##list
##ering
,
and
ex
##folia
##ting
lesions
occurred
in
0
.
15
%
of
patients
.
[SEP]
[CLS]
Following
resolution
of
trans
##ami
##nas
##e
elevations
,
consider
the
benefits
and
risks
of
re
##suming
K
##AL
##Y
##DE
##CO
dos
##ing
[
see
Ad
##verse
Re
##actions
(
6
)
and
Use
in
S
##pecific
Population
##s
(
8
.
6
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
12
-
Month
Trial
Long
-
term
safety
data
is
based
on
a
12
-
month
trial
that
evaluated
the
safety
of
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
once
daily
(
n
=
201
)
,
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
[SEP]
[CLS]
once
daily
(
n
=
202
)
,
and
flu
##tica
##son
##e
prop
##ion
##ate
500
m
##c
##g
twice
daily
(
n
=
100
)
in
adolescent
and
adult
subjects
with
as
##th
##ma
(
Trial
4
[SEP]
[CLS]
)
.
[SEP]
[CLS]
*
Effects
on
serum
liver
bio
##chemist
##ries
in
patients
with
he
##pa
##titis
B
or
C
co
-
infection
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
The
following
adverse
reactions
were
reported
less
frequently
(
<
5
%
)
.
[SEP]
[CLS]
The
in
##fusion
rate
may
be
slowed
or
interrupted
if
the
patient
develops
an
in
##fusion
reaction
.
[SEP]
[CLS]
(
5
.
3
)
*
Can
##di
##da
al
##bic
##ans
infection
of
the
mouth
may
occur
.
[SEP]
[CLS]
Disco
##ntin
##uation
due
to
any
adverse
event
occurred
in
26
%
in
the
K
##R
##d
arm
versus
25
%
in
the
Rd
arm
.
[SEP]
[CLS]
The
dos
##age
of
P
##OT
##IG
##A
should
be
reduced
over
a
period
of
at
least
3
weeks
,
unless
safety
concerns
require
abrupt
withdrawal
.
[SEP]
[CLS]
5
.
12
He
##pa
##tic
I
##mp
##air
##ment
The
systemic
exposure
to
a
##xi
##tin
##ib
was
higher
in
subjects
with
moderate
he
##pa
##tic
imp
##air
##ment
(
Child
-
P
##ugh
class
B
)
compared
to
subjects
with
normal
he
##pa
##tic
function
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
10
%
)
observed
across
pre
-
marketing
clinical
trials
were
similar
in
type
and
frequency
as
those
observed
in
the
place
##bo
-
controlled
trial
(
see
[SEP]
[CLS]
Table
##1
)
.
[SEP]
[CLS]
Monitor
with
periodic
liver
testing
.
[SEP]
[CLS]
Anyone
considering
pre
##s
##cribing
P
##OT
##IG
##A
or
any
other
A
##ED
must
balance
this
risk
with
the
risk
of
un
##tre
##ated
illness
.
[SEP]
[CLS]
Basel
##ine
Follow
Up
Ren
##al
Fun
##ction
Status
n
Normal
##n
(
%
)
Mi
##ld
##n
(
%
)
Mi
##ld
to
Mode
##rate
##n
(
%
)
Mode
##rate
to
Se
##vere
##n
(
%
)
Se
##vere
##n
(
%
[SEP]
[CLS]
)
Kid
##ney
F
##ail
##uren
(
%
)
Notes
:
G
##rading
is
based
on
Mo
##di
##fication
in
Diet
in
Ren
##al
Disease
method
(
MD
##RD
)
.
K
##DI
##G
##O
Classification
by
e
##G
##F
##R
:
Normal
:
greater
[SEP]
[CLS]
than
or
equal
to
90
,
Mi
##ld
:
60
to
less
than
90
,
Mi
##ld
to
Mode
##rate
:
45
to
less
than
60
,
Mode
##rate
to
Se
##vere
:
30
to
[SEP]
[CLS]
less
than
45
,
Se
##vere
:
15
to
less
than
30
,
Kid
##ney
F
##ail
##ure
:
less
than
15
m
##l
/
min
/
1
.
73
m
2
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
A
##cc
##redo
Health
Group
Inc
.
at
1
-
88
##8
-
45
##4
-
88
##60
,
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Basel
##ine
re
##nal
function
was
normal
or
mildly
impaired
(
mean
e
##G
##F
##R
81
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
Additionally
,
the
observed
incidence
of
a
positive
anti
##body
(
including
neutral
##izing
anti
##body
)
test
result
may
be
influenced
by
several
factors
,
including
ass
##ay
methodology
,
sample
handling
,
[SEP]
[CLS]
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
In
clinical
trials
with
V
##im
##iz
##im
,
44
of
235
(
18
.
7
%
)
patients
experienced
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
S
##ym
##pt
##oms
have
included
h
##y
##pot
##ens
##ion
,
d
##ys
##p
##nea
,
throat
tight
##ness
,
upper
air
##way
ed
##ema
,
p
##ru
##rit
##us
,
and
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Administration
of
T
##EC
##FI
##DE
##RA
with
food
may
reduce
the
incidence
of
flush
##ing
.
[SEP]
[CLS]
[
See
Do
##sa
##ge
and
Administration
(
2
.
3
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Reports
include
cases
of
pulmonary
T
##B
.
[SEP]
[CLS]
Pat
##ients
with
abnormal
co
##agu
##lation
(
except
for
patients
taking
low
-
dose
as
##pi
##rin
,
e
.
g
.
,
up
to
150
mg
per
day
)
were
excluded
from
participating
in
these
studies
.
[SEP]
[CLS]
The
most
commonly
reported
adverse
reactions
occurring
in
>
=
20
%
of
patients
treated
with
the
recommended
dose
and
frequency
of
N
##U
##L
##O
##J
##IX
were
an
##emia
,
di
##ar
##r
##hea
,
[SEP]
[CLS]
u
##rina
##ry
tract
infection
,
peripheral
ed
##ema
,
con
##st
##ip
##ation
,
h
##yper
##tens
##ion
,
p
##yre
##xia
,
g
##raft
d
##ys
##function
,
cough
,
nausea
,
vomit
##ing
,
headache
,
h
##y
##po
##kal
##emia
,
h
##yper
##kal
##emia
,
and
[SEP]
[CLS]
le
##uk
##ope
##nia
.
[SEP]
[CLS]
*
P
##OT
##IG
##A
can
cause
re
##tina
##l
abnormal
##ities
,
which
are
known
to
result
in
damage
to
the
photo
##re
##ceptor
##s
and
vision
loss
.
[SEP]
[CLS]
Do
not
use
BR
##E
##O
E
##LL
##IP
##TA
for
patients
whose
as
##th
##ma
is
adequately
controlled
on
low
-
or
medium
-
dose
inhaled
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
There
were
four
suicide
##s
in
drug
treated
patients
in
the
trials
and
none
in
place
##bo
treated
patients
,
but
the
number
is
too
small
to
allow
any
conclusion
about
drug
[SEP]
[CLS]
effect
on
suicide
.
[SEP]
[CLS]
5
.
6
Car
##bo
##hy
##dra
##te
and
Li
##pid
Met
##ab
##olic
Effects
Care
##fully
monitor
pre
##dia
##bet
##ic
and
di
##abe
##tic
women
who
are
taking
Nat
##azi
##a
.
[SEP]
[CLS]
In
the
lung
cancer
study
,
80
%
of
patients
were
male
,
the
median
age
was
58
years
,
and
95
%
of
patients
were
Caucasian
.
[SEP]
[CLS]
5
.
2
In
##fect
##ions
Ser
##ious
and
sometimes
fatal
infections
,
including
pneumonia
and
se
##psis
,
have
occurred
with
Bel
##eo
##da
##q
.
[SEP]
[CLS]
5
.
4
Q
##T
Inter
##val
Pro
##long
##ation
Q
##T
##c
interval
pro
##long
##ation
,
which
may
lead
to
an
increased
risk
for
vent
##ric
##ular
ta
##chy
##ar
##r
##hy
##th
##mia
##s
(
e
.
g
.
,
Tor
##sad
##e
de
point
##es
)
or
sudden
death
,
occurred
[SEP]
[CLS]
in
patients
treated
with
Z
##Y
##KA
##DI
##A
in
clinical
trials
.
[SEP]
[CLS]
St
##ero
##id
hormones
may
be
poorly
meta
##bol
##ized
in
patients
with
impaired
liver
function
.
[SEP]
[CLS]
Monitor
liver
function
tests
(
he
##pa
##tic
trans
##ami
##nas
##e
and
bi
##li
##ru
##bin
levels
)
and
assess
patients
for
signs
and
symptoms
of
he
##pa
##to
##to
##xi
##city
before
each
dose
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
Monitor
blood
counts
at
least
every
two
weeks
for
the
first
3
months
of
therapy
,
and
at
least
weekly
in
patients
while
ne
##ut
##rop
##hil
counts
are
less
than
1
.
0
G
##i
/
L
[SEP]
[CLS]
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
Control
h
##yper
##tens
##ion
and
correct
h
##y
##po
##kal
##emia
before
and
during
treatment
with
Z
##Y
##TI
##GA
.
[SEP]
[CLS]
(
5
.
8
)
5
.
1
He
##pa
##to
##to
##xi
##city
Fat
##al
and
/
or
serious
he
##pa
##to
##to
##xi
##city
occurred
in
14
%
of
patients
treated
with
Z
##yd
##eli
##g
.
[SEP]
[CLS]
In
Study
RA
-
III
,
too
few
patients
developed
antibodies
to
allow
for
meaningful
analysis
of
AC
##R
##20
response
by
anti
##body
status
.
[SEP]
[CLS]
The
safety
of
two
concurrent
injection
##s
of
XI
##AF
##LE
##X
0
.
58
mg
into
Du
##pu
##yt
##ren
'
s
cord
##s
in
the
same
hand
was
evaluated
in
a
historically
-
controlled
,
open
-
label
multi
-
center
trial
in
71
##5
adult
[SEP]
[CLS]
subjects
with
Du
##pu
##yt
##ren
'
s
contract
##ure
(
Study
3
)
.
[SEP]
[CLS]
Consider
the
benefits
and
risks
before
ne
##ura
##xial
intervention
in
patients
who
are
or
who
need
to
be
anti
##coa
##gu
##lated
(
5
.
3
)
.
[SEP]
[CLS]
If
re
##tina
##l
pig
##mentary
abnormal
##ities
or
vision
changes
are
detected
,
P
##OT
##IG
##A
should
be
discontinued
unless
no
other
suitable
treatment
options
are
available
and
the
benefits
of
treatment
out
##wei
##gh
the
potential
[SEP]
[CLS]
risk
of
vision
loss
.
[SEP]
[CLS]
In
this
study
,
159
patients
received
X
##E
##OM
##IN
(
78
were
random
##ized
to
receive
a
total
dose
of
120
Units
,
and
81
were
random
##ized
to
receive
a
total
dose
[SEP]
[CLS]
of
240
Units
)
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
therapy
due
to
adverse
reactions
occurred
in
18
%
of
patients
treated
with
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
,
5
.
3
,
5
.
4
,
5
.
5
)
.
]
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
in
patients
who
experience
a
per
##fo
##ration
or
a
fist
##ula
.
[SEP]
[CLS]
Approximately
86
%
of
the
population
studied
was
Caucasian
,
and
0
.
8
%
of
the
population
was
aged
65
years
or
older
.
[SEP]
[CLS]
In
##fect
##ions
were
more
frequently
reported
in
females
than
in
males
(
see
Table
1
)
.
[SEP]
[CLS]
5
.
5
Se
##vere
and
Di
##sa
##bling
Art
##hra
##l
##gia
There
have
been
post
##market
##ing
reports
of
severe
and
di
##sa
##bling
art
##hra
##l
##gia
in
patients
taking
D
##PP
-
4
inhibitor
##s
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Same
Active
In
##g
##red
##ient
:
Pat
##ients
receiving
Pro
##lia
should
not
receive
X
##GE
##VA
(
r
)
(
5
.
1
)
*
H
##yper
##sen
##si
##ti
##vity
including
an
##aph
##yla
##ctic
reactions
may
[SEP]
[CLS]
occur
.
[SEP]
[CLS]
5
.
3
H
##y
##po
##cal
##ce
##mia
and
Mine
##ral
Met
##ab
##olis
##m
H
##y
##po
##cal
##ce
##mia
may
be
ex
##ace
##rb
##ated
by
the
use
of
Pro
##lia
.
[SEP]
[CLS]
In
pre
##market
##ing
clinical
trials
,
18
of
235
(
7
.
7
%
)
patients
treated
with
V
##im
##iz
##im
experienced
signs
and
symptoms
consistent
with
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
It
is
important
to
exclude
cases
where
the
clinical
presentation
includes
both
serious
medical
illness
(
e
.
g
.
[SEP]
[CLS]
In
this
pool
,
IN
##VO
##KA
##NA
was
also
associated
with
the
adverse
reactions
of
fatigue
(
1
.
7
%
with
com
##par
##ator
,
2
.
2
%
with
IN
##VO
##KA
##NA
100
mg
,
and
2
.
0
%
[SEP]
[CLS]
with
IN
##VO
##KA
##NA
300
mg
)
and
loss
of
strength
(
i
.
e
.
,
as
##the
##nia
)
(
0
.
6
%
with
com
##par
##ator
,
0
.
7
%
with
IN
##VO
##KA
##NA
100
mg
,
and
1
.
1
%
[SEP]
[CLS]
with
IN
##VO
##KA
##NA
300
mg
)
.
[SEP]
[CLS]
The
median
time
to
onset
of
increased
AL
##T
was
30
and
33
days
,
respectively
,
and
the
median
duration
for
each
was
21
days
.
[SEP]
[CLS]
5
.
6
Depression
In
the
controlled
clinical
trials
,
psychiatric
events
were
reported
more
frequently
with
B
##EN
##L
##Y
##ST
##A
(
16
%
)
than
with
place
##bo
(
12
%
)
,
related
primarily
[SEP]
[CLS]
to
depression
-
related
events
(
6
.
3
%
B
##EN
##L
##Y
##ST
##A
and
4
.
7
%
place
##bo
)
,
ins
##om
##nia
(
6
.
0
%
B
##EN
##L
##Y
##ST
##A
and
5
.
3
%
place
##bo
)
,
and
anxiety
(
3
.
9
%
B
##EN
##L
##Y
##ST
##A
[SEP]
[CLS]
and
2
.
8
%
place
##bo
)
.
[SEP]
[CLS]
Management
of
cardiac
failure
may
require
permanent
disco
##ntin
##uation
of
IN
##L
##Y
##TA
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
pneumonia
.
[SEP]
[CLS]
Grade
3
/
4
ve
##nous
th
##rom
##boe
##mbo
##lic
events
were
reported
in
9
/
35
##9
patients
(
3
%
)
receiving
IN
##L
##Y
##TA
(
including
pulmonary
em
##bol
##ism
,
deep
vein
th
##rom
##bos
##is
,
re
##tina
##l
vein
o
##cc
##lusion
and
[SEP]
[CLS]
re
##tina
##l
vein
th
##rom
##bos
##is
)
and
2
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
The
increase
may
be
larger
when
co
##ad
##mini
##stered
with
ch
##lor
##thal
##ido
##ne
or
h
##ydro
##ch
##lor
##oth
##ia
##zi
##de
.
[SEP]
[CLS]
X
##E
##OM
##IN
treated
subjects
were
24
to
74
years
old
,
and
were
predominantly
female
(
88
%
)
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
for
acute
onset
or
worse
##ning
of
pulmonary
symptoms
.
[SEP]
[CLS]
5
.
3
Gas
##tro
##int
##est
##inal
-
Re
##lated
Ad
##verse
Re
##actions
in
Op
##io
##id
-
To
##ler
##ant
Pat
##ients
Pat
##ients
recently
exposed
to
op
##io
##ids
are
expected
to
be
more
sensitive
to
the
effects
of
m
##u
-
op
##io
##id
receptor
antagonist
##s
,
such
as
E
##NT
##ER
##EG
.
[SEP]
[CLS]
As
##th
##ma
-
related
hospital
##izations
occurred
in
10
subjects
(
1
%
)
treated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
compared
with
7
subjects
(
0
.
7
%
)
treated
with
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
.
[SEP]
[CLS]
Do
not
use
if
the
b
##list
##er
package
has
been
open
for
more
than
60
days
.
[SEP]
[CLS]
The
reactions
listed
are
those
that
could
be
of
clinical
importance
,
as
well
as
reactions
that
are
p
##laus
##ibly
drug
-
related
on
p
##har
##ma
##co
##log
##ic
or
other
grounds
.
[SEP]
[CLS]
Over
the
course
of
a
typical
10
-
week
controlled
trial
,
the
rate
of
death
in
drug
-
treated
patients
was
about
4
.
5
%
,
compared
to
a
rate
of
about
2
.
6
%
[SEP]
[CLS]
in
the
place
##bo
group
.
[SEP]
[CLS]
The
types
of
adverse
events
that
led
to
disco
##ntin
##uation
were
similar
for
the
FA
##NA
##P
##T
-
and
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Man
##ife
##sta
##tions
included
h
##y
##pot
##ens
##ion
,
an
##gio
##ede
##ma
,
u
##rt
##ica
##ria
or
other
r
##ash
,
p
##ru
##rit
##us
,
and
d
##ys
##p
##nea
.
[SEP]
[CLS]
In
open
label
extension
trials
in
MS
patients
,
the
incidence
of
seizure
##s
during
treatment
with
da
##lf
##amp
##rid
##ine
15
mg
twice
daily
(
1
.
7
/
100
##P
##Y
)
was
over
4
times
higher
than
[SEP]
[CLS]
the
incidence
during
treatment
with
10
mg
twice
daily
(
0
.
4
/
100
##P
##Y
)
.
[SEP]
[CLS]
The
fatal
case
of
PM
##L
was
reported
in
a
patient
receiving
higher
than
recommended
doses
of
N
##U
##L
##O
##J
##IX
and
M
##MF
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Major
32
##7
(
2
.
13
)
46
##2
(
3
.
09
)
0
.
69
(
0
.
60
,
0
.
80
)
<
0
.
000
##1
In
##tra
##c
##rani
##al
(
I
##CH
)
?
[SEP]
[CLS]
Beta
-
block
##er
use
for
this
purpose
is
not
recommended
.
[SEP]
[CLS]
Inc
##reased
U
##rina
##tion
In
the
pool
of
five
place
##bo
-
controlled
clinical
trials
,
adverse
reactions
of
increased
u
##rina
##tion
(
e
.
g
.
,
p
##oly
##uria
,
poll
##aki
##uria
,
and
no
##ct
##uria
)
occurred
more
frequently
on
[SEP]
[CLS]
J
##AR
##DI
##AN
##CE
than
on
place
##bo
(
see
Table
1
)
.
[SEP]
[CLS]
Consider
disco
##ntin
##uing
Pro
##lia
if
severe
symptoms
develop
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Clinical
W
##orse
##ning
/
Suicide
Risk
:
Monitor
for
clinical
worse
##ning
and
suicide
risk
(
5
.
1
)
.
[SEP]
[CLS]
Generally
,
the
observed
infections
responded
to
standard
therapy
.
[SEP]
[CLS]
5
.
12
Po
##ten
##tial
for
Co
##gni
##tive
and
Motor
I
##mp
##air
##ment
So
##m
##no
##len
##ce
was
reported
in
patients
treated
with
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Pat
##ients
experiencing
these
symptoms
should
be
advised
to
stop
taking
ST
##EN
##DR
##A
and
seek
pro
##mpt
medical
attention
.
[SEP]
[CLS]
Auto
##im
##mu
##ne
Di
##sor
##ders
and
Auto
##anti
##bo
##dies
The
use
of
T
##NF
-
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
,
has
been
associated
with
the
formation
of
auto
##anti
##bo
##dies
and
,
rarely
,
with
[SEP]
[CLS]
the
development
of
a
l
##up
##us
-
like
syndrome
.
[SEP]
[CLS]
(
5
.
2
)
*
Q
##T
pro
##long
##ing
drugs
,
including
q
##uin
##ine
and
q
##uin
##id
##ine
,
should
be
used
cautiously
following
Co
##arte
##m
Table
##ts
.
[SEP]
[CLS]
5
.
4
Risk
of
Card
##iac
A
##rr
##hy
##th
##mia
and
Su
##dden
Card
##iac
Death
During
General
An
##est
##hesia
for
Central
V
##eno
##us
Cat
##he
##ter
Place
##ment
Administration
of
general
an
##est
##hesia
can
be
complicated
by
the
presence
of
severe
cardiac
[SEP]
[CLS]
and
skeletal
(
including
respiratory
)
muscle
weakness
.
[SEP]
[CLS]
(
4
,
5
.
1
)
In
patients
with
permanent
at
##rial
fi
##bri
##lla
##tion
,
M
##U
##LT
##A
##Q
doubles
the
risk
of
death
,
stroke
and
hospital
##ization
for
heart
failure
.
[SEP]
[CLS]
*
Bone
Effects
of
Ten
##of
##ov
##ir
D
##F
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
Some
of
these
reactions
occurred
after
the
first
administration
of
C
##IM
##Z
##IA
.
[SEP]
[CLS]
These
patients
may
have
an
increased
risk
for
a
h
##yper
##sen
##si
##ti
##vity
reaction
to
E
##O
##VI
##ST
.
[SEP]
[CLS]
During
the
entire
course
of
treatment
,
the
proportion
of
subjects
who
discontinued
treatment
due
to
adverse
reactions
was
13
%
for
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
[SEP]
[CLS]
and
12
%
for
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
At
Week
20
in
Trial
1
,
17
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
and
13
%
of
control
patients
were
newly
AN
##A
-
positive
(
at
t
##iter
##s
of
1
:
160
or
greater
)
[SEP]
[CLS]
.
[SEP]
[CLS]
In
patients
who
report
upper
abdominal
or
shoulder
pain
after
receiving
G
##RA
##NI
##X
,
disco
##ntin
##ue
G
##RA
##NI
##X
and
evaluate
for
an
enlarged
s
##ple
##en
or
s
##ple
##nic
r
##up
##ture
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
were
detected
in
11
of
the
25
patients
who
tested
positive
for
anti
-
g
##lu
##car
##pid
##ase
binding
antibodies
.
[SEP]
[CLS]
D
##AM
##PA
(
4
-
de
##ox
##y
-
4
-
amino
-
N
10
-
met
##hyl
##pt
##ero
##ic
acid
)
is
an
inactive
meta
##bol
##ite
of
met
##hot
##re
##xa
##te
resulting
from
treatment
with
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
In
addition
to
di
##ar
##r
##hea
and
nausea
(
see
Table
1
)
,
the
following
gas
##tro
##int
##est
##inal
adverse
reactions
also
occurred
more
frequently
in
patients
receiving
T
##AN
##Z
##E
##UM
:
vomit
##ing
(
2
.
6
%
[SEP]
[CLS]
versus
4
.
2
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
gas
##tro
##es
##op
##hage
##al
re
##f
##lux
disease
(
1
.
9
%
versus
3
.
5
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
and
d
##ys
##pe
##ps
##ia
(
2
.
8
%
versus
[SEP]
[CLS]
3
.
4
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
.
[SEP]
[CLS]
Sign
##s
and
symptoms
have
included
respiratory
compromise
,
u
##rt
##ica
##ria
,
and
an
##gio
##ede
##ma
of
the
throat
.
[SEP]
[CLS]
In
Trial
2
,
the
incidence
of
basal
cell
car
##cin
##oma
was
increased
in
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
:
9
%
(
5
/
55
)
of
patients
receiving
T
##AF
##IN
##LA
##R
[SEP]
[CLS]
in
combination
with
tram
##eti
##ni
##b
compared
with
2
%
(
1
/
53
)
of
patients
receiving
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
The
common
adverse
reactions
for
C
##lev
##ip
##re
##x
in
severe
h
##yper
##tens
##ion
included
headache
(
6
.
3
%
)
,
nausea
(
4
.
8
%
)
,
and
vomit
##ing
(
3
.
2
%
)
.
[SEP]
[CLS]
If
a
patient
develops
symptoms
suggest
##ive
of
a
l
##up
##us
-
like
syndrome
following
treatment
with
C
##IM
##Z
##IA
,
disco
##ntin
##ue
treatment
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Ad
##e
##qua
##tel
##y
supplement
all
patients
with
calcium
and
vitamin
D
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
,
Con
##tra
##ind
##ica
##tions
(
4
.
1
)
,
Ad
##verse
Re
##actions
(
6
.
1
)
,
and
[SEP]
[CLS]
Pat
##ient
Counsel
##ing
Information
(
17
.
3
)
]
.
[SEP]
[CLS]
De
##mo
##graphic
Di
##fference
##s
in
Ad
##verse
Re
##actions
in
Clinical
Trials
An
examination
of
population
subgroup
##s
in
the
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
did
not
reveal
any
[SEP]
[CLS]
evidence
of
differences
in
safety
on
the
basis
of
age
,
gender
or
race
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
most
common
Grade
3
/
4
adverse
reactions
(
incidence
>
=
2
%
)
were
s
##tom
##ati
##tis
,
infections
,
h
##yper
##gly
##ce
##mia
,
fatigue
,
d
##ys
##p
##nea
,
p
##ne
##um
##oni
##tis
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
Part
##icular
caution
should
be
exercised
when
administer
##ing
n
##uc
##leo
##side
analog
##s
to
any
patient
with
known
risk
factors
for
liver
disease
;
however
,
cases
have
also
been
reported
in
patients
with
[SEP]
[CLS]
no
known
risk
factors
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
for
clinical
##ly
significant
or
severe
immune
-
mediated
adverse
reactions
.
[SEP]
[CLS]
*
Take
D
##U
##AV
##EE
exactly
as
your
healthcare
provider
tells
you
to
take
it
.
[SEP]
[CLS]
In
addition
,
one
case
of
h
##yper
##par
##athy
##roid
##ism
has
been
reported
.
[SEP]
[CLS]
Further
information
is
available
at
www
.
E
##NT
##ER
##EG
##RE
##MS
.
com
or
1
-
800
-
278
-
03
##40
.
[SEP]
[CLS]
Extreme
care
should
be
exercised
,
with
appropriate
re
##sus
##citation
measures
available
,
if
the
decision
is
made
to
re
-
administer
the
product
[
see
##A
##d
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
Do
not
use
in
combination
with
an
additional
medicine
containing
a
LA
##BA
because
of
risk
of
over
##dos
##e
.
[SEP]
[CLS]
The
most
common
serious
adverse
events
reported
in
the
K
##R
##d
arm
as
compared
with
the
Rd
arm
were
pneumonia
(
14
%
versus
11
%
)
,
[SEP]
[CLS]
respiratory
tract
infection
(
4
%
versus
1
.
5
%
)
,
p
##yre
##xia
(
4
%
versus
2
%
)
,
and
pulmonary
em
##bol
##ism
(
3
%
versus
2
%
)
[SEP]
[CLS]
.
[SEP]
[CLS]
G
##la
##bella
##r
Lines
In
place
##bo
-
controlled
clinical
trials
of
D
##Y
##SP
##OR
##T
(
r
)
,
the
most
common
adverse
reactions
(
>
=
2
%
)
following
injection
of
D
##Y
##SP
##OR
##T
(
r
)
were
[SEP]
[CLS]
na
##so
##pha
##ryn
##git
##is
,
headache
,
injection
site
pain
,
injection
site
reaction
,
upper
respiratory
tract
infection
,
eye
##lid
ed
##ema
,
eye
##lid
p
##tosis
,
sin
##us
##itis
,
and
nausea
.
[SEP]
[CLS]
See
Table
6
for
steps
to
prevent
or
manage
these
possible
and
known
significant
drug
interactions
,
including
dos
##ing
recommendations
[
see
Drug
Inter
##actions
(
7
.
5
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
:
Man
##age
with
immediate
disco
##ntin
##uation
and
close
monitoring
.
[SEP]
[CLS]
Of
these
reports
,
1
patient
in
the
place
##bo
group
and
all
8
patients
in
the
Pro
##lia
group
had
serious
events
,
including
one
death
in
the
Pro
##lia
group
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
Control
##led
Trials
evaluating
J
##AR
##DI
##AN
##CE
10
and
25
mg
The
data
in
Table
1
are
derived
from
a
pool
of
four
24
-
week
place
##bo
-
controlled
trials
and
18
-
week
data
from
a
[SEP]
[CLS]
place
##bo
-
controlled
trial
with
insulin
.
[SEP]
[CLS]
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
5
.
7
With
##dra
##wal
of
A
##ED
##s
As
with
all
anti
##ep
##ile
##ptic
drugs
,
AP
##TI
##OM
should
be
withdrawn
gradually
because
of
the
risk
of
increased
seizure
frequency
and
status
e
##pile
##ptic
##us
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
antibodies
to
den
##os
##uma
##b
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
The
time
to
onset
of
symptoms
following
initiation
of
drug
therapy
varied
from
one
day
to
years
.
[SEP]
[CLS]
The
most
common
non
-
hem
##ato
##log
##ic
Grade
3
or
4
adverse
reactions
(
>
=
5
%
)
were
fatigue
(
11
%
)
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
(
6
%
)
,
and
[SEP]
[CLS]
pneumonia
,
h
##y
##po
##kal
##emia
and
de
##hy
##dra
##tion
,
each
reported
in
5
%
of
patients
.
[SEP]
[CLS]
The
majority
of
cases
occurred
in
countries
with
high
endemic
rates
of
T
##B
.
[SEP]
[CLS]
5
.
2
He
##mor
##r
##hage
Ser
##ious
and
sometimes
fatal
hem
##or
##r
##hage
occurred
with
CO
##ME
##TR
##I
##Q
.
[SEP]
[CLS]
Long
-
standing
h
##yper
##p
##rol
##act
##ine
##mia
when
associated
with
h
##y
##po
##gon
##adi
##sm
may
lead
to
decreased
bone
density
in
both
female
and
male
patients
.
[SEP]
[CLS]
Ce
##r
##vic
##al
D
##ys
##ton
##ia
The
data
described
below
reflect
exposure
to
a
single
in
##tra
##mus
##cular
dose
of
X
##E
##OM
##IN
in
a
place
##bo
-
controlled
,
Phase
3
trial
in
patients
with
c
##er
##vic
##al
d
##ys
##ton
##ia
[
see
Clinical
[SEP]
[CLS]
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##y
##pot
##ens
##ion
:
Before
in
##iti
##ating
FA
##R
##X
##IG
##A
,
assess
volume
status
and
correct
h
##y
##po
##vo
##lem
##ia
in
the
elderly
,
in
patients
with
re
##nal
imp
##air
##ment
or
low
[SEP]
[CLS]
s
##ys
##to
##lic
blood
pressure
,
and
in
patients
on
di
##ure
##tics
.
[SEP]
[CLS]
Approximately
70
%
of
patients
were
male
;
67
%
were
white
,
11
%
were
black
,
and
22
%
other
races
.
[SEP]
[CLS]
5
.
12
Em
##b
##ryo
-
f
##etal
To
##xi
##city
CO
##ME
##TR
##I
##Q
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
Ch
##lo
##as
##ma
may
occasionally
occur
,
especially
in
women
with
a
history
of
ch
##lo
##as
##ma
g
##ra
##vid
##aru
##m
.
[SEP]
[CLS]
Pat
##ients
in
the
treatment
studies
who
rolled
over
into
the
R
##E
-
S
##ON
##AT
##E
study
had
combined
treatment
duration
up
to
9
months
,
with
mean
exposure
of
165
days
.
[SEP]
[CLS]
5
.
8
Em
##b
##ryo
-
f
##etal
To
##xi
##city
Based
on
findings
in
animals
,
Z
##yd
##eli
##g
may
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
Long
-
term
cumulative
radiation
exposure
is
associated
with
an
increased
risk
of
cancer
.
[SEP]
[CLS]
Common
Ad
##verse
Re
##actions
Clinical
AD
##R
##s
of
moderate
intensity
or
greater
(
greater
than
or
equal
to
Grade
2
)
and
reported
in
at
least
2
%
of
subjects
treated
with
[SEP]
[CLS]
IN
##TE
##LE
##NC
##E
(
r
)
and
occurring
at
a
higher
rate
compared
to
place
##bo
(
excess
of
1
%
)
are
presented
in
Table
1
.
[SEP]
[CLS]
To
reduce
this
risk
,
consider
coverage
with
another
anti
##coa
##gu
##lant
if
PR
##AD
##A
##X
##A
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
(
2
.
4
[SEP]
[CLS]
,
2
.
5
,
2
.
6
,
5
.
1
)
.
[SEP]
[CLS]
5
.
4
Local
Effects
of
In
##hale
##d
Co
##rt
##ico
##ster
##oids
In
clinical
trials
,
the
development
of
localized
infections
of
the
mouth
and
p
##har
##ynx
with
Can
##di
##da
al
##bic
##ans
has
occurred
in
subjects
treated
with
BR
##E
##O
[SEP]
[CLS]
E
##LL
##IP
##TA
.
[SEP]
[CLS]
End
##ome
##tri
##al
bio
##ps
##ies
performed
in
a
subset
of
subjects
in
a
Phase
3
Nat
##azi
##a
clinical
trial
did
not
reveal
any
unexpected
or
concerning
findings
for
subjects
taking
CO
##Cs
.
[SEP]
[CLS]
The
majority
of
the
1
,
222
patients
were
women
(
82
%
)
with
a
median
age
of
58
years
(
range
:
26
to
91
years
)
.
[SEP]
[CLS]
In
clinical
trials
,
so
##m
##no
##len
##ce
or
se
##dation
was
reported
at
all
effective
doses
and
was
dose
-
related
.
[SEP]
[CLS]
Women
of
child
##be
##aring
potential
should
be
advised
to
avoid
pregnancy
while
receiving
Bel
##eo
##da
##q
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
in
patients
who
develop
an
acute
my
##oc
##ard
##ial
in
##far
##ction
or
any
other
clinical
##ly
significant
art
##erial
th
##rom
##boe
##mbo
##lic
com
##plication
.
[SEP]
[CLS]
Therefore
N
##U
##L
##O
##J
##IX
is
recommended
for
use
only
in
patients
who
are
E
##B
##V
se
##rop
##os
##itive
[
see
Box
##ed
Warning
and
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Inc
##rease
in
Low
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
In
the
pool
of
13
place
##bo
-
controlled
studies
,
changes
from
base
##line
in
mean
lip
##id
values
were
reported
in
FA
##R
##X
##IG
##A
-
treated
patients
compared
to
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Ser
##ious
infections
included
tuberculosis
,
pneumonia
,
cell
##uli
##tis
,
and
p
##ye
##lone
##ph
##rit
##is
.
[SEP]
[CLS]
He
##mo
##dial
##ys
##is
can
remove
da
##bi
##gat
##ran
;
however
the
clinical
experience
supporting
the
use
of
hem
##od
##ial
##ys
##is
as
a
treatment
for
bleeding
is
limited
[
see
Over
##dos
##age
(
10
)
]
.
[SEP]
[CLS]
(
5
.
3
)
*
Gen
##ital
my
##cot
##ic
infections
:
Monitor
and
treat
if
indicated
.
[SEP]
[CLS]
B
##le
##pha
##ros
##pas
##m
:
The
most
commonly
observed
adverse
reactions
(
>
=
5
%
of
patients
and
>
place
##bo
)
are
eye
##lid
p
##tosis
,
dry
eye
,
dry
mouth
,
di
##ar
##r
##hea
,
[SEP]
[CLS]
headache
,
visual
imp
##air
##ment
,
d
##ys
##p
##nea
,
na
##so
##pha
##ryn
##git
##is
,
and
respiratory
tract
infection
(
6
.
1
)
.
[SEP]
[CLS]
Pre
-
treatment
with
anti
##his
##tamine
##s
with
or
without
anti
##py
##ret
##ics
is
recommended
prior
to
the
start
of
in
##fusion
(
5
.
1
)
.
[SEP]
[CLS]
Grade
3
or
4
increased
bi
##li
##ru
##bin
occurred
in
3
%
of
patients
.
[SEP]
[CLS]
Pat
##ients
,
their
care
##gi
##vers
,
and
families
should
be
informed
that
A
##ED
##s
increase
the
risk
of
su
##icidal
thoughts
and
behavior
and
should
be
advised
of
the
need
to
be
alert
[SEP]
[CLS]
for
the
emergence
or
worse
##ning
of
the
signs
and
symptoms
of
depression
;
any
unusual
changes
in
mood
or
behavior
;
or
the
emergence
of
su
##icidal
thoughts
,
behavior
,
[SEP]
[CLS]
or
thoughts
about
self
-
harm
.
[SEP]
[CLS]
No
evidence
of
altered
p
##har
##ma
##co
##kin
##etic
profile
,
toxicity
profile
,
or
clinical
response
was
associated
with
binding
anti
##body
development
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
and
h
##yper
##sen
##si
##ti
##vity
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
is
not
approved
for
the
treatment
of
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
[
see
also
##B
##ox
##ed
Warning
##and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Similar
events
have
been
reported
with
G
##IL
##EN
##Y
##A
0
.
5
mg
in
the
post
##market
##ing
setting
although
a
ca
##usal
relationship
has
not
been
established
.
[SEP]
[CLS]
EP
##S
-
related
events
include
:
bra
##dy
##kin
##esi
##a
,
d
##ys
##kin
##esi
##a
,
d
##ys
##ton
##ia
,
or
##oman
##di
##bula
##r
d
##ys
##ton
##ia
,
muscle
contraction
##s
in
##vo
##lu
##ntary
,
muscle
twitch
##ing
,
m
##us
##cu
##los
##kel
##etal
stiff
##ness
,
park
##ins
##oni
##sm
,
pro
##trusion
tongue
,
[SEP]
[CLS]
resting
t
##rem
##or
,
and
t
##rem
##or
.
[SEP]
[CLS]
The
most
common
adverse
reaction
leading
to
treatment
disco
##ntin
##uation
was
seizure
,
which
occurred
in
0
.
9
%
of
the
X
##TA
##ND
##I
-
treated
patients
compared
to
none
(
0
%
)
of
the
[SEP]
[CLS]
place
##bo
-
treated
patients
.
[SEP]
[CLS]
E
##os
##ino
##phi
##lia
is
often
present
.
[SEP]
[CLS]
These
adverse
events
were
related
to
cardiac
disorders
in
10
(
2
%
)
patients
,
infections
in
8
(
1
%
)
patients
,
re
##nal
disorders
in
4
(
[SEP]
[CLS]
<
1
%
)
patients
,
and
other
adverse
events
in
8
(
1
%
)
patients
.
[SEP]
[CLS]
*
Ad
##mini
##ster
D
##OT
##AR
##EM
only
in
situations
where
trained
personnel
and
the
##rap
##ies
are
promptly
available
for
the
treatment
of
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
personnel
trained
in
re
##sus
##citation
.
[SEP]
[CLS]
Because
of
its
mechanism
of
action
,
B
##EN
##L
##Y
##ST
##A
may
interfere
with
the
response
to
im
##mu
##ni
##zation
##s
.
[SEP]
[CLS]
Because
these
reactions
were
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
[SEP]
[CLS]
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
*
P
##sor
##ia
##tic
Art
##hr
##itis
:
The
most
common
adverse
reactions
(
>
=
5
%
)
are
di
##ar
##r
##hea
,
nausea
,
and
headache
(
6
.
1
)
*
[SEP]
[CLS]
P
##sor
##ias
##is
:
The
most
common
adverse
reactions
(
>
=
5
%
)
are
di
##ar
##r
##hea
,
nausea
,
upper
respiratory
tract
infection
,
and
headache
,
including
tension
headache
(
6
.
1
[SEP]
[CLS]
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Ce
##lge
##ne
Corporation
at
1
-
88
##8
-
42
##3
-
54
##36
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
[SEP]
[CLS]
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trial
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
[SEP]
[CLS]
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Of
these
disco
##ntin
##uations
,
8
in
the
ST
##RI
##BI
##LD
group
and
1
in
the
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
group
occurred
during
the
first
48
weeks
.
[SEP]
[CLS]
Monitor
patients
for
clinical
signs
and
symptoms
of
h
##y
##pop
##hy
##si
##tis
,
ad
##rena
##l
ins
##uff
##iciency
(
including
ad
##rena
##l
crisis
)
,
and
h
##yper
-
or
h
##y
##pot
##hy
##roid
##ism
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
In
addition
to
adverse
reactions
reported
from
clinical
trials
,
the
following
adverse
reactions
have
been
identified
during
post
##ap
##p
##rov
##al
use
of
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
The
safety
and
effectiveness
of
H
##OR
##I
##Z
##AN
##T
in
patients
with
e
##pile
##psy
have
not
been
studied
.
[SEP]
[CLS]
(
5
.
3
)
*
For
48
hours
after
V
##OR
##A
##X
##A
##Z
##E
administration
,
determine
the
le
##uc
##ovo
##rin
dose
based
on
the
patient
'
s
pre
-
V
##OR
##A
##X
##A
##Z
##E
met
##hot
##re
##xa
##te
concentration
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
T
##AF
##IN
##LA
##R
for
RA
##S
mutation
-
positive
non
-
cut
##aneous
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
Figure
1
:
Major
B
##lee
##ding
Ha
##zard
Rat
##ios
by
Basel
##ine
Character
##istic
##s
-
AR
##IS
##TO
##TL
##E
Study
Note
:
The
figure
above
presents
effects
in
various
subgroup
##s
,
all
of
which
are
base
##line
characteristics
[SEP]
[CLS]
and
all
of
which
were
pre
-
specified
,
if
not
the
grouping
##s
.
[SEP]
[CLS]
Co
##rt
##ico
##ster
##oid
u
##til
##ization
should
be
consistent
with
the
N
##U
##L
##O
##J
##IX
clinical
trial
experience
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
and
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
For
patients
requiring
invasive
dental
procedures
,
clinical
judgment
of
the
treating
physician
and
/
or
oral
surgeon
should
guide
the
management
plan
of
each
patient
based
on
individual
benefit
-
risk
assessment
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
Ad
##verse
reactions
have
been
identified
during
post
##ap
##p
##rov
##al
use
of
U
##L
##OR
##IC
.
[SEP]
[CLS]
Almost
all
of
these
patients
had
received
treatment
with
the
im
##mu
##nos
##up
##press
##ants
a
##za
##thi
##op
##rine
and
/
or
6
-
me
##rca
##pt
##op
##uri
##ne
(
6
-
MP
)
con
##com
##ita
##ntly
with
a
T
##NF
block
##er
at
or
prior
to
diagnosis
.
[SEP]
[CLS]
5
.
6
Alpha
-
Block
##ers
and
Other
Anti
##hy
##pert
##ens
##ives
Physicians
should
discuss
with
patients
the
potential
for
ST
##EN
##DR
##A
to
au
##gment
the
blood
pressure
-
lowering
effect
of
alpha
-
block
##ers
and
other
anti
##hy
##pert
##ens
##ive
medications
[
see
##D
##rug
Inter
##actions
(
[SEP]
[CLS]
7
.
1
)
and
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
Table
6
presents
the
most
common
adverse
drug
reactions
(
experienced
by
greater
than
or
equal
to
3
%
of
p
##ediatric
patients
6
years
and
older
receiving
PR
##OM
##AC
##TA
)
across
[SEP]
[CLS]
the
two
place
##bo
-
controlled
trials
,
with
a
higher
incidence
for
PR
##OM
##AC
##TA
versus
place
##bo
.
[SEP]
[CLS]
Across
clinical
trials
of
T
##AF
##IN
##LA
##R
(
N
=
58
##6
)
,
the
incidence
of
cu
##SC
##C
was
11
%
.
[SEP]
[CLS]
5
.
8
Co
##mb
##ination
with
Other
PD
##E
##5
In
##hibit
##ors
or
E
##re
##ct
##ile
D
##ys
##function
The
##rap
##ies
The
safety
and
efficacy
of
combinations
of
ST
##EN
##DR
##A
with
other
treatments
for
E
##D
has
not
been
studied
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
adult
trials
of
therapeutic
doses
(
5
-
10
mg
twice
daily
)
,
so
##m
##no
##len
##ce
was
reported
in
24
%
(
90
/
37
##9
)
of
patients
on
[SEP]
[CLS]
SA
##P
##H
##RI
##S
compared
to
6
%
(
13
/
203
)
of
place
##bo
patients
.
[SEP]
[CLS]
Such
an
event
may
be
a
sign
of
non
-
art
##eri
##tic
anterior
is
##che
##mic
op
##tic
ne
##uro
##pathy
(
N
##A
##ION
)
,
a
rare
condition
and
a
cause
of
decreased
vision
including
[SEP]
[CLS]
permanent
loss
of
vision
that
has
been
reported
rarely
post
##market
##ing
in
temporal
association
with
the
use
of
all
PD
##E
##5
inhibitor
##s
.
[SEP]
[CLS]
In
the
W
##H
##I
est
##rogen
-
alone
sub
##st
##ud
##y
,
after
an
average
follow
-
up
of
7
.
1
years
,
daily
con
##ju
##gated
est
##rogen
(
0
.
625
mg
)
-
alone
was
not
associated
with
an
increased
risk
of
[SEP]
[CLS]
invasive
breast
cancer
(
relative
risk
[
R
##R
]
0
.
80
)
.
[SEP]
[CLS]
5
.
13
Body
Te
##mper
##ature
Regulation
Di
##s
##rup
##tion
of
the
body
'
s
ability
to
reduce
core
body
temperature
has
been
attributed
to
anti
##psy
##cho
##tic
agents
.
[SEP]
[CLS]
M
##U
##LT
##A
##Q
is
con
##tra
##ind
##ica
##ted
in
patients
in
at
##rial
fi
##bri
##lla
##tion
(
A
##F
)
who
will
not
or
can
not
be
card
##io
##verted
into
normal
sin
##us
rhythm
.
[SEP]
[CLS]
U
##L
##OR
##IC
should
not
be
restart
##ed
in
these
patients
without
another
explanation
for
the
liver
test
abnormal
##ities
.
[SEP]
[CLS]
If
p
##eg
##int
##er
##fer
##on
al
##fa
is
permanently
discontinued
,
then
rib
##avi
##rin
and
VI
##CT
##RE
##L
##IS
must
also
be
discontinued
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
No
adverse
reactions
representing
hem
##oly
##tic
an
##emia
were
reported
in
any
treatment
group
.
[SEP]
[CLS]
The
median
time
to
first
cu
##SC
##C
was
9
weeks
(
range
:
1
to
53
weeks
)
.
[SEP]
[CLS]
P
##ediatric
Pat
##ients
:
The
data
described
below
reflect
median
exposure
to
PR
##OM
##AC
##TA
of
91
days
for
82
p
##ediatric
patients
(
aged
6
to
17
years
)
with
chronic
IT
##P
,
[SEP]
[CLS]
of
whom
52
%
were
female
,
across
the
random
##ized
phase
of
two
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
In
these
patients
,
re
##nal
bio
##psy
was
consistent
with
immune
complex
deposition
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
Need
for
As
##ept
##ic
Tech
##ni
##que
Use
as
##ept
##ic
technique
and
disc
##ard
any
unused
product
within
12
hours
of
stop
##per
pu
##nc
##ture
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
5
.
8
I
##mm
##uni
##zation
##s
The
use
of
live
vaccine
##s
should
be
avoided
during
treatment
with
N
##U
##L
##O
##J
##IX
,
including
but
not
limited
to
the
following
:
in
##tra
##nas
##al
in
##fluenza
,
me
##as
##les
,
mum
##ps
,
[SEP]
[CLS]
rub
##ella
,
oral
p
##olio
,
BC
##G
,
yellow
fever
,
var
##ice
##lla
,
and
T
##Y
##21
##a
t
##y
##ph
##oid
vaccine
##s
.
[SEP]
[CLS]
In
Trial
2
,
the
incidence
of
Grade
3
h
##yper
##gly
##ce
##mia
based
on
laboratory
values
was
5
%
(
3
/
55
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
compared
[SEP]
[CLS]
with
2
%
(
1
/
53
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
and
Ad
##verse
Re
##actions
(
6
)
]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
AN
##AP
##H
##Y
##LA
##X
##IS
See
full
pre
##s
##cribing
information
[SEP]
[CLS]
for
complete
box
##ed
warning
Ana
##phy
##lax
##is
has
been
reported
after
administration
of
K
##AL
##BI
##TO
##R
(
r
)
.
[SEP]
[CLS]
Monitor
patients
receiving
the
combination
closely
for
signs
or
symptoms
of
non
-
cut
##aneous
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
In
the
random
##ized
,
place
##bo
-
controlled
portion
of
S
##J
##IA
Study
2
,
high
AL
##T
greater
than
or
equal
to
3
times
upper
limit
of
normal
(
U
##L
##N
)
were
reported
in
[SEP]
[CLS]
2
(
4
.
1
%
)
IL
##AR
##IS
-
treated
patients
and
1
(
2
.
0
%
)
place
##bo
patient
.
[SEP]
[CLS]
For
advanced
H
##R
+
BC
,
advanced
P
##NE
##T
,
advanced
RC
##C
,
and
re
##nal
an
##gio
##my
##oli
##po
##ma
with
T
##SC
patients
with
severe
he
##pa
##tic
imp
##air
##ment
(
Child
-
P
##ugh
class
C
)
,
A
##FI
##NI
##TO
##R
may
be
[SEP]
[CLS]
used
at
a
reduced
dose
if
the
desired
benefit
out
##wei
##gh
##s
the
risk
.
[SEP]
[CLS]
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
.
]
[SEP]
[CLS]
IL
##AR
##IS
has
not
been
studied
in
patients
with
a
positive
tuberculosis
screen
,
and
the
safety
of
IL
##AR
##IS
in
individuals
with
late
##nt
tuberculosis
infection
is
unknown
.
[SEP]
[CLS]
In
Study
1
,
all
patients
were
evaluated
for
L
##VE
##F
at
screening
and
every
9
weeks
thereafter
in
the
G
##IL
##OT
##RI
##F
-
treated
group
and
as
needed
in
the
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
group
.
[SEP]
[CLS]
*
Eye
disorders
:
in
##f
##re
##quent
:
dip
##lop
##ia
,
vision
blurred
*
Gas
##tro
##int
##est
##inal
disorders
:
in
##f
##re
##quent
:
gas
##tro
##es
##op
##hage
##al
re
##f
##lux
disease
*
In
##ju
##ry
,
Po
##ison
##ing
,
and
Pro
##cedural
Co
##mp
##lication
##s
:
in
##f
##re
##quent
:
[SEP]
[CLS]
fall
*
Skin
and
sub
##cut
##aneous
tissue
disorders
:
in
##f
##re
##quent
:
photos
##ens
##iti
##vity
reaction
*
Ren
##al
and
u
##rina
##ry
disorders
:
in
##f
##re
##quent
:
en
##ures
##is
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
[SEP]
[CLS]
identified
during
post
-
approval
use
of
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Physicians
should
exercise
caution
when
considering
the
use
of
B
##EN
##L
##Y
##ST
##A
in
patients
with
chronic
infections
.
[SEP]
[CLS]
*
Inc
##reased
incidence
of
my
##oc
##ard
##ial
in
##far
##ction
was
seen
in
a
clinical
trial
of
patients
taking
al
##vi
##mo
##pan
for
long
-
term
use
.
[SEP]
[CLS]
(
5
.
8
)
5
.
1
Lac
##tic
A
##cid
##osis
/
Se
##vere
He
##pa
##tom
##eg
##aly
with
St
##eat
##osis
Lac
##tic
acid
##osis
and
severe
he
##pa
##tom
##eg
##aly
with
s
##te
##ato
##sis
,
including
fatal
cases
,
have
been
reported
with
the
use
of
n
##uc
##leo
##side
analog
##s
[SEP]
[CLS]
,
including
ten
##of
##ov
##ir
D
##F
,
a
component
of
ST
##RI
##BI
##LD
,
in
combination
with
other
anti
##ret
##rov
##ira
##ls
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
,
reported
in
at
least
10
%
of
patients
,
that
led
to
dose
reduction
##s
or
interrupt
##ions
were
:
increased
AL
##T
(
29
%
)
[SEP]
[CLS]
,
nausea
(
20
%
)
,
increased
AS
##T
(
16
%
)
,
di
##ar
##r
##hea
(
16
%
)
,
and
vomit
##ing
(
16
%
)
.
[SEP]
[CLS]
5
.
8
Con
##com
##ita
##nt
Use
with
Other
B
##iol
##og
##ic
The
##rap
##ies
or
In
##tra
##ven
##ous
Cy
##c
##lop
##hos
##pha
##mi
##de
B
##EN
##L
##Y
##ST
##A
has
not
been
studied
in
combination
with
other
bio
##log
##ic
the
##rap
##ies
,
including
B
-
cell
targeted
the
##rap
##ies
,
or
in
##tra
##ven
##ous
c
##y
##c
##lop
##hos
##pha
##mi
##de
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
7
)
*
Women
of
child
##be
##aring
potential
should
use
effective
con
##tra
##ception
during
and
for
2
months
after
stopping
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
L
##ymph
##oma
##s
Case
##s
of
l
##ymph
##oma
have
occurred
in
pre
##market
##ing
clinical
trials
and
in
the
post
##market
##ing
setting
.
[SEP]
[CLS]
Death
##s
due
to
adverse
events
within
30
days
of
the
last
dose
of
K
##y
##p
##rol
##is
occurred
in
30
/
59
##8
(
5
%
)
patients
receiving
K
##y
##p
##rol
##is
mon
##otherapy
.
[SEP]
[CLS]
*
I
##mm
##une
Re
##con
##st
##itution
S
##yn
##drome
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
enter
##oc
##oli
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Among
these
patients
,
2
patients
discontinued
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
5
.
3
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
A
potentially
fatal
s
##ym
##pt
##om
complex
sometimes
referred
to
as
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
(
N
##MS
)
has
been
reported
in
association
with
administration
of
anti
##psy
##cho
##tic
drugs
,
[SEP]
[CLS]
including
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
The
following
serious
adverse
reactions
are
described
below
and
elsewhere
in
the
label
##ing
:
.
[SEP]
[CLS]
None
of
the
patients
tested
positive
for
neutral
##izing
antibodies
,
as
was
assessed
using
a
ch
##em
##il
##umi
##nes
##cent
cell
-
based
in
v
##it
##ro
biological
ass
##ay
.
[SEP]
[CLS]
No
data
are
available
on
the
response
to
live
v
##ac
##cin
##ations
or
the
secondary
transmission
of
infection
by
live
vaccine
##s
in
patients
receiving
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Table
2
identifies
the
shift
from
base
##line
to
lowest
observed
estimated
g
##lo
##mer
##ular
fi
##ltration
rate
(
e
##G
##F
##R
)
during
B
##OS
##U
##L
##IF
therapy
for
patients
in
the
global
Ph
+
Le
##uke
##mia
studies
.
[SEP]
[CLS]
(
5
.
11
)
*
Po
##ten
##tial
for
Motor
I
##mp
##air
##ment
:
Use
caution
when
operating
machinery
.
[SEP]
[CLS]
Consider
D
##PP
-
4
inhibitor
##s
as
a
possible
cause
for
severe
joint
pain
and
disco
##ntin
##ue
drug
if
appropriate
.
[SEP]
[CLS]
.
[SEP]
[CLS]
In
addition
,
the
following
clinical
trials
have
also
been
conducted
[
see
Clinical
Ph
##arma
##cology
(
12
)
and
Clinical
Studies
(
14
)
]
:
*
An
8
-
week
crossover
[SEP]
[CLS]
design
trial
(
Trial
4
)
involving
39
patients
between
the
ages
of
6
and
57
years
with
a
G
##12
##44
##E
,
G
##13
##4
##9
##D
,
G
##17
##8
##R
,
G
##55
##1
##S
,
G
##9
##70
##R
,
S
##12
##51
##N
[SEP]
[CLS]
,
S
##12
##55
##P
,
S
##5
##4
##9
##N
,
or
S
##5
##4
##9
##R
mutation
in
the
CF
##TR
gene
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
in
N
##U
##L
##O
##J
##IX
-
treated
patients
were
c
##yt
##ome
##gal
##ov
##ir
##us
infection
(
1
.
5
%
)
and
complications
of
transplant
##ed
kidney
(
1
.
5
%
)
.
[SEP]
[CLS]
G
##la
##bella
##r
Lines
:
The
most
commonly
observed
adverse
reaction
(
>
1
%
of
patients
and
>
place
##bo
)
is
headache
(
6
.
1
)
.
[SEP]
[CLS]
It
is
not
possible
to
determine
whether
P
##OT
##IG
##A
caused
this
decreased
visual
a
##cu
##ity
.
[SEP]
[CLS]
Some
patients
with
re
##tina
##l
abnormal
##ities
have
been
found
to
have
abnormal
visual
a
##cu
##ity
.
[SEP]
[CLS]
Pat
##ients
should
be
caution
##ed
about
operating
hazardous
machinery
,
including
automobiles
,
until
they
are
reasonably
certain
that
therapy
with
FA
##NA
##P
##T
does
not
affect
them
adverse
##ly
.
[SEP]
[CLS]
(
5
.
7
)
5
.
1
H
##y
##pot
##ens
##ion
FA
##R
##X
##IG
##A
causes
in
##tra
##vas
##cular
volume
contraction
.
[SEP]
[CLS]
Table
2
:
Su
##mma
##ry
of
PT
##LD
Report
##ed
in
Studies
1
,
2
,
and
3
Through
Three
Years
of
Treatment
N
##U
##L
##O
##J
##IX
Non
-
Re
##com
##men
##ded
Reg
##ime
##n
*
(
N
=
47
##7
)
N
##U
##L
##O
##J
##IX
Re
##com
##men
##ded
Reg
##ime
##n
(
[SEP]
[CLS]
N
=
47
##2
)
Cy
##c
##los
##por
##ine
(
N
=
47
##6
)
Trial
E
##B
##V
Po
##sitive
(
n
=
40
##6
)
E
##B
##V
N
##eg
##ative
(
n
=
43
)
E
##B
##V
Unknown
(
n
=
28
)
E
##B
##V
Po
##sitive
(
n
=
404
)
E
##B
##V
N
##eg
##ative
(
[SEP]
[CLS]
n
=
48
)
E
##B
##V
Unknown
(
n
=
20
)
E
##B
##V
Po
##sitive
(
n
=
39
##9
)
E
##B
##V
N
##eg
##ative
(
n
=
57
)
E
##B
##V
Unknown
(
n
=
20
)
*
Reg
##ime
##n
with
higher
cumulative
dose
and
more
[SEP]
[CLS]
frequent
dos
##ing
than
the
recommended
N
##U
##L
##O
##J
##IX
regime
##n
.
[SEP]
[CLS]
Ad
##verse
reactions
for
F
##IR
##A
##Z
##Y
##R
were
similar
in
nature
and
frequency
to
those
reported
in
Table
1
.
[SEP]
[CLS]
In
clinical
trials
,
H
##AL
##AV
##EN
has
been
administered
to
1
,
222
patients
with
multiple
tumor
types
,
including
240
patients
exposed
to
H
##AL
##AV
##EN
for
6
months
or
longer
.
[SEP]
[CLS]
O
##bt
##ain
a
complete
blood
cell
(
CBC
)
count
,
including
a
white
blood
cell
(
W
##BC
)
count
corrected
for
the
presence
of
n
##uc
##lea
##ted
red
blood
cells
,
an
[SEP]
[CLS]
absolute
ne
##ut
##rop
##hil
count
(
AN
##C
)
,
and
a
plate
##let
count
daily
until
recovery
(
AN
##C
>
=
1
.
5
x
10
9
/
L
)
.
[SEP]
[CLS]
When
beginning
treatment
with
BR
##E
##O
E
##LL
##IP
##TA
,
patients
who
have
been
taking
oral
or
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
##s
on
a
regular
basis
(
e
.
g
.
,
4
times
a
day
)
[SEP]
[CLS]
should
be
instructed
to
disco
##ntin
##ue
the
regular
use
of
these
drugs
and
to
use
them
only
for
s
##ym
##pt
##oma
##tic
relief
of
acute
respiratory
symptoms
.
[SEP]
[CLS]
5
.
4
In
##test
##inal
Per
##fo
##ration
Fat
##al
and
serious
in
##test
##inal
per
##fo
##ration
occurred
in
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
(
5
.
2
)
*
Fat
##al
and
serious
p
##ne
##um
##oni
##tis
can
occur
in
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
other
clinical
trials
of
the
same
or
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
5
.
3
Risk
##s
for
Benz
##yl
Al
##co
##hol
To
##xi
##city
in
In
##fant
##s
Ad
##re
##V
##ie
##w
contains
ben
##zy
##l
alcohol
at
a
concentration
of
10
.
3
mg
/
m
##L
.
[SEP]
[CLS]
In
Study
1
,
sin
##us
bra
##dy
##card
##ia
,
defined
as
a
heart
rate
of
less
than
50
beats
per
minute
,
was
noted
as
a
new
finding
in
1
%
of
[SEP]
[CLS]
255
patients
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
following
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
5
.
0
%
of
Sub
##jects
Who
Re
##ceived
Two
Con
##current
In
##jection
##s
of
XI
##AF
##LE
##X
in
Study
3
Ad
##verse
Re
##action
XI
##AF
##LE
##X
##N
=
71
##5
Sub
##jects
with
>
=
1
adverse
reaction
95
%
[SEP]
[CLS]
Ed
##ema
peripheral
77
%
Con
##tus
##ion
59
%
Pain
in
ex
##tre
##mity
51
%
Lac
##eration
22
%
P
##ru
##rit
##us
15
%
In
##jection
site
pain
14
%
L
##ymph
##ade
##no
##pathy
13
%
Blood
b
##list
##er
12
%
[SEP]
[CLS]
In
##jection
site
hem
##ato
##ma
8
%
A
##xi
##llar
##y
pain
7
%
In
##jection
site
hem
##or
##r
##hage
6
%
In
##jection
site
swelling
5
%
E
##cc
##hy
##mos
##is
5
%
Safety
of
Re
##tre
##at
##ment
of
Re
##current
Con
##tract
##ures
An
observation
##al
[SEP]
[CLS]
,
open
label
study
was
conducted
in
subjects
who
had
participated
in
XI
##AF
##LE
##X
clinical
trials
for
Du
##pu
##yt
##ren
'
s
contract
##ure
(
Study
4
)
.
[SEP]
[CLS]
*
In
other
XI
##AF
##LE
##X
-
treated
patients
(
9
of
104
##4
;
0
.
9
%
)
,
a
combination
of
pen
##ile
e
##cc
##hy
##mos
##es
,
sudden
pen
##ile
de
##tum
##es
##cence
,
and
/
or
a
pen
##ile
`
`
popping
'
'
[SEP]
[CLS]
sound
was
reported
,
and
in
these
cases
,
a
diagnosis
of
co
##rp
##oral
r
##up
##ture
can
not
be
excluded
.
[SEP]
[CLS]
When
possible
,
avoid
use
of
Z
##Y
##KA
##DI
##A
in
patients
with
con
##gen
##ital
long
Q
##T
syndrome
.
[SEP]
[CLS]
(
2
.
2
,
5
.
3
)
*
Tu
##mor
l
##ys
##is
syndrome
:
Monitor
patients
with
advanced
stage
disease
and
/
or
high
tumor
burden
and
take
appropriate
pre
##ca
##ution
##s
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
8
.
2
years
and
had
a
mean
H
##b
##A
##1
##c
of
7
.
6
-
8
.
5
%
.
[SEP]
[CLS]
Ser
##ious
infections
observed
included
viral
infections
,
pneumonia
,
and
p
##ye
##lone
##ph
##rit
##is
.
[SEP]
[CLS]
If
an
##aph
##yla
##xi
##s
or
severe
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
immediately
stop
the
in
##fusion
and
initiate
appropriate
medical
treatment
.
[SEP]
[CLS]
The
percentage
of
patients
who
withdrew
from
the
study
due
to
adverse
events
was
0
%
and
2
.
5
%
for
the
place
##bo
and
Pro
##lia
groups
,
respectively
.
[SEP]
[CLS]
Similar
proportions
of
patients
developed
protective
levels
of
anti
-
vaccine
antibodies
between
C
##IM
##Z
##IA
and
place
##bo
treatment
groups
;
however
patients
receiving
C
##IM
##Z
##IA
and
con
##com
##ita
##nt
met
##hot
##re
##xa
##te
had
a
lower
humor
##al
response
compared
[SEP]
[CLS]
with
patients
receiving
C
##IM
##Z
##IA
alone
.
[SEP]
[CLS]
In
these
trials
,
which
had
a
median
treatment
duration
of
12
weeks
,
the
estimated
incidence
of
su
##icidal
behavior
among
27
,
86
##3
A
##ED
-
treated
patients
was
0
.
43
%
compared
with
0
.
24
[SEP]
[CLS]
%
among
16
,
02
##9
place
##bo
-
treated
patients
,
representing
an
increase
of
approximately
1
case
of
su
##icidal
thinking
for
every
530
patients
treated
.
[SEP]
[CLS]
J
##AR
##DI
##AN
##CE
was
used
as
mon
##otherapy
in
one
trial
and
as
add
-
on
therapy
in
four
trials
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
In
clinical
studies
,
treatment
with
IN
##VO
##KA
##NA
was
associated
with
a
dose
-
dependent
increase
in
the
incidence
of
volume
de
##ple
##tion
-
related
adverse
reactions
(
e
.
g
.
,
h
##y
##pot
##ens
##ion
,
post
##ural
di
##zzi
##ness
,
[SEP]
[CLS]
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
s
##ync
##ope
,
and
de
##hy
##dra
##tion
)
.
[SEP]
[CLS]
Grade
3
/
4
hem
##or
##r
##ha
##gic
events
were
reported
in
5
/
35
##9
(
1
%
)
patients
receiving
IN
##L
##Y
##TA
(
including
cerebral
hem
##or
##r
##hage
,
hem
##at
##uria
,
hem
##op
##ty
##sis
,
lower
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
,
and
[SEP]
[CLS]
me
##lena
)
and
11
/
35
##5
(
3
%
)
patients
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Mode
##rate
end
##oc
##rino
##pathy
(
requiring
hormone
replacement
or
medical
intervention
;
Grade
2
)
occurred
in
12
(
2
.
3
%
)
patients
and
consisted
of
h
##y
##pot
##hy
##roid
##ism
,
ad
##rena
##l
ins
##uff
##iciency
,
[SEP]
[CLS]
h
##y
##pop
##it
##uit
##aris
##m
,
and
1
case
each
of
h
##yper
##thy
##roid
##ism
and
C
##ushing
'
s
syndrome
.
[SEP]
[CLS]
(
6
.
5
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
In
##iti
##ate
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
pre
##dn
##ison
##e
or
equivalent
for
severe
immune
-
mediated
adverse
reactions
.
[SEP]
[CLS]
Re
##actions
are
further
categorized
by
Me
##d
##DR
##A
system
organ
class
and
listed
in
order
of
decreasing
frequency
according
to
the
following
definitions
:
those
occurring
in
at
least
1
/
100
patients
(
[SEP]
[CLS]
frequent
)
(
only
those
not
already
listed
in
the
ta
##bula
##ted
results
from
place
##bo
-
controlled
trials
appear
in
this
listing
)
;
those
occurring
in
1
/
100
to
1
/
1000
patients
(
in
##f
##re
##quent
[SEP]
[CLS]
)
;
and
those
occurring
in
fewer
than
1
/
1000
patients
(
rare
)
.
[SEP]
[CLS]
T
##hr
##omb
##otic
events
included
five
patients
with
pulmonary
em
##bol
##us
in
the
ever
##oli
##mus
arm
and
one
in
the
place
##bo
arm
as
well
as
three
patients
with
th
##rom
##bos
##is
in
the
ever
##oli
##mus
arm
and
[SEP]
[CLS]
two
in
the
place
##bo
arm
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ang
##io
##ede
##ma
of
the
face
has
been
reported
with
f
##es
##oter
##od
##ine
.
[SEP]
[CLS]
Consider
interrupting
therapy
with
B
##EN
##L
##Y
##ST
##A
in
patients
who
develop
a
new
infection
while
undergoing
treatment
with
B
##EN
##L
##Y
##ST
##A
and
monitor
these
patients
closely
.
[SEP]
[CLS]
Ad
##vise
families
and
care
##gi
##vers
of
the
need
for
close
observation
and
communication
with
the
pre
##s
##cribe
##r
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
mean
age
was
63
years
,
80
%
were
male
and
20
%
were
female
,
and
100
%
were
white
.
[SEP]
[CLS]
All
had
grade
4
ne
##ut
##rop
##enia
and
one
had
f
##eb
##ril
##e
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
Pro
##lia
therapy
should
be
considered
based
on
individual
benefit
-
risk
assessment
.
[SEP]
[CLS]
Care
##ful
monitoring
and
appropriate
dose
adjustments
for
adverse
reactions
are
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
Use
in
S
##pecific
Population
##s
(
8
.
5
)
]
.
[SEP]
[CLS]
The
evaluation
of
adverse
reactions
in
patients
treated
with
V
##OR
##A
##X
##A
##Z
##E
is
con
##founded
by
the
population
in
which
it
was
studied
,
patients
with
toxic
plasma
met
##hot
##re
##xa
##te
levels
due
to
impaired
[SEP]
[CLS]
re
##nal
function
.
[SEP]
[CLS]
Total
bi
##li
##ru
##bin
greater
than
or
equal
to
1
.
5
x
U
##L
##N
was
reported
in
76
%
and
50
%
of
patients
receiving
PR
##OM
##AC
##TA
and
place
##bo
,
respectively
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
medical
support
and
monitoring
measures
should
be
readily
available
during
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
,
and
some
patients
may
require
prolonged
observation
times
that
should
be
individual
##ized
based
on
the
[SEP]
[CLS]
needs
of
the
patient
.
[SEP]
[CLS]
Inter
##st
##iti
##al
in
##fi
##ltration
and
/
or
inflammation
were
observed
on
radio
##graphs
and
com
##puted
to
##mo
##graphic
imaging
of
the
chest
.
[SEP]
[CLS]
There
may
be
circumstances
when
it
is
necessary
to
initiate
treatment
with
a
MA
##O
##I
such
as
line
##zo
##lid
or
in
##tra
##ven
##ous
met
##hyl
##ene
blue
in
a
patient
taking
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
Ser
##ious
adverse
events
were
reported
in
11
%
of
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
and
in
8
%
of
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
.
[SEP]
[CLS]
Because
IL
-
1
blockade
may
interfere
with
immune
response
to
infections
,
it
is
recommended
that
prior
to
initiation
of
therapy
with
IL
##AR
##IS
,
adult
and
p
##ediatric
patients
receive
all
recommended
[SEP]
[CLS]
v
##ac
##cin
##ations
,
as
appropriate
,
including
p
##ne
##um
##oc
##oc
##cal
vaccine
and
inactivated
in
##fluenza
vaccine
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
led
to
disco
##ntin
##uation
in
0
%
,
3
%
,
1
%
,
and
2
%
of
patients
treated
with
place
##bo
,
and
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
,
[SEP]
[CLS]
5
mg
twice
daily
,
and
10
mg
twice
daily
,
respectively
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
St
##oma
##titis
,
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
Because
these
events
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
[SEP]
[CLS]
exposure
.
[SEP]
[CLS]
Pat
##ients
typically
reported
cough
and
d
##ys
##p
##nea
.
[SEP]
[CLS]
Pat
##ients
improved
following
treatment
interrupt
##ion
.
[SEP]
[CLS]
Major
45
(
1
.
41
)
29
(
0
.
92
)
1
.
54
(
0
.
96
,
2
.
45
)
0
.
07
Fat
##al
5
(
0
.
16
)
5
(
0
.
16
)
0
.
99
(
0
.
23
,
4
.
29
[SEP]
[CLS]
)
-
In
##tra
##c
##rani
##al
11
(
0
.
34
)
11
(
0
.
35
)
0
.
99
(
0
.
39
,
2
.
51
)
-
AR
##IS
##TO
##TL
##E
Major
B
##lee
##ding
Forest
P
##lot
Other
Ad
##verse
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
(
including
[SEP]
[CLS]
drug
h
##yper
##sen
##si
##ti
##vity
,
such
as
skin
r
##ash
,
and
an
##aph
##yla
##ctic
reactions
,
such
as
all
##ergic
ed
##ema
)
and
s
##ync
##ope
were
reported
in
<
1
%
of
patients
receiving
E
##L
##I
##Q
##UI
##S
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
to
e
##cal
##lant
##ide
were
determined
in
v
##it
##ro
to
be
present
in
8
.
8
%
of
patients
and
were
not
associated
with
loss
of
efficacy
.
[SEP]
[CLS]
Ad
##verse
reactions
related
to
toxic
met
##hot
##re
##xa
##te
levels
due
to
prolonged
met
##hot
##re
##xa
##te
clearance
include
my
##elo
##su
##pp
##ression
,
m
##uc
##os
##itis
,
acute
he
##pa
##titis
,
and
re
##nal
d
##ys
##function
and
failure
.
[SEP]
[CLS]
There
was
considerable
variation
in
risk
of
su
##icidal
##ity
among
drugs
,
but
a
tendency
toward
an
increase
in
the
younger
patients
for
almost
all
drugs
studied
.
[SEP]
[CLS]
(
5
.
5
)
*
Act
##ivation
of
Man
##ia
:
Use
cautiously
in
patients
with
B
##ip
##olar
Di
##sor
##der
.
[SEP]
[CLS]
5
.
5
Cap
##illa
##ry
Lea
##k
S
##yn
##drome
Cap
##illa
##ry
leak
syndrome
(
C
##LS
)
can
occur
in
patients
receiving
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
and
is
characterized
by
h
##y
##pot
##ens
##ion
,
h
##y
##po
##al
##bu
##mine
##mia
,
ed
##ema
and
[SEP]
[CLS]
hem
##oc
##on
##cent
##ration
.
[SEP]
[CLS]
With
##hold
T
##AF
##IN
##LA
##R
,
and
tram
##eti
##ni
##b
if
used
in
combination
,
for
any
serious
f
##eb
##ril
##e
reaction
or
fever
complicated
by
h
##y
##pot
##ens
##ion
,
rig
##ors
or
chill
##s
,
de
##hy
##dra
##tion
,
or
re
##nal
failure
[SEP]
[CLS]
and
evaluate
for
signs
and
symptoms
of
infection
.
[SEP]
[CLS]
When
possible
,
optimal
glucose
and
lip
##id
control
should
be
achieved
before
starting
a
patient
on
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
These
trials
were
comprised
of
37
##4
patients
of
whom
249
and
125
received
0
.
58
mg
of
XI
##AF
##LE
##X
and
place
##bo
,
respectively
.
[SEP]
[CLS]
System
##ic
and
local
co
##rt
##ico
##ster
##oid
use
may
result
in
the
following
:
*
Can
##di
##da
al
##bic
##ans
infection
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Inc
##reased
risk
of
pneumonia
in
[SEP]
[CLS]
CO
##PD
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
*
I
##mm
##uno
##su
##pp
##ression
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
*
H
##yper
##cor
##tic
##ism
and
ad
##rena
##l
suppression
[
see
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
8
)
]
*
Red
##uction
in
bone
mineral
density
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
13
)
]
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
[SEP]
[CLS]
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
with
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
[SEP]
[CLS]
rates
observed
in
practice
.
[SEP]
[CLS]
PR
##IS
##TI
##Q
is
not
approved
for
use
in
p
##ediatric
patients
[
see
Use
in
S
##pecific
Population
##s
(
8
.
4
)
]
.
[SEP]
[CLS]
With
##hold
or
disco
##ntin
##ue
G
##IL
##OT
##RI
##F
for
confirmed
ul
##cer
##ative
k
##era
##titis
.
[SEP]
[CLS]
6
.
2
Post
-
marketing
Experience
The
following
events
have
been
reported
in
association
with
f
##es
##oter
##od
##ine
use
in
worldwide
post
-
marketing
experience
:
Eye
disorders
:
Blu
##rred
vision
;
Card
##iac
disorders
:
Pa
##l
##pit
##ations
;
[SEP]
[CLS]
General
disorders
and
administrative
site
conditions
:
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##gio
##ede
##ma
with
air
##way
o
##bs
##truction
,
face
ed
##ema
;
Central
nervous
system
disorders
:
Di
##zzi
##ness
,
headache
,
so
##m
##no
##len
##ce
;
[SEP]
[CLS]
Skin
and
sub
##cut
##aneous
tissue
disorders
:
U
##rt
##ica
##ria
,
p
##ru
##rit
##us
Because
these
spontaneous
##ly
reported
events
are
from
the
worldwide
post
-
marketing
experience
,
the
frequency
of
events
and
the
role
of
f
##es
##oter
##od
##ine
[SEP]
[CLS]
in
their
ca
##usa
##tion
can
not
be
re
##lia
##bly
determined
.
[SEP]
[CLS]
Do
##sing
should
be
interrupted
in
patients
with
AL
##T
or
AS
##T
of
greater
than
5
times
the
upper
limit
of
normal
(
U
##L
##N
)
.
[SEP]
[CLS]
The
mean
change
from
base
##line
observed
for
selected
lip
##id
values
is
presented
in
Table
4
.
[SEP]
[CLS]
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
Case
##s
of
J
##C
virus
-
associated
PM
##L
resulting
in
ne
##uro
##logical
deficit
##s
,
including
fatal
cases
,
have
been
reported
in
patients
with
SL
##E
receiving
im
##mu
##nos
##up
##press
##ants
,
[SEP]
[CLS]
including
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
The
most
common
reasons
for
disco
##ntin
##uation
of
therapy
with
M
##U
##LT
##A
##Q
were
gas
##tro
##int
##est
##inal
disorders
(
3
.
2
%
versus
1
.
8
%
in
the
place
##bo
group
)
and
Q
##T
pro
##long
##ation
(
1
.
5
%
[SEP]
[CLS]
versus
0
.
5
%
in
the
place
##bo
group
)
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
/
se
##dation
led
to
withdrawal
in
2
%
of
patients
receiving
600
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
.
[SEP]
[CLS]
The
most
common
adverse
reactions
that
led
to
disco
##ntin
##uation
in
p
##ediatric
patients
treated
with
SA
##P
##H
##RI
##S
(
rates
at
least
2
%
in
any
SA
##P
##H
##RI
##S
arm
and
at
least
twice
the
[SEP]
[CLS]
place
##bo
rate
)
were
so
##m
##no
##len
##ce
(
3
%
in
the
2
.
5
##m
##g
twice
daily
group
,
1
%
in
the
5
##m
##g
twice
daily
group
,
and
2
%
in
the
10
##m
##g
[SEP]
[CLS]
twice
daily
group
)
,
abdominal
pain
(
2
%
in
the
10
##m
##g
twice
daily
group
)
,
and
nausea
(
2
%
in
the
10
##m
##g
twice
daily
group
)
[SEP]
[CLS]
No
place
##bo
-
treated
patients
dropped
out
for
these
events
.
[SEP]
[CLS]
[
see
##D
##osa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
*
D
##U
##AV
##EE
comes
in
a
b
##list
##er
package
.
[SEP]
[CLS]
Disco
##ntin
##ue
ER
##WI
##NA
##Z
##E
for
a
th
##rom
##bot
##ic
or
hem
##or
##r
##ha
##gic
event
until
symptoms
resolve
;
after
resolution
,
treatment
with
ER
##WI
##NA
##Z
##E
may
be
resumed
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
[SEP]
[CLS]
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Other
adverse
reactions
occurring
more
frequently
on
IN
##VO
##KA
##NA
than
on
com
##par
##ator
were
:
Volume
De
##ple
##tion
-
Re
##lated
Ad
##verse
Re
##actions
IN
##VO
##KA
##NA
results
in
an
o
##smo
##tic
di
##ures
##is
,
which
may
lead
to
[SEP]
[CLS]
reduction
##s
in
in
##tra
##vas
##cular
volume
.
[SEP]
[CLS]
When
beginning
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
,
patients
who
have
been
taking
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
##s
on
a
regular
basis
(
e
.
g
.
,
four
times
a
day
)
should
be
instructed
to
[SEP]
[CLS]
disco
##ntin
##ue
the
regular
use
of
these
drugs
and
use
them
only
for
s
##ym
##pt
##oma
##tic
relief
of
acute
respiratory
symptoms
.
[SEP]
[CLS]
Poole
##d
analyses
of
199
place
##bo
-
controlled
clinical
trials
(
mon
##o
-
and
ad
##junct
##ive
-
therapy
)
of
11
different
A
##ED
##s
showed
that
patients
random
##ized
to
one
of
the
A
##ED
##s
had
approximately
twice
the
risk
[SEP]
[CLS]
(
adjusted
relative
risk
1
.
8
,
95
%
confidence
interval
[
C
##I
]
:
1
.
2
,
2
.
7
)
of
su
##icidal
thinking
compared
with
patients
random
##ized
to
place
##bo
.
[SEP]
[CLS]
Therefore
,
avoid
the
use
of
strong
C
##YP
##3
##A
##4
inhibitor
##s
for
more
than
14
consecutive
days
while
on
S
##IR
##TU
##RO
,
unless
the
benefit
of
treatment
with
the
drug
combination
out
##wei
##gh
##s
the
[SEP]
[CLS]
risk
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
DR
##ES
##S
may
be
fatal
or
life
-
threatening
.
[SEP]
[CLS]
B
##lee
##ding
events
of
any
grade
,
including
br
##ui
##sing
and
pet
##ech
##iae
,
occurred
in
approximately
half
of
patients
treated
with
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
B
##lee
##ding
:
PR
##AD
##A
##X
##A
can
cause
serious
and
fatal
bleeding
(
5
.
2
)
*
B
##io
##p
##ros
##the
##tic
heart
valves
:
PR
##AD
##A
##X
##A
use
not
recommended
(
5
.
4
[SEP]
[CLS]
)
5
.
1
Inc
##reased
Risk
of
T
##hr
##omb
##otic
Events
after
Pre
##mat
##ure
Disco
##ntin
##uation
Pre
##mat
##ure
disco
##ntin
##uation
of
any
oral
anti
##coa
##gu
##lant
,
including
PR
##AD
##A
##X
##A
,
in
the
absence
of
adequate
alternative
anti
##coa
##gu
##lation
increases
the
risk
[SEP]
[CLS]
of
th
##rom
##bot
##ic
events
.
[SEP]
[CLS]
PR
##AD
##A
##X
##A
'
s
anti
##coa
##gu
##lant
activity
and
half
-
life
are
increased
in
patients
with
re
##nal
imp
##air
##ment
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
incidence
of
antibodies
to
Y
##ER
##VO
##Y
with
the
incidence
##s
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
The
majority
of
these
events
were
infections
.
[SEP]
[CLS]
Eight
of
79
(
10
.
1
%
)
patients
in
the
S
##IR
##TU
##RO
group
and
16
of
81
(
19
.
8
%
)
patients
in
the
place
##bo
treatment
group
were
HIV
-
infected
.
[SEP]
[CLS]
(
5
.
1
)
*
Me
##as
##ure
the
absolute
ne
##ut
##rop
##hil
count
(
AN
##C
)
before
starting
Fe
##rri
##p
##ro
##x
and
monitor
the
AN
##C
weekly
on
therapy
.
[SEP]
[CLS]
Clinical
##ly
significant
card
##iovascular
effects
and
fatalities
have
been
reported
in
association
with
excessive
use
of
inhaled
s
##ym
##path
##omi
##met
##ic
drugs
.
[SEP]
[CLS]
BR
##E
##O
E
##LL
##IP
##TA
should
not
be
used
for
the
relief
of
acute
symptoms
,
i
.
e
.
,
as
rescue
therapy
for
the
treatment
of
acute
episodes
of
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
Con
##current
elevations
in
AL
##T
greater
than
3
times
the
U
##L
##N
and
total
bi
##li
##ru
##bin
greater
than
2
times
the
U
##L
##N
,
with
normal
al
##kal
##ine
p
##hos
##pha
##tase
,
occurred
in
less
than
1
[SEP]
[CLS]
%
of
patients
in
clinical
studies
.
[SEP]
[CLS]
A
##gra
##nu
##loc
##yt
##osis
and
ne
##ut
##rop
##enia
usually
resolve
upon
disco
##ntin
##uation
of
Fe
##rri
##p
##ro
##x
,
but
there
have
been
reports
of
a
##gra
##nu
##loc
##yt
##osis
leading
to
death
.
[SEP]
[CLS]
Monitor
weekly
for
liver
toxicity
if
the
AL
##T
or
AS
##T
rises
above
3
times
the
upper
limit
of
normal
until
resolved
.
[SEP]
[CLS]
(
5
.
13
)
*
Close
monitoring
for
g
##lau
##com
##a
and
cat
##ara
##cts
is
warrant
##ed
.
[SEP]
[CLS]
Pat
##ients
should
be
closely
monitored
for
signs
or
symptoms
of
S
##J
##S
/
T
##EN
,
especially
during
the
first
8
weeks
of
treatment
initiation
or
when
re
-
introducing
therapy
.
[SEP]
[CLS]
5
.
4
Gen
##ital
My
##cot
##ic
In
##fect
##ions
FA
##R
##X
##IG
##A
increases
the
risk
of
g
##eni
##tal
my
##cot
##ic
infections
.
[SEP]
[CLS]
With
##dra
##wal
symptoms
occurred
following
abrupt
disco
##ntin
##uation
of
ON
##FI
;
the
risk
of
withdrawal
symptoms
is
greater
with
higher
doses
.
[SEP]
[CLS]
Clinical
My
##oc
##ard
##ial
In
##far
##ction
Events
In
the
active
-
controlled
V
##TE
studies
,
a
higher
rate
of
clinical
my
##oc
##ard
##ial
in
##far
##ction
was
reported
in
patients
who
received
PR
##AD
##A
##X
##A
[
20
(
0
.
66
per
100
[SEP]
[CLS]
patient
-
years
)
]
than
in
those
who
received
war
##fari
##n
[
5
(
0
.
17
per
100
patient
-
years
)
]
.
[SEP]
[CLS]
An
increase
in
frequency
or
severity
of
mi
##gra
##ine
during
CO
##C
use
(
which
may
be
pro
##dr
##oma
##l
of
a
c
##ere
##bro
##vas
##cular
event
)
may
be
a
reason
for
immediate
disco
##ntin
##uation
of
the
[SEP]
[CLS]
CO
##C
.
[SEP]
[CLS]
5
.
3
Ex
##cess
##ive
Use
of
BR
##E
##O
E
##LL
##IP
##TA
and
Use
with
Other
Long
-
Acting
Beta
##2
-
A
##gon
##ists
BR
##E
##O
E
##LL
##IP
##TA
should
not
be
used
more
often
than
recommended
,
at
higher
doses
than
recommended
,
or
[SEP]
[CLS]
in
conjunction
with
other
medicines
containing
LA
##BA
,
as
an
over
##dos
##e
may
result
.
[SEP]
[CLS]
Table
3
shows
the
incidence
of
adverse
reactions
that
were
reported
in
greater
than
or
equal
to
5
%
of
XI
##AF
##LE
##X
-
treated
patients
and
at
a
frequency
greater
than
place
##bo
-
treated
patients
[SEP]
[CLS]
after
up
to
3
injection
##s
in
the
pool
##ed
place
##bo
-
controlled
trials
through
Day
90
(
Studies
1
and
2
)
.
[SEP]
[CLS]
Anti
-
b
##lina
##tum
##oma
##b
anti
##body
formation
may
affect
p
##har
##ma
##co
##kin
##etics
of
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
related
to
B
##L
##IN
##C
##Y
##TO
treatment
were
h
##yper
##sen
##si
##ti
##vity
(
1
%
)
and
br
##on
##cho
##sp
##as
##m
(
<
1
%
)
.
[SEP]
[CLS]
For
some
T
##NF
block
##ers
,
more
cases
of
ma
##li
##gna
##ncies
have
been
observed
among
patients
receiving
those
T
##NF
block
##ers
compared
to
control
patients
.
[SEP]
[CLS]
5
.
3
XI
##AF
##LE
##X
R
##EM
##S
Program
Because
of
the
risks
of
co
##rp
##oral
r
##up
##ture
(
pen
##ile
fracture
)
or
other
serious
pen
##ile
injury
in
the
treatment
of
P
##ey
##ron
##ie
'
s
disease
,
XI
##AF
##LE
##X
is
[SEP]
[CLS]
available
only
through
the
XI
##AF
##LE
##X
R
##EM
##S
Program
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Leading
to
Study
Disco
##ntin
##uation
:
11
.
4
%
of
the
women
discontinued
from
the
clinical
trials
due
to
an
adverse
reaction
;
the
most
frequent
adverse
reactions
leading
to
[SEP]
[CLS]
disco
##ntin
##uation
were
men
##st
##ru
##al
disorder
(
metro
##rr
##ha
##gia
,
men
##or
##r
##ha
##gia
,
men
##st
##ru
##ation
irregular
,
g
##eni
##tal
hem
##or
##r
##hage
,
v
##agi
##nal
hem
##or
##r
##hage
,
d
##ys
##function
##al
u
##ter
##ine
bleeding
)
(
2
.
3
%
)
;
mood
changes
(
[SEP]
[CLS]
depression
,
mood
swings
,
mood
altered
,
depressed
mood
,
d
##ys
##thy
##mic
disorder
,
crying
)
(
1
.
2
%
)
;
a
##c
##ne
(
1
.
1
%
)
,
headache
(
including
[SEP]
[CLS]
mi
##gra
##ines
)
(
1
.
1
%
)
,
and
weight
increased
(
0
.
7
%
)
.
[SEP]
[CLS]
Pat
##ients
using
supplement
##al
oxygen
or
continuous
positive
air
##way
pressure
(
CP
##AP
)
during
sleep
should
have
these
treatments
readily
available
during
in
##fusion
in
the
event
of
an
acute
reaction
,
[SEP]
[CLS]
or
extreme
d
##rows
##iness
/
sleep
induced
by
anti
##his
##tamine
use
.
[SEP]
[CLS]
Given
the
potential
for
delay
in
l
##ymph
##oc
##yte
recovery
after
disco
##ntin
##uation
of
T
##EC
##FI
##DE
##RA
,
consider
following
l
##ymph
##oc
##yte
counts
until
l
##ymph
##ope
##nia
is
resolved
.
[SEP]
[CLS]
Ren
##al
c
##ys
##ts
occurred
in
8
(
5
%
)
patients
treated
with
X
##AL
##KO
##RI
and
1
(
1
%
)
patient
treated
with
ch
##em
##otherapy
in
Study
1
.
[SEP]
[CLS]
Inter
##rup
##t
,
dose
reduce
or
disco
##ntin
##ue
B
##OS
##U
##L
##IF
as
necessary
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
occurring
in
at
least
10
%
of
patients
,
using
the
NC
##I
CT
##C
Version
4
,
are
shown
in
Table
3
.
[SEP]
[CLS]
6
.
1
Clinical
Study
Experience
The
data
from
clinical
studies
reflect
exposure
to
Da
##T
##sca
##n
in
94
##2
subjects
with
a
mean
age
of
66
years
(
range
25
to
90
years
)
[SEP]
[CLS]
.
[SEP]
[CLS]
Common
Ad
##verse
Re
##actions
The
most
commonly
reported
adverse
reactions
(
occurring
in
more
than
5
%
of
patients
who
received
500
Units
of
D
##Y
##SP
##OR
##T
(
r
)
in
the
place
##bo
[SEP]
[CLS]
controlled
clinical
trials
)
in
c
##er
##vic
##al
d
##ys
##ton
##ia
patients
were
:
muscular
weakness
,
d
##ys
##pha
##gia
,
dry
mouth
,
injection
site
discomfort
,
fatigue
,
headache
,
neck
pain
,
[SEP]
[CLS]
m
##us
##cu
##los
##kel
##etal
pain
,
d
##ys
##phon
##ia
,
injection
site
pain
,
and
eye
disorders
(
consisting
of
blurred
vision
,
dip
##lop
##ia
,
and
reduced
visual
a
##cu
##ity
)
.
[SEP]
[CLS]
Se
##vere
reactions
are
generally
managed
with
in
##fusion
interrupt
##ion
,
administration
of
anti
##his
##tamine
##s
,
co
##rt
##ico
##ster
##oids
,
in
##tra
##ven
##ous
fluids
,
and
/
or
oxygen
,
when
clinical
##ly
indicated
.
[SEP]
[CLS]
D
##U
##AV
##EE
may
also
affect
how
your
other
medicines
work
.
[SEP]
[CLS]
In
a
3
-
week
,
place
##bo
-
controlled
p
##ediatric
trial
with
bi
##pol
##ar
I
disorder
,
the
incidence
##s
of
EP
##S
-
related
events
,
excluding
events
related
to
aka
##thi
##sia
,
were
4
%
,
3
%
[SEP]
[CLS]
,
and
5
%
for
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
,
5
mg
,
and
10
mg
twice
daily
,
respectively
,
as
compared
to
3
%
for
place
##bo
-
treated
[SEP]
[CLS]
patients
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Co
##rre
##ct
volume
or
salt
de
##ple
##tion
prior
to
administration
of
Ed
##ar
##bi
.
[SEP]
[CLS]
Do
not
take
D
##U
##AV
##EE
if
you
:
*
currently
have
or
have
had
blood
c
##lot
##s
*
are
all
##ergic
to
est
##rogen
##s
or
b
##azed
##ox
##ife
##ne
,
the
active
ingredients
in
D
##U
##AV
##EE
,
or
[SEP]
[CLS]
any
of
its
ingredients
.
[SEP]
[CLS]
These
patients
may
have
an
increased
risk
for
a
h
##yper
##sen
##si
##ti
##vity
reaction
to
D
##OT
##AR
##EM
.
[SEP]
[CLS]
For
those
patients
who
reported
dry
mouth
,
most
had
their
first
occurrence
of
the
event
within
the
first
month
of
treatment
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
El
##eva
##ted
trans
##ami
##nas
##es
)
:
Trans
##ami
##nas
##es
(
AL
##T
and
AS
##T
)
should
be
assessed
prior
to
in
##iti
##ating
K
##AL
##Y
##DE
##CO
,
every
3
months
during
the
[SEP]
[CLS]
first
year
of
treatment
,
and
annually
thereafter
.
[SEP]
[CLS]
Risk
by
In
##dication
for
Anti
##ep
##ile
##ptic
Drugs
in
the
Poole
##d
Analysis
In
##dication
Place
##bo
##P
##ati
##ents
With
##E
##vent
##s
Per
##1
,
000
Pat
##ients
Drug
Pat
##ients
##W
##ith
Events
Per
##1
,
000
Pat
##ients
Re
##lative
Risk
:
Inc
##iden
##ce
of
Events
##in
Drug
##P
##ati
##ents
/
Inc
##iden
##ce
##in
Place
##bo
Pat
##ients
Risk
[SEP]
[CLS]
Di
##fference
:
Additional
Drug
##P
##ati
##ents
With
##E
##vent
##s
Per
1
,
000
##P
##ati
##ents
E
##pile
##psy
1
.
0
3
.
4
3
.
5
2
.
4
P
##sy
##chia
##tric
5
.
7
8
.
5
1
.
5
2
.
9
Other
1
.
0
1
.
8
1
.
9
0
.
9
Total
2
.
4
4
.
3
1
.
8
1
.
9
The
relative
risk
[SEP]
[CLS]
for
su
##icidal
thoughts
was
higher
in
clinical
trials
for
e
##pile
##psy
than
in
clinical
trials
for
psychiatric
or
other
conditions
,
but
the
absolute
risk
differences
were
similar
for
the
e
##pile
##psy
[SEP]
[CLS]
and
psychiatric
indication
##s
.
[SEP]
[CLS]
5
.
6
Live
##r
Trans
##p
##lant
Use
of
N
##U
##L
##O
##J
##IX
in
liver
transplant
patients
is
not
recommended
[
see
Box
##ed
Warning
]
.
[SEP]
[CLS]
Only
Study
1
included
a
place
##bo
group
,
allowing
comparison
of
adverse
reaction
rates
on
ON
##FI
at
several
doses
to
place
##bo
.
[SEP]
[CLS]
Disco
##ntin
##uation
due
to
G
##I
adverse
reactions
occurred
in
2
%
of
individuals
on
T
##AN
##Z
##E
##UM
or
place
##bo
.
[SEP]
[CLS]
Ad
##vise
all
patients
to
seek
immediate
medical
attention
if
they
develop
signs
and
symptoms
suggest
##ive
of
blood
d
##ys
##c
##ras
##ias
or
infection
(
e
.
g
.
,
persistent
fever
,
br
##ui
##sing
,
bleeding
,
[SEP]
[CLS]
p
##allo
##r
)
while
on
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Treatment
with
medications
that
work
through
in
##hibition
of
IL
-
1
has
been
associated
with
an
increased
risk
of
serious
infections
.
[SEP]
[CLS]
Per
##form
der
##mat
##olo
##gic
evaluation
##s
prior
to
initiation
of
T
##AF
##IN
##LA
##R
as
a
single
agent
or
in
combination
with
tram
##eti
##ni
##b
,
every
2
months
while
on
therapy
,
and
for
up
to
6
[SEP]
[CLS]
months
following
disco
##ntin
##uation
of
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
5
.
6
Inter
##ference
with
Visual
##ization
of
Live
##r
Les
##ions
Se
##vere
re
##nal
or
he
##pa
##tic
failure
may
imp
##air
E
##O
##VI
##ST
imaging
performance
.
[SEP]
[CLS]
Physicians
should
consider
whether
their
patients
with
underlying
N
##A
##ION
risk
factors
could
be
adverse
##ly
affected
by
use
of
PD
##E
##5
inhibitor
##s
.
[SEP]
[CLS]
Table
5
presents
the
most
common
treatment
-
related
adverse
reactions
(
experienced
by
greater
than
or
equal
to
3
%
of
patients
receiving
PR
##OM
##AC
##TA
)
from
the
extension
trial
.
[SEP]
[CLS]
In
a
3
-
week
,
place
##bo
-
controlled
,
bi
##pol
##ar
I
p
##ediatric
trial
,
the
incidence
of
so
##m
##no
##len
##ce
(
including
se
##dation
and
h
##yper
##so
##m
##nia
)
for
place
##bo
,
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
,
[SEP]
[CLS]
5
mg
twice
daily
,
and
10
mg
twice
daily
,
was
12
%
(
12
/
101
)
,
46
%
(
48
/
104
)
,
53
%
(
52
/
99
)
,
[SEP]
[CLS]
and
49
%
(
49
/
99
)
,
respectively
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
unknown
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
casual
relationship
to
drug
[SEP]
[CLS]
exposure
.
[SEP]
[CLS]
5
.
5
Development
of
Drug
-
Re
##sist
##ant
Ba
##cter
##ia
Pre
##s
##cribing
D
##AL
##VA
##NC
##E
in
the
absence
of
a
proven
or
strongly
suspected
bacterial
infection
is
unlikely
to
provide
benefit
to
the
patient
and
increases
the
risk
[SEP]
[CLS]
of
the
development
of
drug
-
resistant
bacteria
.
[SEP]
[CLS]
Mali
##gna
##ncies
,
some
fatal
,
have
been
reported
among
children
,
adolescent
##s
,
and
young
adults
who
received
treatment
with
T
##NF
-
blocking
agents
(
initiation
of
therapy
<
=
18
years
[SEP]
[CLS]
of
age
)
,
of
which
C
##IM
##Z
##IA
is
a
member
.
[SEP]
[CLS]
5
.
4
Effects
on
Eye
Physicians
should
advise
patients
to
stop
use
of
all
PD
##E
##5
inhibitor
##s
,
including
ST
##EN
##DR
##A
,
and
seek
medical
attention
in
the
event
of
a
sudden
loss
[SEP]
[CLS]
of
vision
in
one
or
both
eyes
.
[SEP]
[CLS]
O
##bt
##ain
a
liver
test
panel
(
serum
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
[
AL
##T
]
,
as
##par
##tate
amino
##tra
##ns
##fer
##ase
[
AS
##T
]
,
al
##kal
##ine
p
##hos
##pha
##tase
,
and
total
bi
##li
##ru
##bin
)
as
a
base
##line
before
[SEP]
[CLS]
in
##iti
##ating
U
##L
##OR
##IC
.
[SEP]
[CLS]
ST
##EN
##DR
##A
should
be
used
with
caution
in
patients
with
an
##ato
##mic
##al
def
##orm
##ation
of
the
penis
(
such
as
an
##gu
##lation
,
cavern
##osa
##l
fi
##bro
##sis
,
or
P
##ey
##ron
##ie
'
s
disease
)
,
or
in
[SEP]
[CLS]
patients
who
have
conditions
which
may
pre
##dis
##pose
them
to
p
##ria
##pis
##m
(
such
as
sick
##le
cell
an
##emia
,
multiple
my
##elo
##ma
,
or
le
##uke
##mia
)
.
[SEP]
[CLS]
Ad
##e
##qua
##te
diagnostic
measures
,
including
directed
or
random
end
##ome
##tri
##al
sampling
when
indicated
,
should
be
undertaken
to
rule
out
ma
##li
##gna
##ncy
in
post
##men
##op
##aus
##al
women
with
und
##ia
##gno
##sed
persistent
or
recurring
abnormal
g
##eni
##tal
[SEP]
[CLS]
bleeding
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
20
%
)
,
regardless
of
ca
##usal
##ity
,
were
ne
##ut
##rop
##enia
,
peripheral
sensory
ne
##uro
##pathy
,
fatigue
,
upper
respiratory
tract
infection
,
[SEP]
[CLS]
nausea
,
di
##ar
##r
##hea
,
an
##emia
,
p
##yre
##xia
,
th
##rom
##bo
##cy
##top
##enia
,
r
##ash
,
abdominal
pain
,
cough
,
and
vomit
##ing
.
[SEP]
[CLS]
The
increase
in
V
##TE
risk
was
demonstrated
during
the
first
2
years
[
see
Clinical
Studies
(
14
.
5
)
]
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
(
including
se
##dation
)
led
to
disco
##ntin
##uation
in
0
.
6
%
(
12
/
1953
)
of
patients
in
short
-
term
,
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
5
.
4
I
##mm
##uni
##zation
##s
Live
vaccine
##s
should
not
be
given
concurrently
with
IL
##AR
##IS
[
see
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
From
this
information
,
it
is
not
possible
to
determine
whether
these
events
are
related
directly
to
the
use
of
PD
##E
##5
inhibitor
##s
or
to
other
factors
[
see
##A
##d
##verse
Re
##actions
(
[SEP]
[CLS]
6
.
2
)
]
.
[SEP]
[CLS]
While
taking
A
##FI
##NI
##TO
##R
,
be
v
##igi
##lant
for
signs
and
symptoms
of
infection
;
if
a
diagnosis
of
an
infection
is
made
,
institute
appropriate
treatment
promptly
and
consider
interrupt
##ion
or
[SEP]
[CLS]
disco
##ntin
##uation
of
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
H
##y
##po
##gly
##ce
##mia
The
proportion
of
patients
experiencing
at
least
one
documented
s
##ym
##pt
##oma
##tic
h
##y
##po
##gly
##ce
##mic
episode
on
T
##AN
##Z
##E
##UM
and
the
proportion
of
patients
experiencing
at
least
one
severe
[SEP]
[CLS]
h
##y
##po
##gly
##ce
##mic
episode
on
T
##AN
##Z
##E
##UM
in
clinical
trials
[
see
Clinical
Studies
(
14
)
]
is
shown
in
Table
2
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Inter
##le
##uki
##n
-
1
blockade
may
interfere
with
immune
response
to
infections
.
[SEP]
[CLS]
Poole
##d
analyses
of
short
-
term
place
##bo
-
controlled
studies
of
anti
##de
##press
##ant
drugs
(
SSR
##I
##s
and
others
)
showed
that
these
drugs
increase
the
risk
of
su
##icidal
thinking
(
su
##icidal
##ity
)
in
children
,
[SEP]
[CLS]
adolescent
##s
,
and
young
adults
(
ages
18
to
24
)
with
major
de
##pressive
disorder
(
MD
##D
)
and
other
psychiatric
disorders
.
[SEP]
[CLS]
5
.
6
Re
##sp
##ira
##tory
Effects
Do
##se
-
dependent
reduction
##s
in
forced
ex
##pi
##rator
##y
volume
over
1
second
)
were
observed
in
patients
treated
with
G
##IL
##EN
##Y
##A
as
early
as
1
month
after
treatment
initiation
.
[SEP]
[CLS]
Consider
disco
##ntin
##uation
of
C
##IM
##Z
##IA
therapy
in
patients
with
confirmed
significant
hem
##ato
##log
##ic
abnormal
##ities
.
[SEP]
[CLS]
The
incidence
of
adverse
reactions
below
is
based
upon
2
place
##bo
-
controlled
,
clinical
trials
(
E
##DE
##MA
##3
(
r
)
and
E
##DE
##MA
##4
(
r
)
)
in
a
total
of
143
[SEP]
[CLS]
unique
patients
with
H
##A
##E
.
[SEP]
[CLS]
Through
48
weeks
,
the
rates
of
adverse
events
leading
to
disco
##ntin
##uation
were
2
%
in
subjects
receiving
T
##I
##VI
##CA
##Y
and
4
%
in
subjects
receiving
da
##run
##avi
##r
/
r
##ito
##na
##vir
.
[SEP]
[CLS]
Anyone
considering
pre
##s
##cribing
H
##OR
##I
##Z
##AN
##T
must
balance
the
risk
of
su
##icidal
thoughts
or
behavior
with
the
risk
of
un
##tre
##ated
illness
.
[SEP]
[CLS]
The
rates
of
treatment
-
emerge
##nt
adverse
events
resulting
in
permanent
disco
##ntin
##uation
were
24
%
and
5
%
for
the
A
##FI
##NI
##TO
##R
plus
ex
##em
##esta
##ne
and
place
##bo
plus
ex
##em
##esta
##ne
treatment
groups
,
respectively
.
[SEP]
[CLS]
These
events
were
observed
primarily
in
subjects
with
a
pre
-
existing
history
of
depression
or
other
psychiatric
illness
.
[SEP]
[CLS]
Two
of
the
four
subjects
had
re
##nal
imp
##air
##ment
(
i
.
e
.
[SEP]
[CLS]
Alternative
##s
to
NSA
##ID
##s
should
be
considered
,
if
needed
,
in
patients
at
risk
for
re
##nal
d
##ys
##function
.
[SEP]
[CLS]
Some
of
these
reactions
occurred
after
the
first
administration
of
go
##lim
##uma
##b
.
[SEP]
[CLS]
Falls
and
Fall
-
related
In
##ju
##ries
In
the
two
random
##ized
clinical
trials
,
falls
including
fall
-
related
injuries
,
occurred
in
9
%
of
patients
treated
with
X
##TA
##ND
##I
compared
to
4
%
of
[SEP]
[CLS]
patients
treated
with
place
##bo
.
[SEP]
[CLS]
Although
co
##bic
##ista
##t
(
a
component
of
ST
##RI
##BI
##LD
)
may
cause
modest
increases
in
serum
c
##rea
##tin
##ine
and
modest
decline
##s
in
estimated
c
##rea
##tin
##ine
clearance
without
affecting
re
##nal
g
##lo
##mer
##ular
function
[
see
Ad
##verse
[SEP]
[CLS]
Re
##actions
(
6
.
1
)
]
,
patients
who
experience
a
confirmed
increase
in
serum
c
##rea
##tin
##ine
of
greater
than
0
.
4
mg
per
d
##L
from
base
##line
should
be
closely
monitored
for
re
##nal
[SEP]
[CLS]
safety
.
[SEP]
[CLS]
In
clinical
trials
with
IN
##L
##Y
##TA
,
art
##erial
th
##rom
##boe
##mbo
##lic
events
(
including
trans
##ient
is
##che
##mic
attack
,
c
##ere
##bro
##vas
##cular
accident
,
my
##oc
##ard
##ial
in
##far
##ction
,
and
re
##tina
##l
artery
o
##cc
##lusion
)
were
reported
in
17
/
71
##5
[SEP]
[CLS]
patients
(
2
%
)
,
with
two
deaths
secondary
to
c
##ere
##bro
##vas
##cular
accident
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
the
post
##market
##ing
use
of
E
##DA
##RB
##I
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
s
##chi
##zophrenia
adult
trials
,
the
mean
increase
in
trans
##ami
##nas
##e
levels
for
SA
##P
##H
##RI
##S
-
treated
patients
was
1
.
6
units
/
L
compared
to
a
decrease
of
0
.
4
units
/
L
for
place
##bo
-
treated
patients
[SEP]
[CLS]
.
[SEP]
[CLS]
Do
not
take
D
##U
##AV
##EE
if
the
test
is
positive
and
talk
to
your
healthcare
provider
.
[SEP]
[CLS]
No
disc
##ern
##ible
pattern
between
death
and
s
##put
##um
culture
conversion
,
re
##lap
##se
,
sensitivity
to
other
drugs
used
to
treat
tuberculosis
,
HIV
status
,
or
severity
of
disease
could
be
[SEP]
[CLS]
observed
.
[SEP]
[CLS]
There
were
4
suicide
##s
in
drug
-
treated
patients
in
the
trials
and
none
in
place
##bo
-
treated
patients
,
but
the
number
is
too
small
to
allow
any
conclusion
about
drug
effect
on
[SEP]
[CLS]
suicide
.
[SEP]
[CLS]
The
patient
recovered
fully
following
disco
##ntin
##uation
of
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
Ren
##al
c
##ys
##ts
occurred
in
8
(
5
%
)
patients
treated
with
X
##AL
##KO
##RI
and
1
(
1
%
)
patient
treated
with
ch
##em
##otherapy
in
Study
2
.
[SEP]
[CLS]
I
##MB
##R
##U
##VI
##CA
may
increase
the
risk
of
hem
##or
##r
##hage
in
patients
receiving
anti
##plate
##let
or
anti
##coa
##gu
##lant
the
##rap
##ies
.
[SEP]
[CLS]
Evaluation
of
air
##way
pat
##ency
should
be
considered
prior
to
initiation
of
treatment
with
V
##im
##iz
##im
.
[SEP]
[CLS]
NE
##SI
##NA
should
not
be
restart
##ed
in
these
patients
without
another
explanation
for
the
liver
test
abnormal
##ities
.
[SEP]
[CLS]
In
Studies
1
and
2
,
Grade
3
s
##ync
##ope
occurred
in
2
.
0
%
of
X
##AL
##KO
##RI
-
treated
patients
and
in
0
.
6
%
of
the
ch
##em
##otherapy
-
treated
patients
.
[SEP]
[CLS]
If
a
patient
develops
any
of
these
reactions
after
treatment
with
AP
##TI
##OM
,
the
drug
should
be
discontinued
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
in
patients
who
develop
ne
##ph
##rot
##ic
syndrome
.
[SEP]
[CLS]
Ad
##mini
##ster
systemic
high
-
dose
co
##rt
##ico
##ster
##oids
for
severe
,
persistent
,
or
recurring
immune
-
mediated
reactions
.
[SEP]
[CLS]
Ad
##vise
patients
regarding
good
oral
h
##ygiene
practices
.
[SEP]
[CLS]
Across
the
treatment
arms
,
the
mean
age
of
patients
was
56
years
,
1
%
were
75
years
or
older
and
53
%
were
male
.
[SEP]
[CLS]
In
##f
##lix
##ima
##b
was
administered
to
5
of
the
62
patients
(
8
%
)
with
moderate
,
severe
,
or
life
-
threatening
immune
-
mediated
enter
##oc
##oli
##tis
following
inadequate
response
to
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
No
association
was
seen
between
anti
##body
development
and
development
of
adverse
events
.
[SEP]
[CLS]
5
.
3
A
##vo
##ida
##nce
of
Contact
Len
##ses
Pat
##ients
should
not
wear
contact
lenses
if
they
have
signs
or
symptoms
of
bacterial
con
##junct
##iv
##itis
or
during
the
course
of
therapy
with
Be
##si
##vance
.
[SEP]
[CLS]
Most
of
the
adverse
reactions
appear
to
be
dose
related
(
especially
those
classified
as
psychiatric
and
nervous
system
symptoms
)
,
including
di
##zzi
##ness
,
so
##m
##no
##len
##ce
,
confusion
##al
state
,
[SEP]
[CLS]
t
##rem
##or
,
abnormal
coordination
,
memory
imp
##air
##ment
,
blurred
vision
,
g
##ait
disturbance
,
a
##pha
##sia
,
balance
disorder
,
con
##st
##ip
##ation
,
d
##ys
##uria
,
and
ch
##roma
##tur
##ia
.
[SEP]
[CLS]
Me
##as
##ure
serum
trans
##ami
##nas
##es
(
AL
##T
and
AS
##T
)
and
bi
##li
##ru
##bin
levels
prior
to
starting
treatment
with
Z
##Y
##TI
##GA
,
every
two
weeks
for
the
first
three
months
of
treatment
and
monthly
[SEP]
[CLS]
thereafter
.
[SEP]
[CLS]
Management
of
h
##yper
##am
##mon
##emia
due
to
N
##AG
##S
deficiency
should
be
done
in
coordination
with
medical
personnel
experienced
in
metabolic
disorders
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
events
have
been
identified
during
post
##market
##ing
use
of
IN
##TE
##LE
##NC
##E
(
r
)
.
[SEP]
[CLS]
As
with
all
anti
##ep
##ile
##ptic
drugs
,
ON
##FI
should
be
withdrawn
gradually
to
minimize
the
risk
of
pre
##ci
##pit
##ating
seizure
##s
,
seizure
ex
##ace
##rb
##ation
,
or
status
e
##pile
##ptic
##us
.
[SEP]
[CLS]
5
.
7
Head
##ache
If
a
woman
taking
Nat
##azi
##a
develops
new
headache
##s
that
are
re
##current
,
or
severe
,
evaluate
the
cause
and
disco
##ntin
##ue
Nat
##azi
##a
if
indicated
.
[SEP]
[CLS]
One
treatment
-
related
death
associated
with
he
##pa
##tic
failure
was
reported
in
the
trial
.
[SEP]
[CLS]
6
.
2
Clinical
Studies
Experience
in
Pat
##ients
with
P
##ey
##ron
##ie
'
s
Disease
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
[SEP]
[CLS]
drug
can
not
be
directly
compared
to
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##ders
:
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
including
DR
##ES
##S
and
cases
of
he
##pa
##tic
failure
have
been
reported
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
A
treatment
-
related
death
from
vent
##ric
##ular
fi
##bri
##lla
##tion
was
reported
in
another
mon
##otherapy
clinical
trial
with
Bel
##eo
##da
##q
.
[SEP]
[CLS]
(
5
.
14
)
*
Use
with
caution
in
patients
with
con
##vu
##lsive
disorders
,
thy
##rot
##ox
##ico
##sis
,
diabetes
me
##lli
##tus
,
and
k
##eto
##ac
##ido
##sis
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
g
##eni
##tal
my
##cot
##ic
infections
were
more
likely
to
develop
g
##eni
##tal
my
##cot
##ic
infections
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
other
most
common
reactions
were
flush
##ing
(
0
.
3
%
)
and
headache
(
0
.
4
%
)
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
drug
reactions
(
>
=
25
%
)
in
the
XI
##AF
##LE
##X
clinical
trials
in
patients
with
Du
##pu
##yt
##ren
'
s
contract
##ure
included
ed
##ema
peripheral
(
mostly
[SEP]
[CLS]
swelling
of
the
injected
hand
)
,
con
##tus
##ion
,
injection
site
hem
##or
##r
##hage
,
injection
site
reaction
,
and
pain
in
the
treated
ex
##tre
##mity
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
(
5
.
2
)
.
[SEP]
[CLS]
Table
4
B
##lee
##ding
Events
in
R
##E
-
ME
##D
##Y
T
##reate
##d
Pat
##ients
Note
:
MBE
can
belong
to
more
than
one
criterion
.
[SEP]
[CLS]
Pro
##mpt
##ly
measure
serum
total
bi
##li
##ru
##bin
,
AS
##T
,
and
AL
##T
if
clinical
symptoms
or
signs
suggest
##ive
of
he
##pa
##to
##to
##xi
##city
develop
.
[SEP]
[CLS]
In
the
short
-
term
trials
,
FA
##NA
##P
##T
was
associated
with
modest
levels
of
pro
##la
##ct
##in
elevation
compared
to
greater
pro
##la
##ct
##in
elevations
observed
with
some
other
anti
##psy
##cho
##tic
agents
.
[SEP]
[CLS]
H
##y
##po
##gly
##ce
##mia
was
more
frequent
when
FA
##R
##X
##IG
##A
was
added
to
su
##lf
##ony
##lu
##rea
or
insulin
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Po
##ssi
##ble
risk
factors
for
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
include
pre
##ex
##ist
##ing
low
white
blood
cell
count
(
W
##BC
)
and
history
of
drug
induced
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Further
information
is
available
at
www
.
XI
##AF
##LE
##X
##RE
##MS
.
com
or
1
-
87
##7
-
313
-
123
##5
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
was
reported
in
a
post
-
marketing
clinical
trial
(
Study
3
)
in
one
patient
who
had
previous
exposure
to
XI
##AF
##LE
##X
for
the
treatment
of
Du
##pu
##yt
##ren
'
s
contract
##ure
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
To
minimize
the
risk
of
contamination
,
do
not
touch
drop
##per
tip
to
any
surface
.
[SEP]
[CLS]
Pat
##ients
eligible
for
Trial
6
were
those
with
the
G
##55
##1
##D
,
G
##12
##44
##E
,
G
##13
##4
##9
##D
,
G
##17
##8
##R
,
G
##55
##1
##S
,
G
##9
##70
##R
,
S
##12
##51
##N
,
S
##12
##55
##P
,
S
##5
##4
##9
##N
,
or
S
##5
##4
##9
##R
mutation
[SEP]
[CLS]
in
the
CF
##TR
gene
.
[SEP]
[CLS]
Monitor
patients
frequently
for
signs
and
symptoms
of
ne
##uro
##logical
imp
##air
##ment
(
e
.
g
.
,
numb
##ness
or
weakness
of
the
legs
,
bow
##el
,
or
bladder
d
##ys
##function
)
.
[SEP]
[CLS]
Local
c
##ys
##tic
invasion
beyond
the
kidney
occurred
,
in
some
cases
with
imaging
characteristics
suggest
##ive
of
a
##bs
##cess
formation
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IR
##TU
##RO
and
all
other
Q
##T
pro
##long
##ing
drugs
if
the
patient
develops
:
*
Clinical
##ly
significant
vent
##ric
##ular
a
##rr
##hy
##th
##mia
*
A
Q
##T
##c
##F
interval
of
greater
than
500
m
##s
(
confirmed
by
[SEP]
[CLS]
repeat
EC
##G
)
If
s
##ync
##ope
occurs
,
obtain
an
EC
##G
to
detect
Q
##T
pro
##long
##ation
.
[SEP]
[CLS]
5
.
5
Drug
Re
##action
With
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
/
Multi
##or
##gan
H
##yper
##sen
##si
##ti
##vity
Drug
Re
##action
with
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
,
also
known
as
multi
##or
##gan
h
##yper
##sen
##si
##ti
##vity
,
[SEP]
[CLS]
has
been
reported
in
patients
taking
anti
##ep
##ile
##ptic
drugs
,
including
g
##aba
##pent
##in
.
[SEP]
[CLS]
(
2
,
5
.
1
)
*
In
##fect
##ions
:
G
##IL
##EN
##Y
##A
may
increase
the
risk
of
infections
.
[SEP]
[CLS]
During
the
clinical
studies
,
two
patients
(
<
1
%
)
experienced
adverse
reactions
leading
to
withdrawal
.
[SEP]
[CLS]
In
clinical
trials
,
no
serious
adverse
reactions
were
reported
.
[SEP]
[CLS]
Other
Finding
##s
:
Oral
h
##y
##po
##est
##hesia
and
/
or
oral
par
##est
##hesia
may
occur
directly
after
administration
of
SA
##P
##H
##RI
##S
and
usually
resolve
##s
within
1
hour
.
[SEP]
[CLS]
Co
##rre
##ct
volume
or
salt
de
##ple
##tion
prior
to
administration
of
Ed
##ar
##bi
,
or
start
treatment
at
40
mg
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
*
Post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
:
Most
common
adverse
reactions
(
>
5
%
and
more
common
than
place
##bo
)
were
:
back
pain
,
pain
in
ex
##tre
##mity
,
[SEP]
[CLS]
h
##yper
##cho
##les
##tero
##lem
##ia
,
m
##us
##cu
##los
##kel
##etal
pain
,
and
c
##ys
##titis
.
[SEP]
[CLS]
The
adverse
reactions
below
reflect
exposure
to
X
##E
##OM
##IN
with
g
##la
##bella
##r
lines
in
place
##bo
-
controlled
studies
.
[SEP]
[CLS]
The
GB
##CA
-
associated
N
##SF
risk
appears
highest
for
patients
with
chronic
,
severe
kidney
disease
(
G
##F
##R
<
30
m
##L
/
min
/
1
.
73
##m
2
)
as
well
as
patients
with
acute
kidney
injury
.
[SEP]
[CLS]
More
than
two
-
thirds
of
patients
were
from
Asia
(
G
##IL
##OT
##RI
##F
70
%
;
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
72
%
)
.
[SEP]
[CLS]
5
.
4
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
including
Ana
##phy
##lax
##is
A
##cute
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
and
death
,
have
been
reported
in
association
with
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
The
most
commonly
reported
adverse
event
in
patients
treated
with
To
##via
##z
was
dry
mouth
.
[SEP]
[CLS]
The
rates
of
treatment
-
emerge
##nt
adverse
events
resulting
in
permanent
disco
##ntin
##uation
were
20
%
and
6
%
for
the
A
##FI
##NI
##TO
##R
and
place
##bo
treatment
groups
,
respectively
.
[SEP]
[CLS]
Common
and
Drug
-
Re
##lated
Ad
##verse
Re
##actions
in
Clinical
Trials
Based
on
the
pool
##ed
data
from
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
,
the
following
adverse
reactions
[SEP]
[CLS]
occurred
in
>
=
5
%
incidence
in
the
patients
treated
with
FA
##NA
##P
##T
and
at
least
twice
the
place
##bo
rate
for
at
least
1
dose
:
di
##zzi
##ness
,
dry
mouth
,
[SEP]
[CLS]
fatigue
,
nasal
congestion
,
so
##m
##no
##len
##ce
,
ta
##chy
##card
##ia
,
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
and
weight
increased
.
[SEP]
[CLS]
In
patients
with
a
history
of
trans
##ami
##nas
##e
elevations
,
more
frequent
monitoring
of
liver
function
tests
should
be
considered
.
[SEP]
[CLS]
For
mild
to
moderate
der
##mat
##itis
,
such
as
localized
r
##ash
and
p
##ru
##rit
##us
,
treat
s
##ym
##pt
##oma
##tically
.
[SEP]
[CLS]
Ser
##ious
infections
occurred
in
6
.
0
%
of
patients
treated
with
B
##EN
##L
##Y
##ST
##A
and
in
5
.
2
%
of
patients
who
received
place
##bo
.
[SEP]
[CLS]
(
5
.
2
)
*
Con
##tin
##ue
therapy
with
le
##uc
##ovo
##rin
until
the
met
##hot
##re
##xa
##te
concentration
has
been
maintained
below
the
le
##uc
##ovo
##rin
treatment
threshold
for
a
minimum
of
3
days
.
[SEP]
[CLS]
(
6
.
1
)
*
As
##th
##ma
:
Most
common
adverse
reactions
(
incidence
greater
than
or
equal
to
2
%
)
are
na
##so
##pha
##ryn
##git
##is
,
oral
can
##di
##dia
##sis
,
headache
,
in
##fluenza
,
[SEP]
[CLS]
upper
respiratory
tract
infection
,
br
##on
##chi
##tis
,
sin
##us
##itis
,
or
##op
##har
##yn
##ge
##al
pain
,
d
##ys
##phon
##ia
,
and
cough
.
[SEP]
[CLS]
De
##fine
##d
as
clinical
##ly
over
##t
bleeding
accompanied
by
one
or
more
of
the
following
:
a
decrease
in
hem
##og
##lo
##bin
of
>
=
2
g
/
d
##L
,
a
trans
##fusion
of
2
or
more
units
[SEP]
[CLS]
of
packed
red
blood
cells
,
compartment
syndrome
or
with
fatal
outcome
.
[SEP]
[CLS]
Do
not
administer
G
##RA
##NI
##X
to
patients
with
a
history
of
serious
all
##ergic
reactions
to
fi
##l
##gra
##st
##im
or
p
##eg
##fi
##l
##gra
##st
##im
.
[SEP]
[CLS]
With
##hold
T
##AF
##IN
##LA
##R
for
fever
of
101
.
3
##o
##F
or
higher
.
[SEP]
[CLS]
Thus
,
the
ability
to
differentiate
the
adverse
event
profile
between
treatments
is
limited
.
[SEP]
[CLS]
Additional
Ad
##verse
Re
##actions
Other
adverse
reactions
known
to
occur
following
administration
of
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
include
my
##al
##gia
,
headache
,
vomit
##ing
,
Sweet
'
s
syndrome
(
[SEP]
[CLS]
acute
f
##eb
##ril
##e
ne
##ut
##rop
##hil
##ic
der
##mat
##osis
)
,
cut
##aneous
v
##as
##cu
##lit
##is
and
th
##rom
##bo
##cy
##top
##enia
.
[SEP]
[CLS]
Table
1
Age
Range
Drug
-
Place
##bo
Di
##fference
in
Number
of
Case
##s
of
Su
##icidal
##ity
per
1
,
000
Pat
##ients
T
##reate
##d
Inc
##rease
##s
Compared
to
Place
##bo
<
18
14
additional
cases
18
to
24
5
additional
[SEP]
[CLS]
cases
Dec
##rease
##s
Compared
to
Place
##bo
25
to
64
1
fewer
case
>
=
65
6
fewer
cases
No
suicide
##s
occurred
in
any
of
the
p
##ediatric
studies
.
[SEP]
[CLS]
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
,
some
with
a
fatal
outcome
,
has
been
reported
in
patients
who
received
ever
##oli
##mus
.
[SEP]
[CLS]
Pat
##ients
with
o
##ste
##osa
##rc
##oma
were
eligible
for
these
studies
if
the
plasma
met
##hot
##re
##xa
##te
concentration
was
greater
than
50
mum
##ol
/
L
at
24
hours
,
greater
that
5
mum
##ol
/
L
at
48
hours
,
[SEP]
[CLS]
or
greater
than
2
standard
de
##viation
##s
above
the
mean
met
##hot
##re
##xa
##te
elimination
curve
at
least
12
hours
after
met
##hot
##re
##xa
##te
administration
and
there
was
a
2
-
fold
or
greater
increase
in
serum
c
##rea
##tin
##ine
[SEP]
[CLS]
above
base
##line
.
[SEP]
[CLS]
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
the
adverse
reaction
rates
observed
can
not
be
directly
compared
to
rates
in
other
trials
and
[SEP]
[CLS]
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
In
##jection
site
p
##ru
##rit
##us
also
contributed
to
the
frequently
reported
reactions
.
[SEP]
[CLS]
Thirty
-
three
patients
receiving
D
##IF
##IC
##ID
(
5
.
9
%
)
withdrew
from
trials
as
a
result
of
adverse
reactions
(
AR
)
.
[SEP]
[CLS]
(
5
.
11
,
8
.
1
)
E
##X
##CE
##RP
##T
:
5
.
1
New
Primary
Mali
##gna
##ncies
New
primary
ma
##li
##gna
##ncies
,
cut
##aneous
,
can
occur
when
T
##AF
##IN
##LA
##R
is
administered
as
a
single
agent
or
when
used
[SEP]
[CLS]
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
In
##fect
##ions
and
In
##fest
##ations
:
Cell
##uli
##tis
,
f
##oll
##ic
##uli
##tis
,
par
##ony
##chia
,
r
##ash
pu
##st
##ular
.
[SEP]
[CLS]
Among
29
##9
patients
with
chronic
IT
##P
who
received
PR
##OM
##AC
##TA
in
the
single
-
arm
extension
trial
,
the
adverse
reactions
occurred
in
a
pattern
similar
to
that
seen
in
the
place
##bo
-
controlled
trials
[SEP]
[CLS]
.
[SEP]
[CLS]
The
results
suggest
an
approximate
2
-
fold
increase
in
the
risk
of
N
##A
##ION
within
5
half
-
lives
of
PD
##E
##5
inhibitor
use
.
[SEP]
[CLS]
If
not
treated
immediately
,
pen
##ile
tissue
damage
and
permanent
loss
of
pot
##ency
could
result
.
[SEP]
[CLS]
Ex
##tensive
brain
at
##rop
##hy
may
limit
the
ability
to
distinguish
grey
and
white
matter
on
a
V
##iza
##my
##l
scan
[
see
Do
##sa
##ge
and
Administration
(
2
.
5
)
]
.
[SEP]
[CLS]
Media
##n
duration
of
treatment
was
9
cycles
(
range
,
1
-
16
)
[
see
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##mor
##r
##hage
:
Major
hem
##or
##r
##ha
##gic
events
can
occur
in
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
These
risk
differences
(
drug
-
place
##bo
difference
in
the
number
of
cases
of
su
##icidal
##ity
per
1
,
000
patients
treated
)
are
provided
in
Table
1
.
[SEP]
[CLS]
In
both
studies
,
patients
received
X
##TA
##ND
##I
160
mg
oral
##ly
once
daily
in
the
active
treatment
arm
or
place
##bo
in
the
control
arm
.
[SEP]
[CLS]
Gen
##ital
my
##cot
##ic
infections
occurred
more
frequently
in
female
than
male
patients
(
see
Table
1
)
.
[SEP]
[CLS]
(
5
.
1
)
*
Me
##as
##ure
##ment
of
met
##hot
##re
##xa
##te
using
im
##mu
##no
##ass
##ays
is
unreliable
for
samples
collected
within
48
hours
following
V
##OR
##A
##X
##A
##Z
##E
administration
.
[SEP]
[CLS]
Do
not
give
J
##E
##V
##TA
##NA
if
ne
##ut
##rop
##hil
counts
are
<
=
1
,
500
cells
/
mm
##3
.
[SEP]
[CLS]
In
2
of
the
trials
(
Trial
1
and
Trial
3
)
,
treatment
was
given
for
48
weeks
,
while
in
the
other
trial
(
Trial
2
)
treatment
[SEP]
[CLS]
was
given
for
72
weeks
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
In
these
trials
,
patients
were
treated
with
up
to
3
injection
##s
of
0
.
58
mg
of
XI
##AF
##LE
##X
or
place
##bo
with
approximately
4
-
week
intervals
between
injection
##s
and
the
patients
had
finger
[SEP]
[CLS]
extension
procedures
the
day
after
injection
,
if
needed
,
to
facilitate
disruption
of
the
cord
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
5
.
8
Ser
##ious
Skin
To
##xi
##city
Ser
##ious
skin
toxicity
can
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
and
with
tram
##eti
##ni
##b
as
a
single
agent
[
refer
to
Full
Pre
##s
##cribing
Information
[SEP]
[CLS]
for
tram
##eti
##ni
##b
]
.
[SEP]
[CLS]
?
[SEP]
[CLS]
Pat
##ients
who
develop
increased
trans
##ami
##nas
##e
levels
should
be
closely
monitored
until
the
abnormal
##ities
resolve
.
[SEP]
[CLS]
(
2
.
3
,
5
.
5
)
*
Em
##b
##ryo
##fe
##tal
toxicity
:
Can
cause
f
##etal
harm
.
[SEP]
[CLS]
Do
##se
delay
or
reduction
was
necessary
in
61
%
of
ever
##oli
##mus
patients
and
29
%
of
place
##bo
patients
.
[SEP]
[CLS]
Basel
##ine
and
follow
-
up
examinations
are
recommended
in
p
##ediatric
patients
in
##iti
##ating
K
##AL
##Y
##DE
##CO
treatment
.
[SEP]
[CLS]
*
Lac
##tic
acid
##osis
and
severe
he
##pa
##tom
##eg
##aly
with
s
##te
##ato
##sis
,
including
fatal
cases
,
have
been
reported
with
the
use
of
n
##uc
##leo
##side
analog
##s
,
including
ten
##of
##ov
##ir
di
##so
##p
##ro
##xi
##l
f
##uma
##rate
(
D
##F
)
[SEP]
[CLS]
,
a
component
of
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
Currently
available
data
are
inadequate
to
determine
whether
concurrent
use
of
inhaled
co
##rt
##ico
##ster
##oids
(
I
##CS
)
or
other
long
-
term
as
##th
##ma
control
drugs
mit
##igate
##s
the
increased
risk
of
as
##th
##ma
-
related
death
from
[SEP]
[CLS]
LA
##BA
.
[SEP]
[CLS]
Pat
##ients
should
be
informed
of
the
signs
and
symptoms
of
an
acute
h
##yper
##sen
##si
##ti
##vity
reaction
and
be
instructed
to
seek
immediate
medical
care
should
a
reaction
occur
.
[SEP]
[CLS]
Grade
3
protein
##uria
was
reported
in
11
/
35
##9
patients
(
3
%
)
receiving
IN
##L
##Y
##TA
and
6
/
35
##5
patients
(
2
%
)
receiving
so
##ra
##fen
##ib
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
The
mechanism
of
action
of
B
##EN
##L
##Y
##ST
##A
could
increase
the
risk
for
the
development
of
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
(
5
.
8
)
*
If
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
occurs
,
disco
##ntin
##ue
BR
##E
##O
E
##LL
##IP
##TA
and
institute
alternative
therapy
.
[SEP]
[CLS]
C
##aut
##ion
should
be
exercised
when
using
T
##NF
-
block
##ers
,
including
S
##IM
##PO
##NI
ARIA
,
in
patients
who
have
or
have
had
significant
c
##yt
##ope
##nia
##s
.
[SEP]
[CLS]
Pan
##cre
##ati
##tis
has
been
reported
in
clinical
trials
(
6
.
1
)
*
Male
O
##ste
##op
##oro
##sis
:
Most
common
adverse
reactions
(
>
5
%
and
more
common
than
place
##bo
)
were
:
[SEP]
[CLS]
back
pain
,
art
##hra
##l
##gia
,
and
na
##so
##pha
##ryn
##git
##is
(
6
.
1
)
*
Bone
loss
due
to
hormone
a
##bla
##tion
for
cancer
:
Most
common
adverse
reactions
(
>
=
10
%
and
[SEP]
[CLS]
more
common
than
place
##bo
)
were
:
art
##hra
##l
##gia
and
back
pain
.
[SEP]
[CLS]
In
SP
##RI
##NG
-
2
,
82
##2
subjects
were
random
##ized
and
received
at
least
1
dose
of
either
T
##I
##VI
##CA
##Y
50
mg
once
daily
or
r
##al
##te
##gra
##vir
400
mg
twice
daily
,
both
in
combination
[SEP]
[CLS]
with
fixed
-
dose
dual
n
##uc
##leo
##side
reverse
trans
##cript
##ase
inhibitor
(
N
##RT
##I
)
treatment
(
either
a
##ba
##ca
##vir
su
##lf
##ate
and
la
##mi
##vu
##dine
[
EP
##Z
##IC
##OM
(
r
)
]
or
em
##tric
##ita
##bine
/
ten
##of
##ov
##ir
[
T
##R
##U
##VA
##DA
(
r
)
[SEP]
[CLS]
]
)
.
[SEP]
[CLS]
In
a
random
##ized
trial
comparing
K
##y
##p
##rol
##is
as
a
single
agent
versus
co
##rt
##ico
##ster
##oids
with
optional
oral
c
##y
##c
##lop
##hos
##pha
##mi
##de
for
patients
with
re
##lap
##sed
and
re
##fra
##ctor
##y
multiple
my
##elo
##ma
,
mortality
was
higher
in
the
[SEP]
[CLS]
patients
treated
with
K
##y
##p
##rol
##is
in
comparison
to
the
control
arm
in
the
subgroup
of
48
patients
>
=
75
years
of
age
.
[SEP]
[CLS]
In
the
short
-
term
,
place
##bo
-
controlled
s
##chi
##zophrenia
adult
trials
,
the
incidence
of
reported
EP
##S
-
related
events
,
excluding
events
related
to
aka
##thi
##sia
,
for
SA
##P
##H
##RI
##S
-
treated
patients
was
10
%
versus
7
[SEP]
[CLS]
%
for
place
##bo
;
and
the
incidence
of
aka
##thi
##sia
-
related
events
for
SA
##P
##H
##RI
##S
-
treated
patients
was
6
%
versus
3
%
for
place
##bo
.
[SEP]
[CLS]
The
median
duration
of
treatment
was
17
.
5
months
with
X
##TA
##ND
##I
and
4
.
6
months
with
place
##bo
.
[SEP]
[CLS]
A
recent
CBC
should
be
available
before
in
##iti
##ating
treatment
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Spectrum
Ph
##arma
##ce
##utical
##s
,
Inc
.
at
1
-
88
##8
-
29
##2
-
96
##17
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
[SEP]
[CLS]
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
Bel
##eo
##da
##q
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
The
majority
of
re
##nal
c
##ys
##ts
.
[SEP]
[CLS]
If
traumatic
pu
##nc
##ture
occurs
,
delay
the
administration
of
E
##L
##I
##Q
##UI
##S
for
48
hours
.
[SEP]
[CLS]
Pat
##ients
received
IN
##VO
##KA
##NA
100
mg
(
N
=
30
##9
##2
)
,
IN
##VO
##KA
##NA
300
mg
(
N
=
308
##5
)
or
com
##par
##ator
(
N
=
32
##6
##2
)
once
daily
.
[SEP]
[CLS]
T
##EC
##FI
##DE
##RA
has
not
been
studied
in
patients
with
pre
-
existing
low
l
##ymph
##oc
##yte
counts
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
and
an
##gio
##ede
##ma
associated
with
la
##ryn
##ge
##al
ed
##ema
can
be
fatal
.
[SEP]
[CLS]
Of
34
patients
enrolled
,
32
had
the
G
##55
##1
##D
mutation
and
2
had
the
S
##5
##4
##9
##N
mutation
.
[SEP]
[CLS]
With
##hold
CO
##ME
##TR
##I
##Q
in
patients
who
develop
into
##ler
##able
Grade
2
PP
##ES
or
Grade
3
-
4
PP
##ES
until
improvement
to
Grade
1
;
resume
CO
##ME
##TR
##I
##Q
at
a
reduced
dose
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
infections
consisted
primarily
of
upper
respiratory
tract
infections
,
her
##pes
infections
,
u
##rina
##ry
tract
infections
,
and
lower
respiratory
tract
infections
.
[SEP]
[CLS]
H
##y
##po
##gly
##ce
##mia
The
frequency
of
h
##y
##po
##gly
##ce
##mia
by
study
[
see
Clinical
Studies
(
14
)
]
is
shown
in
Table
5
.
[SEP]
[CLS]
Basel
##ine
estimated
re
##nal
function
was
normal
or
mildly
impaired
(
e
##G
##F
##R
>
=
60
m
##l
/
min
/
1
.
73
m
##2
)
in
95
.
7
%
of
the
T
##R
##U
##L
##IC
##IT
##Y
population
.
[SEP]
[CLS]
Re
##sume
CO
##ME
##TR
##I
##Q
therapy
after
surgery
based
on
clinical
judgment
of
adequate
wound
healing
.
[SEP]
[CLS]
Laboratory
Tests
Inc
##rease
in
He
##mat
##oc
##rit
In
the
pool
of
13
place
##bo
-
controlled
studies
,
increases
from
base
##line
in
mean
hem
##ato
##c
##rit
values
were
observed
in
FA
##R
##X
##IG
##A
-
treated
patients
starting
at
Week
1
and
[SEP]
[CLS]
continuing
up
to
Week
16
,
when
the
maximum
mean
difference
from
base
##line
was
observed
.
[SEP]
[CLS]
The
data
described
below
represent
adverse
reactions
observed
from
the
two
place
##bo
-
controlled
trials
,
consisting
of
77
patients
who
received
F
##IR
##A
##Z
##Y
##R
at
a
dose
of
30
mg
SC
,
and
[SEP]
[CLS]
75
who
received
place
##bo
.
[SEP]
[CLS]
A
##vo
##id
using
Z
##Y
##KA
##DI
##A
in
combination
with
other
agents
known
to
cause
bra
##dy
##card
##ia
(
e
.
g
.
,
beta
-
block
##ers
,
non
-
di
##hy
##dr
##opy
##rid
##ine
calcium
channel
block
##ers
,
c
##lon
##id
##ine
,
and
dig
##ox
##in
)
to
the
extent
[SEP]
[CLS]
possible
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
r
##hab
##dom
##yo
##lysis
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
Fat
##al
cases
of
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
have
been
reported
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
The
use
of
clinical
information
in
the
interpretation
of
N
##eur
##ace
##q
images
has
not
been
evaluated
and
may
lead
to
errors
.
[SEP]
[CLS]
5
.
3
With
##dra
##wal
S
##ym
##pt
##oms
A
##b
##rup
##t
disco
##ntin
##uation
of
ON
##FI
should
be
avoided
.
[SEP]
[CLS]
(
5
.
3
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
5
.
1
H
##yper
##am
##mon
##emia
Any
episode
of
acute
s
##ym
##pt
##oma
##tic
h
##yper
##am
##mon
##emia
should
be
treated
as
a
life
-
threatening
emergency
.
[SEP]
[CLS]
Data
are
not
available
to
determine
whether
the
rate
of
death
in
patients
with
CO
##PD
is
increased
by
LA
##BA
.
[SEP]
[CLS]
In
all
three
studies
a
place
##bo
(
Cycle
1
of
the
breast
cancer
study
only
)
or
a
non
-
US
-
approved
fi
##l
##gra
##st
##im
product
were
used
as
controls
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
T
##hr
##omb
##oc
##yt
##ope
##nia
,
le
##uk
##ope
##nia
(
ne
##ut
##rop
##enia
and
l
##ymph
##ope
##nia
)
,
and
an
##emia
:
Monitor
blood
counts
and
modify
dos
##age
for
hem
##ato
##log
##ic
toxic
##ities
.
[SEP]
[CLS]
The
majority
of
these
cases
were
mild
to
moderate
and
occurred
during
the
first
year
of
exposure
.
[SEP]
[CLS]
5
.
9
Rev
##ers
##ible
Post
##eri
##or
Le
##uk
##oe
##nce
##pha
##lop
##athy
S
##yn
##drome
Rev
##ers
##ible
Post
##eri
##or
Le
##uk
##oe
##nce
##pha
##lop
##athy
S
##yn
##drome
(
R
##PL
##S
)
,
a
syndrome
of
sub
##cor
##tical
v
##as
##ogenic
ed
##ema
diagnosed
by
characteristic
finding
on
MR
##I
,
occurred
in
one
(
[SEP]
[CLS]
<
1
%
)
patient
.
[SEP]
[CLS]
5
.
5
Risk
of
bleeding
in
Pat
##ients
with
A
##b
##nor
##mal
Co
##agu
##lation
In
the
XI
##AF
##LE
##X
trials
in
Du
##pu
##yt
##ren
'
s
contract
##ure
(
Studies
1
and
2
)
,
70
%
and
38
%
of
[SEP]
[CLS]
XI
##AF
##LE
##X
-
treated
patients
developed
an
e
##cc
##hy
##mos
##is
/
con
##tus
##ion
or
an
injection
site
hem
##or
##r
##hage
,
respectively
(
see
Table
3
)
.
[SEP]
[CLS]
5
.
3
H
##y
##po
##gly
##ce
##mia
with
Con
##com
##ita
##nt
Use
with
In
##sul
##in
and
In
##sul
##in
Secret
##ago
##gues
In
##sul
##in
and
insulin
secret
##ago
##gues
are
known
to
cause
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
The
safety
of
CO
##ME
##TR
##I
##Q
was
evaluated
in
330
patients
with
progressive
meta
##static
me
##du
##llar
##y
thy
##roid
cancer
random
##ized
to
receive
140
mg
CO
##ME
##TR
##I
##Q
(
n
=
214
)
or
place
##bo
(
n
[SEP]
[CLS]
=
109
)
administered
daily
until
disease
progression
or
into
##ler
##able
toxicity
in
a
random
##ized
,
double
##blin
##d
,
controlled
trial
.
[SEP]
[CLS]
Pat
##ients
with
a
prior
DR
##ES
##S
reaction
with
either
o
##x
##car
##ba
##ze
##pine
or
AP
##TI
##OM
should
not
be
treated
with
AP
##TI
##OM
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Monitor
patients
for
pulmonary
symptoms
in
##dicative
of
IL
##D
/
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
suspected
,
NE
##SI
##NA
should
promptly
be
discontinued
and
appropriate
management
should
be
initiated
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
W
##ye
##th
Ph
##arma
##ce
##utical
##s
Inc
.
,
a
subsidiary
of
P
##fi
##zer
Inc
.
,
at
1
-
800
-
43
##8
-
1985
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Studies
Experience
Because
[SEP]
[CLS]
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
[SEP]
[CLS]
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
(
5
.
2
)
*
Re
##mo
##ve
contact
lenses
prior
to
ins
##til
##lation
of
B
##EP
##RE
##VE
.
[SEP]
[CLS]
These
metabolic
changes
include
h
##yper
##gly
##ce
##mia
,
d
##ys
##lip
##ide
##mia
,
and
weight
gain
.
[SEP]
[CLS]
This
case
represented
1
out
of
120
##9
patients
in
B
##OS
##U
##L
##IF
clinical
trials
.
[SEP]
[CLS]
Do
not
start
in
patients
with
active
infections
.
[SEP]
[CLS]
Disco
##ntin
##uations
due
to
adverse
events
were
reported
for
6
%
of
X
##TA
##ND
##I
-
treated
patients
and
6
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Similar
results
may
be
anticipated
in
patients
treated
with
Ed
##ar
##bi
[
see
##D
##rug
Inter
##actions
(
7
)
,
Use
in
S
##pecific
Population
##s
(
8
.
6
)
,
and
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
3
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
less
than
1
%
of
subjects
were
:
facial
par
##esis
(
brow
p
##tosis
)
,
muscle
disorder
(
elevation
of
eyebrow
)
,
[SEP]
[CLS]
injection
site
pain
,
and
eye
##lid
ed
##ema
.
[SEP]
[CLS]
In
some
patients
,
heart
rate
decrease
during
the
second
period
is
more
pronounced
than
the
decrease
observed
in
the
first
6
hours
.
[SEP]
[CLS]
6
##I
##nc
##lude
##s
the
preferred
terms
so
##m
##no
##len
##ce
,
se
##dation
,
and
h
##yper
##so
##m
##nia
.
[SEP]
[CLS]
Disco
##ntin
##ue
IN
##L
##Y
##TA
if
h
##yper
##tens
##ion
is
severe
and
persistent
despite
anti
-
h
##yper
##tensive
therapy
and
dose
reduction
of
IN
##L
##Y
##TA
,
and
disco
##ntin
##uation
should
be
considered
if
there
is
evidence
of
h
##yper
##tensive
crisis
.
[SEP]
[CLS]
While
these
symptoms
can
occur
at
low
doses
,
they
occur
more
frequently
and
with
greater
severity
with
high
pot
##ency
and
at
higher
doses
of
first
generation
anti
##psy
##cho
##tic
drugs
.
[SEP]
[CLS]
The
information
presented
in
these
sections
was
derived
from
pool
##ed
data
from
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
in
patients
who
received
FA
##NA
##P
##T
at
daily
[SEP]
[CLS]
doses
within
a
range
of
10
to
24
mg
(
n
=
87
##4
)
.
[SEP]
[CLS]
Pat
##ients
treated
with
O
##TE
##Z
##LA
should
have
their
weight
monitored
regularly
.
[SEP]
[CLS]
In
the
controlled
clinical
trials
,
ma
##li
##gna
##ncies
(
including
non
-
me
##lan
##oma
skin
cancer
##s
)
were
reported
in
0
.
4
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
0
.
4
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Ma
##gnetic
resonance
imaging
is
necessary
to
confirm
the
diagnosis
of
R
##PL
##S
.
[SEP]
[CLS]
5
.
2
So
##m
##no
##len
##ce
/
Se
##dation
and
Di
##zzi
##ness
H
##OR
##I
##Z
##AN
##T
causes
so
##m
##no
##len
##ce
/
se
##dation
and
di
##zzi
##ness
(
see
Table
##s
4
and
5
)
.
[SEP]
[CLS]
Stop
treatment
with
IN
##L
##Y
##TA
at
least
24
hours
prior
to
scheduled
surgery
.
[SEP]
[CLS]
Di
##ar
##r
##hea
,
headache
,
and
nausea
were
the
most
commonly
reported
adverse
reactions
.
[SEP]
[CLS]
The
overall
incidence
of
bone
pain
in
Cycle
1
of
treatment
was
3
.
4
%
(
3
.
4
%
G
##RA
##NI
##X
,
1
.
4
%
place
##bo
,
7
.
5
%
non
-
US
-
approved
fi
##l
##gra
##st
##im
product
)
.
[SEP]
[CLS]
5
.
14
Ex
##ace
##rb
##ation
of
Other
Con
##ditions
E
##stro
##gens
may
cause
an
ex
##ace
##rb
##ation
of
as
##th
##ma
,
diabetes
me
##lli
##tus
,
e
##pile
##psy
,
mi
##gra
##ine
or
p
##or
##phy
##ria
,
systemic
l
##up
##us
er
##yt
##hem
##ato
##sus
,
and
he
##pa
##tic
hem
##ang
##io
##mas
and
[SEP]
[CLS]
should
be
used
with
caution
in
women
with
these
conditions
.
[SEP]
[CLS]
Treatment
of
late
##nt
tuberculosis
infection
should
be
initiated
prior
to
N
##U
##L
##O
##J
##IX
use
.
[SEP]
[CLS]
At
##y
##pical
f
##em
##oral
fracture
##s
most
commonly
occur
with
minimal
or
no
trauma
to
the
affected
area
.
[SEP]
[CLS]
5
.
5
Other
Ser
##ious
In
##fect
##ions
Pat
##ients
receiving
im
##mu
##nos
##up
##press
##ants
,
including
N
##U
##L
##O
##J
##IX
,
are
at
increased
risk
of
developing
pro
##to
##zo
##al
infections
,
including
op
##port
##uni
##stic
infections
.
[SEP]
[CLS]
(
5
.
2
)
*
N
##eu
##tro
##pen
##ia
-
The
addition
of
VI
##CT
##RE
##L
##IS
to
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
may
result
in
worse
##ning
of
ne
##ut
##rop
##enia
associated
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
therapy
alone
.
[SEP]
[CLS]
In
children
,
the
adverse
reactions
were
p
##yre
##xia
,
cough
,
vomit
##ing
,
an
##ore
##xia
,
and
headache
.
[SEP]
[CLS]
Therefore
,
PD
##E
##5
inhibitor
##s
,
including
ST
##EN
##DR
##A
,
should
be
used
with
caution
in
these
patients
and
only
when
the
anticipated
benefits
out
##wei
##gh
the
risks
.
[SEP]
[CLS]
Rate
##s
in
clinical
studies
for
C
##IM
##Z
##IA
can
not
be
compared
to
the
rates
of
clinical
trials
of
other
T
##NF
block
##ers
and
may
not
predict
the
rates
observed
when
C
##IM
##Z
##IA
is
[SEP]
[CLS]
used
in
a
broader
patient
population
.
[SEP]
[CLS]
The
majority
of
the
T
##B
cases
occurred
in
countries
with
a
high
incidence
rate
of
T
##B
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
V
##iza
##my
##l
scan
results
are
in
##dicative
of
the
brain
ne
##uri
##tic
am
##yl
##oid
plaque
content
only
at
the
time
of
image
acquisition
and
a
negative
scan
result
does
not
pre
##c
##lude
the
development
of
[SEP]
[CLS]
brain
am
##yl
##oid
in
the
future
.
[SEP]
[CLS]
(
5
.
5
,
2
.
3
)
*
O
##cular
To
##xi
##ci
##ties
:
Per
##form
op
##ht
##hal
##mo
##log
##ic
evaluation
for
any
visual
disturbance
##s
.
[SEP]
[CLS]
The
following
serious
adverse
reactions
of
tram
##eti
##ni
##b
as
a
single
agent
,
which
may
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
,
are
not
described
in
the
Full
[SEP]
[CLS]
Pre
##s
##cribing
Information
for
T
##AF
##IN
##LA
##R
:
*
Re
##tina
##l
vein
o
##cc
##lusion
*
Inter
##st
##iti
##al
lung
disease
*
New
primary
ma
##li
##gna
##ncies
,
cut
##aneous
,
can
occur
when
T
##AF
##IN
##LA
##R
is
administered
as
a
single
agent
[SEP]
[CLS]
or
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
5
.
2
Card
##iovascular
Events
In
the
random
##ized
controlled
studies
,
there
was
a
higher
rate
of
card
##iovascular
th
##rom
##boe
##mbo
##lic
events
(
card
##iovascular
deaths
,
non
-
fatal
my
##oc
##ard
##ial
in
##far
##ctions
,
and
non
-
fatal
strokes
)
[SEP]
[CLS]
in
patients
treated
with
U
##L
##OR
##IC
(
0
.
74
per
100
P
-
Y
[
95
%
Con
##fi
##dence
Inter
##val
(
C
##I
)
0
.
36
-
1
.
37
]
)
than
all
##op
##uri
##no
##l
(
0
.
60
per
100
P
-
Y
[
95
[SEP]
[CLS]
%
C
##I
0
.
16
-
1
.
53
]
)
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
A
dental
examination
with
appropriate
prevent
##ive
den
##tist
##ry
is
recommended
prior
to
treatment
with
Pro
##lia
in
patients
with
risk
factors
for
ON
##J
such
as
invasive
dental
procedures
(
e
.
g
.
[SEP]
[CLS]
A
higher
risk
of
serious
infections
was
also
observed
in
combination
use
of
T
##NF
block
##ers
with
a
##bat
##ace
##pt
and
r
##it
##ux
##ima
##b
.
[SEP]
[CLS]
AM
##P
##Y
##RA
has
not
been
evaluated
in
patients
with
a
history
of
seizure
##s
or
with
evidence
of
e
##pile
##pt
##iform
activity
on
an
E
##EG
,
as
these
patients
were
excluded
from
clinical
trials
[SEP]
[CLS]
.
[SEP]
[CLS]
In
a
pool
##ed
analysis
of
random
##ized
double
-
blind
on
##cology
clinical
trials
,
the
incidence
of
an
##gio
##ede
##ma
in
patients
taking
ever
##oli
##mus
with
an
AC
##E
inhibitor
was
6
.
8
%
compared
to
1
.
3
%
[SEP]
[CLS]
in
the
control
arm
with
an
AC
##E
inhibitor
.
[SEP]
[CLS]
Most
patients
who
developed
I
##g
##G
antibodies
did
so
within
the
first
3
months
of
exposure
(
median
time
to
se
##ro
##con
##version
was
4
weeks
)
.
[SEP]
[CLS]
N
##er
##vous
System
Di
##sor
##ders
T
##rem
##or
.
[SEP]
[CLS]
The
detection
of
anti
##body
formation
is
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
Limited
data
suggest
that
patients
with
a
history
of
multiple
drug
all
##er
##gies
or
significant
h
##yper
##sen
##si
##ti
##vity
may
be
at
increased
risk
.
[SEP]
[CLS]
Tell
your
healthcare
provider
if
you
have
any
side
effects
that
bother
you
or
do
not
go
away
.
[SEP]
[CLS]
(
5
.
3
)
*
Not
recommended
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
.
[SEP]
[CLS]
If
the
recommended
dose
is
exceeded
,
the
dose
should
be
reduced
to
600
mg
daily
for
1
week
prior
to
disco
##ntin
##uation
to
minimize
the
potential
of
withdrawal
seizure
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
adult
man
##ia
trials
,
the
mean
increase
in
trans
##ami
##nas
##e
levels
for
SA
##P
##H
##RI
##S
-
treated
patients
was
8
.
9
units
/
L
compared
to
a
decrease
of
4
.
9
units
/
L
in
place
##bo
-
treated
[SEP]
[CLS]
patients
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ana
##phy
##lax
##is
and
H
##yper
##sen
##si
##ti
##vity
Re
##actions
:
Life
-
threatening
an
##aph
##yla
##xi
##s
and
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
observed
in
some
patients
during
and
after
treatment
with
al
##g
##lu
##cos
##idas
##e
al
##fa
[SEP]
[CLS]
.
[SEP]
[CLS]
Screen
patients
for
acute
kidney
injury
and
other
conditions
that
may
reduce
re
##nal
function
.
[SEP]
[CLS]
Because
of
physiological
di
##urn
##al
variation
,
there
is
a
second
period
of
heart
rate
decrease
within
24
hours
after
the
first
dose
.
[SEP]
[CLS]
Head
##ache
was
the
most
common
adverse
reaction
,
reported
for
57
subjects
(
7
.
1
%
)
,
followed
by
injection
site
hem
##ato
##ma
in
8
subjects
(
1
.
0
%
)
.
[SEP]
[CLS]
ST
##RI
##BI
##LD
should
be
discontinued
if
estimated
c
##rea
##tin
##ine
clearance
decline
##s
below
50
m
##L
per
minute
as
dose
interval
adjustment
required
for
em
##tric
##ita
##bine
and
ten
##of
##ov
##ir
D
##F
can
not
be
achieved
with
the
[SEP]
[CLS]
fixed
-
dose
combination
tablet
.
[SEP]
[CLS]
Monitor
for
infection
during
treatment
and
for
2
months
after
disco
##ntin
##uation
.
[SEP]
[CLS]
In
the
54
##6
patients
from
the
safety
population
,
the
incidence
of
AL
##T
elevation
was
17
%
and
AS
##T
elevation
was
14
%
.
[SEP]
[CLS]
Ren
##al
Cy
##sts
Ren
##al
c
##ys
##ts
were
experienced
by
50
(
3
%
)
of
166
##9
patients
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
described
in
more
detail
in
other
sections
of
the
pre
##s
##cribing
information
.
[SEP]
[CLS]
Inter
##rup
##t
or
disco
##ntin
##ue
B
##L
##IN
##C
##Y
##TO
as
recommended
.
[SEP]
[CLS]
Additional
Ad
##verse
Re
##actions
O
##bs
##erve
##d
during
All
Phase
2
and
3
Clinical
Trials
Following
is
a
list
of
adverse
reactions
reported
by
patients
treated
with
P
##OT
##IG
##A
during
all
clinical
trials
:
[SEP]
[CLS]
r
##ash
,
n
##ys
##tag
##mus
,
d
##ys
##p
##nea
,
le
##uk
##ope
##nia
,
muscle
spa
##sm
##s
,
al
##ope
##cia
,
ne
##ph
##rol
##ith
##ias
##is
,
s
##ync
##ope
,
ne
##ut
##rop
##enia
,
th
##rom
##bo
##cy
##top
##enia
,
e
##up
##hor
##ic
mood
,
re
##nal
co
##lic
,
coma
,
[SEP]
[CLS]
en
##ce
##pha
##lop
##athy
.
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
1
.
5
mg
resulted
in
a
mean
increase
in
heart
rate
)
of
2
-
4
beats
per
minute
(
b
##pm
)
.
[SEP]
[CLS]
Basel
##ine
estimated
re
##nal
function
was
normal
or
mildly
impaired
(
e
##G
##F
##R
>
=
60
##m
##L
/
min
/
1
.
73
m
2
)
in
96
.
0
%
of
the
pool
##ed
study
populations
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
Pat
##ients
were
tested
at
multiple
time
points
for
antibodies
to
c
##ert
##oli
##zu
##ma
##b
p
##ego
##l
during
Studies
CD
##1
and
CD
##2
.
[SEP]
[CLS]
An
increase
in
blood
pressure
has
been
reported
in
women
taking
CO
##Cs
,
and
this
increase
is
more
likely
in
older
women
and
with
extended
duration
of
use
.
[SEP]
[CLS]
5
.
6
B
##lad
##der
Cancer
Across
22
clinical
studies
,
newly
diagnosed
cases
of
bladder
cancer
were
reported
in
10
/
60
##45
patients
(
0
.
17
%
)
treated
with
FA
##R
##X
##IG
##A
and
1
/
35
##12
patient
(
[SEP]
[CLS]
0
.
03
%
)
treated
with
place
##bo
/
com
##par
##ator
.
[SEP]
[CLS]
Do
##sa
##ge
Mo
##di
##fication
##s
due
to
Ad
##verse
Re
##actions
In
the
trial
,
dos
##age
adjustments
due
to
adverse
reactions
occurred
in
12
%
of
Bel
##eo
##da
##q
-
treated
patients
.
[SEP]
[CLS]
D
##ys
##pe
##ps
##ia
(
including
abdominal
pain
upper
,
abdominal
pain
,
abdominal
discomfort
,
and
e
##pi
##gas
##tric
discomfort
)
occurred
in
patients
on
PR
##AD
##A
##X
##A
in
7
.
5
%
vs
.
5
.
5
%
on
war
##fari
##n
[SEP]
[CLS]
,
and
gas
##tri
##tis
-
like
symptoms
(
including
gas
##tri
##tis
,
GE
##RD
,
es
##op
##ha
##git
##is
,
er
##os
##ive
gas
##tri
##tis
and
gas
##tric
hem
##or
##r
##hage
)
occurred
at
3
.
0
%
vs
.
1
.
7
%
,
respectively
.
[SEP]
[CLS]
No
trial
adequate
to
determine
whether
the
rate
of
as
##th
##ma
-
related
death
is
increased
in
subjects
treated
with
BR
##E
##O
E
##LL
##IP
##TA
has
been
conducted
.
[SEP]
[CLS]
In
patients
with
prior
history
of
bladder
cancer
,
the
benefits
of
g
##ly
##ce
##mic
control
versus
unknown
risks
for
cancer
re
##cu
##rrence
with
FA
##R
##X
##IG
##A
should
be
considered
.
[SEP]
[CLS]
A
small
proportion
of
women
will
have
adverse
lip
##id
changes
while
on
CO
##Cs
.
[SEP]
[CLS]
Ad
##vise
women
of
potential
risk
to
a
f
##etus
and
to
avoid
pregnancy
while
taking
Z
##yd
##eli
##g
.
[SEP]
[CLS]
EC
##G
monitoring
is
recommended
if
therapy
is
initiated
in
patients
with
con
##ges
##tive
heart
failure
,
bra
##dy
##ar
##r
##hy
##th
##mia
##s
,
drugs
known
to
pro
##long
the
Q
##T
interval
,
including
Class
I
##a
and
III
[SEP]
[CLS]
anti
##ar
##r
##hy
##th
##mic
##s
,
and
electro
##ly
##te
abnormal
##ities
.
[SEP]
[CLS]
With
##hold
H
##AL
##AV
##EN
in
patients
who
experience
Grade
3
or
4
peripheral
ne
##uro
##pathy
until
resolution
to
Grade
2
or
less
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
a
patient
becomes
pregnant
while
taking
this
drug
,
she
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[SEP]
[CLS]
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
5
.
7
N
##eu
##tro
##pen
##ia
Treatment
-
emerge
##nt
Grade
3
or
4
ne
##ut
##rop
##enia
occurred
in
31
%
of
Z
##yd
##eli
##g
-
treated
patients
across
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Grade
2
or
higher
laboratory
abnormal
##ities
that
represent
a
worse
##ning
from
base
##line
of
AS
##T
occurred
in
27
.
8
%
,
25
.
0
%
and
7
.
1
%
respectively
,
of
IN
##TE
##LE
##NC
##E
(
r
[SEP]
[CLS]
)
-
treated
co
-
infected
subjects
as
compared
to
6
.
7
%
,
7
.
5
%
and
1
.
8
%
of
non
-
co
-
infected
IN
##TE
##LE
##NC
##E
(
r
)
-
treated
subjects
.
[SEP]
[CLS]
5
.
5
Inc
##rease
##s
in
Low
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
(
L
##D
##L
-
C
)
Inc
##rease
##s
in
L
##D
##L
-
C
occur
with
FA
##R
##X
##IG
##A
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Monitor
fast
##ing
serum
glucose
prior
to
the
start
of
Z
##Y
##KA
##DI
##A
treatment
and
periodically
thereafter
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Co
-
administration
of
a
co
##rt
##ico
##ster
##oid
suppress
##es
ad
##ren
##oc
##ort
##ico
##tro
##pic
hormone
(
ACT
##H
)
drive
,
resulting
in
a
reduction
in
the
incidence
and
severity
of
these
adverse
reactions
.
[SEP]
[CLS]
CO
##Cs
may
decrease
glucose
tolerance
in
a
dose
-
related
fashion
.
[SEP]
[CLS]
When
plasma
am
##monia
level
is
normal
##ized
,
diet
##ary
protein
intake
can
usually
be
re
##int
##roduced
.
[SEP]
[CLS]
Report
##ed
infections
include
:
*
Active
tuberculosis
,
including
react
##ivation
of
late
##nt
tuberculosis
.
[SEP]
[CLS]
A
28
-
week
,
place
##bo
-
controlled
,
US
trial
that
compared
the
safety
of
another
LA
##BA
(
sa
##lm
##eter
##ol
)
with
place
##bo
,
each
added
to
usual
as
##th
##ma
therapy
,
showed
an
increase
[SEP]
[CLS]
in
as
##th
##ma
-
related
deaths
in
subjects
receiving
sa
##lm
##eter
##ol
(
13
/
13
,
176
in
subjects
treated
with
sa
##lm
##eter
##ol
vs
.
3
/
13
,
179
in
subjects
treated
with
place
##bo
;
relative
risk
:
4
.
37
[
95
%
C
##I
[SEP]
[CLS]
:
1
.
25
,
15
.
34
]
)
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
for
severe
h
##yper
##tens
##ion
that
can
not
be
controlled
with
anti
-
h
##yper
##tensive
therapy
.
[SEP]
[CLS]
These
adverse
reactions
were
not
present
at
base
##line
,
occurred
more
commonly
on
T
##R
##U
##L
##IC
##IT
##Y
than
on
place
##bo
,
and
occurred
in
at
least
5
%
of
patients
treated
with
T
##R
##U
##L
##IC
##IT
##Y
[SEP]
[CLS]
.
[SEP]
[CLS]
[
See
Clinical
Studies
(
14
)
.
]
[SEP]
[CLS]
Six
of
the
8
cases
presented
with
C
##NS
involvement
.
[SEP]
[CLS]
In
a
short
-
term
place
##bo
-
controlled
trial
(
4
-
weeks
)
,
the
mean
change
from
base
##line
to
end
##point
in
plasma
pro
##la
##ct
##in
levels
for
the
FA
##NA
##P
##T
24
mg
/
day
-
treated
group
was
an
increase
of
[SEP]
[CLS]
2
.
6
ng
/
m
##L
compared
to
a
decrease
of
6
.
3
ng
/
m
##L
in
the
place
##bo
-
group
.
[SEP]
[CLS]
Pre
-
existing
h
##y
##po
##cal
##ce
##mia
must
be
corrected
prior
to
in
##iti
##ating
therapy
with
Pro
##lia
.
[SEP]
[CLS]
The
finding
of
increased
risk
with
A
##ED
##s
of
varying
mechanism
of
action
and
across
a
range
of
indication
##s
suggests
that
the
risk
applies
to
all
A
##ED
##s
used
for
any
indication
[SEP]
[CLS]
.
[SEP]
[CLS]
In
these
trials
6
%
of
patients
on
P
##OT
##IG
##A
and
1
.
2
%
on
place
##bo
discontinued
treatment
because
of
di
##zzi
##ness
;
3
%
of
patients
on
P
##OT
##IG
##A
and
<
1
.
0
%
[SEP]
[CLS]
on
place
##bo
discontinued
because
of
so
##m
##no
##len
##ce
.
[SEP]
[CLS]
Most
cases
of
trans
##ami
##nas
##e
elevations
occurred
early
in
treatment
;
of
patients
who
experienced
trans
##ami
##nas
##e
elevations
of
any
grade
,
more
than
80
%
experienced
their
first
event
within
the
[SEP]
[CLS]
first
3
months
.
[SEP]
[CLS]
If
such
effects
occur
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
may
need
to
be
discontinued
.
[SEP]
[CLS]
D
##U
##AV
##EE
is
not
for
pregnant
women
.
[SEP]
[CLS]
(
5
.
2
)
*
Progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
;
With
##hold
G
##IL
##EN
##Y
##A
at
the
first
sign
or
s
##ym
##pt
##om
suggest
##ive
of
PM
##L
.
[SEP]
[CLS]
If
an
##aph
##yla
##xi
##s
or
severe
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
immediately
disco
##ntin
##ue
in
##fusion
and
initiate
appropriate
medical
treatment
(
5
.
1
)
.
[SEP]
[CLS]
In
a
52
-
week
,
double
-
blind
,
com
##par
##ator
-
controlled
trial
that
included
primarily
adult
patients
with
s
##chi
##zophrenia
,
the
mean
increase
from
base
##line
of
AL
##T
was
1
.
7
units
/
L
.
[SEP]
[CLS]
An
elevated
risk
of
acute
d
##ys
##ton
##ia
is
observed
in
males
and
younger
age
groups
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
,
Use
in
S
##pecific
Population
##s
(
8
.
4
)
[SEP]
[CLS]
,
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Your
healthcare
provider
will
let
you
know
if
you
need
to
stop
taking
D
##U
##AV
##EE
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
Abd
##omi
##nal
pain
,
abdominal
discomfort
,
flat
##ule
##nce
,
upper
abdominal
pain
,
vomit
##ing
.
[SEP]
[CLS]
Monitor
C
##L
##c
##r
,
urine
glucose
,
and
urine
protein
in
all
patients
.
[SEP]
[CLS]
The
only
treatment
-
emerge
##nt
AD
##R
of
moderate
to
severe
intensity
with
at
least
2
%
frequency
in
either
treatment
group
was
di
##ar
##r
##hea
,
2
%
(
6
of
35
##4
)
in
[SEP]
[CLS]
subjects
receiving
T
##I
##VI
##CA
##Y
50
mg
once
daily
+
background
regime
##n
and
1
%
(
5
of
36
##1
)
in
subjects
receiving
r
##al
##te
##gra
##vir
400
mg
twice
daily
+
background
regime
##n
.
[SEP]
[CLS]
With
##hold
Y
##ER
##VO
##Y
dos
##ing
in
patients
with
moderate
ne
##uro
##pathy
(
not
interfering
with
daily
activities
)
.
[SEP]
[CLS]
The
extent
to
which
the
findings
of
increased
mortality
in
observation
##al
studies
may
be
attributed
to
the
anti
##psy
##cho
##tic
drug
as
opposed
to
some
characteristic
(
s
)
of
the
patients
[SEP]
[CLS]
is
not
clear
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
during
and
for
an
appropriate
period
of
time
after
administration
of
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
was
observed
in
0
.
6
%
(
9
/
1
,
45
##8
)
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
0
.
4
%
(
3
/
67
##5
)
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Whether
the
imp
##air
##ment
is
related
to
so
##m
##no
##len
##ce
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
or
other
effects
of
H
##OR
##I
##Z
##AN
##T
is
unknown
.
[SEP]
[CLS]
Therefore
,
the
use
of
C
##IM
##Z
##IA
in
combination
with
other
biological
D
##MA
##RD
##s
is
not
recommended
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
The
most
common
(
>
=
10
%
)
grade
1
-
4
adverse
reactions
were
an
##emia
,
le
##uk
##ope
##nia
,
ne
##ut
##rop
##enia
,
th
##rom
##bo
##cy
##top
##enia
,
di
##ar
##r
##hea
,
fatigue
,
nausea
,
vomit
##ing
,
[SEP]
[CLS]
con
##st
##ip
##ation
,
as
##the
##nia
,
abdominal
pain
,
hem
##at
##uria
,
back
pain
,
an
##ore
##xia
,
peripheral
ne
##uro
##pathy
,
p
##yre
##xia
,
d
##ys
##p
##nea
,
d
##ys
##gues
##ia
,
cough
,
art
##hra
##l
##gia
,
and
al
##ope
##cia
.
[SEP]
[CLS]
*
Inter
##st
##iti
##al
Lu
##ng
Disease
and
E
##os
##ino
##phi
##lic
P
##ne
##um
##onia
:
Can
occur
(
5
.
10
)
.
[SEP]
[CLS]
Use
of
D
##U
##AV
##EE
in
patients
with
re
##nal
imp
##air
##ment
is
not
recommended
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
Le
##uk
##oc
##yt
##osis
In
clinical
studies
,
le
##uk
##oc
##yt
##osis
(
W
##BC
counts
>
100
,
000
x
10
6
/
L
)
was
observed
in
less
than
1
%
patients
with
non
-
my
##elo
##id
ma
##li
##gna
##ncies
receiving
G
##RA
##NI
##X
.
[SEP]
[CLS]
Recent
(
i
.
e
.
,
within
last
6
months
)
trans
##ami
##nas
##e
and
bi
##li
##ru
##bin
levels
should
be
available
before
initiation
of
G
##IL
##EN
##Y
##A
therapy
.
[SEP]
[CLS]
In
patients
who
develop
serious
infections
while
on
Pro
##lia
,
pre
##s
##cribe
##rs
should
assess
the
need
for
continued
Pro
##lia
therapy
.
[SEP]
[CLS]
Pat
##ients
should
disco
##ntin
##ue
use
of
any
product
containing
4
-
amino
##py
##rid
##ine
prior
to
in
##iti
##ating
treatment
with
AM
##P
##Y
##RA
in
order
to
reduce
the
potential
for
dose
-
related
adverse
reactions
.
[SEP]
[CLS]
In
the
group
treated
with
T
##AN
##Z
##E
##UM
,
investigators
graded
the
severity
of
G
##I
reactions
as
`
`
mild
'
'
in
56
%
of
cases
,
`
`
moderate
'
'
in
37
%
[SEP]
[CLS]
of
cases
,
and
`
`
severe
'
'
in
7
%
of
cases
.
[SEP]
[CLS]
5
.
12
Em
##b
##ryo
-
f
##etal
To
##xi
##city
Based
on
the
mechanism
of
action
,
A
##FI
##NI
##TO
##R
can
cause
f
##etal
harm
.
[SEP]
[CLS]
Re
##cu
##rrence
of
liver
trans
##ami
##nas
##e
elevations
occurred
with
re
##chal
##len
##ge
in
some
patients
.
[SEP]
[CLS]
Before
therapy
with
Te
##f
##lar
##o
is
instituted
,
careful
inquiry
about
previous
h
##yper
##sen
##si
##ti
##vity
reactions
to
other
c
##ep
##hal
##os
##por
##ins
,
pen
##ici
##llin
##s
,
or
car
##ba
##pen
##ems
should
be
made
.
[SEP]
[CLS]
Extreme
care
must
be
taken
to
avoid
pregnancy
in
female
patients
and
in
female
partners
of
male
patients
.
[SEP]
[CLS]
O
##bs
##erve
patients
for
signs
and
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
during
and
following
G
##ada
##vist
administration
.
[SEP]
[CLS]
(
5
.
6
,
2
.
3
)
*
Ser
##ious
Feb
##ril
##e
Re
##actions
:
Inc
##iden
##ce
and
severity
of
p
##yre
##xia
are
increased
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
of
potential
risk
to
a
f
##etus
.
[SEP]
[CLS]
Drugs
that
have
a
mixed
effect
on
C
##YP
##3
##A
##4
,
especially
anti
##ret
##rov
##ira
##l
drugs
such
as
HIV
pro
##te
##ase
inhibitor
##s
and
non
-
n
##uc
##leo
##side
reverse
trans
##cript
##ase
inhibitor
##s
,
and
those
that
have
an
effect
on
[SEP]
[CLS]
the
Q
##T
interval
should
be
used
with
caution
in
patients
taking
Co
##arte
##m
Table
##ts
[
see
Drug
Inter
##actions
(
7
.
3
,
7
.
7
)
]
.
[SEP]
[CLS]
Main
##tain
clinical
supervision
if
this
product
is
to
be
given
to
a
pen
##ici
##llin
-
or
other
beta
-
la
##ct
##am
-
all
##ergic
patient
,
because
cross
sensitivity
among
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
agents
has
been
clearly
established
.
[SEP]
[CLS]
5
.
3
A
##cute
Kid
##ney
In
##ju
##ry
In
patients
with
chronic
re
##nal
imp
##air
##ment
,
acute
kidney
injury
sometimes
requiring
dial
##ys
##is
has
been
observed
with
the
use
of
some
GB
##CA
##s
.
[SEP]
[CLS]
Table
4
presents
the
most
common
adverse
drug
reactions
(
experienced
by
greater
than
or
equal
to
3
%
of
patients
receiving
PR
##OM
##AC
##TA
)
from
the
three
place
##bo
-
controlled
trials
,
[SEP]
[CLS]
with
a
higher
incidence
in
PR
##OM
##AC
##TA
versus
place
##bo
.
[SEP]
[CLS]
The
median
time
to
onset
of
skin
toxicity
in
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
was
37
days
(
range
:
1
to
225
days
)
and
median
[SEP]
[CLS]
time
to
resolution
of
skin
toxicity
was
33
days
(
range
:
3
to
42
##1
days
)
.
[SEP]
[CLS]
Table
1
shows
adverse
reactions
occurring
in
>
=
3
%
of
K
##AL
##BI
##TO
##R
-
treated
patients
that
also
occurred
at
a
higher
rate
than
in
the
place
##bo
-
treated
patients
in
the
two
controlled
trials
[SEP]
[CLS]
(
E
##DE
##MA
##3
and
E
##DE
##MA
##4
)
of
the
30
mg
sub
##cut
##aneous
dose
.
[SEP]
[CLS]
Con
##st
##ip
##ation
also
contributed
to
the
frequently
reported
reactions
.
[SEP]
[CLS]
Forty
-
eight
percent
of
patients
were
white
,
15
%
African
/
African
American
,
9
%
Asian
,
and
26
%
were
Hispanic
/
Latino
.
[SEP]
[CLS]
Li
##pid
intake
restrictions
may
be
necessary
for
patients
with
significant
disorders
of
lip
##id
metabolism
.
[SEP]
[CLS]
Da
##bra
##fen
##ib
was
te
##rato
##genic
and
em
##b
##ryo
##to
##xi
##c
in
rats
at
doses
three
times
greater
than
the
human
exposure
at
the
recommended
clinical
dose
.
[SEP]
[CLS]
This
may
be
associated
with
con
##com
##ita
##nt
use
of
co
##rt
##ico
##ster
##oids
or
other
im
##mu
##nos
##up
##pressive
agents
.
[SEP]
[CLS]
*
H
##y
##po
##nat
##rem
##ia
:
Can
occur
in
association
with
S
##IA
##D
##H
(
5
.
9
)
.
[SEP]
[CLS]
The
majority
of
injection
site
reactions
were
judged
as
`
`
mild
'
'
by
investigators
in
both
groups
(
73
%
for
T
##AN
##Z
##E
##UM
versus
94
%
for
place
##bo
)
.
[SEP]
[CLS]
6
.
4
Laboratory
Finding
##s
He
##mat
##ology
During
clinical
trials
with
IL
##AR
##IS
,
mean
values
decreased
for
white
blood
cells
.
[SEP]
[CLS]
In
Trial
2
,
treatment
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
resulted
in
an
increased
incidence
and
severity
of
any
hem
##or
##r
##ha
##gic
event
:
16
%
(
9
/
55
)
of
patients
[SEP]
[CLS]
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
compared
with
2
%
(
1
/
53
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
In
the
controlled
clinical
trials
,
h
##yper
##sen
##si
##ti
##vity
reactions
(
occurring
on
the
same
day
of
in
##fusion
)
were
reported
in
13
%
(
191
/
1
,
45
##8
)
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
[SEP]
[CLS]
11
%
(
76
/
67
##5
)
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
With
##hold
Y
##ER
##VO
##Y
dos
##ing
in
s
##ym
##pt
##oma
##tic
patients
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Te
##va
Ph
##arma
##ce
##utical
##s
at
1
-
800
-
89
##6
-
58
##55
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
It
is
recommended
that
AL
##T
and
AS
##T
be
assessed
prior
to
in
##iti
##ating
K
##AL
##Y
##DE
##CO
,
every
3
months
during
the
first
year
of
treatment
,
and
annually
thereafter
.
[SEP]
[CLS]
cut
##aneous
immune
-
mediated
reactions
,
including
protein
##uria
and
ne
##ph
##rot
##ic
syndrome
secondary
to
me
##mb
##rano
##us
g
##lo
##mer
##ulon
##ep
##hr
##itis
,
and
ne
##c
##rot
##izing
skin
lesions
have
been
reported
in
post
##market
##ing
safety
experience
with
al
##g
##lu
##cos
##idas
##e
al
##fa
[
see
##W
##ar
##ning
##s
[SEP]
[CLS]
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Consider
initiation
of
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
pre
##dn
##ison
##e
or
equivalent
for
severe
ne
##uro
##path
##ies
.
[SEP]
[CLS]
The
stated
frequencies
of
adverse
reactions
represent
the
proportions
of
individuals
who
experienced
a
treatment
-
emerge
##nt
adverse
reaction
of
the
type
listed
.
[SEP]
[CLS]
During
the
24
-
week
,
open
-
label
,
clinical
trial
in
34
patients
ages
2
to
less
than
6
years
(
Trial
6
)
,
where
patients
received
either
50
mg
(
[SEP]
[CLS]
less
than
14
kg
)
or
75
mg
(
14
kg
or
greater
)
i
##va
##ca
##ft
##or
g
##ran
##ules
twice
daily
,
the
incidence
of
patients
experiencing
trans
##ami
##nas
##e
elevations
(
[SEP]
[CLS]
AS
##T
)
>
3
*
U
##L
##N
was
14
.
7
%
(
5
/
34
)
.
[SEP]
[CLS]
Table
3
:
Key
Laboratory
A
##b
##nor
##mal
##ities
Report
##ed
in
>
=
10
%
of
Pat
##ients
with
Advanced
H
##R
+
BC
G
##rading
according
to
CT
##CA
##E
Version
3
.
0
a
Ex
##em
##esta
##ne
(
25
mg
/
day
)
[SEP]
[CLS]
b
Re
##fle
##cts
corresponding
adverse
drug
reaction
reports
of
an
##emia
,
le
##uk
##ope
##nia
,
l
##ymph
##ope
##nia
,
ne
##ut
##rop
##enia
,
and
th
##rom
##bo
##cy
##top
##enia
(
collectively
as
pan
##cy
##top
##enia
)
,
which
occurred
at
lower
frequency
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
an
##aph
##yla
##ct
##oid
reactions
have
been
reported
with
D
##OT
##AR
##EM
,
involving
card
##iovascular
,
respiratory
,
and
/
or
cut
##aneous
manifest
##ations
.
[SEP]
[CLS]
One
(
0
.
3
%
)
subject
who
received
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
developed
laboratory
findings
consistent
with
pro
##ximal
re
##nal
tub
##ular
d
##ys
##function
leading
to
disco
##ntin
##uation
of
AT
##V
+
R
##TV
+
[SEP]
[CLS]
T
##R
##U
##VA
##DA
after
Week
96
.
[SEP]
[CLS]
In
controlled
clinical
trials
,
adverse
reactions
of
s
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
following
the
first
dose
were
reported
in
0
.
6
%
of
patients
receiving
G
##IL
##EN
##Y
##A
0
.
5
mg
and
in
0
.
1
%
of
[SEP]
[CLS]
patients
on
place
##bo
.
[SEP]
[CLS]
5
.
5
A
##cute
P
##E
in
He
##mo
##dynamic
##ally
Un
##stable
Pat
##ients
or
Pat
##ients
who
Re
##quire
T
##hr
##omb
##oly
##sis
or
P
##ul
##mona
##ry
Em
##bol
##ec
##tom
##y
In
##iti
##ation
of
E
##L
##I
##Q
##UI
##S
is
not
recommended
as
an
alternative
to
un
##fra
##ction
##ated
he
##par
##in
for
the
initial
[SEP]
[CLS]
treatment
of
patients
with
P
##E
who
present
with
hem
##ody
##nam
##ic
instability
or
who
may
receive
th
##rom
##bol
##ys
##is
or
pulmonary
em
##bol
##ec
##tom
##y
.
[SEP]
[CLS]
(
5
.
6
)
*
Or
##th
##ost
##atic
H
##y
##pot
##ens
##ion
,
S
##ync
##ope
,
and
Other
He
##mo
##dynamic
Effects
:
Di
##zzi
##ness
,
ta
##chy
##card
##ia
or
bra
##dy
##card
##ia
,
and
s
##ync
##ope
may
occur
,
especially
early
in
treatment
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ce
##re
##bro
##vas
##cular
Ad
##verse
Events
:
An
increased
incidence
of
c
##ere
##bro
##vas
##cular
adverse
events
(
e
.
g
.
,
stroke
,
[SEP]
[CLS]
trans
##ient
is
##che
##mic
attack
)
has
been
seen
in
elderly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##ose
##s
treated
with
at
##y
##pical
anti
##psy
##cho
##tic
drugs
.
[SEP]
[CLS]
Seven
##teen
patients
(
1
.
0
%
)
required
permanent
disco
##ntin
##uation
due
to
elevated
trans
##ami
##nas
##es
.
[SEP]
[CLS]
In
a
trial
carried
out
in
patients
with
moderate
re
##nal
imp
##air
##ment
with
a
base
##line
e
##G
##F
##R
of
30
to
less
than
50
m
##L
/
min
/
1
.
73
m
2
(
mean
base
##line
e
##G
##F
##R
39
m
##L
/
min
/
1
.
73
[SEP]
[CLS]
m
2
)
[
see
Clinical
Studies
(
14
.
3
)
]
,
the
proportion
of
patients
who
experienced
at
least
one
event
of
significant
re
##nal
function
decline
,
defined
as
[SEP]
[CLS]
an
e
##G
##F
##R
30
%
lower
than
base
##line
,
was
6
.
9
%
with
place
##bo
,
18
%
with
IN
##VO
##KA
##NA
100
mg
,
and
22
.
5
%
with
IN
##VO
##KA
##NA
300
mg
.
At
the
[SEP]
[CLS]
end
of
treatment
,
4
.
6
%
with
place
##bo
,
3
.
4
%
with
IN
##VO
##KA
##NA
100
mg
,
and
2
.
2
%
with
IN
##VO
##KA
##NA
300
mg
had
a
significant
re
##nal
function
decline
.
[SEP]
[CLS]
Monitor
symptoms
(
such
as
fatigue
,
an
##ore
##xia
,
nausea
,
j
##au
##ndi
##ce
,
dark
urine
,
liver
tender
##ness
and
he
##pa
##tom
##eg
##aly
)
and
laboratory
tests
(
AL
##T
,
AS
##T
,
al
##kal
##ine
[SEP]
[CLS]
p
##hos
##pha
##tase
,
and
bi
##li
##ru
##bin
)
at
base
##line
,
monthly
while
on
treatment
,
and
as
needed
.
[SEP]
[CLS]
These
cases
of
an
##aph
##yla
##xi
##s
occurred
as
early
as
30
minutes
from
the
start
of
in
##fusion
and
up
to
three
hours
after
in
##fusion
.
[SEP]
[CLS]
Me
##as
##ure
##ment
of
serum
sodium
and
chloride
levels
should
be
considered
during
maintenance
treatment
with
AP
##TI
##OM
,
particularly
if
the
patient
is
receiving
other
medications
known
to
decrease
serum
sodium
levels
[SEP]
[CLS]
and
should
be
performed
if
symptoms
of
h
##y
##po
##nat
##rem
##ia
develop
(
e
.
g
.
,
nausea
/
vomit
##ing
,
ma
##lai
##se
,
headache
,
let
##har
##gy
,
confusion
,
i
##rri
##ta
##bility
,
muscle
weakness
/
spa
##sm
##s
,
o
##bt
##unda
##tion
,
or
[SEP]
[CLS]
increase
in
seizure
frequency
or
severity
)
.
[SEP]
[CLS]
Four
weeks
after
stopping
T
##EC
##FI
##DE
##RA
,
mean
l
##ymph
##oc
##yte
counts
increased
but
did
not
return
to
base
##line
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Shire
Human
Gene
##tic
The
##rap
##ies
at
the
One
##P
##ath
(
r
)
phone
#
1
-
86
##6
-
88
##8
-
06
##60
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
[SEP]
[CLS]
Clinical
Trials
Experience
The
safety
of
i
##cat
##iba
##nt
was
evaluated
in
three
controlled
trials
that
included
223
patients
who
received
F
##IR
##A
##Z
##Y
##R
30
mg
(
n
=
113
)
,
place
##bo
(
n
=
75
)
[SEP]
[CLS]
,
or
com
##par
##ator
(
n
=
38
)
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Gen
##ital
my
##cot
##ic
infections
were
reported
in
0
.
9
%
of
patients
on
place
##bo
,
5
.
7
%
on
FA
##R
##X
##IG
##A
5
mg
,
and
4
.
8
%
on
FA
##R
##X
##IG
##A
10
mg
,
in
the
[SEP]
[CLS]
12
-
study
place
##bo
-
controlled
pool
.
[SEP]
[CLS]
Se
##vere
pen
##ile
hem
##ato
##ma
was
also
reported
as
an
adverse
reaction
in
39
of
104
##4
patients
(
3
.
7
%
)
in
the
controlled
and
un
##con
##tro
##lled
clinical
trials
in
P
##ey
##ron
##ie
'
s
disease
[SEP]
[CLS]
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Auto
##anti
##bo
##dies
In
clinical
studies
in
C
##ro
##hn
'
s
disease
,
4
%
of
patients
treated
with
C
##IM
##Z
##IA
and
2
%
of
patients
treated
with
place
##bo
that
had
negative
base
##line
[SEP]
[CLS]
AN
##A
t
##iter
##s
developed
positive
t
##iter
##s
during
the
studies
.
[SEP]
[CLS]
At
study
base
##line
,
approximately
25
%
had
mild
,
50
%
had
moderate
,
and
25
%
had
severe
c
##er
##vic
##al
d
##ys
##ton
##ia
.
[SEP]
[CLS]
With
##hold
CO
##ME
##TR
##I
##Q
for
h
##yper
##tens
##ion
that
is
not
adequately
controlled
with
medical
management
;
when
controlled
,
resume
CO
##ME
##TR
##I
##Q
at
a
reduced
dose
.
[SEP]
[CLS]
Consider
alternative
con
##tra
##ception
for
women
with
un
##con
##tro
##lled
d
##ys
##lip
##ide
##mia
.
[SEP]
[CLS]
In
the
majority
of
cases
,
r
##ash
type
,
and
occurred
in
the
second
week
of
therapy
.
[SEP]
[CLS]
5
.
6
Su
##icidal
Be
##ha
##vior
and
I
##dea
##tion
Anti
##ep
##ile
##ptic
drugs
(
A
##ED
##s
)
,
including
ON
##FI
,
increase
the
risk
of
su
##icidal
thoughts
in
patients
taking
these
drugs
for
any
indication
.
[SEP]
[CLS]
In
patients
who
develop
serious
all
##ergic
reactions
,
disco
##ntin
##ue
Z
##yd
##eli
##g
permanently
and
institute
appropriate
supportive
measures
.
[SEP]
[CLS]
Monitor
liver
function
tests
before
treatment
and
before
the
start
of
each
cycle
.
[SEP]
[CLS]
Feb
##ril
##e
ne
##ut
##rop
##enia
has
been
reported
with
treatment
with
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
Pat
##ients
received
place
##bo
(
N
=
139
##3
)
,
FA
##R
##X
##IG
##A
5
mg
(
N
=
114
##5
)
,
or
FA
##R
##X
##IG
##A
10
mg
(
N
=
119
##3
)
once
daily
.
[SEP]
[CLS]
At
one
year
after
transplant
##ation
these
values
were
183
mg
/
d
##L
,
50
mg
/
d
##L
,
102
mg
/
d
##L
,
and
151
mg
/
d
##L
,
respectively
,
in
401
patients
treated
with
the
N
##U
##L
##O
##J
##IX
[SEP]
[CLS]
recommended
regime
##n
and
196
mg
/
d
##L
,
48
mg
/
d
##L
,
108
mg
/
d
##L
,
and
195
mg
/
d
##L
,
respectively
,
in
405
patients
treated
with
the
c
##y
##c
##los
##por
##ine
control
regime
##n
.
[SEP]
[CLS]
Follow
instructions
for
preparation
(
including
ad
##mi
##xing
)
and
administration
strictly
to
minimize
medication
errors
(
including
under
##dos
##e
and
over
##dos
##e
)
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
[SEP]
[CLS]
(
2
.
4
)
]
.
[SEP]
[CLS]
In
other
XI
##AF
##LE
##X
-
treated
patients
(
9
of
104
##4
;
0
.
9
%
)
,
a
combination
of
pen
##ile
e
##cc
##hy
##mos
##es
,
sudden
pen
##ile
de
##tum
##es
##cence
,
and
/
or
a
pen
##ile
`
`
popping
'
'
[SEP]
[CLS]
sound
was
reported
,
and
in
these
cases
,
a
diagnosis
of
co
##rp
##oral
r
##up
##ture
can
not
be
excluded
.
[SEP]
[CLS]
The
information
below
is
derived
from
a
clinical
trial
database
for
FA
##NA
##P
##T
consisting
of
207
##0
patients
exposed
to
FA
##NA
##P
##T
at
doses
of
10
mg
/
day
or
greater
,
for
the
treatment
[SEP]
[CLS]
of
s
##chi
##zophrenia
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
were
reported
in
54
(
49
%
)
subjects
treated
with
Z
##yd
##eli
##g
+
r
##it
##ux
##ima
##b
.
[SEP]
[CLS]
Ser
##ious
adverse
events
that
may
be
associated
with
CR
##S
included
p
##yre
##xia
,
headache
,
nausea
,
as
##the
##nia
,
h
##y
##pot
##ens
##ion
,
increased
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
,
increased
as
##par
##tate
amino
##tra
##ns
##fer
##ase
,
and
[SEP]
[CLS]
increased
total
bi
##li
##ru
##bin
;
these
events
in
##f
##re
##quent
##ly
led
to
B
##L
##IN
##C
##Y
##TO
disco
##ntin
##uation
.
[SEP]
[CLS]
(
2
.
3
)
,
(
5
.
2
)
5
.
[SEP]
[CLS]
*
Mac
##rov
##as
##cular
outcomes
:
There
have
been
no
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
T
##R
##U
##L
##IC
##IT
##Y
or
any
other
anti
##dia
##bet
##ic
drug
(
5
.
7
)
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
While
all
at
##y
##pical
anti
##psy
##cho
##tic
drugs
have
been
shown
to
produce
some
metabolic
changes
,
each
drug
in
the
class
has
its
own
specific
risk
profile
.
[SEP]
[CLS]
In
a
mon
##otherapy
study
comparing
NE
##SI
##NA
to
a
su
##lf
##ony
##lu
##rea
in
elderly
patients
,
the
incidence
of
h
##y
##po
##gly
##ce
##mia
was
5
.
4
%
with
NE
##SI
##NA
compared
to
26
%
with
g
##lip
##iz
##ide
(
Table
[SEP]
[CLS]
2
)
.
[SEP]
[CLS]
Pat
##ients
who
experience
Grade
3
or
worse
all
##ergic
-
type
reactions
should
not
be
re
##chal
##len
##ged
.
[SEP]
[CLS]
The
data
described
below
reflect
exposure
to
E
##NT
##ER
##EG
12
mg
in
1
,
79
##3
patients
in
10
place
##bo
-
controlled
studies
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
5
%
and
at
least
twice
the
rate
of
place
##bo
)
reported
with
acute
mon
##otherapy
treatment
of
man
##ic
or
mixed
episodes
associated
with
[SEP]
[CLS]
bi
##pol
##ar
I
disorder
in
adults
were
so
##m
##no
##len
##ce
,
di
##zzi
##ness
,
extra
##py
##ram
##idal
symptoms
other
than
aka
##thi
##sia
,
and
increased
weight
and
during
the
ad
##junct
##ive
therapy
trial
in
bi
##pol
##ar
I
disorder
in
[SEP]
[CLS]
adults
were
so
##m
##no
##len
##ce
and
oral
h
##y
##po
##est
##hesia
.
[SEP]
[CLS]
The
incidence
of
all
-
cause
mortality
was
2
.
3
%
(
n
=
90
)
in
the
place
##bo
group
and
1
.
8
%
(
n
=
70
)
in
the
Pro
##lia
group
.
[SEP]
[CLS]
(
5
.
1
)
Q
##T
Pro
##long
##ation
*
Q
##T
pro
##long
##ation
can
occur
with
S
##IR
##TU
##RO
.
[SEP]
[CLS]
The
safety
of
SA
##P
##H
##RI
##S
was
evaluated
in
40
##3
p
##ediatric
patients
with
bi
##pol
##ar
I
disorder
who
participated
in
a
3
-
week
,
place
##bo
-
controlled
,
double
-
blind
trial
,
of
whom
302
patients
received
[SEP]
[CLS]
SA
##P
##H
##RI
##S
at
fixed
doses
ranging
from
2
.
5
mg
to
10
mg
twice
daily
.
[SEP]
[CLS]
Other
important
considerations
in
the
differential
diagnosis
include
central
anti
##cho
##liner
##gic
toxicity
,
heat
stroke
,
drug
fever
,
and
primary
central
nervous
system
(
C
##NS
)
path
##ology
.
[SEP]
[CLS]
The
following
additional
adverse
reactions
occurred
in
less
than
10
%
of
A
##FI
##NI
##TO
##R
-
treated
patients
:
e
##pis
##ta
##xi
##s
(
9
%
)
,
decreased
appetite
(
6
%
)
,
[SEP]
[CLS]
o
##titis
media
(
6
%
)
,
depression
(
5
%
)
,
abnormal
taste
(
5
%
)
,
increased
blood
l
##ute
##ini
##zing
hormone
(
L
##H
)
levels
(
4
[SEP]
[CLS]
%
)
,
increased
blood
f
##oll
##icle
s
##ti
##mulating
hormone
(
F
##S
##H
)
levels
(
3
%
)
,
h
##yper
##sen
##si
##ti
##vity
(
3
%
)
,
o
##var
##ian
c
##ys
##t
(
3
%
)
,
[SEP]
[CLS]
p
##ne
##um
##oni
##tis
(
1
%
)
,
and
an
##gio
##ede
##ma
(
1
%
)
.
[SEP]
[CLS]
Most
patients
(
>
70
%
)
in
both
trials
were
enrolled
in
Eastern
Europe
and
were
White
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
2
%
and
more
common
than
place
##bo
)
are
cough
,
or
##op
##har
##yn
##ge
##al
pain
,
na
##so
##pha
##ryn
##git
##is
,
headache
and
nausea
.
[SEP]
[CLS]
The
safety
of
D
##Y
##SP
##OR
##T
(
r
)
for
the
treatment
of
h
##yper
##hi
##dr
##osis
has
not
been
established
.
[SEP]
[CLS]
C
##rea
##tin
##ine
increases
were
comparable
by
background
N
##RT
##I
##s
and
were
similar
in
treatment
-
experienced
subjects
.
[SEP]
[CLS]
(
5
.
13
)
*
Po
##ten
##tial
for
motor
imp
##air
##ment
:
Use
caution
when
operating
machinery
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
chronic
infections
.
[SEP]
[CLS]
*
Oral
ul
##cer
##ation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
h
##y
##pot
##ens
##ion
after
in
##iti
##ating
therapy
and
increase
monitoring
in
clinical
situations
where
volume
contraction
is
expected
[
see
Use
in
S
##pecific
Population
##s
(
8
.
5
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Re
##hy
##dra
##te
and
treat
with
anti
-
em
##etics
and
anti
-
di
##ar
##r
##hea
##ls
as
needed
.
[SEP]
[CLS]
Pro
##mpt
##ly
evaluate
signs
and
symptoms
of
blood
loss
.
[SEP]
[CLS]
Re
##fer
to
the
pre
##s
##cribing
information
for
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
for
pre
-
treatment
,
on
-
treatment
and
post
-
treatment
laboratory
testing
recommendations
including
hem
##ato
##logy
,
bio
##chemistry
(
including
he
##pa
##tic
function
tests
)
,
[SEP]
[CLS]
and
pregnancy
testing
requirements
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
important
adverse
reactions
are
described
elsewhere
in
label
##ing
:
*
Ana
##phy
##lax
##is
and
Ang
##io
##ede
##ma
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
*
e
Rate
of
documented
s
##ym
##pt
##oma
##tic
h
##y
##po
##gly
##ce
##mia
for
active
controls
18
%
(
g
##lim
##ep
##iri
##de
)
and
2
%
(
sit
##ag
##lip
##tin
)
.
[SEP]
[CLS]
Monitor
patients
for
the
development
of
signs
and
symptoms
of
tuberculosis
including
patients
who
tested
negative
for
late
##nt
tuberculosis
infection
prior
to
in
##iti
##ating
therapy
,
patients
who
are
on
treatment
[SEP]
[CLS]
for
late
##nt
tuberculosis
,
or
patients
who
were
previously
treated
for
tuberculosis
infection
.
[SEP]
[CLS]
(
5
.
4
)
*
Elder
##ly
patients
:
Pat
##ients
>
=
65
years
of
age
were
more
likely
to
experience
fatal
outcomes
not
related
to
disease
progression
and
certain
adverse
reactions
[SEP]
[CLS]
,
including
ne
##ut
##rop
##enia
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
disorders
:
he
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
8
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
AL
##T
elevations
with
D
##AL
##VA
##NC
##E
treatment
were
reported
in
clinical
trials
.
[SEP]
[CLS]
Consul
##tation
with
a
physician
with
expertise
in
the
treatment
of
tuberculosis
is
recommended
to
aid
in
the
decision
of
whether
in
##iti
##ating
anti
-
tuberculosis
therapy
is
appropriate
for
an
individual
patient
.
[SEP]
[CLS]
Skin
and
sub
##cut
##aneous
tissue
disorders
:
To
##xi
##c
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
,
including
fatal
outcomes
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
11
)
]
.
[SEP]
[CLS]
Before
pre
##s
##cribing
ST
##EN
##DR
##A
,
it
is
important
to
note
the
following
:
E
##X
##CE
##RP
##T
:
*
Pat
##ients
should
not
use
ST
##EN
##DR
##A
if
sexual
activity
is
in
##ad
##vis
##able
due
to
card
##iovascular
status
or
[SEP]
[CLS]
any
other
reason
(
5
.
1
)
*
Use
of
ST
##EN
##DR
##A
with
alpha
-
block
##ers
,
other
anti
##hy
##pert
##ens
##ives
,
or
substantial
amounts
of
alcohol
(
greater
than
3
units
)
may
lead
to
[SEP]
[CLS]
h
##y
##pot
##ens
##ion
(
2
.
3
,
5
.
6
,
5
.
7
)
*
Pat
##ients
should
seek
emergency
treatment
if
an
erection
lasts
greater
than
4
hours
(
5
.
3
)
*
Pat
##ients
should
stop
ST
##EN
##DR
##A
and
seek
medical
care
[SEP]
[CLS]
if
a
sudden
loss
of
vision
occurs
in
one
or
both
eyes
,
which
could
be
a
sign
of
Non
Arte
##ritic
Is
##che
##mic
Op
##tic
N
##eur
##op
##athy
(
N
##A
##ION
)
.
[SEP]
[CLS]
Table
4
presents
the
adverse
reactions
occurring
in
>
=
2
%
of
subjects
treated
with
ST
##EN
##DR
##A
.
[SEP]
[CLS]
H
##yper
##to
##xin
-
producing
strains
of
C
.
di
##ff
##ici
##le
cause
increased
m
##or
##bid
##ity
and
mortality
,
as
these
infections
can
be
re
##fra
##ctor
##y
to
anti
##ba
##cter
##ial
therapy
and
may
require
co
##lect
##omy
.
[SEP]
[CLS]
co
##rt
##ico
##ster
##oids
or
met
##hot
##re
##xa
##te
)
may
be
at
a
greater
risk
of
infection
.
[SEP]
[CLS]
Six
##ty
-
two
percent
of
these
patients
had
at
least
one
sample
that
was
positive
for
the
presence
of
neutral
##izing
antibodies
.
[SEP]
[CLS]
T
##AN
##Z
##E
##UM
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
personal
or
family
history
of
M
##TC
or
in
patients
with
ME
##N
2
.
[SEP]
[CLS]
In
clinical
trials
with
VI
##CT
##RE
##L
##IS
,
the
proportion
of
subjects
who
experienced
hem
##og
##lo
##bin
values
less
than
10
g
per
d
##L
was
higher
in
subjects
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
[SEP]
[CLS]
with
P
##eg
##I
##nt
##ron
(
r
)
/
R
##E
##BE
##TO
##L
(
r
)
than
in
those
treated
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
(
see
Table
4
)
.
[SEP]
[CLS]
Consider
other
anti
##dia
##bet
##ic
the
##rap
##ies
in
patients
with
a
history
of
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
Su
##sta
##ined
increases
in
in
##tra
##oc
##ular
pressure
have
also
been
reported
after
repeated
in
##tra
##vi
##tre
##al
dos
##ing
with
vascular
end
##oth
##eli
##al
growth
factor
(
V
##EG
##F
)
inhibitor
##s
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
MI
and
stroke
.
[SEP]
[CLS]
In
Study
1
and
Study
2
,
N
##U
##L
##O
##J
##IX
was
studied
at
the
recommended
dose
and
frequency
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
in
a
total
of
401
[SEP]
[CLS]
patients
compared
to
a
c
##y
##c
##los
##por
##ine
control
regime
##n
in
a
total
of
405
patients
.
[SEP]
[CLS]
5
.
6
Inc
##reased
Low
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
(
L
##D
##L
-
C
)
Inc
##rease
##s
in
L
##D
##L
-
C
can
occur
with
J
##AR
##DI
##AN
##CE
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
*
d
Event
requiring
another
person
to
administer
a
re
##sus
##ci
##tative
action
.
[SEP]
[CLS]
The
safety
of
IL
##AR
##IS
compared
to
place
##bo
was
investigated
in
two
phase
3
studies
[
see
Clinical
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
Administration
of
Pi
##cat
##o
(
r
)
gel
is
not
recommended
until
the
skin
is
healed
from
any
previous
drug
or
surgical
treatment
.
[SEP]
[CLS]
Therefore
,
the
use
of
E
##NT
##ER
##EG
is
not
recommended
in
this
population
.
[SEP]
[CLS]
Overall
,
55
%
of
the
patients
were
men
.
[SEP]
[CLS]
In
treatment
-
naive
subjects
,
a
mean
change
from
base
##line
of
0
.
15
mg
per
d
##L
(
range
:
-
0
.
32
mg
per
d
##L
to
0
.
65
mg
per
d
##L
)
was
observed
after
[SEP]
[CLS]
96
weeks
of
treatment
.
[SEP]
[CLS]
D
##Y
##SP
##OR
##T
(
r
)
is
approved
only
for
in
##tra
##mus
##cular
injection
.
[SEP]
[CLS]
In
##stance
##s
of
su
##icidal
idea
##tion
have
been
observed
in
0
.
2
%
(
3
/
144
##1
)
of
subjects
while
receiving
O
##TE
##Z
##LA
,
compared
to
none
in
place
##bo
treated
subjects
(
0
/
49
##5
)
.
[SEP]
[CLS]
5
.
10
T
##hr
##omb
##oc
##yt
##ope
##nia
K
##y
##p
##rol
##is
causes
th
##rom
##bo
##cy
##top
##enia
with
plate
##let
na
##dir
##s
observed
between
Day
8
and
Day
15
of
each
28
-
day
cycle
with
recovery
to
base
##line
plate
##let
count
usually
by
the
start
of
[SEP]
[CLS]
the
next
cycle
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
(
5
.
1
)
*
So
##m
##no
##len
##ce
/
se
##dation
and
di
##zzi
##ness
:
May
imp
##air
the
patient
'
s
ability
to
operate
complex
machinery
.
[SEP]
[CLS]
Contact
lens
use
is
also
a
risk
factor
for
k
##era
##titis
and
ul
##cer
##ation
.
[SEP]
[CLS]
Higher
than
recommended
dos
##ing
or
repeat
dos
##ing
appear
to
increase
the
risk
.
[SEP]
[CLS]
5
.
2
In
##fect
##ions
Risk
of
In
##fect
##ions
G
##IL
##EN
##Y
##A
causes
a
dose
-
dependent
reduction
in
peripheral
l
##ymph
##oc
##yte
count
to
20
%
-
30
%
of
base
##line
values
because
of
re
##versible
[SEP]
[CLS]
se
##quest
##ration
of
l
##ymph
##ocytes
in
l
##ymph
##oid
tissues
.
[SEP]
[CLS]
No
un
##con
##founded
cases
of
N
##SF
have
been
reported
with
D
##OT
##AR
##EM
.
[SEP]
[CLS]
For
moderate
to
severe
protein
##uria
,
reduce
the
dose
or
temporarily
interrupt
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
The
patients
had
no
other
identified
systemic
medical
conditions
resulting
in
compromised
immune
system
function
and
had
not
previously
been
treated
with
na
##tal
##iz
##uma
##b
,
which
has
a
known
association
with
[SEP]
[CLS]
PM
##L
.
[SEP]
[CLS]
It
is
unknown
whether
this
finding
applies
to
younger
post
##men
##op
##aus
##al
women
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
In
the
absence
of
comparable
data
,
these
risks
should
[SEP]
[CLS]
be
assumed
to
be
similar
for
other
doses
of
con
##ju
##gated
est
##rogen
##s
and
other
dos
##age
forms
of
est
##rogen
##s
.
[SEP]
[CLS]
Nearly
all
of
the
reported
T
##NF
-
block
##er
associated
cases
have
occurred
in
patients
with
C
##ro
##hn
'
s
disease
or
ul
##cer
##ative
co
##lit
##is
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
ER
##WI
##NA
##Z
##E
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Use
with
drugs
that
pro
##long
the
Q
##T
interval
may
cause
add
##itive
Q
##T
pro
##long
##ation
.
[SEP]
[CLS]
(
5
.
2
,
5
.
3
)
*
Trans
##ient
increases
in
blood
pressure
may
occur
in
patients
during
and
shortly
after
the
Q
##ute
##nza
treatment
.
[SEP]
[CLS]
The
adverse
reactions
described
in
this
section
reflect
G
##ada
##vist
exposure
in
6
,
330
subjects
(
including
184
p
##ediatric
patients
,
ages
0
to
17
years
)
with
the
majority
receiving
the
[SEP]
[CLS]
recommended
dose
.
[SEP]
[CLS]
The
safety
profile
of
SA
##P
##H
##RI
##S
in
the
maintenance
treatment
of
s
##chi
##zophrenia
in
adults
was
similar
to
that
seen
with
acute
treatment
.
[SEP]
[CLS]
Dec
##rease
of
He
##mo
##g
##lo
##bin
in
Pat
##ients
with
W
##M
(
N
=
63
)
Per
##cent
of
Pat
##ients
(
N
=
63
)
All
Grades
(
%
)
Grade
3
or
4
(
%
)
[SEP]
[CLS]
Plate
##lets
Dec
##reased
43
13
N
##eu
##tro
##phi
##ls
Dec
##reased
44
19
He
##mo
##g
##lo
##bin
Dec
##reased
13
8
6
.
[SEP]
[CLS]
The
adverse
reactions
most
commonly
(
>
=
1
%
in
any
AP
##TI
##OM
treatment
group
,
and
greater
than
place
##bo
)
leading
to
disco
##ntin
##uation
,
in
descending
order
of
frequency
,
[SEP]
[CLS]
were
di
##zzi
##ness
,
nausea
,
vomit
##ing
,
at
##ax
##ia
,
dip
##lop
##ia
,
so
##m
##no
##len
##ce
,
headache
,
blurred
vision
,
ve
##rt
##igo
,
as
##the
##nia
,
fatigue
,
r
##ash
,
d
##ys
##art
##hr
##ia
,
and
[SEP]
[CLS]
t
##rem
##or
.
[SEP]
[CLS]
Pat
##ients
with
my
##elo
##su
##pp
##ression
following
treatment
with
T
##RE
##AN
##DA
are
more
susceptible
to
infections
.
[SEP]
[CLS]
These
metabolic
changes
include
h
##yper
##gly
##ce
##mia
,
d
##ys
##lip
##ide
##mia
,
and
body
weight
gain
[
see
Pat
##ient
Counsel
##ing
Information
(
17
.
3
)
]
.
[SEP]
[CLS]
The
rate
of
progression
of
re
##tina
##l
abnormal
##ities
and
the
re
##vers
##ibility
after
drug
disco
##ntin
##uation
are
unknown
.
[SEP]
[CLS]
If
significant
reduction
##s
in
B
##MD
are
seen
and
BR
##E
##O
E
##LL
##IP
##TA
is
still
considered
medical
##ly
important
for
that
patient
'
s
CO
##PD
therapy
,
use
of
medicine
to
treat
or
prevent
o
##ste
##op
##oro
##sis
[SEP]
[CLS]
should
be
strongly
considered
.
[SEP]
[CLS]
In
##fusion
reactions
have
occurred
with
the
B
##L
##IN
##C
##Y
##TO
in
##fusion
and
may
be
clinical
##ly
in
##dis
##ting
##ui
##sha
##ble
from
manifest
##ations
of
CR
##S
.
[SEP]
[CLS]
If
this
product
is
used
for
10
days
or
longer
,
in
##tra
##oc
##ular
pressure
should
be
monitored
.
[SEP]
[CLS]
Of
these
,
80
##6
received
FA
##NA
##P
##T
for
at
least
6
months
,
with
46
##3
exposed
to
FA
##NA
##P
##T
for
at
least
12
months
.
[SEP]
[CLS]
*
Women
over
35
years
old
who
smoke
should
not
use
Nat
##azi
##a
.
[SEP]
[CLS]
6
.
1
Control
##led
Clinical
Trials
Experience
In
three
place
##bo
-
controlled
clinical
trials
of
up
to
14
weeks
duration
,
4
%
(
15
/
400
)
of
patients
treated
with
AM
##P
##Y
##RA
10
mg
twice
[SEP]
[CLS]
daily
experienced
one
or
more
treatment
emerge
##nt
adverse
events
leading
to
disco
##ntin
##uation
,
compared
to
2
%
(
5
/
238
)
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Table
2
shows
absolute
and
relative
risk
by
indication
for
all
evaluated
A
##ED
##s
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
additional
adverse
reactions
have
been
reported
in
patients
receiving
Fe
##rri
##p
##ro
##x
.
[SEP]
[CLS]
Pat
##ients
,
their
care
##gi
##vers
,
and
families
should
be
informed
that
A
##ED
##s
increase
the
risk
of
su
##icidal
thoughts
and
behavior
and
should
be
advised
of
the
need
to
be
alert
[SEP]
[CLS]
for
the
emergence
or
worse
##ning
of
the
signs
and
symptoms
of
depression
,
any
unusual
changes
in
mood
or
behavior
,
or
the
emergence
of
su
##icidal
thoughts
,
behavior
,
[SEP]
[CLS]
or
thoughts
about
self
-
harm
.
[SEP]
[CLS]
(
5
.
1
)
5
.
1
Se
##vere
Skin
and
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Se
##vere
,
potentially
life
-
threatening
,
and
fatal
skin
reactions
have
been
reported
.
[SEP]
[CLS]
In
case
of
re
##current
events
of
the
same
category
,
the
first
event
was
considered
.
[SEP]
[CLS]
(
5
.
13
,
7
.
1
)
5
.
1
T
##hr
##omb
##oe
##mbo
##lic
Di
##sor
##ders
and
Other
V
##as
##cular
Problems
Stop
Nat
##azi
##a
if
an
art
##erial
or
ve
##nous
th
##rom
##bot
##ic
event
(
V
##TE
)
occurs
.
[SEP]
[CLS]
C
##lev
##ip
##re
##x
was
in
##fused
for
<
24
hours
in
the
majority
of
patients
(
n
=
119
##9
)
;
it
was
in
##fused
as
a
continuous
in
##fusion
in
an
additional
93
patients
for
duration
##s
[SEP]
[CLS]
between
24
and
72
hours
.
[SEP]
[CLS]
Table
3
gives
the
incidence
of
adverse
reactions
that
occurred
in
>
=
2
%
of
subjects
with
partial
-
onset
seizure
##s
in
any
AP
##TI
##OM
treatment
group
and
for
which
the
incidence
was
[SEP]
[CLS]
greater
than
place
##bo
during
the
controlled
clinical
trials
.
[SEP]
[CLS]
(
6
.
1
)
G
##la
##bella
##r
Lines
The
most
frequently
reported
adverse
reactions
(
>
=
2
%
)
are
:
na
##so
##pha
##ryn
##git
##is
,
headache
,
injection
site
pain
,
injection
site
reaction
,
[SEP]
[CLS]
upper
respiratory
tract
infection
,
eye
##lid
ed
##ema
,
eye
##lid
p
##tosis
,
sin
##us
##itis
,
and
nausea
.
[SEP]
[CLS]
5
.
3
Ana
##phy
##lax
##is
and
In
##fusion
Re
##actions
In
##fusion
reactions
to
T
##RE
##AN
##DA
have
occurred
commonly
in
clinical
trials
.
[SEP]
[CLS]
Table
7
:
Non
-
He
##mat
##olo
##gic
Ad
##verse
Re
##actions
in
>
=
10
%
of
Pat
##ients
with
Walden
##strom
'
s
Mac
##rog
##lo
##bul
##ine
##mia
(
N
=
63
)
System
Organ
Class
Pre
##ferred
Te
##rm
All
Grades
(
%
)
[SEP]
[CLS]
Grade
3
or
4
(
%
)
The
system
organ
class
and
individual
AD
##R
terms
are
sorted
in
descending
frequency
order
.
[SEP]
[CLS]
Adult
Pat
##ients
:
Poole
##d
data
from
the
short
-
term
,
place
##bo
-
controlled
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
trials
are
presented
in
Table
3
.
[SEP]
[CLS]
They
represent
an
evaluation
of
the
adverse
reaction
data
from
87
##0
patients
with
Ph
+
le
##uke
##mia
who
received
at
least
1
dose
of
single
-
agent
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
Only
use
S
##IR
##TU
##RO
when
an
effective
treatment
regime
##n
can
not
otherwise
be
provided
[
see
In
##dication
##s
and
Us
##age
(
1
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
was
reported
in
4
%
of
patients
with
H
##A
##E
.
[SEP]
[CLS]
Of
these
4
patients
who
developed
anti
-
ER
##WI
##NA
##Z
##E
antibodies
,
3
experienced
h
##yper
##sen
##si
##ti
##vity
reactions
(
10
%
,
3
of
30
)
during
the
study
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Common
##ly
observed
adverse
reactions
(
incidence
>
=
5
%
and
at
least
twice
that
for
place
##bo
)
were
(
6
.
1
)
:
*
Sc
##hi
##zophrenia
Adults
:
aka
##thi
##sia
,
[SEP]
[CLS]
oral
h
##y
##po
##est
##hesia
,
so
##m
##no
##len
##ce
.
[SEP]
[CLS]
*
Do
not
use
est
##rogen
##s
to
prevent
heart
disease
,
heart
attacks
,
strokes
or
dem
##ent
##ia
(
decline
in
brain
function
)
.
[SEP]
[CLS]
A
##vo
##id
use
of
GB
##CA
##s
in
these
patients
unless
the
diagnostic
information
is
essential
and
not
available
with
non
-
contrasted
MR
##I
or
other
m
##oda
##lities
.
[SEP]
[CLS]
Before
in
##iti
##ating
treatment
with
G
##IL
##EN
##Y
##A
,
a
recent
CBC
(
i
.
e
.
,
within
6
months
or
after
disco
##ntin
##uation
of
prior
therapy
)
should
be
available
.
[SEP]
[CLS]
Pat
##ients
should
be
counsel
##ed
about
the
possibility
of
delayed
-
onset
h
##yper
##sen
##si
##ti
##vity
reactions
and
given
proper
follow
-
up
instructions
.
[SEP]
[CLS]
A
##fa
##tin
##ib
was
em
##b
##ryo
##to
##xi
##c
and
,
in
animals
with
maternal
toxicity
,
led
to
abortion
##s
at
late
g
##esta
##tional
stages
in
rabbits
at
doses
of
5
mg
/
kg
(
approximately
0
.
2
times
the
[SEP]
[CLS]
human
exposure
at
the
recommended
dose
of
40
mg
daily
)
or
greater
.
[SEP]
[CLS]
5
.
4
Mac
##ular
Ed
##ema
Fin
##gol
##imo
##d
increases
the
risk
of
mac
##ular
ed
##ema
.
[SEP]
[CLS]
S
##ym
##pt
##oms
of
mac
##ular
ed
##ema
included
blurred
vision
and
decreased
visual
a
##cu
##ity
.
[SEP]
[CLS]
Changes
in
Ser
##um
C
##rea
##tin
##ine
Do
##lut
##eg
##ra
##vir
has
been
shown
to
increase
serum
c
##rea
##tin
##ine
due
to
in
##hibition
of
tub
##ular
secret
##ion
of
c
##rea
##tin
##ine
without
affecting
re
##nal
g
##lo
##mer
##ular
function
[
see
Clinical
Ph
##arma
##cology
(
[SEP]
[CLS]
12
.
2
)
]
.
[SEP]
[CLS]
In
Studies
102
and
103
,
increases
in
serum
c
##rea
##tin
##ine
and
decreases
in
estimated
c
##rea
##tin
##ine
clearance
occurred
early
in
treatment
with
ST
##RI
##BI
##LD
,
after
which
they
stab
##ilized
.
[SEP]
[CLS]
Disco
##ntin
##ue
tram
##eti
##ni
##b
if
no
improvement
after
3
weeks
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
label
##ing
:
*
He
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
[SEP]
[CLS]
*
Inter
##st
##iti
##al
Lu
##ng
Disease
/
P
##ne
##um
##oni
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
Q
##T
Inter
##val
Pro
##long
##ation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Brady
##card
##ia
[
see
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Se
##vere
Visual
Loss
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
25
[SEP]
[CLS]
%
)
are
vision
disorders
,
di
##ar
##r
##hea
,
nausea
,
vomit
##ing
,
con
##st
##ip
##ation
,
ed
##ema
,
elevated
trans
##ami
##nas
##es
,
upper
respiratory
infection
,
decreased
appetite
,
and
d
##ys
##ge
##us
##ia
.
[SEP]
[CLS]
The
disco
##ntin
##uation
rate
due
to
bleeding
events
was
0
.
7
%
in
the
E
##L
##I
##Q
##UI
##S
-
treated
patients
compared
to
1
.
7
%
in
en
##ox
##apa
##rin
/
war
##fari
##n
-
treated
patients
in
the
AM
##PL
##IF
##Y
study
.
[SEP]
[CLS]
(
2
.
3
)
*
J
##E
##V
##TA
##NA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
Eye
disorders
,
including
severe
eye
pain
,
chemical
con
##junct
##iv
##itis
,
corn
##eal
burn
,
eye
##lid
ed
##ema
,
eye
##lid
p
##tosis
,
per
##ior
##bit
##al
ed
##ema
can
occur
after
exposure
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
additional
adverse
reactions
have
been
reported
during
post
##market
##ing
use
of
G
##ada
##vist
.
[SEP]
[CLS]
Some
deaths
due
to
re
##nal
failure
did
not
have
a
clear
et
##iology
.
[SEP]
[CLS]
The
con
##com
##ita
##nt
use
of
a
T
##NF
-
block
##er
and
a
##bat
##ace
##pt
or
an
##aki
##n
##ra
was
associated
with
a
higher
risk
of
serious
infections
;
therefore
,
the
con
##com
##ita
##nt
use
of
S
##IM
##PO
##NI
ARIA
and
these
[SEP]
[CLS]
bio
##log
##ic
products
is
not
recommended
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
,
5
.
6
)
and
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
E
##Y
##LE
##A
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Po
##ssi
##ble
risk
factors
for
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
include
pre
-
existing
low
white
blood
cell
count
(
W
##BC
)
/
absolute
ne
##ut
##rop
##hil
count
(
AN
##C
)
and
history
of
drug
induced
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
The
anti
-
br
##ent
##ux
##ima
##b
antibodies
were
directed
against
the
anti
##body
component
of
br
##ent
##ux
##ima
##b
ve
##do
##tin
in
all
patients
with
trans
##ient
##ly
or
persistent
##ly
positive
antibodies
.
[SEP]
[CLS]
For
more
information
,
go
to
www
.
D
##U
##AV
##EE
.
com
,
or
call
1
-
800
-
43
##8
-
1985
.
[SEP]
[CLS]
Consider
lowering
su
##lf
##ony
##lu
##rea
or
insulin
dos
##age
when
starting
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
Table
1
Ad
##verse
Re
##actions
Re
##action
Rate
(
%
)
n
=
158
##1
Na
##use
##a
1
.
1
Head
##ache
1
.
1
Feeling
hot
0
.
8
Di
##zzi
##ness
0
.
6
Back
pain
0
.
6
V
##omi
##ting
0
.
4
Blood
pressure
increased
0
.
4
[SEP]
[CLS]
In
##jection
site
reactions
)
0
.
4
D
##ys
##ge
##us
##ia
0
.
4
Pa
##rest
##hesia
0
.
3
F
##lus
##hing
0
.
3
Pa
##ros
##mia
0
.
3
P
##ru
##rit
##us
(
generalized
)
0
.
3
Ra
##sh
0
.
3
Re
##sp
##ira
##tory
disorders
(
d
##ys
##p
##nea
,
respiratory
distress
)
0
.
2
[SEP]
[CLS]
Fat
##ig
##ue
0
.
2
Ch
##est
pain
0
.
1
V
##ert
##igo
0
.
1
Dry
mouth
0
.
1
Chi
##lls
0
.
1
Feeling
abnormal
0
.
1
Ad
##verse
reactions
that
occurred
with
a
frequency
of
<
0
.
1
%
in
subjects
who
received
[SEP]
[CLS]
E
##O
##VI
##ST
include
:
t
##rem
##or
,
aka
##thi
##sia
,
bundle
branch
block
,
p
##al
##pit
##ation
,
oral
discomfort
,
sa
##liva
##ry
h
##yper
##se
##cre
##tion
,
mac
##ulo
##pa
##pu
##lar
r
##ash
,
h
##yper
##hi
##dr
##osis
,
discomfort
,
and
ma
##lai
##se
.
[SEP]
[CLS]
Anti
-
tuberculosis
therapy
should
also
be
considered
prior
to
initiation
of
C
##IM
##Z
##IA
in
patients
with
a
past
history
of
late
##nt
or
active
tuberculosis
in
whom
an
adequate
course
of
treatment
can
[SEP]
[CLS]
not
be
confirmed
,
and
for
patients
with
a
negative
test
for
late
##nt
tuberculosis
but
having
risk
factors
for
tuberculosis
infection
.
[SEP]
[CLS]
This
list
also
includes
adverse
reactions
(
less
than
1
%
of
subjects
)
associated
with
organ
systems
from
Warning
##s
and
Pre
##ca
##ution
##s
.
[SEP]
[CLS]
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
G
##ada
##vist
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
prior
to
re
-
administration
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
2
)
*
H
##y
##po
##gly
##ce
##mia
:
Can
occur
when
used
in
combination
with
insulin
secret
##ago
##gues
(
e
.
g
.
,
su
##lf
##ony
##lu
##rea
##s
)
or
insulin
.
[SEP]
[CLS]
Treatment
with
C
##IM
##Z
##IA
should
not
be
initiated
in
patients
with
an
active
infection
,
including
clinical
##ly
important
localized
infections
.
[SEP]
[CLS]
Treatment
with
anti
##ba
##cter
##ial
agents
can
alter
the
normal
flora
of
the
co
##lon
,
and
may
permit
over
##gro
##wth
of
C
.
di
##ff
##ici
##le
.
[SEP]
[CLS]
Counsel
patients
regarding
the
potential
risk
for
M
##TC
with
the
use
of
T
##AN
##Z
##E
##UM
and
inform
them
of
symptoms
of
thy
##roid
tumors
(
e
.
g
.
,
a
mass
in
the
neck
,
[SEP]
[CLS]
d
##ys
##pha
##gia
,
d
##ys
##p
##nea
,
or
persistent
hoarse
##ness
)
.
[SEP]
[CLS]
The
most
frequent
(
>
=
2
%
)
adverse
reactions
leading
to
dose
reduction
of
T
##AF
##IN
##LA
##R
were
p
##yre
##xia
(
9
%
)
,
PP
##ES
(
3
%
)
,
[SEP]
[CLS]
chill
##s
(
3
%
)
,
fatigue
(
2
%
)
,
and
headache
(
2
%
)
.
[SEP]
[CLS]
*
L
##ymph
##ope
##nia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
(
d
##ys
##p
##nea
,
an
##gio
##ede
##ma
,
r
##ash
,
and
p
##ru
##rit
##us
)
have
been
reported
.
[SEP]
[CLS]
This
information
was
abstract
##ed
and
categorized
using
the
National
Cancer
Institute
(
NC
##I
)
`
`
Common
Te
##rm
##ino
##logy
C
##rite
##ria
for
Ad
##verse
Events
'
'
(
CT
##CA
##E
)
version
3
scale
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
20
%
)
were
p
##yre
##xia
(
62
%
)
,
headache
(
36
%
)
,
peripheral
ed
##ema
(
25
%
)
[SEP]
[CLS]
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
(
25
%
)
,
nausea
(
25
%
)
,
h
##y
##po
##kal
##emia
(
23
%
)
,
and
con
##st
##ip
##ation
(
20
%
)
.
[SEP]
[CLS]
Across
clinical
trials
of
T
##AF
##IN
##LA
##R
administered
in
combination
with
tram
##eti
##ni
##b
(
N
=
202
)
,
the
incidence
of
R
##P
##ED
was
1
%
(
2
/
202
)
.
[SEP]
[CLS]
Monitor
signs
and
symptoms
.
[SEP]
[CLS]
patients
less
than
1
month
of
age
or
pre
##ter
##m
infants
with
a
corrected
age
of
less
than
44
weeks
)
could
be
at
risk
for
gasping
syndrome
if
treated
with
[SEP]
[CLS]
U
##LE
##SF
##IA
(
r
)
Lot
##ion
[
see
Use
in
S
##pecific
Population
##s
(
8
.
4
)
]
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
frequent
(
>
=
0
.
2
%
)
adverse
reactions
in
clinical
studies
were
nausea
,
headache
,
injection
site
pain
,
injection
site
cold
##ness
,
and
[SEP]
[CLS]
burning
sensation
.
[SEP]
[CLS]
5
.
5
End
-
Stage
Ren
##al
Disease
No
studies
have
been
conducted
in
patients
with
end
-
stage
re
##nal
disease
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
L
on
##g
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
##s
,
such
as
A
RCA
##P
##TA
NE
##OH
##AL
##ER
,
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
in
Ch
##ronic
O
##bs
##truct
##ive
P
##ul
##mona
##ry
Disease
The
clinical
program
for
BR
##E
##O
E
##LL
##IP
##TA
included
7
,
700
subjects
with
CO
##PD
in
two
6
-
month
lung
function
trials
,
two
12
-
month
ex
##ace
##rb
##ation
[SEP]
[CLS]
trials
,
and
6
other
trials
of
shorter
duration
.
[SEP]
[CLS]
The
most
commonly
observed
adverse
reactions
(
>
=
10
%
and
greater
than
place
##bo
)
in
this
trial
for
the
1
,
200
mg
dose
of
H
##OR
##I
##Z
##AN
##T
were
di
##zzi
##ness
,
so
##m
##no
##len
##ce
,
[SEP]
[CLS]
and
headache
(
see
Table
5
)
.
[SEP]
[CLS]
If
the
diagnosis
of
T
##TP
/
H
##US
is
excluded
,
K
##y
##p
##rol
##is
may
be
restart
##ed
.
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
may
therefore
increase
the
risk
of
infections
,
some
serious
in
nature
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
In
controlled
trials
of
other
T
##NF
-
block
##ers
in
patients
at
higher
risk
for
ma
##li
##gna
##ncies
(
e
.
g
.
,
patients
with
CO
##PD
,
patients
with
We
##gene
##r
'
s
g
##ran
##ulo
##mat
##osis
treated
with
con
##com
##ita
##nt
c
##y
##c
##lop
##hos
##pha
##mi
##de
)
[SEP]
[CLS]
a
greater
portion
of
ma
##li
##gna
##ncies
occurred
in
the
T
##NF
-
block
##er
group
compared
to
the
controlled
group
.
[SEP]
[CLS]
Your
healthcare
provider
should
check
any
unusual
v
##agi
##nal
bleeding
to
find
out
the
cause
.
[SEP]
[CLS]
(
5
.
1
)
*
H
##yper
##sen
##si
##ti
##vity
:
an
##aph
##yla
##ctic
reactions
with
cut
##aneous
manifest
##ations
,
ranging
from
mild
to
severe
,
including
death
,
have
uncommon
##ly
occurred
.
[SEP]
[CLS]
Seven
##ty
-
eight
percent
of
patients
(
69
##3
of
89
##3
)
were
able
to
receive
all
planned
doses
to
complete
their
prescribed
treatment
regime
##n
.
[SEP]
[CLS]
If
h
##yper
##tens
##ion
can
not
be
adequately
controlled
,
a
risk
-
benefit
decision
on
continued
K
##y
##p
##rol
##is
therapy
is
needed
.
[SEP]
[CLS]
Disco
##ntin
##ue
immediately
.
[SEP]
[CLS]
The
percentage
of
patients
who
withdrew
from
the
study
due
to
adverse
events
was
2
.
1
%
and
2
.
4
%
for
the
place
##bo
and
Pro
##lia
groups
,
respectively
.
[SEP]
[CLS]
Male
g
##eni
##tal
my
##cot
##ic
infections
occurred
more
commonly
in
un
##ci
##rc
##um
##cise
##d
males
and
in
males
with
a
prior
history
of
b
##alan
##itis
or
b
##alan
##op
##ost
##hit
##is
.
[SEP]
[CLS]
The
first
dose
of
E
##NT
##ER
##EG
was
administered
30
minutes
to
5
hours
before
the
scheduled
start
of
surgery
and
then
twice
daily
until
hospital
discharge
(
or
for
a
maximum
[SEP]
[CLS]
of
7
days
of
post
##oper
##ative
treatment
)
.
[SEP]
[CLS]
In
these
patients
,
increases
in
potassium
were
more
commonly
seen
in
those
with
elevated
potassium
at
base
##line
.
[SEP]
[CLS]
Permanent
disco
##ntin
##uation
of
X
##AL
##KO
##RI
treatment
for
adverse
reactions
was
8
.
2
%
.
[SEP]
[CLS]
A
total
of
1964
patients
participated
in
two
12
-
week
,
Phase
3
efficacy
and
safety
studies
and
subsequent
open
-
label
extension
studies
.
[SEP]
[CLS]
Table
5
:
Non
-
He
##mat
##olo
##gic
Ad
##verse
Re
##actions
>
=
10
%
Report
##ed
in
Study
2
I
##MB
##R
##U
##VI
##CA
(
N
=
195
)
Of
##at
##um
##uma
##b
(
N
=
191
)
System
Organ
Class
AD
##R
Te
##rm
All
Grades
(
[SEP]
[CLS]
%
)
Grade
3
or
4
(
%
)
All
Grades
(
%
)
Grade
3
or
4
(
%
)
Sub
##jects
with
multiple
events
for
a
given
AD
##R
term
[SEP]
[CLS]
are
counted
once
only
for
each
AD
##R
term
.
[SEP]
[CLS]
Adult
Pat
##ients
:
Poole
##d
data
on
mean
changes
in
body
weight
and
the
proportion
of
subjects
meeting
a
weight
gain
criterion
of
>
=
7
%
of
body
weight
from
the
[SEP]
[CLS]
short
-
term
,
place
##bo
-
controlled
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
trials
are
presented
in
Table
5
.
[SEP]
[CLS]
PM
##L
is
an
op
##port
##uni
##stic
viral
infection
of
the
brain
caused
by
the
J
##C
virus
(
J
##C
##V
)
that
typically
only
occurs
in
patients
who
are
im
##mu
##no
##com
##p
##rom
##ised
,
and
that
usually
[SEP]
[CLS]
leads
to
death
or
severe
disability
.
[SEP]
[CLS]
Do
not
restart
NE
##SI
##NA
if
liver
injury
is
confirmed
and
no
alternative
et
##iology
can
be
found
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
reactions
in
patients
receiving
AP
##TI
##OM
at
doses
of
800
mg
or
1200
mg
(
>
=
4
%
and
>
=
2
%
greater
than
place
##bo
)
[SEP]
[CLS]
were
di
##zzi
##ness
,
so
##m
##no
##len
##ce
,
nausea
,
headache
,
dip
##lop
##ia
,
vomit
##ing
,
fatigue
,
ve
##rt
##igo
,
at
##ax
##ia
,
blurred
vision
,
and
t
##rem
##or
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
5
.
2
Cat
##ara
##cts
Use
of
co
##rt
##ico
##ster
##oids
may
result
in
posterior
sub
##cap
##sul
##ar
cat
##ara
##ct
formation
.
[SEP]
[CLS]
H
##ydro
##ne
##ph
##rosis
occurred
in
2
patients
,
one
of
whom
had
associated
re
##nal
function
imp
##air
##ment
that
resolved
upon
disco
##ntin
##uation
of
P
##OT
##IG
##A
.
[SEP]
[CLS]
5
.
2
U
##rina
##ry
Re
##ten
##tion
P
##OT
##IG
##A
caused
u
##rina
##ry
retention
in
clinical
trials
.
[SEP]
[CLS]
(
5
.
4
)
*
Pat
##ients
with
abnormal
co
##agu
##lation
:
Use
with
caution
,
including
in
patients
who
have
received
anti
##coa
##gu
##lant
medications
other
than
low
-
dose
as
##pi
##rin
within
7
days
of
the
[SEP]
[CLS]
injection
.
[SEP]
[CLS]
Table
3
:
Overall
In
##fect
##ions
and
Select
In
##fect
##ions
with
I
##dent
##ified
E
##ti
##ology
by
Treatment
Group
following
One
and
Three
Years
of
Treatment
in
Studies
1
and
2
*
Up
to
Year
1
[SEP]
[CLS]
Up
to
Year
3
N
##U
##L
##O
##J
##IX
Re
##com
##men
##ded
Reg
##ime
##n
N
=
401
n
(
%
)
Cy
##c
##los
##por
##ine
N
=
405
n
(
%
)
N
##U
##L
##O
##J
##IX
Re
##com
##men
##ded
Reg
##ime
##n
N
=
401
n
(
%
)
Cy
##c
##los
##por
##ine
N
=
405
n
(
[SEP]
[CLS]
%
)
*
Studies
1
and
2
were
not
designed
to
support
comparative
claims
for
N
##U
##L
##O
##J
##IX
for
the
adverse
reactions
reported
in
this
table
.
[SEP]
[CLS]
(
2
.
3
)
,
(
5
.
1
)
*
N
##eur
##ological
toxic
##ities
,
which
may
be
severe
,
life
-
threatening
,
or
fatal
,
occurred
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
[SEP]
[CLS]
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Table
2
and
Table
3
sum
##mar
##ize
common
adverse
reactions
and
laboratory
abnormal
##ities
reported
for
Z
##yd
##eli
##g
+
r
##it
##ux
##ima
##b
and
place
##bo
+
r
##it
##ux
##ima
##b
arms
.
[SEP]
[CLS]
Table
4
:
Ad
##verse
Re
##actions
Report
##ed
by
>
=
10
%
of
Pat
##ients
T
##reate
##d
with
Either
the
N
##U
##L
##O
##J
##IX
Re
##com
##men
##ded
Reg
##ime
##n
or
Control
in
Studies
1
and
2
Through
Three
Years
*
,
[SEP]
[CLS]
Ad
##verse
Re
##action
N
##U
##L
##O
##J
##IX
Re
##com
##men
##ded
Reg
##ime
##n
N
=
401
%
Cy
##c
##los
##por
##ine
N
=
405
%
*
All
random
##ized
and
transplant
##ed
patients
in
Studies
1
and
2
.
[SEP]
[CLS]
Pre
##dn
##ison
##e
reduction
can
be
accomplished
by
reducing
the
daily
pre
##dn
##ison
##e
dose
by
2
.
5
mg
on
a
weekly
basis
during
therapy
with
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
A
##cor
##da
The
##rap
##eu
##tics
at
1
-
800
-
36
##7
-
510
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
If
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
occurs
following
dos
##ing
with
BR
##E
##O
E
##LL
##IP
##TA
,
it
should
be
treated
immediately
with
an
inhaled
,
short
-
acting
br
##on
##cho
##di
##lator
;
BR
##E
##O
E
##LL
##IP
##TA
should
be
discontinued
immediately
;
and
[SEP]
[CLS]
alternative
therapy
should
be
instituted
.
[SEP]
[CLS]
In
4
studies
FA
##R
##X
##IG
##A
was
used
as
mon
##otherapy
,
and
in
8
studies
FA
##R
##X
##IG
##A
was
used
as
add
-
on
to
background
anti
##dia
##bet
##ic
therapy
or
as
combination
therapy
with
met
##form
##in
[
see
[SEP]
[CLS]
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Table
##s
2
and
3
sum
##mar
##ize
the
common
adverse
reactions
and
laboratory
abnormal
##ities
observed
in
Z
##Y
##KA
##DI
##A
-
treated
patients
.
[SEP]
[CLS]
The
most
common
adverse
reactions
reported
during
clinical
trials
were
ch
##roma
##tur
##ia
,
nausea
,
vomit
##ing
,
abdominal
pain
,
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
increased
,
art
##hra
##l
##gia
and
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
If
feasible
,
stop
Nat
##azi
##a
at
least
4
weeks
before
and
through
2
weeks
after
major
surgery
or
other
surge
##ries
known
to
have
an
elevated
risk
of
th
##rom
##boe
##mbo
##lis
##m
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
:
The
following
additional
adverse
reactions
were
reported
in
>
=
5
%
to
<
10
%
of
the
H
##AL
##AV
##EN
-
treated
group
:
*
Eye
Di
##sor
##ders
:
[SEP]
[CLS]
increased
la
##c
##rima
##tion
*
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
d
##ys
##pe
##ps
##ia
,
abdominal
pain
,
s
##tom
##ati
##tis
,
dry
mouth
*
General
Di
##sor
##ders
and
Administration
Site
Con
##ditions
:
peripheral
ed
##ema
*
In
##fect
##ions
and
In
##fest
##ations
:
[SEP]
[CLS]
upper
respiratory
tract
infection
*
Met
##ab
##olis
##m
and
N
##utrition
Di
##sor
##ders
:
h
##y
##po
##kal
##emia
*
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
muscle
spa
##sm
##s
,
muscular
weakness
*
N
##er
##vous
System
Di
##sor
##ders
:
d
##ys
##ge
##us
##ia
,
[SEP]
[CLS]
di
##zzi
##ness
*
P
##sy
##chia
##tric
Di
##sor
##ders
:
ins
##om
##nia
,
depression
*
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
r
##ash
6
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
to
AU
##X
-
I
or
AU
##X
-
II
,
were
detected
in
60
%
and
51
.
8
%
,
respectively
,
of
patients
tested
.
[SEP]
[CLS]
(
2
.
2
,
5
.
1
)
*
He
##pa
##to
##to
##xi
##city
:
Z
##Y
##KA
##DI
##A
can
cause
he
##pa
##to
##to
##xi
##city
.
[SEP]
[CLS]
A
##vo
##id
the
use
of
AD
##CE
##TR
##IS
in
patients
with
moderate
(
Child
-
P
##ugh
B
)
or
severe
(
Child
-
P
##ugh
C
)
he
##pa
##tic
imp
##air
##ment
[
see
Use
in
S
##pecific
Population
##s
(
8
.
7
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
In
Phase
3
clinical
trials
,
Grade
3
and
4
r
##ash
##es
were
reported
in
1
.
3
%
of
subjects
receiving
IN
##TE
##LE
##NC
##E
(
r
)
compared
to
0
.
2
%
of
place
##bo
subjects
[SEP]
[CLS]
.
[SEP]
[CLS]
During
controlled
clinical
studies
,
the
proportion
of
patients
with
serious
adverse
reactions
was
10
%
for
C
##IM
##Z
##IA
and
9
%
for
place
##bo
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
=
5
%
)
are
fatigue
,
di
##ar
##r
##hea
,
p
##ru
##rit
##us
,
r
##ash
,
and
co
##lit
##is
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reaction
in
adults
was
di
##ar
##r
##hea
(
2
%
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
have
been
associated
with
Z
##yd
##eli
##g
in
clinical
trials
and
are
discussed
in
greater
detail
in
other
sections
of
the
pre
##s
##cribing
information
.
[SEP]
[CLS]
In
some
cases
,
di
##sse
##minated
in
##tra
##vas
##cular
co
##agu
##lation
(
D
##IC
)
,
cap
##illa
##ry
leak
syndrome
(
C
##LS
)
,
and
hem
##op
##ha
##go
##cy
##tic
l
##ymph
##oh
##ist
##io
##cy
##tosis
/
mac
##rop
##hage
activation
syndrome
(
H
##L
##H
/
MA
##S
)
have
been
reported
in
[SEP]
[CLS]
the
setting
of
CR
##S
.
[SEP]
[CLS]
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
The
most
commonly
occurring
adverse
reactions
(
>
=
20
%
)
were
th
##rom
##bo
##cy
##top
##enia
,
di
##ar
##r
##hea
,
ne
##ut
##rop
##enia
,
an
##emia
,
fatigue
,
m
##us
##cu
##los
##kel
##etal
pain
,
peripheral
ed
##ema
,
[SEP]
[CLS]
upper
respiratory
tract
infection
,
nausea
,
br
##ui
##sing
,
d
##ys
##p
##nea
,
con
##st
##ip
##ation
,
r
##ash
,
abdominal
pain
,
vomit
##ing
and
decreased
appetite
(
see
Table
##s
1
and
2
)
.
[SEP]
[CLS]
Pre
##vent
##ive
measures
include
vigorous
h
##yd
##ration
and
close
monitoring
of
blood
chemistry
,
particularly
potassium
and
u
##ric
acid
levels
.
[SEP]
[CLS]
Do
##se
reduction
##s
due
to
adverse
reactions
were
required
in
6
.
4
%
of
X
##AL
##KO
##RI
-
treated
patients
.
[SEP]
[CLS]
A
risk
for
the
development
for
he
##pa
##tos
##ple
##nic
T
-
cell
l
##ymph
##oma
in
patients
treated
with
T
##NF
-
block
##ers
can
not
be
excluded
.
[SEP]
[CLS]
(
5
.
8
)
*
Rev
##ers
##ible
Post
##eri
##or
Le
##uk
##oe
##nce
##pha
##lop
##athy
S
##yn
##drome
(
R
##PL
##S
)
has
been
observed
.
[SEP]
[CLS]
Consider
factors
that
contribute
to
fracture
risk
prior
to
in
##iti
##ating
IN
##VO
##KA
##NA
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Based
on
effective
donor
screening
and
product
manufacturing
processes
,
it
carries
an
extremely
remote
risk
for
transmission
of
viral
diseases
.
[SEP]
[CLS]
Seven
##ty
-
seven
subjects
initiated
a
lip
##id
-
lowering
agent
post
-
base
##line
;
their
last
fast
##ed
on
-
treatment
values
(
prior
to
starting
the
agent
)
were
used
regardless
if
they
discontinued
the
agent
(
SP
##RI
##NG
-
2
[SEP]
[CLS]
:
T
##I
##VI
##CA
##Y
n
=
9
,
r
##al
##te
##gra
##vir
n
=
13
;
S
##ING
##LE
:
T
##I
##VI
##CA
##Y
n
=
25
and
AT
##RI
##PL
##A
:
n
=
30
)
.
[SEP]
[CLS]
Overall
,
the
safety
profile
in
subjects
with
he
##pa
##titis
B
and
/
or
C
virus
co
-
infection
was
similar
to
that
observed
in
subjects
without
he
##pa
##titis
B
or
C
co
-
infection
,
although
the
[SEP]
[CLS]
rates
of
AL
##T
abnormal
##ities
were
higher
in
the
subgroup
with
he
##pa
##titis
B
and
/
or
C
virus
co
-
infection
for
all
treatment
groups
.
[SEP]
[CLS]
5
.
1
Inc
##reased
Risk
##s
in
Elder
##ly
Pat
##ients
with
De
##ment
##ia
-
Re
##lated
P
##sy
##cho
##sis
Inc
##reased
Mortal
##ity
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
treated
with
at
##y
##pical
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
compared
to
[SEP]
[CLS]
place
##bo
.
[SEP]
[CLS]
Overall
,
the
mean
age
of
patients
in
the
P
##H
##N
studies
ranged
from
61
to
64
years
of
age
across
dose
groups
;
the
majority
of
patients
were
male
(
[SEP]
[CLS]
45
%
to
61
%
)
and
Caucasian
(
80
%
to
98
%
)
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
in
CO
##PD
or
loss
of
efficacy
.
[SEP]
[CLS]
(
5
.
7
)
*
Le
##uk
##ope
##nia
,
N
##eu
##tro
##pen
##ia
,
and
A
##gra
##nu
##loc
##yt
##osis
have
been
reported
with
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
G
##IL
##OT
##RI
##F
should
be
used
with
caution
in
patients
with
a
history
of
k
##era
##titis
,
ul
##cer
##ative
k
##era
##titis
,
or
severe
dry
eye
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
resulting
in
disco
##ntin
##uation
of
treatment
(
>
=
1
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
or
place
##bo
)
were
in
##fusion
reactions
(
1
.
6
%
B
##EN
##L
##Y
##ST
##A
and
0
.
9
[SEP]
[CLS]
%
place
##bo
)
,
l
##up
##us
ne
##ph
##rit
##is
(
0
.
7
%
B
##EN
##L
##Y
##ST
##A
and
1
.
2
%
place
##bo
)
,
and
infections
(
0
.
7
%
B
##EN
##L
##Y
##ST
##A
and
1
.
0
%
place
##bo
)
.
[SEP]
[CLS]
U
##LE
##SF
##IA
(
r
)
Lot
##ion
may
cause
eye
irritation
.
[SEP]
[CLS]
Pat
##ients
with
pre
-
V
##OR
##A
##X
##A
##Z
##E
met
##hot
##re
##xa
##te
concentrations
>
100
mum
##ol
/
L
were
to
receive
a
second
dose
of
V
##OR
##A
##X
##A
##Z
##E
48
hours
after
the
first
dose
.
[SEP]
[CLS]
If
toxicity
re
##cu
##rs
at
Grade
3
,
consider
disco
##ntin
##uation
of
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
The
incidence
of
Common
Te
##rm
##ino
##logy
C
##rite
##ria
(
CT
##C
)
Grade
3
and
4
non
-
infectious
p
##ne
##um
##oni
##tis
was
up
to
4
.
0
%
and
up
to
0
.
2
%
,
respectively
[
see
Ad
##verse
[SEP]
[CLS]
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
,
6
.
4
,
6
.
5
)
]
.
[SEP]
[CLS]
Stop
##ping
or
slowing
the
in
##fusion
may
result
in
c
##ess
##ation
of
these
reactions
.
[SEP]
[CLS]
After
initiation
of
T
##AN
##Z
##E
##UM
,
observe
patients
carefully
for
signs
and
symptoms
of
pan
##cre
##ati
##tis
(
including
persistent
severe
abdominal
pain
,
sometimes
radiating
to
the
back
and
which
may
or
[SEP]
[CLS]
may
not
be
accompanied
by
vomit
##ing
)
.
[SEP]
[CLS]
Pat
##ients
should
be
closely
monitored
for
the
development
of
signs
and
symptoms
of
infection
during
and
after
treatment
with
C
##IM
##Z
##IA
,
including
the
possible
development
of
tuberculosis
in
patients
who
[SEP]
[CLS]
tested
negative
for
late
##nt
tuberculosis
infection
prior
to
in
##iti
##ating
therapy
.
[SEP]
[CLS]
No
com
##par
##ator
-
treated
subject
with
normal
base
##line
trans
##ami
##nas
##es
had
post
-
base
##line
AL
##T
elevation
greater
than
10
times
U
##L
##N
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
has
occurred
in
patients
with
impaired
elimination
of
GB
##CA
##s
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
should
be
used
cautiously
when
treating
patients
who
receive
treatment
with
other
drugs
that
can
induce
h
##y
##pot
##ens
##ion
,
bra
##dy
##card
##ia
,
respiratory
or
central
nervous
system
depression
[
see
Drug
[SEP]
[CLS]
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
6
.
2
I
##mm
##uno
##genic
##ity
As
with
all
therapeutic
proteins
,
there
is
a
potential
for
an
immune
response
in
patients
treated
with
E
##Y
##LE
##A
.
[SEP]
[CLS]
If
react
##ivation
occurs
,
stop
S
##IM
##PO
##NI
ARIA
and
begin
anti
-
viral
therapy
(
5
.
1
)
.
[SEP]
[CLS]
In
##active
In
##g
##red
##ients
:
calcium
phosphate
t
##ri
##bas
##ic
,
h
##ydro
##xy
##p
##rop
##yl
cell
##ulos
##e
,
micro
##c
##ry
##stal
##line
cell
##ulos
##e
,
powder
##ed
cell
##ulos
##e
,
h
##y
##p
##rome
##llo
##se
,
la
##ct
##ose
mon
##oh
##yd
##rate
,
ma
##gnesium
s
##te
##arate
,
p
##oly
##eth
##yle
##ne
g
##ly
##co
##l
,
su
##c
##rose
,
as
##cor
##bic
[SEP]
[CLS]
acid
,
su
##c
##rose
palm
##itic
acid
est
##er
,
h
##ydro
##xy
##eth
##yl
##cell
##ulos
##e
,
t
##ita
##nium
dioxide
,
red
iron
oxide
,
yellow
iron
oxide
,
black
iron
oxide
,
p
##ov
##ido
##ne
,
p
##oly
##de
##x
##tro
##se
,
ma
##lt
##ito
##l
,
[SEP]
[CLS]
polo
##xa
##mer
188
,
prop
##yle
##ne
g
##ly
##co
##l
,
is
##op
##rop
##yl
alcohol
.
[SEP]
[CLS]
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
and
media
##st
##inal
disorders
:
non
##in
##fect
##ious
pulmonary
toxicity
including
p
##ne
##um
##oni
##tis
,
inter
##st
##iti
##al
lung
disease
,
and
AR
##DS
(
some
with
fatal
outcomes
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
[SEP]
[CLS]
(
5
.
10
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
2
Management
of
I
##mm
##uno
##su
##pp
##ression
Only
physicians
experienced
in
management
of
systemic
im
##mu
##nos
##up
##press
##ant
therapy
in
transplant
##ation
should
pre
##s
##cribe
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
Table
4
:
Inc
##iden
##ce
(
%
)
of
Pat
##ients
With
Li
##pid
A
##b
##nor
##mal
##ities
of
Po
##ten
##tial
Clinical
Sign
##ific
##ance
*
PR
##IS
##TI
##Q
Place
##bo
50
mg
100
mg
200
mg
400
mg
[SEP]
[CLS]
Total
Cho
##les
##tero
##l
*
(
Inc
##rease
of
>
=
50
mg
/
d
##l
and
an
absolute
value
of
>
=
261
mg
/
d
##l
)
2
3
4
4
10
[SEP]
[CLS]
L
##D
##L
Cho
##les
##tero
##l
*
(
Inc
##rease
>
=
50
mg
/
d
##l
and
an
absolute
value
of
>
=
190
mg
/
d
##l
)
0
1
0
1
2
[SEP]
[CLS]
Tri
##gly
##cer
##ides
,
fast
##ing
*
(
Fast
##ing
:
>
=
32
##7
mg
/
d
##l
)
3
2
1
4
6
Pro
##tein
##uria
Pro
##tein
##uria
,
greater
than
or
equal
to
trace
,
was
observed
in
the
[SEP]
[CLS]
pre
-
marketing
fixed
-
dose
controlled
studies
(
see
Table
5
)
.
[SEP]
[CLS]
A
##FI
##NI
##TO
##R
may
be
re
-
introduced
at
a
daily
dose
approximately
50
%
lower
than
the
dose
previously
administered
depending
on
the
individual
clinical
circumstances
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
None
of
these
antibodies
were
shown
to
neutral
##ize
the
activity
of
al
##bi
##g
##lut
##ide
in
an
in
v
##it
##ro
bio
##ass
##ay
.
[SEP]
[CLS]
V
##OR
##A
##X
##A
##Z
##E
was
given
at
a
dose
of
50
Units
/
kg
as
an
in
##tra
##ven
##ous
injection
over
5
minutes
.
[SEP]
[CLS]
5
.
2
Eye
I
##rri
##tation
A
##vo
##id
eye
exposure
.
[SEP]
[CLS]
Pat
##ients
who
develop
radio
##logical
changes
suggest
##ive
of
non
-
infectious
p
##ne
##um
##oni
##tis
and
have
few
or
no
symptoms
may
continue
A
##FI
##NI
##TO
##R
therapy
without
dose
alter
##ation
.
[SEP]
[CLS]
Post
##her
##pet
##ic
N
##eur
##al
##gia
:
The
exposure
to
H
##OR
##I
##Z
##AN
##T
in
41
##7
patients
with
P
##H
##N
included
207
patients
exposed
for
at
least
3
months
.
[SEP]
[CLS]
Pat
##ients
who
have
experienced
an
##aph
##yla
##xi
##s
or
h
##yper
##sen
##si
##ti
##vity
reactions
should
be
treated
with
caution
when
they
are
re
-
administered
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
Pat
##ients
received
IN
##VO
##KA
##NA
100
mg
(
N
=
83
##3
)
,
IN
##VO
##KA
##NA
300
mg
(
N
=
83
##4
)
or
place
##bo
(
N
=
64
##6
)
once
daily
.
[SEP]
[CLS]
To
prevent
e
##ct
##rop
##ion
,
b
##ot
##ulin
##um
to
##xin
products
should
not
be
injected
into
the
medial
lower
eye
##lid
area
.
[SEP]
[CLS]
5
.
8
Human
Album
##in
and
Trans
##mission
of
V
##ira
##l
Disease
##s
This
product
contains
album
##in
,
a
derivative
of
human
blood
.
[SEP]
[CLS]
The
effect
of
FA
##NA
##P
##T
on
the
Q
##T
interval
was
augmented
by
the
presence
of
C
##YP
##45
##0
2D
##6
or
3
##A
##4
metabolic
in
##hibition
(
par
##ox
##eti
##ne
20
mg
once
daily
and
k
##eto
##cona
##zo
##le
200
mg
[SEP]
[CLS]
twice
daily
,
respectively
)
.
[SEP]
[CLS]
With
##hold
K
##y
##p
##rol
##is
and
evaluate
promptly
.
[SEP]
[CLS]
Mel
##ano
##ma
has
been
reported
in
patients
treated
with
T
##NF
-
blocking
agents
,
including
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
e
.
g
.
[SEP]
[CLS]
*
Lim
##iting
the
dose
injected
into
the
stern
##oc
##le
##ido
##mas
##to
##id
muscle
may
decrease
the
occurrence
of
d
##ys
##pha
##gia
.
[SEP]
[CLS]
Inc
##rease
##s
in
Ser
##um
Ph
##os
##phate
Do
##se
-
related
increases
in
serum
phosphate
levels
were
observed
with
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
Do
##se
-
related
increases
in
non
-
HD
##L
-
C
with
IN
##VO
##KA
##NA
were
observed
.
[SEP]
[CLS]
All
but
one
subject
who
died
of
T
##B
had
not
converted
or
had
re
##lap
##sed
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Man
##tle
Cell
L
##ymph
##oma
The
data
described
below
reflect
exposure
to
I
##MB
##R
##U
##VI
##CA
in
a
clinical
trial
that
included
111
patients
with
previously
treated
MC
##L
treated
with
560
[SEP]
[CLS]
mg
daily
with
a
median
treatment
duration
of
8
.
3
months
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
Place
##bo
-
Control
##led
and
Un
##con
##tro
##lled
Studies
In
place
##bo
-
controlled
and
un
##con
##tro
##lled
clinical
studies
,
a
total
of
251
##3
patients
have
received
T
##EC
##FI
##DE
##RA
and
been
followed
for
periods
up
to
4
[SEP]
[CLS]
years
with
an
overall
exposure
of
460
##3
person
-
years
.
[SEP]
[CLS]
In
##fusion
-
related
reactions
within
one
hour
of
in
##fusion
were
reported
in
5
%
of
patients
treated
with
the
recommended
dose
of
N
##U
##L
##O
##J
##IX
,
similar
to
the
place
##bo
rate
.
[SEP]
[CLS]
Fun
##gal
infections
were
reported
in
18
%
of
patients
receiving
N
##U
##L
##O
##J
##IX
compared
to
22
%
receiving
c
##y
##c
##los
##por
##ine
,
primarily
due
to
m
##uc
##oc
##uta
##ne
##ous
fun
##gal
infections
.
[SEP]
[CLS]
The
best
method
of
detection
of
these
abnormal
##ities
and
the
optimal
frequency
of
periodic
op
##ht
##hal
##mo
##log
##ic
monitoring
are
unknown
.
[SEP]
[CLS]
The
majority
of
patients
in
the
active
group
were
between
the
ages
of
18
and
64
.
[SEP]
[CLS]
A
total
of
2
.
2
%
of
HIV
-
1
-
infected
subjects
receiving
IN
##TE
##LE
##NC
##E
(
r
)
discontinued
from
Phase
3
trials
due
to
r
##ash
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Pat
##ients
who
have
experienced
a
prior
in
##fusion
-
related
reaction
should
be
pre
##med
##ica
##ted
for
subsequent
in
##fusion
##s
.
[SEP]
[CLS]
Disco
##ntin
##uations
resulting
from
these
reactions
were
more
common
in
the
drug
-
treated
group
(
see
Table
2
)
.
[SEP]
[CLS]
5
.
3
I
##mm
##une
Re
##con
##st
##itution
S
##yn
##drome
I
##mm
##une
re
##con
##st
##itution
syndrome
has
been
reported
in
patients
treated
with
combination
anti
##ret
##rov
##ira
##l
therapy
,
including
IN
##TE
##LE
##NC
##E
(
r
)
.
[SEP]
[CLS]
5
.
8
Le
##uk
##oe
##nce
##pha
##lop
##athy
C
##rani
##al
magnetic
resonance
imaging
(
MR
##I
)
changes
showing
le
##uk
##oe
##nce
##pha
##lop
##athy
have
been
observed
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
,
especially
in
patients
with
prior
treatment
with
c
##rani
##al
i
##rra
##diation
and
[SEP]
[CLS]
anti
##le
##uke
##mic
ch
##em
##otherapy
(
including
systemic
high
-
dose
met
##hot
##re
##xa
##te
or
in
##tra
##the
##cal
c
##yt
##ara
##bine
)
.
[SEP]
[CLS]
H
##ydro
##ne
##ph
##rosis
was
not
reported
in
place
##bo
patients
.
[SEP]
[CLS]
Table
2
In
##ves
##ti
##gat
##or
Assessment
of
Maxim
##al
Local
Skin
Re
##actions
in
the
Treatment
Area
during
the
57
Days
Post
Treatment
Period
(
trunk
/
ex
##tre
##mit
##ies
trials
)
T
##runk
and
Ex
##tre
##mit
##ies
(
n
=
45
##7
)
[SEP]
[CLS]
Pi
##cat
##o
(
r
)
gel
,
0
.
05
%
once
daily
for
2
days
Skin
reactions
Any
Grade
##a
>
Basel
##ine
Grade
4
58
(
26
%
)
6
(
3
%
[SEP]
[CLS]
)
2
(
1
%
)
0
(
0
%
)
a
Mi
##ld
(
grade
1
)
,
Mode
##rate
(
grade
2
-
3
)
or
Se
##vere
(
grade
4
)
.
[SEP]
[CLS]
A
single
event
of
serum
sickness
was
reported
in
a
patient
treated
with
NE
##SI
##NA
25
mg
.
H
##y
##po
##gly
##ce
##mia
H
##y
##po
##gly
##ce
##mic
events
were
documented
based
upon
a
blood
glucose
value
and
/
or
clinical
signs
[SEP]
[CLS]
and
symptoms
of
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
Consider
disco
##ntin
##uation
for
Grade
3
in
##fusion
##s
reactions
as
clinical
##ly
appropriate
considering
individual
benefits
,
risks
,
and
supportive
care
.
[SEP]
[CLS]
Ad
##verse
reactions
observed
in
these
studies
were
generally
similar
to
those
observed
and
attributed
to
drug
in
ad
##junct
##ive
place
##bo
-
controlled
studies
.
[SEP]
[CLS]
in
Place
##bo
and
Active
-
Control
##led
Studies
when
NE
##SI
##NA
Was
Used
as
Ad
##d
-
On
Therapy
to
G
##ly
##bur
##ide
,
In
##sul
##in
,
Met
##form
##in
,
Pi
##og
##lit
##az
##one
or
Compared
to
G
##lip
##iz
##ide
Ad
##d
-
On
to
G
##ly
##bur
##ide
(
26
Weeks
[SEP]
[CLS]
)
NE
##SI
##NA
25
mg
+
G
##ly
##bur
##ide
Place
##bo
+
G
##ly
##bur
##ide
N
=
198
N
=
99
Overall
(
%
)
19
(
9
.
6
)
11
(
11
.
1
)
Se
##vere
(
%
)
Se
##vere
events
of
h
##y
##po
##gly
##ce
##mia
were
[SEP]
[CLS]
defined
as
those
events
requiring
medical
assistance
or
exhibiting
depressed
level
or
loss
of
consciousness
or
seizure
.
[SEP]
[CLS]
Pain
in
ex
##tre
##mity
and
m
##us
##cu
##los
##kel
##etal
pain
have
also
been
reported
in
clinical
trials
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Am
##gen
Inc
.
at
1
-
800
-
77
-
AM
##GE
##N
(
1
-
800
-
77
##2
-
64
##36
)
[SEP]
[CLS]
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
For
those
patients
who
require
the
use
of
op
##io
##ids
to
treat
pain
during
or
following
the
procedure
,
their
ability
to
perform
potentially
hazardous
activities
such
as
driving
or
operating
[SEP]
[CLS]
machinery
may
be
affected
.
[SEP]
[CLS]
(
2
.
3
,
5
.
3
)
*
F
##lu
##id
Re
##ten
##tion
:
Monitor
patients
and
manage
using
standard
of
care
treatment
.
[SEP]
[CLS]
*
I
##mme
##dia
##te
medical
attention
may
be
required
in
cases
of
respiratory
,
speech
or
swallowing
difficulties
(
5
.
1
,
5
.
4
)
.
[SEP]
[CLS]
5
.
2
A
##cute
Ren
##al
F
##ail
##ure
Case
##s
of
acute
re
##nal
failure
have
occurred
in
patients
receiving
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
*
Lower
lid
injection
##s
should
not
be
repeated
if
dip
##lop
##ia
occurred
with
previous
b
##ot
##ulin
##um
to
##xin
injection
##s
.
[SEP]
[CLS]
(
5
.
4
)
*
Card
##iac
failure
has
been
observed
and
can
be
fatal
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
T
##TP
/
H
##US
.
[SEP]
[CLS]
Mon
##otherapy
Historical
Control
Trials
In
the
mon
##otherapy
e
##pile
##psy
trials
(
Study
1
and
Study
2
)
,
13
%
of
patients
random
##ized
to
receive
AP
##TI
##OM
at
the
recommended
doses
of
[SEP]
[CLS]
1200
mg
and
1600
mg
once
daily
discontinued
from
the
trials
as
a
result
of
an
adverse
event
.
[SEP]
[CLS]
In
Study
2
all
adverse
events
of
all
Grades
were
prospective
##ly
collected
.
[SEP]
[CLS]
(
5
.
7
)
*
Stop
IN
##L
##Y
##TA
at
least
24
hours
prior
to
scheduled
surgery
.
[SEP]
[CLS]
Pre
##s
##cribe
##rs
should
carefully
evaluate
the
risks
and
benefits
of
continuing
treatment
with
O
##TE
##Z
##LA
if
such
events
occur
.
[SEP]
[CLS]
FA
##NA
##P
##T
is
not
approved
for
the
treatment
of
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
[
s
e
##e
Box
##ed
Warning
]
.
[SEP]
[CLS]
MR
##I
signs
may
be
apparent
before
clinical
symptoms
.
[SEP]
[CLS]
Three
of
these
patients
had
subsequent
tests
which
were
negative
.
[SEP]
[CLS]
The
reduction
in
clinical
cure
rates
was
more
marked
in
the
Z
##ER
##BA
##X
##A
plus
metro
##ni
##da
##zo
##le
arm
compared
to
the
me
##rop
##ene
##m
arm
.
[SEP]
[CLS]
Monitor
for
su
##icidal
thoughts
or
behaviors
.
[SEP]
[CLS]
T
##hr
##omb
##op
##rop
##hyl
##ax
##is
is
recommended
and
should
be
based
on
an
assessment
of
the
patient
'
s
underlying
risks
,
treatment
regime
##n
,
and
clinical
status
.
[SEP]
[CLS]
Eva
##lu
##ate
with
cardiac
imaging
and
/
or
other
tests
as
indicated
.
[SEP]
[CLS]
At
##rial
Fi
##bri
##lla
##tion
/
F
##lut
##te
r
In
the
pool
of
7
place
##bo
-
and
active
-
controlled
trials
,
adverse
reactions
of
at
##rial
fi
##bri
##lla
##tion
(
1
.
0
%
)
and
at
##rial
flutter
(
0
.
2
%
)
were
[SEP]
[CLS]
reported
more
frequently
for
T
##AN
##Z
##E
##UM
than
for
all
com
##par
##ators
(
0
.
5
%
and
0
%
,
respectively
)
.
[SEP]
[CLS]
For
cases
of
Grade
4
non
-
infectious
p
##ne
##um
##oni
##tis
,
disco
##ntin
##ue
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
Table
2
Ad
##verse
Re
##actions
with
a
Fr
##e
##que
##ncy
>
=
0
.
5
%
Report
##ed
in
Clinical
Trials
(
n
=
978
Administration
##s
in
87
##2
Sub
##jects
)
Ad
##verse
drug
reaction
n
(
%
)
[SEP]
[CLS]
application
site
er
##yt
##hem
##a
17
(
1
.
7
)
In
##jection
site
irritation
12
(
1
.
2
)
In
##jection
site
pain
38
(
3
.
9
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
Image
interpretation
errors
[SEP]
[CLS]
(
especially
false
positive
##s
)
have
been
observed
(
5
.
1
)
.
[SEP]
[CLS]
Del
##ay
or
disco
##ntin
##ue
J
##E
##V
##TA
##NA
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
in
greater
detail
in
another
section
of
the
label
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
)
]
:
*
[SEP]
[CLS]
Non
-
infectious
p
##ne
##um
##oni
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Re
##tina
##l
detachment
##s
resulting
from
tram
##eti
##ni
##b
are
often
bilateral
and
multi
##fo
##cal
,
occurring
in
the
mac
##ular
region
of
the
re
##tina
.
[SEP]
[CLS]
Pat
##ients
who
are
E
##B
##V
se
##rop
##os
##itive
and
C
##M
##V
se
##rone
##gat
##ive
may
be
at
increased
risk
for
PT
##LD
compared
to
patients
who
are
E
##B
##V
se
##rop
##os
##itive
and
C
##M
##V
se
##rop
##os
##itive
[
see
Ad
##verse
Re
##actions
(
[SEP]
[CLS]
6
.
1
)
]
.
[SEP]
[CLS]
Monitor
and
treat
promptly
per
standard
of
care
until
signs
and
symptoms
resolve
.
[SEP]
[CLS]
Women
of
child
##be
##aring
potential
and
men
must
use
at
least
two
forms
of
effective
con
##tra
##ception
during
treatment
and
for
at
least
6
months
after
treatment
has
concluded
.
[SEP]
[CLS]
Case
##s
of
other
ma
##li
##gna
##ncies
have
been
observed
among
patients
receiving
T
##NF
-
block
##ers
(
5
.
2
)
.
[SEP]
[CLS]
Di
##abe
##tic
Mac
##ular
Ed
##ema
(
D
##ME
)
The
data
described
below
reflect
exposure
to
E
##Y
##LE
##A
in
57
##8
patients
with
D
##ME
treated
with
the
2
-
mg
dose
in
2
double
-
masked
,
controlled
clinical
[SEP]
[CLS]
studies
(
VI
##VI
##D
and
VI
##ST
##A
)
from
base
##line
to
week
52
and
from
base
##line
to
week
100
[
see
##C
##lini
##cal
Studies
(
14
.
4
)
]
.
[SEP]
[CLS]
5
.
8
Le
##uk
##ope
##nia
,
N
##eu
##tro
##pen
##ia
,
and
A
##gra
##nu
##loc
##yt
##osis
In
clinical
trial
and
post
##market
##ing
experience
,
le
##uk
##ope
##nia
and
ne
##ut
##rop
##enia
have
been
reported
temporal
##ly
related
to
anti
##psy
##cho
##tic
agents
,
including
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
If
the
abnormal
##ities
are
confirmed
,
monitor
serum
liver
tests
weekly
until
resolved
or
stab
##ilized
.
[SEP]
[CLS]
*
Heart
failure
,
may
occur
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
most
serious
adverse
reactions
reported
with
N
##U
##L
##O
##J
##IX
are
:
*
PT
##LD
,
predominantly
C
##NS
PT
##LD
,
and
other
ma
##li
##gna
##ncies
[
see
Box
##ed
Warning
and
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
3
)
]
*
Ser
##ious
infections
,
including
J
##C
virus
-
associated
PM
##L
and
p
##oly
##oma
virus
ne
##ph
##rop
##athy
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
,
5
.
5
,
5
.
6
[SEP]
[CLS]
)
]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
=
20
%
on
N
##U
##L
##O
##J
##IX
treatment
)
are
an
##emia
,
di
##ar
##r
##hea
,
u
##rina
##ry
tract
infection
,
peripheral
ed
##ema
,
con
##st
##ip
##ation
,
[SEP]
[CLS]
h
##yper
##tens
##ion
,
p
##yre
##xia
,
g
##raft
d
##ys
##function
,
cough
,
nausea
,
vomit
##ing
,
headache
,
h
##y
##po
##kal
##emia
,
h
##yper
##kal
##emia
,
and
le
##uk
##ope
##nia
.
[SEP]
[CLS]
If
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
disco
##ntin
##ue
use
of
T
##AN
##Z
##E
##UM
;
treat
promptly
per
standard
of
care
and
monitor
until
signs
and
symptoms
resolve
[
see
Con
##tra
##ind
##ica
##tions
(
4
.
2
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
C
##M
##V
prop
##hyl
##ax
##is
is
recommended
for
at
least
3
months
after
transplant
##ation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
5
.
7
Ser
##ious
Feb
##ril
##e
Re
##actions
Ser
##ious
f
##eb
##ril
##e
reactions
and
fever
of
any
severity
complicated
by
h
##y
##pot
##ens
##ion
,
rig
##ors
or
chill
##s
,
de
##hy
##dra
##tion
,
or
re
##nal
failure
,
can
occur
when
T
##AF
##IN
##LA
##R
[SEP]
[CLS]
is
administered
as
a
single
agent
or
when
used
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Monitor
and
treat
as
appropriate
.
[SEP]
[CLS]
Pat
##ients
should
receive
pre
##med
##ica
##tion
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
A
##cute
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
d
##ys
##p
##nea
,
r
##ash
p
##ru
##rit
##us
,
and
an
##gio
##ede
##ma
of
the
mouth
have
been
reported
with
fi
##da
##x
##omi
##cin
.
[SEP]
[CLS]
In
both
groups
,
patients
with
events
were
generally
male
,
older
,
and
had
underlying
re
##nal
imp
##air
##ment
or
cardiac
disease
(
e
.
g
.
,
history
of
a
##rr
##hy
##th
##mia
,
p
##al
##pit
##ations
,
[SEP]
[CLS]
con
##ges
##tive
heart
failure
,
card
##io
##my
##op
##athy
,
etc
.
[SEP]
[CLS]
)
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
>
=
10
%
and
>
=
2
%
place
##bo
)
were
flush
##ing
,
abdominal
pain
,
di
##ar
##r
##hea
,
and
nausea
.
[SEP]
[CLS]
The
most
commonly
reported
adverse
reactions
(
occurring
in
at
least
0
.
5
%
of
subjects
)
during
N
##eur
##ace
##q
clinical
trials
are
shown
in
Table
2
.
[SEP]
[CLS]
Use
of
a
sensitive
real
-
time
reverse
-
transcription
polymer
##ase
chain
reaction
(
R
##T
-
PC
##R
)
ass
##ay
for
monitoring
HC
##V
-
RNA
levels
during
treatment
is
recommended
.
[SEP]
[CLS]
In
the
two
clinical
trials
in
infant
##ile
-
onset
patients
,
the
majority
of
patients
(
34
of
38
;
89
%
)
tested
positive
for
I
##g
##G
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
Of
these
patients
,
there
were
2
respiratory
-
related
deaths
in
the
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
300
m
##c
##g
dose
group
.
[SEP]
[CLS]
5
.
4
Development
of
Drug
-
Re
##sist
##ant
Ba
##cter
##ia
Pre
##s
##cribing
Z
##ER
##BA
##X
##A
in
the
absence
of
a
proven
or
strongly
suspected
bacterial
infection
is
unlikely
to
provide
benefit
to
the
patient
and
risks
the
development
[SEP]
[CLS]
of
drug
-
resistant
bacteria
.
[SEP]
[CLS]
The
most
commonly
-
reported
adverse
reactions
,
occurring
in
>
=
5
%
of
patients
in
clinical
trials
were
nausea
,
di
##ar
##r
##hea
,
p
##yre
##xia
,
na
##so
##pha
##ryn
##git
##is
,
br
##on
##chi
##tis
,
ins
##om
##nia
,
[SEP]
[CLS]
pain
in
ex
##tre
##mity
,
depression
,
mi
##gra
##ine
,
and
p
##har
##yn
##git
##is
.
[SEP]
[CLS]
Since
E
##NT
##ER
##EG
acts
peripheral
##ly
,
clinical
signs
and
symptoms
of
increased
sensitivity
would
be
related
to
the
gas
##tro
##int
##est
##inal
tract
(
e
.
g
.
,
abdominal
pain
,
nausea
and
vomit
##ing
,
[SEP]
[CLS]
di
##ar
##r
##hea
)
.
[SEP]
[CLS]
Ce
##re
##bro
##vas
##cular
Ad
##verse
Events
,
Including
St
##roke
In
place
##bo
-
controlled
trials
with
r
##is
##per
##ido
##ne
,
a
##rip
##ip
##raz
##ole
,
and
o
##lan
##za
##pine
in
elderly
patients
with
dem
##ent
##ia
,
there
was
a
higher
incidence
of
[SEP]
[CLS]
c
##ere
##bro
##vas
##cular
adverse
events
(
c
##ere
##bro
##vas
##cular
accidents
and
trans
##ient
is
##che
##mic
attacks
)
including
fatalities
compared
to
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Monitor
thy
##roid
function
before
initiation
of
,
and
periodically
throughout
,
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
In
the
E
##MT
##P
trial
,
safety
data
were
derived
from
case
report
forms
that
collected
adverse
event
information
.
[SEP]
[CLS]
Disco
##ntin
##ue
K
##y
##p
##rol
##is
if
suspected
.
[SEP]
[CLS]
There
is
no
clinical
trial
experience
with
X
##TA
##ND
##I
in
patients
who
have
had
a
seizure
.
[SEP]
[CLS]
B
##le
##pha
##ros
##pas
##m
(
5
.
6
)
:
*
Co
##rne
##al
exposure
*
In
##jection
of
X
##E
##OM
##IN
into
the
or
##bic
##ular
##is
o
##cu
##li
muscle
may
lead
to
reduced
blinking
and
corn
##eal
exposure
.
[SEP]
[CLS]
N
##SF
may
result
in
fatal
or
de
##bil
##itating
fi
##bro
##sis
affecting
the
skin
,
muscle
and
internal
organs
.
[SEP]
[CLS]
The
majority
were
in
adolescent
and
young
adult
males
.
[SEP]
[CLS]
T
##AB
##LE
1
:
Changes
in
Fast
##ing
G
##lu
##cos
##e
in
Adult
Pat
##ients
N
*
=
Number
of
patients
who
had
assessments
at
both
Basel
##ine
and
End
##point
.
[SEP]
[CLS]
A
total
of
56
%
of
patients
were
female
and
45
%
of
patients
were
Asian
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Q
##T
pro
##long
##ation
can
occur
with
S
##IR
##TU
##RO
.
[SEP]
[CLS]
Pat
##ients
with
un
##con
##tro
##lled
or
significant
card
##iovascular
disease
including
Q
##T
interval
pro
##long
##ation
were
excluded
by
protocol
.
[SEP]
[CLS]
BR
##AF
V
##60
##0
##E
Un
##res
##ec
##table
or
Met
##ast
##atic
Mel
##ano
##ma
:
The
safety
of
T
##AF
##IN
##LA
##R
as
a
single
agent
was
evaluated
in
58
##6
patients
with
BR
##AF
V
##60
##0
mutation
-
positive
un
##res
##ec
##table
or
meta
##static
me
##lan
##oma
,
previously
[SEP]
[CLS]
treated
or
un
##tre
##ated
,
who
received
T
##AF
##IN
##LA
##R
150
mg
oral
##ly
twice
daily
until
disease
progression
or
unacceptable
toxicity
,
including
181
patients
treated
for
at
least
6
months
and
86
[SEP]
[CLS]
additional
patients
treated
for
more
than
12
months
.
[SEP]
[CLS]
My
##elo
##su
##pp
##ression
may
require
dose
delays
and
/
or
subsequent
dose
reduction
##s
if
recovery
to
the
recommended
values
has
not
occurred
by
the
first
day
of
the
next
scheduled
cycle
.
[SEP]
[CLS]
No
new
adverse
reactions
were
reported
.
[SEP]
[CLS]
The
median
exposure
was
11
.
0
months
for
patients
treated
with
G
##IL
##OT
##RI
##F
and
3
.
4
months
for
patients
treated
with
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
.
[SEP]
[CLS]
Con
##ditions
that
lower
the
seizure
threshold
may
be
more
prevalent
in
a
population
of
65
years
or
older
.
[SEP]
[CLS]
Ren
##al
-
related
adverse
reactions
,
including
re
##nal
failure
and
blood
c
##rea
##tin
##ine
increase
,
were
more
frequent
in
patients
treated
with
FA
##R
##X
##IG
##A
(
see
Table
4
)
.
[SEP]
[CLS]
Counsel
patients
regarding
the
potential
risk
of
M
##TC
with
use
of
T
##R
##U
##L
##IC
##IT
##Y
and
inform
them
of
symptoms
of
thy
##roid
tumors
(
e
.
g
.
,
mass
in
the
neck
,
d
##ys
##pha
##gia
,
[SEP]
[CLS]
d
##ys
##p
##nea
,
persistent
hoarse
##ness
)
.
[SEP]
[CLS]
Ba
##cter
##ial
,
My
##co
##ba
##cter
##ial
,
V
##ira
##l
,
and
Fun
##gal
In
##fect
##ions
Ad
##verse
reactions
of
infectious
et
##iology
were
reported
based
on
clinical
assessment
by
physicians
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
incidence
>
=
30
%
)
are
ne
##ut
##rop
##enia
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
h
##yper
##gly
##ce
##mia
,
AL
##T
elevations
,
and
AS
##T
elevations
(
6
.
1
)
.
[SEP]
[CLS]
0
.
3
2
.
8
2
.
7
Na
##use
##a
2
.
4
2
.
8
2
.
5
In
##fluenza
2
.
3
2
.
7
2
.
3
D
##ys
##lip
##ide
##mia
1
.
5
2
.
1
2
.
5
Con
##st
##ip
##ation
1
.
5
2
.
2
1
.
9
Disco
##m
##fort
with
u
##rina
##tion
0
.
7
1
.
6
2
.
1
Pain
in
ex
##tre
##mity
1
.
4
2
.
0
[SEP]
[CLS]
1
.
7
Pool
of
13
Place
##bo
-
Control
##led
Studies
for
FA
##R
##X
##IG
##A
10
mg
The
safety
and
to
##ler
##ability
of
FA
##R
##X
##IG
##A
10
mg
was
also
evaluated
in
a
larger
place
##bo
-
controlled
study
pool
.
[SEP]
[CLS]
The
following
adverse
reactions
are
described
in
more
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
of
the
label
:
Se
##iz
##ures
,
Ana
##phy
##lax
##is
,
and
U
##rina
##ry
T
##rac
##t
In
##fect
##ions
.
[SEP]
[CLS]
The
risk
did
not
vary
substantially
by
age
(
5
-
100
years
)
in
the
clinical
trials
analyzed
.
[SEP]
[CLS]
5
.
9
Drug
Inter
##actions
with
Strong
Cy
##to
##ch
##rome
P
##45
##0
3
##A
##4
In
##hibit
##ors
C
##aut
##ion
should
be
exercised
when
considering
the
co
##ad
##mini
##stra
##tion
of
BR
##E
##O
E
##LL
##IP
##TA
with
long
-
term
k
##eto
##cona
##zo
##le
and
other
known
strong
C
##YP
##3
##A
##4
inhibitor
##s
(
[SEP]
[CLS]
e
.
g
.
,
r
##ito
##na
##vir
,
c
##lar
##ith
##rom
##y
##cin
,
con
##iva
##pta
##n
,
in
##dina
##vir
,
it
##rac
##ona
##zo
##le
,
lo
##pina
##vir
,
ne
##fa
##zo
##don
##e
,
ne
##lf
##ina
##vir
,
sa
##quin
##avi
##r
,
te
##lit
##hr
##omy
##cin
,
t
##rol
##ean
##dom
##y
##cin
,
v
##ori
##cona
##zo
##le
)
because
increased
systemic
co
##rt
##ico
##ster
##oid
[SEP]
[CLS]
and
increased
card
##iovascular
adverse
effects
may
occur
[
see
Drug
Inter
##actions
(
7
.
1
)
,
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Pat
##ients
receiving
the
drug
should
be
managed
in
facilities
equipped
and
staffed
with
adequate
laboratory
and
supportive
medical
resources
.
[SEP]
[CLS]
If
an
in
##fusion
-
related
reaction
occurs
,
the
in
##fusion
should
be
interrupted
and
appropriate
medical
management
instituted
.
[SEP]
[CLS]
Ch
##ronic
I
##mm
##une
(
I
##dio
##pathic
)
T
##hr
##omb
##oc
##yt
##ope
##nia
:
Adults
:
In
clinical
trials
,
hem
##or
##r
##hage
was
the
most
common
serious
adverse
reaction
and
most
hem
##or
##r
##ha
##gic
reactions
followed
disco
##ntin
##uation
of
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
Table
3
shows
the
number
of
patients
experiencing
bleeding
events
in
the
pool
##ed
analysis
of
R
##E
-
CO
##VE
##R
and
R
##E
-
CO
##VE
##R
II
studies
during
the
full
treatment
including
parent
##eral
and
oral
only
treatment
[SEP]
[CLS]
periods
after
random
##ization
.
[SEP]
[CLS]
Table
1
##sh
##ows
all
adverse
reactions
that
occurred
with
a
frequency
of
greater
than
or
equal
to
1
%
in
the
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
group
in
the
two
3
-
month
and
one
6
-
month
[SEP]
[CLS]
place
##bo
-
controlled
trials
where
the
rates
in
the
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
group
exceeded
place
##bo
.
[SEP]
[CLS]
The
median
duration
of
exposure
was
6
.
1
months
(
range
0
.
3
to
26
.
4
months
)
.
[SEP]
